question_text,nct_id,retrieval_score,matching_terms,trial_title,trial_phase,trial_age_range,diseases_targeted,inclusion_criteria,exclusion_criteria,prior_therapies,gender,model_grade,reasoning,patient_diseases_targeted,patient_biomarkers,patient_inclusion_criteria,patient_exclusion_criteria,patient_prior_therapies,patient_disease_stage,patient_line_of_therapy,patient_age,patient_age_unit,patient_sex,patient_trial_phase_preference,judge_accuracy,judge_correct_grade,judge_comment,human_grade,human_notes
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT00102648,0.8363864421844482,Recurrent Glioblastoma,Phase I/Ib Study of Sarasar and Temodar in Patients with Recurrent or Temodar-Refractory Glioblastoma Multiforme,PHASE1,18 years,Glioblastoma (recurrent); Gliosarcoma (recurrent),"Histologically proven supratentorial glioblastoma multiforme or gliosarcoma | Radiographic evidence of tumor recurrence or progression by MRI/CT after radiation therapy | Imaging within 14 days prior to registration with stable or decreasing steroid dose for >=5 days | Post-resection patients: >=2 weeks from surgery, recovered with adequate wound healing | Post-resection imaging: CT/MRI within 96 hours post-op or >=4 weeks post-op (within 14 days of registration) with stable steroids for 5 days | Karnofsky performance status >=60 | Recovered from prior therapy toxicities | Washouts: >=4 weeks from prior cytotoxic therapy; >=2 weeks from vincristine; >=6 weeks from nitrosoureas; >=3 weeks from procarbazine; >=1 week from non-cytotoxic agents","Current use of enzyme-inducing anticonvulsants (primidone, carbamazepine, phenobarbital, phenytoin) or not off them for at least 72 hours prior to treatment | History of another cancer (except non-melanoma skin cancer or cervical carcinoma in situ) unless in complete remission and off all therapy for >=3 years | Uncontrolled active infection | Serious intercurrent medical illness or conditions that could obscure toxicity or alter drug metabolism | Any prior treatment with farnesyl transferase inhibitors | Prior recurrence while receiving a farnesyl transferase inhibitor | Use of oral contraceptives or other hormonal birth control methods (e.g., depot medroxyprogesterone)",Prior temozolomide required; No prior farnesyl transferase inhibitor therapy allowed; Up to 2 prior chemotherapy regimens for recurrent/progressive disease allowed; Phase 1b expansion: at least 2 cycles of adjuvant temozolomide required; Washout: >=4 weeks from prior cytotoxic therapy; Washout: >=2 weeks from vincristine; Washout: >=6 weeks from nitrosoureas; Washout: >=3 weeks from procarbazine; Washout: >=1 week from non-cytotoxic agents,ALL,A,"Disease and setting match (recurrent GBM), and prior-exposure requirements are met (completed temozolomide after chemoradiation); age and sex are eligible with no stated disallowed therapies. Other details (e.g., supratentorial location, enzyme‑inducing anticonvulsants) are unknown but do not create a conflict from provided data.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),CORRECT,A,"No hard exclusions. Disease and recurrent setting match; prior temozolomide exposure requirement is satisfied. Age/sex fit. Other specifics (supratentorial location, washouts, EIAEDs) are unknown and not counted as soft mismatches per rubric. Thus ≥2 core anchors match (stage/setting and line/prior), supporting grade A.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT00268385,0.7373695373535156,Recurrent Glioblastoma,A Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in Combination With Temozolomide in Patients With Malignant Gliomas,PHASE1,18 years,Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Mixed Glioma; Brain Neoplasm (recurrent),"Histologically proven intracranial malignant glioma (glioblastoma, gliosarcoma, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed oligoastrocytoma, or malignant astrocytoma NOS); prior low-grade glioma allowed if subsequently malignant | Life expectancy > 8 weeks | Karnofsky performance status >= 60 | WBC >= 3,000/µL | ANC >= 1,500/µL | Platelet count >= 100,000/µL | Hemoglobin >= 10 g/dL (transfusion permitted to meet threshold) | AST (SGOT) < 2 x ULN | Bilirubin < 2 x ULN | Creatinine < 1.5 mg/dL | Baseline MRI or CT within 14 days on stable steroid dose >= 5 days; same modality used for follow-up; if steroids increased before registration, new baseline imaging required | Interval >= 3 weeks from completion of radiation therapy to study entry | Women of childbearing potential: negative pregnancy test within 7 days prior to registration | Women of childbearing potential and men agree to use adequate contraception during study | Willing to participate in pharmacokinetic studies | Part I: Stable disease after radiation therapy or progression eligible (unless progressed on temozolomide); prior relapses allowed | Recovered from prior therapy toxicities with required washouts (see prior therapies) | Post-resection eligibility: recovered from surgery; imaging within 96 hours post-op or >= 4 weeks post-op (within 14 days of registration) on stable steroids >= 5 days | Prior brachytherapy or stereotactic radiosurgery requires confirmation of true progression (PET or thallium scan, MR spectroscopy, or surgical documentation) | Part II: Only patients with stable disease after radiation therapy; no recurrent disease | Part II: Only prior therapy allowed is radiation alone or radiation with concomitant temozolomide; patients stable on adjuvant temozolomide may participate",Progressed on temozolomide | Significant uncontrolled medical illness that would compromise therapy tolerance | History of other cancer within 3 years (except non-melanoma skin cancer or carcinoma in situ of the cervix) unless in complete remission and off therapy >= 3 years | Active infection | Pregnant | Breastfeeding (if treated with vorinostat; potential risks may also apply to temozolomide) | Any disease that would obscure toxicity assessment or dangerously alter drug metabolism | HIV positive receiving combination antiretroviral therapy | Receiving other investigational agents | Allergic reactions to vorinostat or compounds of similar chemical or biologic composition | Use of valproic acid within 2 weeks prior to enrollment,">= 3 weeks since completion of radiation therapy; >= 28 days since any investigational agent; >= 28 days since prior cytotoxic therapy (>= 23 days since last standard 5/28 temozolomide); >= 14 days since vincristine; >= 42 days since nitrosoureas; >= 21 days since procarbazine; >= 7 days since non-cytotoxic agents (e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid); Recent resection allowed if recovered from surgery and imaging criteria met; Prior interstitial brachytherapy or stereotactic radiosurgery allowed with confirmation of true progression; Part I: Prior relapses and prior temozolomide with stable disease allowed; progression on temozolomide not allowed; Part II: Only prior therapy permitted is radiation with or without concomitant temozolomide; adjuvant temozolomide allowed if stable; no other prior chemotherapies",ALL,A,"Disease and setting match recurrent glioblastoma, which is eligible in Part I. Prior RT with concurrent and adjuvant temozolomide is allowed, with no indication of progression on temozolomide; age and sex fit trial requirements.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),CORRECT,A,No hard exclusions. Disease matches glioblastoma. Stage/setting (recurrent) fits Part I. Prior RT+temozolomide is allowed and completion of adjuvant TMZ implies no progression on TMZ. ≥2 core anchors (stage/setting and prior-exposure compatibility) match; no soft conflicts. Grade A is appropriate.,,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT01012817,0.7590398788452148,Recurrent Clear Cell Ovarian Carcinoma,"A Phase 1/2 Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase 1) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase 2) After Prior Platinum Containing First-Line Chemotherapy",PHASE1/PHASE2,18 years,Solid Tumor (metastatic); Solid Tumor (unresectable); Ovarian Cancer (recurrent); Fallopian Tube Cancer (recurrent); Primary Peritoneal Cancer (recurrent),"Phase I: Histologically confirmed solid tumor that is metastatic or unresectable and lacks standard curative or life-extending therapy | Phase II: Biopsy-proven ovarian, fallopian tube, or primary peritoneal cancer | Fewer than 3 prior lines of therapy and relapse less than 1 year from last platinum regimen | Measurable disease with at least one lesion >= 2.0 cm (conventional) or >= 1.0 cm (spiral CT) | Absolute neutrophil count >= 1500/µL | Hemoglobin >= 9.0 g/dL | Platelets >= 100,000/µL | Total bilirubin <= 1.5 x ULN | AST or ALT <= 2.5 x ULN (stricter general threshold) | Creatinine <= 1.5 x ULN | INR <= 1.4 unless on therapeutic warfarin | PTT <= 48 s | ECOG performance status 0-2 | Life expectancy >= 12 weeks | Negative pregnancy test for females of childbearing potential | Able to swallow and absorb oral medication","Standard therapy exists that is potentially curative or capable of extending life expectancy | Prior treatment with a PARP inhibitor or topotecan | Uncontrolled intercurrent illness (e.g., active infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, significant psychiatric illness) | Chemotherapy within 4 weeks | Mitomycin C or nitrosoureas within 6 weeks | Immunotherapy within 4 weeks | Biologic therapy within 4 weeks | Radiation therapy within 4 weeks | Radiation to > 25% of bone marrow | Investigational therapy within 4 weeks (hormone therapy for prostate cancer allowed) | Failure to recover from acute reversible effects of prior chemotherapy | NYHA class III or IV heart failure | Known CNS metastases or seizure disorder unless treated and stable >= 6 months without steroids and without seizures | Pregnant or nursing | Men or women of childbearing potential unwilling to use adequate contraception | Significant co-morbid systemic illness that would interfere with safety assessment | Immunocompromised state or known HIV positive | Receiving another investigational agent for the primary neoplasm | Other active malignancy except non-melanoma skin cancer or carcinoma in situ of the cervix | History of myocardial infarction within 6 months | Congestive heart failure requiring ongoing maintenance therapy for life-threatening ventricular arrhythmias | More than 2 prior chemotherapy regimens for the current malignancy",< 3 prior lines of therapy and relapse < 1 year from last platinum regimen; No chemotherapy within 4 weeks prior to registration; No mitomycin C or nitrosoureas within 6 weeks prior to registration; No immunotherapy within 4 weeks prior to registration; No biologic therapy within 4 weeks prior to registration; No radiation therapy within 4 weeks prior to registration; No investigational therapy within 4 weeks prior to registration,ALL,A,"Disease and setting match (recurrent ovarian cancer after prior platinum), and prior therapy criteria are met (<3 lines, relapse <1 year; no prior PARP/topotecan). Age/sex align; measurable disease and lab/PS details are unknown and would need confirmation but are not hard exclusions.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; BRCA1 positive; Optimal debulking surgery performed; Received adjuvant carboplatin + paclitaxel + bevacizumab; Cytology-positive malignant pleural effusion at 5 months post-adjuvant,(none),Carboplatin; Paclitaxel; Bevacizumab; Optimal debulking surgery,Stage III,,36,years,female,(none),CORRECT,A,"No hard exclusions identified. Disease matches (recurrent ovarian cancer). Stage/setting aligns (relapsed within 1 year of platinum), and line/prior exposure criteria match (<3 prior lines; no prior PARP/topotecan). Other requirements (measurable disease, labs) are unknown and not treated as hard exclusions per rubric. Thus ≥2 core anchors match without soft conflicts → A.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT01107522,0.8286921381950378,Recurrent Glioblastoma,A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy With Temodar® for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas,PHASE1,18 years,Solid Tumor (advanced/metastatic); Glioblastoma; Malignant Glioma (recurrent),"Histologically confirmed advanced or metastatic solid tumor refractory to or without standard therapy (Arm A) | Measurable disease per RECIST 1.1 (Arm A) | Received prior anticancer therapy or not eligible for established conventional therapy (Arm A) | Recovered from acute adverse effects of prior therapies to baseline or <= grade 1 (all applicable arms) | ECOG performance status 0–2 (all arms) | Age >= 18 years (all arms) | Adequate bone marrow, renal, and hepatic function (see labs) (Arm A) | Life expectancy >= 12 weeks (Arm A) | Histologically proven malignant glioblastoma or other recurrent malignant gliomas (Arm B) | Measurable tumor on gadolinium-enhanced MRI (Arm B) | Life expectancy >= 8 weeks (Arm B) | Unequivocal radiographic progression by MRI within 14 days; on stable steroid dose >= 5 days or new baseline MRI if dose increased (Arm B) | Postoperative eligibility if recovered from surgery and residual disease assessed by MRI within required windows (Arm B) | Prior radiation therapy with or without chemotherapy and progressed; interval >= 12 weeks from completion of radiation to registration (Arm B) | On stable dose of non–CYP3A4-inhibiting/inducing antiepileptic drugs for >= 2 weeks with no seizures at registration (Arms B and C) | Histologically proven newly diagnosed glioblastoma or other malignant gliomas (Arm C) | Life expectancy >= 8 weeks (Arm C) | MRI within 14 days prior to registration; on stable steroid dose >= 5 days or new baseline MRI if dose increased (Arm C)","Prior chemotherapy, hormonal therapy, radiation therapy, or biologic therapy within 4 weeks (6 weeks for mitomycin C or nitrosoureas); for targeted therapy, < 5 half-lives or < 28 days (whichever is shorter) (Arms A and B) | For Arm B, shorter washouts allowed: 14 days vincristine; 21 days procarbazine; 7 days for non-cytotoxic agents (interferon, tamoxifen, thalidomide, cis-retinoic acid) | Any concomitant condition compromising study objectives/compliance or ability to tolerate therapy (e.g., CHF, uncontrolled angina, MI within 1 year, uncontrolled hypertension, dysrhythmias, active infection, unstable diabetes, psychiatric disorder) (all arms) | Pregnant or breastfeeding (all arms) | Another malignancy within 3 years except curatively treated non-melanoma skin cancer or carcinoma in situ of cervix or breast not requiring further treatment (all arms) | Known HIV, HBV, or HCV infection (all arms) | Underlying diagnosis/disease state with increased risk of bleeding (all arms) | Central nervous system metastases, leptomeningeal disease, brain involvement, or seizure disorder (Arm A) | Uncontrolled seizure activity (Arms B and C) | Treatment with known CYP3A4 inhibitors or inducers (all arms) | No prior chemotherapy, hormonal therapy, or biologic therapy for gliomas (Arm C) | Anaplastic oligodendroglioma with 1p/19q deletion or unknown 1p/19q status (Arm C)","Prior anticancer therapy allowed or ineligible for standard therapy (Arm A); Washout >= 4 weeks from prior chemotherapy, hormonal therapy, radiation therapy, or biologic therapy (>= 6 weeks for mitomycin C or nitrosoureas) (Arms A and B); For prior targeted therapy, washout >= 5 half-lives or 28 days (whichever is shorter) (Arms A and B); Shorter washouts permitted in Arm B: 14 days vincristine; 21 days procarbazine; 7 days non-cytotoxic agents (interferon, tamoxifen, thalidomide, cis-retinoic acid); Prior radiation therapy required with progression; >= 12 weeks since completion of radiation (Arm B); No prior chemotherapy, hormonal therapy, or biologic therapy for gliomas (Arm C); Recovery to baseline or <= grade 1 from prior therapy adverse effects before enrollment (all arms)",ALL,A,"Recurrent glioblastoma after radiation+temozolomide fits the trial’s Arm B for recurrent malignant gliomas; age 40 and ECOG 1 meet general eligibility. Required details like MRI/progression timing, washouts, steroid/AED status, and labs are unknown but pose no identified conflicts.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches Arm B (recurrent GBM). Stage/setting matches (recurrent post standard therapy) and prior-exposure compatibility matches (prior RT±TMZ allowed/required). Other required details (MRI timing, washouts, steroids/AEDs) are unknown, not mismatches. Thus ≥2 core anchors match with no soft conflicts → A.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT01140373,0.7647976875305176,Castration-Resistant Prostate Cancer,Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC),PHASE1,18 years,"Prostate Cancer (metastatic, castration-resistant)","Male, age >= 18 years | Karnofsky >= 70% | Histologic confirmation of prostate cancer at MSKCC | Progressive castrate metastatic prostate cancer | Soft tissue progression per RECIST 1.0 | Bone disease progression per PCWG2 with >= 2 new lesions on bone scan | Rising PSA on >= 3 successive determinations >= 2 weeks apart meeting protocol thresholds (and evidence of metastases present) | PSA rise timing after anti-androgen discontinuation: within 2 weeks if second-line therapy | PSA rise timing after anti-androgen discontinuation: after 4 weeks if first-line therapy | Evidence of metastatic disease on imaging (bone scan, CT, and/or MRI) at any time after initial diagnosis | Castrate serum testosterone < 50 ng/mL achieved by prior orchiectomy or LHRH agonist with or without anti-androgen | WBC >= 3000/µL | Absolute neutrophil count >= 1500/µL | Platelets >= 100000/µL | Hemoglobin >= 10 g/dL | Bilirubin < 1.5 x ULN (Gilbert's permitted) | ALT < 2.5 x ULN | AST < 2.5 x ULN | Creatinine < 1.5 x ULN | Negative screening for HIV, HBV antigen, and HCV","History of non-prostate primary malignant cancer (except non-melanoma skin cancer) within 5 years | History of splenectomy | Autoimmune or antibody-mediated disease (e.g., SLE, rheumatoid arthritis, ulcerative colitis, Crohn's disease, temporal arteritis, thyroiditis) | Clinically significant cardiac disease (NYHA Class III/IV) or severe debilitating pulmonary disease | Radiation therapy within 4 weeks prior to Day -1 | More than one prior chemotherapy regimen | Use within 4 weeks before Week 1: systemic radiopharmaceuticals (e.g., samarium-153), hematopoietic growth factors other than erythropoietin, medroxyprogesterone as appetite stimulant, or alternative prostate cancer treatments (e.g., Prostasol, saw palmetto, Zyflamend) | Active CNS or symptomatic epidural metastatic disease | Infection requiring antibiotics within 7 days of Day -1 | Requirement for daily systemic corticosteroids or other immunosuppressive/immunomodulatory agents (topical/nasal/physiologic steroids permitted) | Live attenuated vaccines within 8 weeks prior to Day -1 and throughout the study | Subunit or killed vaccines within 2 weeks prior to Day -1 and throughout the study (influenza vaccination permitted between Week 12–16 and after Week 20) | Positive stool guaiac (excluding hemorrhoids or documented radiation-induced proctitis if tested) | Participation in a therapeutic study or receipt of an investigational drug within 4 weeks of leukapheresis | Allergy to ganciclovir or acyclovir","Prior orchiectomy or LHRH agonist to achieve castrate testosterone required; If anti-androgen discontinued: document PSA rise within 2 weeks (second-line) or after 4 weeks (first-line) before enrollment; Washout: radiation therapy >= 4 weeks before Day -1; Washout: systemic radiopharmaceuticals, non-erythropoietin hematopoietic growth factors, medroxyprogesterone as appetite stimulant, and alternative prostate cancer treatments >= 4 weeks before Week 1; Washout: live attenuated vaccines >= 8 weeks before Day -1; subunit/killed vaccines >= 2 weeks before Day -1; Washout: investigational drug >= 4 weeks before leukapheresis",MALE,A,"Male age 66 with metastatic castration-resistant prostate cancer, PSMA-positive, and progression after enzalutamide matches the trial’s setting. Prior LHRH therapy aligns with requirements and no explicit exclusions are identified from the available data.",Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),CORRECT,A,"Disease and setting match (metastatic castration-resistant prostate cancer). Line/prior exposure is compatible (prior LHRH and AR-targeted therapy allowed; no chemo listed). PSMA-positive aligns with likely target. No hard exclusions identified from provided data. ≥2 core anchors match without soft conflicts, so A is appropriate.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT01366144,0.8286312222480774,Metastatic Urothelial Carcinoma,An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors,PHASE1,18 years,Breast Cancer; Carcinoma of Unknown Primary; Endometrial Cancer; Esophageal Cancer; Lung Cancer; Head and Neck Cancer; Testicular Cancer; Melanoma; Ovarian Cancer; Urothelial Carcinoma,"Histologically confirmed metastatic or unresectable malignancy with expected responsiveness to carboplatin/paclitaxel | ECOG <=2 | Life expectancy >12 weeks | Absolute neutrophil count >= 1,500/µL | Platelets >= 100,000/µL | Hemoglobin >= 8.0 g/dL | All degrees of renal dysfunction allowed, including hemodialysis | Mild to severe hepatic dysfunction allowed | Total bilirubin <= 5 x ULN | AST and ALT <= 10 x ULN | For patients with biliary stent: stable labs within hepatic group from two readings 3 days apart, taken >=10 days after stent placement; no obstruction within last 2 months if stent placed >2 months ago","Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or unresolved toxicities from prior therapy | Concurrent treatment with other investigational agents | Allergy to veliparib or compounds of similar chemical/biologic composition or to study agents | Peripheral neuropathy > grade 1 | Inability to take oral medications continuously | Bleeding diathesis | Active or unstable CNS metastases or requirement for steroid treatment | Uncontrolled intercurrent illness (e.g., active infection, symptomatic congestive heart failure, unstable angina, significant arrhythmia, psychiatric illness limiting compliance) | Pregnant or breastfeeding | HIV-positive on combination antiretroviral therapy with potential for PK interactions | Concurrent hepatic and renal dysfunction | Progressed on prior carboplatin plus paclitaxel therapy | Active seizure or history of seizure disorder",Prior chemotherapy or radiotherapy allowed with washout >=4 weeks (>=6 weeks for nitrosoureas or mitomycin C); Prior veliparib permitted,ALL,A,"Disease matches (urothelial carcinoma) and the metastatic setting fits the trial; prior therapies are compatible since the patient has not progressed on carboplatin/paclitaxel, and renal dysfunction is allowed. No hard exclusions are triggered, though standard requirements (e.g., ECOG ≤2 and washout ≥4 weeks) are not specified.",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),CORRECT,A,No hard exclusions apply. Disease matches (urothelial carcinoma included). Stage/setting matches (metastatic/unresectable allowed). Line/prior exposure compatible (no prior carboplatin/paclitaxel progression; prior therapies allowed with washout unknown). No required biomarkers. No identified soft conflicts. Meets ≥2 core anchors → A.,,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT01552434,0.7143569588661194,Recurrent Glioblastoma,"A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications",PHASE1,Not specified,Advanced Malignant Neoplasm; Metastatic Malignant Neoplasm; Recurrent Malignant Neoplasm; Refractory Malignant Neoplasm; Lymphangioleiomyomatosis; Neurofibromatosis Type 2; Erdheim-Chester Disease; Castleman Disease,"Advanced or metastatic cancer refractory to standard therapy, relapsed after standard therapy, or without effective standard therapy | Relentlessly progressive benign diseases eligible: lymphangioleiomyomatosis, neurofibromatosis type 2, Erdheim-Chester disease, Castleman disease | >= 4 weeks since last therapeutic radiation or cytotoxic chemotherapy or antibody therapy | >= 5 half-lives since last non-cytotoxic targeted or biologic therapy | Palliative radiation allowed if not to the only target lesion | ECOG performance status <=2 | Karnofsky >= 60% | Lansky >= 60% (for participants <=16 years) | Absolute neutrophil count >= 1,000/µL | Platelets >= 50,000/µL | Creatinine <= 3 x ULN | Total bilirubin <= 3.0 mg/dL | AST <= 5 x ULN | ALT <= 5 x ULN | Fasting total cholesterol <= 350 mg/dL | Triglycerides <= 400 mg/dL","Clinically significant unexplained bleeding within 28 days prior to enrollment | Uncontrolled hypertension (systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg on medication) | History of cerebrovascular accident within 6 months | Myocardial infarction within 6 months | Unstable angina or unstable angina pectoris | Pregnant or breast-feeding | Hypersensitivity to bevacizumab or murine products or any component of its formulation | Hypersensitivity to temsirolimus, sirolimus, polysorbate 80, or any component of its formulation | Hypersensitivity to cetuximab, murine products, or any component of its formulation | Concurrent use of CYP3A4 inducers or inhibitors | Colorectal cancer with known KRAS mutation (for cetuximab-containing arm) | Major surgery within 6 weeks of enrollment | Receiving other investigational agents or other concurrent anticancer agents or therapies",">= 4-week washout from therapeutic radiation, cytotoxic chemotherapy, or antibody therapy; >= 5 half-life washout from non-cytotoxic targeted or biologic therapy; Palliative radiation permitted if not to the only target lesion",ALL,A,"The basket Phase I trial includes advanced/recurrent malignancies, matching this patient’s recurrent glioblastoma after standard therapy (stage/setting and prior-therapy criteria align), and ECOG 1 is within the allowed ≤2. No age/sex limits or known exclusion conflicts are apparent from the provided data.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),CORRECT,A,No hard exclusions. Disease matches a basket trial for advanced/recurrent malignancies. Core anchors: Stage/setting (recurrent after standard therapy) matches; Line/prior-exposure (post-standard therapy with washout possible) matches. No required biomarkers or mets pattern constraints. Thus ≥2 anchors match and no soft conflicts → A. Grader’s reasoning aligns.,,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT01906385,0.7714753150939941,Recurrent Glioblastoma,"A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC# 12-02)",PHASE1/PHASE2,18 years,Glioma (recurrent),"Age >= 18 years | Histologically confirmed recurrent Grade III/IV glioma (e.g., Astrocytoma, IDH-mutant grade 3 or 4; Glioblastoma, IDH-wildtype grade 4) | Disease progression by RANO or other accepted neuro-oncology criteria after standard treatment options with known survival benefit for any recurrence, or medically unable/unwilling to receive them | Stable dose of antiepileptic medication for >= 2 weeks without seizures prior to dosing (if on antiepileptics) | Corticosteroid dose stable or decreasing for >= 2 weeks without symptom progression prior to dosing (if on corticosteroids) | Tumor within the treatment field volume | ECOG performance status 0–2 | Karnofsky Performance Status >= 60% | Life expectancy >= 2 months | Bilirubin <= 1.5 x ULN | AST <= 3.0 x ULN | ALT <= 3.0 x ULN | Serum creatinine <= 1.5 x ULN | ANC >= 1000/µL (without hematologic support) | Platelet count >= 100000/µL (without hematologic support) | Hemoglobin >= 9.0 g/dL (without hematologic support)","Acute intracranial or intratumoral hemorrhage on MRI or CT (resolving changes/punctate/hemosiderin allowed) | Contraindication or inability to undergo MRI | Not recovered to CTCAE v4.0 Grade <= 1 from prior therapy-related adverse events (except alopecia, anemia, lymphopenia) | Pregnant or breastfeeding | Uncontrolled hypertension (>150/100 mmHg on two readings) despite optimal treatment | Active medically significant infection unresponsive to antibiotics or uncontrolled systemic infection | Clinically significant cardiac arrhythmias not controlled by medications | Untreated hypothyroidism | Symptomatic congestive heart failure or unstable angina within 3 months prior to study drug | Myocardial infarction within 6 months prior to study drug | Stroke or transient ischemic attack within 6 months prior to study drug | Known active malignancy other than glioma (except non-melanoma skin cancer or cervical carcinoma in situ unless deemed not impactful by PI) | Inherited bleeding diathesis or coagulopathy with bleeding risk | Prior treatment with bevacizumab | Prior non-standard radiation to target site (brachytherapy, systemic radioisotope therapy, or intra-operative radiotherapy) | External beam radiation therapy within 12 weeks of screening | Systemic therapy (including investigational agents and small-molecule kinase inhibitors) or non-cytotoxic hormonal therapy within 14 days or 5 half-lives (whichever is shorter) prior to dosing | Biologic agents (antibodies, immune modulators, vaccines, cytokines) within 21 days prior to dosing | Nitrosoureas or mitomycin C within 42 days prior to dosing | Metronomic/protracted low-dose chemotherapy within 14 days prior to dosing | Other cytotoxic chemotherapy within 28 days prior to dosing | Prior treatment with carmustine wafers | Receipt of another investigational agent within 28 days prior to dosing or currently receiving investigational therapy | Multifocal progression or leptomeningeal involvement | Psychiatric illness or social situations limiting compliance | Infratentorial disease | Tumor within 1–2 cm of a ventricle with risk for extravasation to subarachnoid space per surgeon/PI/sponsor assessment | Phase 2 only: tumor volume > 20 cm3","Received standard treatments with known survival benefit for recurrence (e.g., surgery, temozolomide, radiation, tumor treating fields) or medically unable/unwilling to receive them; Washout: external beam radiation >= 12 weeks before screening; Washout: systemic therapy or non-cytotoxic hormonal therapy >= 14 days or 5 half-lives (whichever is shorter) before dosing; Washout: biologic agents >= 21 days before dosing; Washout: nitrosoureas or mitomycin C >= 42 days before dosing; Washout: metronomic/protracted low-dose chemotherapy >= 14 days before dosing; Washout: other cytotoxic chemotherapy >= 28 days before dosing; No investigational agents within 28 days before dosing",ALL,A,"Recurrent IDH-wildtype glioblastoma after standard chemoradiation with ECOG 1 and age 40 fits the trial’s recurrent Grade IV glioma criteria, and no explicit exclusions (e.g., prior bevacizumab, non-standard radiation) are evident. Some required details (labs, lesion location/proximity to ventricles, MRI suitability) are unknown but not conflicting based on provided data.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),CORRECT,A,"No hard exclusions identified. Disease matches (recurrent GBM fits recurrent grade IV glioma). Stage/setting (recurrent) and line/prior exposure (post standard chemoradiation, no disallowed prior therapy noted) both match. Required subtype acceptable (GBM IDH-wildtype). Unknowns (labs, MRI suitability, lesion location) are neutral. Thus ≥2 core anchors match with no soft conflicts → A.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT02062827,0.7755840420722961,Recurrent Glioblastoma,"A Phase 1 Study of M032 (NSC 733972), a Genetically Engineered HSV-1 Expressing IL-12, in Patients With Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma",PHASE1,18 years,Glioblastoma (recurrent/progressive); Anaplastic Astrocytoma; Gliosarcoma,"Histologically or cytologically confirmed glioblastoma multiforme, anaplastic astrocytoma, or gliosarcoma | Failed external beam radiotherapy to the brain | If eligible and tolerated, prior temozolomide chemotherapy | All radiation and additional chemotherapies completed >=4 weeks before enrollment | Prior nitrosoureas completed >=6 weeks before enrollment | Age >=18 years | Karnofsky Performance Status >=70% | Life expectancy >4 weeks | Leukocytes >3000/µL | Absolute neutrophil count >1500/µL | Platelets >100000/µL | Total bilirubin within normal limits | AST/ALT <2.5 x ULN | Creatinine within normal limits or creatinine clearance >60 mL/min | Residual lesion >=1.0 cm and <5.5 cm in diameter without bilateral corpus callosum extension, suitable for local catheter-based delivery by MRI | Women of childbearing potential: negative serum pregnancy test within 14 days prior to treatment | Use of adequate contraception; barrier method required for 6 months after M032 | Steroid use allowed if dose not increased within 2 weeks; preferably <=2 mg dexamethasone daily at treatment","Chemotherapy, cytotoxic therapy, or immunotherapy within 4 weeks (6 weeks for nitrosoureas) prior to enrollment | Surgical resection within 4 weeks prior to enrollment | Any prior experimental viral therapy or gene therapy (e.g., adenovirus, retrovirus, herpes virus) | Not recovered from adverse events from prior therapy administered >4 weeks earlier | Receiving other investigational agents | History of allergic reactions to compounds similar to M032 or to interleukin-12 | Tumor location requiring ventricular, brainstem, basal ganglia, or posterior fossa inoculation, or requiring ventricular access for delivery | Bilateral extension through the corpus callosum, actively growing multifocal disease by MRI, or CSF/leptomeningeal dissemination | Prior history of encephalitis, multiple sclerosis, or other CNS infection | Required steroid dose increase within 2 weeks of scheduled M032 administration | Active oral herpes lesion | Concurrent therapy with anti-HSV drugs (e.g., acyclovir, valacyclovir, penciclovir, famciclovir, ganciclovir, foscarnet, cidofovir) | Uncontrolled intercurrent illness (e.g., active infection, symptomatic heart failure, unstable angina, cardiac arrhythmia) or any condition precluding surgery | Psychiatric illness or social situation limiting compliance | Pregnant or breastfeeding | HIV-seropositive | Allergy to IV contrast not amenable to premedication | MRI contraindications (e.g., pacemaker, ferromagnetic aneurysm clips, metal infusion pumps, metal/shrapnel fragments, certain stents) | Receipt of Gliadel therapy | Receipt of bevacizumab within 4 weeks of scheduled M032 administration | Any other reason deemed unfit by investigator","Must have failed external beam radiotherapy to the brain; If eligible and tolerated, prior temozolomide chemotherapy required; Washout: radiation and additional chemotherapies completed >=4 weeks before enrollment; Washout: prior nitrosoureas completed >=6 weeks before enrollment; Washout: surgical resection completed >=4 weeks before enrollment; Washout: bevacizumab >=4 weeks before M032 administration",ALL,A,"Disease and setting match (recurrent glioblastoma), and the patient previously received radiotherapy with temozolomide as required. Age and sex are eligible; no exclusions are evident from provided data, though lesion size/location, washout timing, and KPS are not specified.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),CORRECT,A,"No hard exclusions identified. Disease matches (recurrent GBM). Core anchors: Stage/setting matches and prior therapy/exposure (failed RT, prior temozolomide) matches—giving ≥2 anchors. Biomarker not required. Unknowns (KPS, lesion size/location, washout timing) are not mismatches. Grade A is appropriate per rubric.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT02099058,0.7885686755180359,Metastatic Non-Small Cell Lung Cancer,"A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors",PHASE1,18 years,Non-Small Cell Lung Cancer (advanced/metastatic),"Advanced non-small cell lung cancer not amenable to surgery or other approved therapy with clinical benefit | ECOG performance status 0–2 (Monotherapy Expansion Cohort: ECOG 0–1) | Measurable disease per RECIST v1.1 | Archived FFPE tumor tissue available for analyses | Adequate bone marrow, renal, and hepatic function | Women of childbearing potential have a negative serum pregnancy test at baseline | Eligible to receive erlotinib or nivolumab per local labeling (for Arms A and D) | Arm E: Metastatic/locally advanced nonsquamous NSCLC with EGFR del19 or L858R (with or without T790M) and no EGFR mutations known to be resistant to osimertinib | Arm E: Received 1–2 prior regimens, one containing osimertinib, with progression on osimertinib (only 1 prior regimen may have contained chemotherapy; consecutive EGFR TKIs count as 1) | Arm E: Post-progression tumor tissue available for central c-MET IHC testing | Monotherapy Expansion: Locally advanced or metastatic, nonsquamous, EGFR wild-type, c-MET positive NSCLC (no adenosquamous histology) | Monotherapy Expansion: No more than 2 prior systemic therapies in advanced setting (no more than 1 line of cytotoxic chemotherapy) | Monotherapy Expansion: Progressed on cytotoxic chemotherapy (or ineligible) and on an immune checkpoint inhibitor (or ineligible), and prior targeted therapy for driver alterations if applicable","Radiation therapy to the lung within 6 months before first dose | Anticancer therapy (chemotherapy, immunotherapy, biologic, investigational) within 21 days before first dose | Herbal therapy within 7 days before first dose | Uncontrolled CNS metastases; eligible 2–4 weeks after definitive therapy if asymptomatic and steroid dose stable/not increasing and not on anticonvulsants for progressive CNS metastases | History of interstitial lung disease or pneumonitis requiring systemic steroids | Pulmonary fibrosis on imaging or any history of pneumonitis/ILD within 3 months of first dose | Unresolved clinically significant adverse events >= Grade 2 from prior anticancer therapy (except alopecia or anemia) | Major surgery within 21 days before first dose | History of major immunologic reaction to any IgG-containing agent | Pregnant or lactating female | Known active COVID-19 infection or recent exposure/signs within 14 days prior to screening | Combination arms: Any condition placing participant at unacceptably high risk for toxicities from the combination | Nivolumab: Active autoimmune disease (except vitiligo, type 1 diabetes, hypothyroidism, psoriasis) | Nivolumab: Systemic corticosteroids >10 mg prednisone equivalent or other immunosuppressants within 14 days (except inhaled/locally injected/topical) | Nivolumab: Known immunosuppressive disease (e.g., HIV infection, history of bone marrow transplant, chronic lymphocytic leukemia) | Osimertinib: Hypersensitivity to osimertinib or excipients | Osimertinib: History of osimertinib dose reduction | Osimertinib: Conditions interfering with absorption (refractory nausea/vomiting, chronic GI disease, inability to swallow, prior significant bowel resection) | Osimertinib: QTc >470 ms, significant ECG conduction abnormalities (e.g., LBBB, 2nd/3rd degree block, PR >250 ms), or risk factors for QT prolongation/arrhythmia (e.g., heart failure, hypokalemia, congenital long QT, QT-prolonging meds) | Monotherapy Expansion: Prior c-MET–targeted antibody-based therapies",Arm E: 1–2 prior regimens with mandatory prior osimertinib and progression on osimertinib; only 1 prior chemotherapy-containing regimen allowed; Monotherapy Expansion: <=2 prior systemic therapies in advanced setting with <=1 cytotoxic chemotherapy line; Monotherapy Expansion: Progression on cytotoxic chemotherapy and on an immune checkpoint inhibitor or ineligible for these therapies; Washout: No anticancer therapy within 21 days before first dose; Washout: No herbal therapy within 7 days before first dose; Washout: No major surgery within 21 days before first dose,ALL,A,"Disease and stage match, and the EGFR exon 19 deletion with prior osimertinib aligns with Arm E requirements. Progression on osimertinib and controlled/asymptomatic brain metastases would need confirmation at screening.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,A,"No hard exclusions identified. Disease and metastatic setting match. Required EGFR del19 biomarker for Arm E is satisfied. Line/prior exposure anchor (progression on osimertinib) is unknown rather than a mismatch, and metastatic pattern constraints (brain mets control) are also unknown. With stage/setting and required biomarker anchors matching and no soft conflicts, grade A is appropriate.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT02123758,0.7902567386627197,Castration-Resistant Prostate Cancer,"A Drug-Drug Interaction, Safety and Efficacy Study With JNJ-56021927 (ARN-509) and Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancer",PHASE1,18 years to 99 years,Prostate Cancer (metastatic castration-resistant),ECOG performance status <= 2 | Histologically or cytologically confirmed adenocarcinoma of the prostate | Documented metastatic disease | Evidence of prostate cancer progression | Surgically or medically castrated with testosterone < 50 ng/dL | Adequate bone marrow and organ function,"Known brain metastases | Pathology consistent with small cell carcinoma of the prostate | Investigational agent within 4 weeks prior to Cycle 1 Day 1 | Chemotherapy or immunotherapy for prostate cancer within 4 weeks prior to Cycle 1 Day 1 | Concomitant medications that lower the seizure threshold | Use of herbal or non-herbal products that may decrease PSA levels (e.g., saw palmetto, pomegranate products) | Use of strong enzyme inducers (e.g., rifampin, carbamazepine, phenytoin, phenobarbital, St. John's wort) or dexamethasone | Use of potent inhibitors of CYP3A4 or CYP2C8",Surgical or medical castration required (testosterone < 50 ng/dL); Washout >= 4 weeks since last investigational agent; Washout >= 4 weeks since last chemotherapy or immunotherapy for prostate cancer,MALE,A,"Disease and setting match metastatic castration-resistant prostate cancer, and age/sex fit. The trial does not prohibit prior abiraterone or enzalutamide in the provided criteria, and there are no exclusion flags (e.g., brain mets) noted, so stage/setting and metastatic pattern anchors match.",Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),CORRECT,A,"No hard exclusions. Disease and stage/setting (mCRPC) clearly match. Line/prior-exposure is compatible because castration is required and the patient is medically castrated; no disallowed prior therapies are specified. Metastatic pattern constraint (no brain mets) is unknown from patient data, but A is still supported by ≥2 anchors (stage/setting and line/prior) with no soft conflicts. The grader’s reliance on absence of brain mets mention is slightly inferential, but the assigned A remains correct.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT02142803,0.7361185550689697,Recurrent Clear Cell Ovarian Carcinoma,A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors,PHASE1,18 years,Glioblastoma; Endometrial Clear Cell Carcinoma; Endometrial Serous Carcinoma; Ovarian Clear Cell Carcinoma; Ovarian Endometrioid Carcinoma; Ovarian Mucinous Carcinoma; Ovarian Serous Carcinoma; Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Malignant Uterine Corpus Neoplasm,"Histologically/cytologically confirmed recurrent glioblastoma or advanced solid tumor where bevacizumab has shown benefit and no standard/curative options remain | Measurable or evaluable disease (RECIST 1.1 for non-GBM; RANO for GBM) | Prior therapy: Stage 1 and Stage 2 endometrial/ovarian cohorts allow unlimited prior therapy; Stage 2 GBM: no more than 2 prior relapses (intent: no more than 3 prior therapies total) | Recovery from prior therapy toxicities to grade <= 1 or baseline | Washouts before day 1: 12 weeks from completion of radiation for recurrent GBM (unless surgical diagnosis of recurrence or new non-irradiated lesion) | Washouts before day 1: 6 weeks from nitrosourea chemotherapy | Washouts before day 1: 3 weeks from non-nitrosourea chemotherapy | Washouts before day 1: 4 weeks from an investigational (non-FDA-approved) agent or 5 half-lives (whichever is shorter) | Washouts before day 1: 2 weeks from a non-cytotoxic FDA-approved agent or 5 half-lives (whichever is shorter) | ECOG performance status <= 2 (Karnofsky >= 60%) | Absolute neutrophil count >= 1,500/µL | Platelets >= 100,000/µL | Hemoglobin >= 9.0 g/dL | Total bilirubin < 1.5 x ULN (direct bilirubin normal; exception: Gilbert's disease) | AST <= 2.5 x ULN (<= 5 x ULN with liver metastases) | ALT <= 2.5 x ULN (<= 5 x ULN with liver metastases) | Creatinine < 1.5 x ULN or creatinine clearance >= 50 mL/min | Fasting serum glucose <= 130 mg/dL | Fasting triglycerides <= 300 mg/dL | Solid tumor patients off corticosteroids prior to registration; GBM: on stable or decreasing corticosteroid dose >= 5 days before baseline imaging; new/increased steroids require new baseline imaging | Able to swallow whole capsules | Stage 2 GBM: archival tissue (block or 30 unstained slides) available | Stage 2 endometrial/ovarian: at least one lesion amenable to biopsy | Stage 2 solid tumor histologies limited to specified endometrial (papillary serous, endometrioid, clear cell) and ovarian/fallopian/primary peritoneal (high-grade serous, clear cell, endometrioid, mucinous) carcinoma","Concurrent investigational agents | Allergy to compounds similar to sapanisertib or bevacizumab | Stage 2: prior mTOR/PI3K/Akt inhibitors not allowed (allowed in Stage 1 only) | Stage 2 GBM: prior bevacizumab/VEGFR inhibitors not allowed (allowed in Stage 1 and Stage 2 endometrial/ovarian) | Stage 1 solid tumor and Stage 2 endometrial/ovarian: symptomatic or progressing CNS metastases (treated, asymptomatic, stable >= 1 month allowed) | Concurrent enzyme-inducing antiepileptic drugs (must be off >= 10 days); non-enzyme–inducing AEDs allowed | Strong CYP3A4/CYP2C19 inhibitors/inducers require caution; avoid if possible | Concurrent herbal supplements or non-traditional medications (must stop before registration) | Concurrent anticoagulants other than LMWH (must stop before registration); if recently on warfarin, INR <= 2 required | Significant intracranial hemorrhage within 6 weeks or on screening MRI | Uncontrolled intercurrent illness (active infection, symptomatic CHF, unstable angina, significant arrhythmia, psychiatric illness limiting compliance) | Cardiac exclusions within 6 months: LVEF <= 55%, NYHA class >= 3 heart failure, significant ischemic changes, complete LBBB, bifascicular block, congenital long QT, QTcF > 450 ms, inotropic support (excluding digoxin), clinically significant tachyarrhythmias or cardiac arrest, clinically significant bradycardia, unstable atrial fibrillation (>100 bpm), arrhythmia requiring ICD, angina within 12 months, acute MI within 12 months, significant valvular disease, ischemic events requiring therapy or revascularization, pacemaker placement, pulmonary embolism, ischemic cerebrovascular events or revascularization | GI impairment that may alter absorption (e.g., active ulcerative disease, uncontrolled N/V/D, malabsorption, small bowel resection requiring nutritional support) | Use of hematopoietic growth factors <= 2 weeks before start (ESAs allowed if started >= 2 weeks prior) | Pregnant or nursing women | HIV-positive on combination antiretroviral therapy with strong CYP inhibitors are ineligible (eligible if CD4 adequate and ART without strong CYP inhibitors) | Uncontrolled hypertension (SBP >= 160 mmHg or DBP >= 90 mmHg) | Pulmonary hypertension | Uncontrolled asthma or O2 saturation < 90% on room air | Poorly controlled diabetes (HbA1c > 7%) | Proteinuria: if urine dipstick >= 2+, 24-hour urine protein must be < 1000 mg for enrollment | Serious or non-healing wound, ulcer, or bone fracture | History of abdominal fistula, GI perforation, or intra-abdominal abscess within 6 months | Recent invasive procedures: major surgery/open biopsy/significant trauma within 28 days; anticipated major surgery; core biopsy within 7 days | Significant vascular disease within 6 months (e.g., aortic aneurysm requiring repair, recent peripheral arterial thrombosis) | Bleeding diathesis or coagulopathy | Hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies",Stage 1 and Stage 2 endometrial/ovarian: unlimited prior therapy allowed; Stage 2 GBM: no more than 2 prior relapses (no more than 3 prior therapies total including initial); Recovery from prior therapy toxicities to grade <= 1 required before enrollment; Washout: >= 12 weeks since radiation for recurrent GBM (unless surgical diagnosis of recurrence or new non-irradiated lesion); Washout: >= 6 weeks since nitrosourea chemotherapy; Washout: >= 3 weeks since non-nitrosourea chemotherapy; Washout: >= 4 weeks or 5 half-lives (whichever shorter) since investigational non-FDA-approved agent; Washout: >= 2 weeks or 5 half-lives (whichever shorter) since non-cytotoxic FDA-approved agent,ALL,A,"Recurrent ovarian clear cell carcinoma is an included cohort, and the setting aligns (recurrent/advanced); prior bevacizumab and chemotherapy are allowed with unlimited prior lines in the ovarian cohort. Age/sex are within bounds and no explicit exclusion conflicts are evident from the provided data.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; BRCA1 positive; Optimal debulking surgery performed; Received adjuvant carboplatin + paclitaxel + bevacizumab; Cytology-positive malignant pleural effusion at 5 months post-adjuvant,(none),Carboplatin; Paclitaxel; Bevacizumab; Optimal debulking surgery,Stage III,,36,years,female,(none),CORRECT,A,"No hard exclusions. Disease (ovarian clear cell) is explicitly included. Stage/setting (recurrent/advanced) matches, and prior exposure/line requirements are compatible (unlimited prior therapy for ovarian cohort; prior bevacizumab allowed). Required subtype matches; no soft conflicts identified. Thus ≥2 core anchors match → Grade A.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT02192359,0.7554177641868591,Recurrent Glioblastoma,A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination With Intravenous Irinotecan in Patients With Recurrent High-Grade Gliomas,PHASE1,18 years to 69 years,Anaplastic Astrocytoma (recurrent); Anaplastic Oligoastrocytoma (recurrent); Anaplastic Oligodendroglioma (recurrent); Glioblastoma (recurrent); Gliosarcoma (recurrent),"Karnofsky performance status >= 70% | Life expectancy >= 3 months | Histologically confirmed grade III or IV glioma or prior grade II glioma now with radiographic high-grade (grade III or IV) | Radiographic evidence of recurrent tumor | Recurrent or progressive high-grade glioma after prior brain radiation and temozolomide | Requires craniotomy for tumor resection or stereotactic brain biopsy | No anticipated connection between post-resection cavity and cerebral ventricles | Medically able to undergo neurosurgery | Any number of prior therapies permitted with washouts: >= 6 weeks from nitrosoureas; >= 4 weeks from non-nitrosourea cytotoxic chemotherapy (23 days from last daily temozolomide in 5/28 regimen); >= 2 weeks from last targeted agent (>= 4 weeks for bevacizumab) | Toxicities from prior therapy improved to grade 0 or 1 | ANC >= 1,500/µL | Platelets > 100,000/µL | Total bilirubin <= 2.0 mg/dL | AST <= 4 x ULN | Serum creatinine <= 1.5 x ULN | Homozygous negative for UGT1A1*28 | Absence of anti-HLA class I antibodies specific for the NSCs | Negative pregnancy test (women of childbearing potential) | Effective contraception during study (women of childbearing potential and sexually active men) | For enrollment at dose level >= 2: presence of supratentorial disease amenable to resection or biopsy for Rickham reservoir/catheter placement","Prior therapy with neural stem cells | Use of CYP3A4 inducers (including enzyme-inducing anticonvulsants) within 2 weeks prior to start of study treatment | Use of moderate to strong CYP3A4 inhibitors within 2 weeks prior to start of study treatment | Use of drugs that inhibit UGT1A1 (e.g., atazanavir, gemfibrozil, indinavir, ketoconazole) within 2 weeks prior to start of study treatment | Use of systemic immunosuppressive agents other than corticosteroids (e.g., cyclosporine, tacrolimus) | Flucytosine within 2 weeks prior to start of study treatment | Use of herbal medications | Concurrent use or planned use of other investigational agents or anti-tumor therapy (biologic, chemotherapy, or radiation) | Known HIV infection or hepatitis C infection | Unable to undergo MRI with contrast | Known chronic or active CNS viral infections | Clinically significant uncontrolled illness | Active infection requiring antibiotics | Diagnosis of Gilbert's disease | History of allergic reactions to compounds similar to irinotecan | Known sensitivity to any study products | Any other active malignancy | Pregnant or breastfeeding | Serious medical or psychiatric illness that may interfere with safety monitoring or treatment completion | Investigator deems participant may be unable to comply with study procedures",Prior brain radiation and temozolomide required; Any number of prior therapies permitted; Washout: >= 6 weeks from nitrosoureas; Washout: >= 4 weeks from non-nitrosourea cytotoxic chemotherapy (23 days from last daily temozolomide in 5/28 regimen); Washout: >= 2 weeks from last targeted agent (>= 4 weeks for bevacizumab),ALL,A,"Disease and setting match (recurrent GBM after prior radiation/temozolomide), and age/sex are within limits; prior-therapy requirements are satisfied. Several required factors (UGT1A1*28 homozygous negative, KPS ≥70, absence of anti-HLA antibodies, and need for surgical access) are unknown but not conflicting.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches recurrent GBM; stage/setting (recurrent) and prior exposure (post RT/TMZ) both match, satisfying ≥2 core anchors. Other required factors (UGT1A1*28 status, KPS, surgical requirement) are unknown but not soft mismatches per rubric. Grade A is appropriate.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT02208362,0.7896373271942139,Recurrent Glioblastoma,"Phase I Study of Cellular ImmunoTx Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Pts With Rec/Ref MaligGlioma",PHASE1,12 years to 75 years,Glioblastoma (recurrent/refractory); Malignant Glioma (recurrent/refractory); WHO Grade II Glioma (recurrent/refractory); WHO Grade III Glioma (recurrent/refractory),"Histologically confirmed grade III or IV glioma, or prior grade II glioma with radiographic progression consistent with grade III or IV after standard therapy | Radiographic progression/recurrence of measurable disease >12 weeks after completion of initial radiation therapy | Karnofsky performance status >=60% | Life expectancy >4 weeks | Tumor IL13RA2 expression by immunohistochemistry >=20% (>=1+) | Dexamethasone requirement <=2 mg TID at PBMC collection | Creatinine <1.6 mg/dL (for Rickham placement eligibility) | White blood cell count >2000/µL (for Rickham placement eligibility) | Absolute neutrophil count >1000/µL (for Rickham placement eligibility) | Platelets >=100000/µL (for Rickham placement eligibility) | INR <1.3 (for Rickham placement eligibility) | Total bilirubin <1.5 mg/dL (for Rickham placement eligibility) | ALT and AST <=2.5 x ULN (for Rickham placement eligibility) | Released cryopreserved T cell product available | No supplemental oxygen required to maintain O2 saturation >95% and no progressive chest radiographic abnormalities prior to infusion | No pressor support required and no symptomatic cardiac arrhythmias prior to infusion | Afebrile (<=38.5 C) with no positive blood cultures or signs of meningitis within 48 hours prior to infusion | Total bilirubin <=2 x ULN prior to infusion | Transaminases <=2 x ULN prior to infusion | Serum creatinine <=1.8 mg/dL prior to infusion | No uncontrolled seizure activity following surgery prior to first T cell dose | Platelets >=100000/µL prior to infusion (or transfuse to >=100000/µL) | Dexamethasone requirement <=2 mg TID during T cell therapy","Requires supplemental oxygen to keep saturation >95% with no expected resolution within 2 weeks | Requires pressor support and/or has symptomatic cardiac arrhythmias | Requires dialysis | Uncontrolled seizure activity and/or clinically evident progressive encephalopathy | Non-malignant intercurrent illness that is poorly controlled or severe enough to preclude participation | Any other active malignancy | Severe infection under treatment or recovering from major surgery until recovery is complete | Uncontrolled illness including ongoing or active infection | Known active hepatitis B infection | Known active hepatitis C infection | Signs or symptoms of active infection, positive blood cultures, or radiologic evidence of infection | Confirmed human immunodeficiency virus (HIV) infection within 4 weeks of screening",At least 12 weeks since completion of initial radiation therapy; At least 2 weeks since last chemotherapy or radiation before PBMC collection; At least 6 weeks since completion of nitrosourea-containing chemotherapy; At least 23 days since completion of temozolomide; At least 4 weeks since completion of other non-nitrosourea cytotoxic chemotherapy; At least 2 weeks since last targeted agent if recovered from toxicity (except bevacizumab); At least 4 weeks since last dose of bevacizumab,ALL,A,"Recurrent glioblastoma after standard RT/TMZ aligns with the trial’s recurrent/refractory malignant glioma setting, and prior therapy exposure is compatible; age and sex are within limits. Eligibility will still require confirming IL13RA2 tumor expression and meeting KPS/lab thresholds, which are not provided.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),INCORRECT,B,"Disease matches and stage/setting (recurrent post-standard therapy) matches. Line/prior exposure compatibility is uncertain due to missing washout and other timing details, and the required IL13RA2 biomarker is unknown. Because A requires required biomarkers be satisfied, A is not appropriate; with exactly one clear anchor match and no soft conflicts, the correct grade is B.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT02208375,0.782426118850708,Recurrent Clear Cell Ovarian Carcinoma,"A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",PHASE1,18 years,Endometrial Adenocarcinoma (recurrent); High-Grade Serous Ovarian Carcinoma (recurrent); Primary Peritoneal Carcinoma (recurrent); Fallopian Tube Carcinoma (recurrent); Ovarian Carcinoma (recurrent); Triple-Negative Breast Cancer (metastatic),"Recurrent endometrial adenocarcinoma (no carcinosarcoma) with no curative option | Recurrent high-grade serous ovarian, primary peritoneal, or fallopian tube carcinoma; or deleterious BRCA-mutant recurrent ovarian/primary peritoneal/fallopian tube cancer | Metastatic triple-negative breast cancer (ER and PR < 10% by IHC and HER2 negative) | Unlimited prior regimens allowed; frontline therapy for metastatic disease allowed | Measurable disease by RECIST 1.1 or assessable disease (e.g., effusion/ascites per CA125 GCIG criteria) | ECOG performance status 0-1 | Women of childbearing potential: negative pregnancy test and agree to effective contraception during treatment and for 30 days after last dose | Able to swallow and tolerate oral medications; no GI illnesses precluding absorption | Life expectancy > 4 months | Absolute neutrophil count >= 1,500/µL | Hemoglobin >= 10 g/dL | Platelets >= 100,000/µL | Blasts < 4% on hematologic studies | Total bilirubin <= 1.5 x ULN | AST/ALT <= 2.5 x ULN (<= 5 x ULN if liver involvement) | Creatinine clearance > 50 mL/min (Cockcroft-Gault) | Type II diabetes eligible if diet-controlled with HbA1c < 8% | FOR EXPANSION PHASE ONLY: Measurable disease accessible for biopsy | FOR EXPANSION PHASE ONLY: Archival tumor specimens available","Receipt of other investigational agents or additional anti-cancer agents | Endometrial carcinosarcoma | Ovarian cancer histology other than high-grade serous without a deleterious BRCA mutation | Recurrences amenable to potentially curative radiation therapy or surgery | History of other malignancy within 5 years except adequately treated basal/squamous skin cancer or in situ cervical cancer (dual primaries of endometrial, ovarian, or breast cancer allowed) | History of myelodysplastic syndrome | Symptomatic, uncontrolled spinal cord compression and/or brain metastases | Prior chemotherapy, biologic therapy, radiation therapy, androgens, thalidomide, immunotherapy, other anticancer agents, or investigational agents within 28 days before starting study treatment (palliative focal RT excepted as noted) | Prohibited corticosteroids within 14 days prior to starting study treatment | Major surgery within 28 days or minor surgery within 2 weeks prior to study entry, or not recovered from surgery | QTcF >= 470 ms at 2 or more time points within 24 hours or family history of long QT syndrome | Blood transfusion required within 28 days prior to study start | Receipt of hematopoietic growth factors (e.g., G-CSF, GM-CSF) within 2 weeks prior to study start | Concomitant prohibited medications/substances within specified washout periods | Known hypersensitivity to olaparib, capivasertib (AZD5363), vistusertib (AZD2014), or their excipients; or to drugs of similar class | Intolerable adverse events to prior PARP, mTOR, PI3K, or AKT inhibitors per investigator | Within 12 months: CABG, angioplasty, vascular stent, myocardial infarction, angina pectoris, CHF NYHA >= 2, ventricular arrhythmias requiring continuous therapy, uncontrolled supraventricular arrhythmias including atrial fibrillation, hemorrhagic or thrombotic stroke including TIA or other CNS bleeding | Abnormal ECHO or MUGA with LVEF < 50% | Torsades de pointes within 12 months | Uncontrolled hypotension (SBP < 90 mmHg and/or DBP < 50 mmHg) | Proteinuria (>= 3+ dipstick or 300 mg/dL on urinalysis or > 500 mg/24 hours) | Type I diabetes or uncontrolled type II diabetes (HbA1c > 8%) | Severe or uncontrolled systemic disease (e.g., severe hepatic impairment, interstitial lung disease, uncontrolled chronic renal disease), unstable/uncompensated respiratory or cardiac conditions, uncontrolled hypertension (>= 140/90), active bleeding diathesis, or active infection including hepatitis B, hepatitis C, or HIV | Investigator deems patient unsuitable or unlikely to comply | FOR EXPANSION PHASE ONLY: No accessible tumor for biopsy | No archival tumor specimens available",Unlimited prior chemotherapy allowed; Prior PARP inhibitor allowed if not discontinued for toxicity (progression allowed); Prior mTOR inhibitor allowed if not discontinued for toxicity (progression allowed); Prior AKT inhibitor allowed if not discontinued for toxicity (progression allowed); Frontline therapy for metastatic disease permitted; No anticancer therapy or investigational agents within 28 days before study start; No prohibited corticosteroids within 14 days before study start; No hematopoietic growth factors within 14 days before study start; No major surgery within 28 days or minor surgery within 2 weeks before study start,FEMALE,A,"Recurrent clear cell ovarian cancer with BRCA1 positivity fits the trial cohort for deleterious BRCA-mutant recurrent ovarian cancer; the patient (female, 36) has assessable disease via pleural effusion. Prior carbo/taxol/bevacizumab is permitted and no exclusionary factors are evident.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; BRCA1 positive; Optimal debulking surgery performed; Received adjuvant carboplatin + paclitaxel + bevacizumab; Cytology-positive malignant pleural effusion at 5 months post-adjuvant,(none),Carboplatin; Paclitaxel; Bevacizumab; Optimal debulking surgery,Stage III,,36,years,female,(none),CORRECT,A,"No hard exclusions. Disease matches (recurrent ovarian cancer cohort with BRCA). Stage/setting matches (recurrent), line/prior exposure compatible (adjuvant carbo/taxol/bev allowed), and biomarker requirement appears satisfied (BRCA1 positive for the BRCA-mutant ovarian cohort). No soft conflicts identified. Grade A is appropriate.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT02312557,0.7735065221786499,Castration-Resistant Prostate Cancer,Addition of Pembrolizumab Upon Progression on Enzalutamide in Men With mCRPC,PHASE2,18 years,Prostate Adenocarcinoma (castration-resistant),"Metastatic castration-resistant prostate cancer progressing on enzalutamide after initial response | Histologically or cytologically confirmed prostate adenocarcinoma (no pure small cell) | Age >= 18 years | Metastatic disease | Lesion amenable to biopsy | ECOG performance status 0–1 | ANC >= 1,500/µL within 28 days of treatment initiation | Platelets >= 100,000/µL within 28 days of treatment initiation | Hemoglobin >= 9 g/dL within 28 days of treatment initiation | Serum creatinine <= 1.5 x ULN or creatinine clearance >= 60 mL/min within 28 days of treatment initiation | Total bilirubin <= 1.5 x ULN or direct bilirubin <= ULN within 28 days of treatment initiation | AST <= 2.5 x ULN (<= 5 x ULN with liver metastases) within 28 days of treatment initiation | ALT <= 2.5 x ULN (<= 5 x ULN with liver metastases) within 28 days of treatment initiation | INR or PT <= 1.5 x ULN unless on therapeutic anticoagulation (if undergoing biopsy) within 28 days of treatment initiation | aPTT <= 1.5 x ULN unless on therapeutic anticoagulation (if undergoing biopsy) within 28 days of treatment initiation | PSA or radiographic progression on enzalutamide per RECIST 1.1 or >= 2 new bone lesions | Prior surgical castration or ongoing LHRH agonist/antagonist with serum testosterone < 50 ng/dL and agreement to continue LHRH therapy","Participation in another investigational study or use of an investigational device within 4 weeks before first dose | Immunodeficiency or systemic steroid/immunosuppressive therapy within 7 days before first dose (physiologic corticosteroid doses may be permitted) | Prior monoclonal antibody within 4 weeks before day 1 or unresolved toxicities > grade 1 from prior therapies; denosumab prohibited within 4 weeks before day 1 and on study | Prior chemotherapy for castration-resistant disease | Prior chemotherapy, targeted small molecule therapy, or radiation within 2 weeks before day 1 or unresolved toxicities > grade 1 (<= grade 2 neuropathy allowed) | Major surgery without adequate recovery before starting therapy | Another active malignancy requiring treatment (except certain skin cancers or in situ bladder cancer after curative therapy) | Known brain metastases or carcinomatous meningitis | History of seizure | Allergy to enzalutamide | Active autoimmune disease requiring systemic treatment within the past 3 months or history of clinically severe autoimmune disease requiring systemic therapy (exceptions: vitiligo, resolved childhood asthma/atopy, stable hypothyroidism on replacement, Sjogren's syndrome) | History of non-infectious pneumonitis requiring steroids or current pneumonitis | Active infection requiring systemic therapy | Prior therapy with PD-1, PD-L1, PD-L2, CD137, or CTLA-4 inhibitors | Plans to receive cytotoxic chemotherapy, immune checkpoint inhibitors, sipuleucel-T, radiopharmaceuticals, abiraterone, or other experimental therapy during the study | Known HIV infection | Active hepatitis B or active hepatitis C infection | Receipt of a live vaccine within 30 days before first dose | Rapidly progressive visceral disease making the patient a candidate for docetaxel per treating physician judgment",Prior enzalutamide with initial response followed by progression; Prior surgical castration or ongoing LHRH agonist/antagonist therapy,MALE,A,"Male age 66 with metastatic castration‑resistant prostate cancer and documented progression on enzalutamide after prior LHRH therapy matches the stage/setting and prior‑exposure requirements; no disallowed prior chemotherapy or checkpoint inhibitors are reported. Some elements (initial response to enzalutamide, biopsy‑amenable lesion, ECOG/labs) are unknown but not conflicting.",Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),INCORRECT,B,"No hard exclusions identified. Stage/setting (mCRPC) clearly matches. However, the line/prior-exposure anchor is not a clear match because the trial requires progression on enzalutamide after initial response and ongoing LHRH therapy—both are unknown. Histology (adenocarcinoma) and metastatic pattern constraints (no brain mets) are also unknown. That yields exactly 1 core anchor match, so grade B. The grader over-counted the line/prior anchor and gave A.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT02365597,0.8148103356361389,Metastatic Urothelial Carcinoma,"A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects With Metastatic or Surgically Unresectable Urothelial Cancer With FGFR Genomic Alterations",PHASE2,18 years,Urothelial Cancer (metastatic/unresectable),"Histologic metastatic or surgically unresectable urothelial cancer; minor variant histology allowed | Measurable disease per RECIST v1.1 | ECOG performance status 0–2 | Adequate bone marrow, liver, and renal function | Negative pregnancy test for women of childbearing potential | Disease progression per RECIST v1.1 after prior chemotherapy for metastatic or unresectable disease | Neoadjuvant or adjuvant chemotherapy with recurrence/progression within 12 months of last dose counts as metastatic setting | Prior anti-PD-1/PD-L1 therapy with progression also eligible","Systemic anticancer therapy (chemotherapy, targeted therapy) within 2 weeks before first dose (6 weeks for nitrosoureas or mitomycin C) | Immunotherapy within 4 weeks before first dose | Definitive radiotherapy within 2 weeks before first dose (localized palliative RT allowed; not to target lesions) | Persistent serum phosphate > ULN during screening despite medical management | History of or current uncontrolled cardiovascular disease | Pregnant or breastfeeding | Planning to conceive during study or within 3 months (female) or 5 months (male) after last dose | Not recovered from reversible toxicities of prior anticancer therapy (except nonclinically significant toxicities such as alopecia, skin discoloration, or Grade 1 neuropathy)",Prior chemotherapy for metastatic or unresectable urothelial cancer with progression required; Neoadjuvant or adjuvant chemotherapy with recurrence/progression within 12 months qualifies as prior chemotherapy in the metastatic setting; Prior anti-PD-1/PD-L1 therapy allowed,ALL,A,"Disease and setting match (metastatic urothelial carcinoma), and the patient has progressed after anti–PD-1 therapy, satisfying prior-exposure requirements; age and sex also fit. The trial requires an FGFR alteration, which is unknown here (not a hard exclusion), and other eligibility labs/timing are not specified.",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),INCORRECT,B,"No hard exclusions. Stage/setting matches. However, the trial requires prior chemotherapy for metastatic/unresectable disease (or adjuvant/neoadjuvant with relapse ≤12 months), which is not established here—progression after anti–PD-1 does not meet that requirement—so Line/prior is unknown, not a match. Required FGFR alteration is unknown, so cannot be counted as a match and also prevents an A. With exactly one anchor match and no soft conflicts, the correct grade is B.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT02420847,0.8805802464485168,Metastatic Urothelial Carcinoma,"A Phase I Two-Dimensional Dose-Finding Study of Ixazomib in Combination With Gemcitabine and Doxorubicin, Followed by a Phase II Extension to Assess the Efficacy of This Combination in Metastatic, Surgically Unresectable Urothelial Cancer",PHASE1/PHASE2,18 years,Urothelial Carcinoma (metastatic); Urothelial Carcinoma (unresectable),"Histologically confirmed metastatic or locally unresectable urothelial (transitional cell) carcinoma; variant histology allowed with urothelial component | Measurable or evaluable disease | At least one prior therapy unless not candidates for or refuse cisplatin-based therapy | Phase I: any number of prior regimens allowed | Phase II: no prior proteasome inhibitor (e.g., bortezomib, carfilzomib) and no prior gemcitabine >= 800 mg/m^2 plus doxorubicin >= 30 mg/m^2 in the same regimen | Prior neoadjuvant chemotherapy failure eligible | If prior ischemic heart disease or >= 200 mg/m^2 prior doxorubicin, left ventricular ejection fraction >= 45% | ALT <= 3 x ULN | AST <= 3 x ULN | ECOG performance status <= 2; PS 3 allowed if due to malignancy","Platelet count < 100 x 10^9/L | Absolute neutrophil count < 1.0 x 10^9/L | Creatinine clearance < 30 mL/min | Peripheral neuropathy >= grade 3 or grade 2 with pain | Total bilirubin >= 1.5 x ULN | Allergy to study drugs or excipients | Pregnant or breastfeeding | Participation in other investigational trials within 30 days | Myocardial infarction within 6 months, NYHA class III/IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, acute ischemia or active conduction abnormalities | Symptomatic congestive heart failure | Claudication limiting activity | Cerebrovascular event within the last year (including TIA) | Unstable angina | Active brain metastases (previously treated and stable allowed) | Radiotherapy within 28 days (14 days if small field) | Another malignancy within 2 years unless meeting specified exceptions | Strong CYP1A2/3A inhibitors or strong CYP3A inducers within 14 days of first ixazomib dose; use of Ginkgo biloba or St. John's wort | Not recovered to <= grade 1 from prior chemotherapy toxicities | Major surgery within 14 days | Infection requiring current IV antibiotics | Active systemic infection, active hepatitis B or C, or HIV positive | Serious medical or psychiatric illness interfering with protocol treatment | GI disease or procedure interfering with oral absorption of ixazomib","At least one prior systemic therapy required unless cisplatin-ineligible or refuse cisplatin-based therapy; Phase I: any number of prior regimens permitted, including prior bortezomib or gemcitabine+doxorubicin; Phase II: exclude prior proteasome inhibitor therapy and exclude prior combination gemcitabine >= 800 mg/m^2 plus doxorubicin >= 30 mg/m^2; Prior neoadjuvant chemotherapy allowed; Radiotherapy washout: >= 28 days (>= 14 days if small field); Other investigational agents washout: >= 30 days; Major surgery washout: >= 14 days; Recovered to <= grade 1 from prior chemotherapy toxicities before enrollment",ALL,A,"Metastatic urothelial carcinoma matches the trial setting, and prior therapies are compatible (≥1 prior regimen; no proteasome inhibitor or gemcitabine+doxorubicin exposure). No explicit exclusions are evident; age/sex fit and renal function (eGFR 35 mL/min) is above the trial’s CrCl ≥30 mL/min cutoff.",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),CORRECT,A,No hard exclusions. Disease matches (metastatic UC). Stage/setting matches (metastatic/unresectable allowed). Line/prior exposure compatible (≥1 prior regimen; no prior proteasome inhibitor or gemcitabine+doxorubicin combo). Age/sex OK. Renal function above CrCl ≥30 mL/min cutoff. No identified soft conflicts. Grade A is appropriate.,,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT02484404,0.7770707011222839,Castration-Resistant Prostate Cancer,"Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers",PHASE1/PHASE2,18 years,Solid Tumor; Ovarian Cancer; Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Prostate Cancer (metastatic castrate-resistant); Triple Negative Breast Cancer; Colorectal Cancer,"Age >= 18 years | Adequately controlled blood pressure on <= 3 antihypertensive medications | Phase I: Advanced or recurrent solid tumor | ECOG performance status 0–2 | Adequate organ and marrow function | Off prior chemotherapy, radiation therapy, or biologic therapy >= 3 weeks | Ovarian/fallopian tube/primary peritoneal cancer: persistent or recurrent disease with >= 2 prior regimens or platinum-resistant/refractory after first platinum | Ovarian/fallopian tube/primary peritoneal cancer: at least one lesion safe to biopsy and willing to undergo mandatory baseline biopsy | Ovarian cancer: prior PARP inhibitor and/or prior anti-angiogenesis therapy allowed (but not both olaparib and cediranib previously) | Triple negative breast cancer: histologically confirmed persistent or recurrent TNBC | Triple negative breast cancer: ER/PR/HER2 status documented | Triple negative breast cancer: documentation of germline BRCA1/2 mutation status required | Triple negative breast cancer: measurable disease per RECIST v1.1 | Triple negative breast cancer: at least one lesion safe to biopsy and willing to undergo mandatory baseline biopsy | NSCLC: histologically or cytologically confirmed advanced disease with >= 1 prior line of platinum-based chemotherapy or appropriate targeted therapy for EGFR/ALK/BRAF alterations | NSCLC: measurable disease per RECIST v1.1 | NSCLC: at least one lesion safe to biopsy and willing to undergo mandatory baseline biopsy | mCRPC: metastatic, progressive, castrate-resistant prostate cancer | mCRPC: at least one lesion safe to biopsy and willing to undergo mandatory baseline biopsy | mCRPC: prior treatment with enzalutamide and/or abiraterone (exceptions for prior docetaxel with ADT in castrate-sensitive disease as specified) | mCRPC: ongoing GnRH agonist/antagonist therapy or prior bilateral orchiectomy | SCLC: advanced or recurrent disease eligible for Durvalumab + olaparib cohort | CRC: advanced or recurrent colorectal cancer eligible for Durvalumab + cediranib cohort","Cardiac events within 1 year: myocardial infarction, pericardial effusion, or myocarditis | Cardiac arrhythmia (e.g., atrial fibrillation or flutter) or need for pro-arrhythmic drugs/biologics within 1 year | NYHA Class II or greater heart failure | Left ventricular ejection fraction < 55% or below institutional normal if assessed | QTc > 470 ms or other significant ECG abnormality within 14 days of treatment | Hypertensive crisis or hypertensive encephalopathy | Clinically significant peripheral or vascular disease, including rapidly growing aortic aneurysm, abdominal aortic aneurysm > 5 cm, or aortic dissection | Unstable angina | Cerebrovascular accident or transient ischemic attack within 1 year | History of tuberculosis | Autoimmune disease requiring steroid maintenance or primary immunodeficiency | HIV-positive on antiretroviral therapy ineligible unless long-standing (> 5 years), undetectable viral load, CD4 > 150/µL, and no anticipated drug-drug interactions per PI | HBV-positive or HCV-positive due to risk of viral reactivation | History of severe allergic reactions to MEDI4736 (durvalumab), olaparib, cediranib, other humanized monoclonal antibodies, or similar compounds; history of anaphylaxis, angioedema, laryngeal edema, serum sickness, or uncontrolled asthma | Pregnant or breastfeeding | Any other concomitant or prior invasive malignancy | NSCLC: prior treatment with cediranib (monotherapy or combination) not eligible | NSCLC: current or prior immunosuppressive medication within 28 days before first durvalumab dose (except allowed low-dose steroids and inhaled/intranasal corticosteroids) | NSCLC: prior history of pneumonitis and/or interstitial lung disease | NSCLC: prior PARP inhibitor not eligible | Triple negative breast cancer: prior PARP inhibitor not eligible | Triple negative breast cancer: CNS metastasis or leptomeningeal disease within 1 year | mCRPC: progression on prior docetaxel for castrate-sensitive disease | mCRPC: prior PARP inhibitor not eligible | mCRPC: radionuclide treatment within 6 weeks prior to first dose | Ovarian cancer: prior treatment with both olaparib and cediranib (combination or sequentially) not eligible","Phase II Ovarian cancer: >= 2 prior regimens or platinum-resistant/refractory after first platinum; Ovarian cancer: prior PARP inhibitor allowed; Ovarian cancer: prior anti-angiogenesis therapy allowed; NSCLC: at least one prior line of platinum-based chemotherapy or prior EGFR/ALK/BRAF-targeted therapy when indicated by tumor genotype; mCRPC: prior treatment with enzalutamide and/or abiraterone required (with specified exceptions); mCRPC: continue GnRH agonist/antagonist therapy during study; All cohorts: washout from prior chemotherapy, radiation therapy, or biologic therapy >= 3 weeks",ALL,A,"Matches the mCRPC cohort: metastatic castration-resistant prostate cancer with prior abiraterone and progression on enzalutamide; age and sex appropriate. No explicit exclusions (e.g., prior PARP or prohibited therapies) are evident.",Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches mCRPC cohort. Stage/setting (metastatic CRPC) and line/prior exposure (prior abiraterone and enzalutamide) both match, satisfying ≥2 core anchors. Other requirements (e.g., ongoing GnRH, biopsy willingness) are unknown and not soft conflicts per rubric. Grade A is appropriate.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT02496208,0.847374439239502,Metastatic Urothelial Carcinoma,A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors,PHASE1,18 years,Urothelial Carcinoma (bladder); Urethral Urothelial Carcinoma; Ureter Urothelial Carcinoma; Renal Pelvis Urothelial Carcinoma; Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Sarcomatoid Urothelial Carcinoma; Plasmacytoid Urothelial Carcinoma; Renal Medullary Carcinoma; Penile Squamous Cell Carcinoma; Small Cell Neuroendocrine Carcinoma (bladder),"Age >= 18 years | Histologically confirmed metastatic genitourinary solid tumor (phase I) | Expansion: metastatic urothelial carcinoma (bladder, urethra, ureter, renal pelvis), or clear cell renal cell carcinoma, or adenocarcinoma of the bladder, or non-resectable penile squamous cell carcinoma, or rare GU histologies (squamous or small cell bladder carcinoma, renal medullary carcinoma, sarcomatoid bladder or renal cell carcinoma, plasmacytoid bladder carcinoma, or other rare bladder/kidney histology) | Metastatic disease with at least one evaluable/measurable site or new bone lesion (per cohort definitions) | For urothelial carcinoma or renal cell carcinoma expansion: progressive metastatic disease with at least one measurable site (RECIST) or bone disease by NaF PET/CT | Progressed on >= 1 standard therapy or no standard therapy conferring survival benefit; cisplatin-ineligible urothelial carcinoma may receive protocol therapy first-line | Any number of prior cytotoxic agents permitted | Karnofsky performance status >= 70% | Tissue available for PD-L1 expression (archival or consent to pre/post-treatment biopsies)","Cytotoxic chemotherapy or biologic therapy within 3 weeks (nitrosoureas/mitomycin C within 6 weeks) before first dose | Radiation therapy to thorax/abdomen within 3 months; to bone or brain within 3 weeks; to any other site within 28 days | Radionuclide treatment within 6 weeks | Small molecule kinase inhibitor within 14 days or 5 half-lives (whichever longer) | Hormonal therapy within 14 days or 5 half-lives (GnRH agonists/antagonists allowed) | Investigational agent within 28 days | Unresolved toxicities from prior therapy > grade 1 (except alopecia and asymptomatic lab abnormalities) | Prior MET or VEGFR inhibitors excluded from expansion cohorts (allowed in phase I) | Prior PD-1/PD-L1 or CTLA-4 therapy excluded unless enrolling in designated cohort | Active brain metastases or epidural disease unless previously treated and stable off steroids >= 2 weeks; baseline contrast brain imaging required if history present | PT/INR or PTT >= 1.5 x ULN within 7 days before first dose | Concurrent warfarin prohibited (except <= 1 mg/day); aspirin up to 325 mg/day, factor Xa/thrombin inhibitors, and LMWH permitted | Chronic treatment with strong CYP3A4 inducers not permitted | Clinically significant gastrointestinal bleeding within 6 months; hemoptysis >= 2.5 mL within 3 months; signs of pulmonary hemorrhage within 3 months | Tumor invading major blood vessels | Tumor invasion of GI tract or endotracheal/endobronchial tumor within 28 days before cabozantinib | Cardiovascular disorders: NYHA class III/IV heart failure; uncontrolled hypertension > 140/90 mmHg; QTcF > 500 ms; history of congenital long QT; within 6 months: unstable angina, clinically significant arrhythmias, stroke/TIA, myocardial infarction, or cardiomyopathy | GI disorders at high risk for perforation/fistula: unresolved mucosal invasion, active peptic ulcer disease, diverticulitis, cholecystitis, symptomatic cholangitis, appendicitis, malabsorption; within 6 months: abdominal fistula, GI perforation, bowel or gastric outlet obstruction, intra-abdominal abscess | PEG tube placement within 3 months | Severe active infection requiring systemic therapy within 14 days | Serious non-healing wound/ulcer/bone fracture within 28 days | History of organ transplant | Uncontrolled thyroid dysfunction within 7 days (replacement allowed if indicated) | Recent major surgery within 3 months (or as early as 6 weeks if completely healed and no complications); minor surgery within 1 month (or within 3 months if wound complications); complete wound healing required >= 28 days pre-cabozantinib | Unable to swallow tablets | Severe hypersensitivity to monoclonal antibodies or to cabozantinib, nivolumab, ipilimumab | Another malignancy within 2 years requiring systemic treatment (disease-specific studies) | Pregnancy or breastfeeding | Active hepatitis B (HBsAg positive) or active hepatitis C infection (HCV RNA positive) | Active autoimmune disease or history at risk for recurrence requiring systemic immunosuppression; exceptions include vitiligo, type 1 diabetes, residual hypothyroidism on replacement, psoriasis not requiring systemic therapy, and stable minor autoimmune conditions | Systemic corticosteroids > 10 mg/day prednisone equivalents or other immunosuppressives within 14 days (physiologic or topical/inhaled allowed) | Conditions predisposing to bowel perforation (e.g., active diverticulitis, intra-abdominal abscess, GI obstruction, abdominal carcinomatosis) without appropriate management",Progressed on >= 1 standard therapy or no available standard therapy; cisplatin-ineligible urothelial carcinoma allowed first-line; Any number of prior cytotoxic agents allowed; Washout: cytotoxic/biologic therapy >= 3 weeks (nitrosoureas/mitomycin C >= 6 weeks); Washout: radiation therapy per site (thorax/abdomen >= 3 months; bone/brain >= 3 weeks; other sites >= 28 days); Washout: radionuclide therapy >= 6 weeks; Washout: small molecule kinase inhibitors >= 14 days or 5 half-lives (whichever longer); Washout: hormonal therapy >= 14 days or 5 half-lives (GnRH agonists/antagonists allowed); Washout: other investigational agents >= 28 days,ALL,A,"Disease and stage match (metastatic urothelial carcinoma), and the patient has progressed after standard therapies, aligning with trial requirements. No explicit exclusions are triggered; prior PD-1 therapy is allowed in designated cohorts, and other exclusion factors are not evidenced.",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),CORRECT,A,"No hard exclusions identified. Disease and metastatic setting match, and patient has progressed after ≥1 standard therapy, satisfying line/prior exposure. Prior PD-1 exposure is allowed in designated cohorts per trial, so no soft mismatch. Thus ≥2 core anchors match with no conflicts → A.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT02795052,1.0,Dementia,Neurologic Bone Marrow Derived Stem Cell Treatment Study,NA,18 years,Amyotrophic Lateral Sclerosis; Alzheimer Disease; CADASIL; Cerebral Hemorrhage; Cerebral Infarction; Cerebral Ischemia; Chronic Traumatic Encephalopathy; Cognitive Impairment; Dementia; Diabetic Neuropathy; Frontotemporal Dementia; Lewy Body Disease; Lewy Body Variant of Alzheimer Disease; Multiple System Atrophy; Neuropathy; Parkinson Disease; Progressive Supranuclear Palsy; Stroke; Traumatic Brain Injury,"Documented functional damage to the central or peripheral nervous system unlikely to improve with current standard of care | >= 6 months since disease onset | If on pharmacologic or surgical therapy, clinically stable and unlikely to have reversal of neurologic damage from that therapy | Investigator assessment that there is potential for improvement with BMSC and minimal risk from the procedure | Age > 18 years | Medically stable and able to be cleared by a primary care practitioner for the procedure",Not medically stable or at significant risk to health from undergoing the procedure | Pregnant at the time of treatment or planning pregnancy within 3 months post-treatment,Current pharmacologic or surgical therapy allowed if stable,ALL,A,"Disease matches (dementia is included), age 68 meets ≥18, and the 2-year progressive cognitive decline fits the ≥6 months/documented CNS damage setting; prior therapy constraints are compatible. No required biomarkers or explicit exclusions apply.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches (Dementia listed). Stage/setting aligns (symptomatic, >6 months since onset). Line/prior exposure compatible (no restrictions; current therapy allowed but not required). No required biomarkers or metastasis constraints. Thus ≥2 core anchors match with no soft conflicts → A.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT02795052,1.0,Amyotrophic Lateral Sclerosis,Neurologic Bone Marrow Derived Stem Cell Treatment Study,NA,18 years,Amyotrophic Lateral Sclerosis; Alzheimer Disease; CADASIL; Cerebral Hemorrhage; Cerebral Infarction; Cerebral Ischemia; Chronic Traumatic Encephalopathy; Cognitive Impairment; Dementia; Diabetic Neuropathy; Frontotemporal Dementia; Lewy Body Disease; Lewy Body Variant of Alzheimer Disease; Multiple System Atrophy; Neuropathy; Parkinson Disease; Progressive Supranuclear Palsy; Stroke; Traumatic Brain Injury,"Documented functional damage to the central or peripheral nervous system unlikely to improve with current standard of care | >= 6 months since disease onset | If on pharmacologic or surgical therapy, clinically stable and unlikely to have reversal of neurologic damage from that therapy | Investigator assessment that there is potential for improvement with BMSC and minimal risk from the procedure | Age > 18 years | Medically stable and able to be cleared by a primary care practitioner for the procedure",Not medically stable or at significant risk to health from undergoing the procedure | Pregnant at the time of treatment or planning pregnancy within 3 months post-treatment,Current pharmacologic or surgical therapy allowed if stable,ALL,A,"ALS is explicitly included; the patient is >18 and >6 months from disease onset, and current pharmacologic therapy (riluzole) is allowed if stable. No exclusion criteria are triggered, and there are no stage/line conflicts.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),INCORRECT,B,"No hard exclusions. Disease matches. Only one CORE ANCHOR clearly matches (line/prior-exposure compatibility). Stage/setting is unspecified, biomarker not required, and metastatic pattern not applicable. General inclusion items (age >18, >6 months since onset) are not CORE ANCHORS. Therefore the correct grade is B, not A.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT02834013,0.7218565940856934,Recurrent Clear Cell Ovarian Carcinoma,DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors,PHASE2,18 years,Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortical Carcinoma; Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Metaplastic Breast Carcinoma; Cervical Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Cervical Adenocarcinoma (HPV-independent); Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Neuroendocrine Tumor; Sarcomatoid Lung Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Testicular Sex Cord-Stromal Tumor; Pituitary Neuroendocrine Tumor (metastatic); Minimally Invasive Lung Adenocarcinoma; Mixed Mullerian Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Low Grade Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; PEComa; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Carcinoma; Penile Squamous Cell Carcinoma; Peritoneal Mesothelial Neoplasm; Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Spindle Cell Neoplasm; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma; Vulvar Carcinoma; Cancer of Unknown Primary,"Rare cancer histologically and/or biochemically confirmed (specimen submission required; GTD confirmed by quantitative serum beta-hCG) | PD-L1 amplification cohort: solid tumors (excluding lymphoma) with PD-L1 amplification defined as DNA copy number >= 6 by CLIA-approved assay performed in advanced disease | Cancer of unknown primary: metastatic malignancy with no discernible primary after standard evaluation | Progressed after at least one line of standard systemic therapy or no standard therapy exists that prolongs overall survival | Measurable disease by RECIST v1.1 on CT or MRI within 28 days (cohorts except GTD) | Age >= 18 years | Zubrod performance status 0-2 | Prior malignancy allowed if stage I-II in complete remission, or any cancer disease-free >= 1 year; stage I-II follicular thyroid or prostate cancer eligible without complete remission requirement | Prior anti-CTLA-4 or prior anti-PD-1/PD-L1 allowed (but not both); must be completed >= 4 weeks before registration (except PD-L1 amplified cohort must be PD-1/PD-L1 naive; prior CTLA-4 allowed >= 4 weeks) | Adequate thyroid function (TSH or free T4 within normal range) or on stable replacement | Adequate adrenal axis function (cortisol within normal range or ACTH within normal range) | Brain metastases or primary brain tumors treated and stable; local therapy completed >= 28 days before registration; off steroids >= 7 days | Off other systemic anti-cancer therapy >= 7 days before registration with toxicities recovered to <= grade 1 (except alopecia and <= grade 2 neuropathy) | Hormonal/endocrine blockade permitted if progressed on prior therapy; long-acting somatostatin analogs and androgen deprivation therapy permitted during protocol therapy","Prior grade >= 3 immune-related adverse event with prior immunotherapy | History of or planned solid organ transplant | Active autoimmune disease requiring systemic treatment in the past 2 years (except replacement therapy); autoimmune patients must not have received steroids or immunosuppressives within 28 days prior to registration | Currently receiving investigational agents or systemic anti-cancer therapy (including radiation); planned radiation must be completed before registration | Known hypersensitivity or allergy to nivolumab or ipilimumab | Pregnant or nursing | Active hepatitis B or C infection (allowed if viral load undetectable and no residual hepatic impairment) | HIV-positive patients ineligible if CD4+ < 250 cells/mm^3 or history of non-malignancy AIDS-defining conditions (other than historical low CD4) | Uncontrolled intercurrent illness including symptomatic CHF (NYHA III/IV), unstable angina or coronary angioplasty/stenting within 24 weeks, unstable cardiac arrhythmia (CTCAE v4 grade >= 2), known cardiac metastases, abnormal cardiac valve morphology (>= grade 3), or psychiatric illness limiting compliance | Symptomatic interstitial lung disease or pneumonitis | Not fully recovered from major surgery to <= grade 1 within 14 days before registration","Progressed after >= 1 prior line of standard systemic therapy or no standard OS-prolonging therapy exists; Prior anti-CTLA-4 or prior anti-PD-1/PD-L1 allowed, but not both; must be completed >= 4 weeks before registration; PD-L1 amplified cohort: no prior anti-PD-1/PD-L1; prior anti-CTLA-4 allowed if completed >= 4 weeks; Off other systemic anti-cancer therapy >= 7 days before registration with toxicities recovered to <= grade 1 (except alopecia and <= grade 2 neuropathy); Brain metastases local therapy completed >= 28 days before registration; off steroids >= 7 days; Major surgery recovered to <= grade 1 at least 14 days before registration; Planned radiation must be completed before registration; Hormonal/endocrine therapy may continue if progressed on prior therapy (e.g., GnRH, somatostatin analogs, androgen deprivation)",ALL,A,"Disease is included (ovarian adenocarcinoma cohort) and the patient has recurrent disease after prior standard systemic therapy, meeting stage/setting and line/prior anchors; age and sex fit and no exclusions are evident from the data provided.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; BRCA1 positive; Optimal debulking surgery performed; Received adjuvant carboplatin + paclitaxel + bevacizumab; Cytology-positive malignant pleural effusion at 5 months post-adjuvant,(none),Carboplatin; Paclitaxel; Bevacizumab; Optimal debulking surgery,Stage III,,36,years,female,(none),CORRECT,A,"Disease fits under the trial’s ovarian adenocarcinoma cohort; patient has recurrent/advanced disease after prior standard chemotherapy, satisfying stage/setting and line/prior anchors. Age/sex eligible and no explicit exclusions identified. Thus ≥2 anchors match with no soft conflicts → A.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT03113487,0.7289372682571411,Recurrent Clear Cell Ovarian Carcinoma,"P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",PHASE2,18 years,"Ovarian Carcinoma (platinum-resistant, recurrent); Primary Peritoneal Carcinoma (platinum-resistant, recurrent); Fallopian Tube Carcinoma (platinum-resistant, recurrent)","Histologically or cytologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube cancer | Recurrent or progressive disease within 6 months after completion of platinum-based chemotherapy (platinum-resistant or refractory) | Measurable disease per RECIST 1.1 or detectable disease | CA-125 >= 2 x ULN if no measurable disease | Ascites and/or pleural effusion attributed to tumor if no measurable disease | Non-measurable solid and/or cystic abnormalities on imaging not meeting target lesion criteria if no measurable disease | TP53 mutation and/or p53 overexpression by IHC (>= 10% tumor cells) | ECOG <=2 | Life expectancy >= 3 months | Up to 4 prior chemotherapy regimens for recurrent disease allowed","Positive pregnancy test or pregnant/breastfeeding | Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, or other T-cell checkpoint agents (e.g., CTLA-4, OX-40, CD137) | Systemic anti-cancer therapy within 4 weeks before start | Radiotherapy within 3 weeks before start (1-week washout allowed for short palliative non-CNS RT) | Live vaccine within 30 days before first dose | Participation in another investigational agent or device study within 4 weeks before start | Immunodeficiency (including organ grafts or HIV) or systemic immunosuppression >10 mg prednisone equivalent within 7 days before start | Another malignancy requiring active treatment within the past 3 years (except certain in situ and non-melanoma skin cancers) | Active CNS metastases or carcinomatous meningitis (previously treated, stable brain metastases allowed off steroids >=14 days) | Severe hypersensitivity (>= grade 3) to pembrolizumab or excipients | Active autoimmune disease requiring systemic treatment in the past 2 years | History of non-infectious pneumonitis requiring steroids or current pneumonitis | Active infection requiring systemic therapy | Known HIV infection | Active hepatitis A, hepatitis B surface antigen positive, or active hepatitis C (HCV RNA detectable) | Active tuberculosis infection | Significant cardiac disease: myocardial infarction or arterial thromboembolic event within 6 months, severe/unstable angina, NYHA class III/IV heart failure, QTcB > 470 ms, uncontrolled hypertension (>150/100 mm Hg), abnormal EKG/echo/troponin (>= grade 2) | Li-Fraumeni syndrome (family history or confirmed) | Severe environmental allergies or allergy to egg proteins | Psychiatric or substance use disorders interfering with study requirements",Up to 4 prior chemotherapy regimens for recurrent disease allowed; Adjuvant chemotherapy and maintenance paclitaxel not counted toward regimen limit; Prior targeted agents or hormone therapy not counted as systemic chemotherapy regimens; No prior anti-PD-1/PD-L1/PD-L2 or other T-cell checkpoint therapy; No systemic anti-cancer therapy within 4 weeks before start (toxicities recovered to <= grade 1 except <= grade 2 neuropathy); No radiotherapy within 3 weeks before start (1-week washout allowed for short palliative non-CNS RT); No investigational agents or devices within 4 weeks before start; No live vaccines within 30 days before first dose; No non-oncology viral vaccines within 30 days before start,FEMALE,A,"Excellent stage/setting and prior-therapy fit for platinum-resistant recurrent epithelial ovarian cancer; pleural effusion qualifies as detectable disease and age/sex match. Note the trial requires TP53 mutation or p53 overexpression, which is not provided here and would need confirmation for eligibility.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; BRCA1 positive; Optimal debulking surgery performed; Received adjuvant carboplatin + paclitaxel + bevacizumab; Cytology-positive malignant pleural effusion at 5 months post-adjuvant,(none),Carboplatin; Paclitaxel; Bevacizumab; Optimal debulking surgery,Stage III,,36,years,female,(none),INCORRECT,B,"No hard exclusions. Disease matches and stage/setting plus prior-therapy compatibility match, but the trial requires TP53 mutation/p53 overexpression, which is unknown. Grade A requires required biomarkers satisfied; with biomarker unknown, the appropriate grade is B (good fit without confirmed required biomarker).",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT03340675,0.7850351333618164,Duchenne Muscular Dystrophy,"A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study With an Open-Label Extension to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy",PHASE2,7 years,Duchenne Muscular Dystrophy Cardiomyopathy,"Male, age >= 7 years | Diagnosis of Duchenne muscular dystrophy (phenotype consistent with DMD) with either positive genotype, first-degree relative with positive genotype, or confirmatory muscle biopsy | Stable corticosteroid dose for >= 8 weeks or no corticosteroids for >= 30 days | Stable cardiac function with change in LVEF < 15% and no heart failure admission over the last 12 months | LVEF >= 35% by cardiac MRI or echocardiography | Myocardial damage by late gadolinium enhancement permitted | Concurrent ACE inhibitor, beta-blocker, or ARB therapy allowed if started >= 3 months prior to first dose without dose change | Aldosterone receptor antagonists (e.g., spironolactone or eplerenone) allowed if started >= 12 months prior to first dose | Late-stage cohort eligibility: LVEF 35%-45% by MRI or echocardiography, or historical LVEF 35%-45% with baseline MRI < 50%","Clinically significant illness other than Duchenne muscular dystrophy | Clinically significant laboratory abnormality not associated with Duchenne muscular dystrophy | Major surgery within 6 weeks prior to first dose or planned surgery that would interfere with study procedures | Requires antiarrhythmic therapy and/or initiation of diuretic therapy for acute heart failure within the last 6 months | LVEF < 35% by cardiac MRI and/or fractional shortening < 15% by echocardiography during screening | Known bleeding disorder or receipt of anticoagulant treatment within 2 weeks of study entry | Allergy to gadolinium contrast or known renal insufficiency defined as abnormal cystatin C or creatinine above the upper limit of normal for age | Non–MRI-compatible implants (e.g., neurostimulator, AICD) | Participation in a therapeutic clinical trial within 30 days or 5 half-lives (whichever is longer) of study entry | Any other condition that could interfere with participation","Stable oral corticosteroids for >= 8 weeks or off corticosteroids for >= 30 days before enrollment; Concurrent ACE inhibitor, beta-blocker, or ARB permitted if initiated >= 3 months prior without dose change; Aldosterone receptor antagonists permitted if initiated >= 12 months prior; No participation in another therapeutic clinical trial within 30 days or 5 half-lives prior to entry",MALE,A,"Disease and cardiomyopathy status match; male age 11 meets criteria. On stable corticosteroids and ACE inhibitor (allowed), with LVEF 52% (>=35%); no stated exclusions apply.",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,A,"No hard exclusions. Disease aligns (DMD with cardiac involvement). Core anchors: Stage/setting compatible (LVEF 52% within required ≥35% and cardiomyopathy focus), and prior exposure compatibility (stable corticosteroids; ACE inhibitor permitted). No identified soft mismatches. Grade A is appropriate.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT03355976,0.7311069965362549,Recurrent Clear Cell Ovarian Carcinoma,BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas,PHASE2,18 years,Ovarian Clear Cell Carcinoma; Fallopian Tube Clear Cell Carcinoma; Primary Peritoneal Clear Cell Carcinoma; Clear Cell Carcinoma (extra-renal),"Recurrent, advanced, or metastatic pure clear cell carcinoma of ovarian, fallopian tube, primary peritoneal, or extra-renal origin | Measurable disease by RECIST: >=20 mm by conventional imaging or >=10 mm by spiral CT/MRI/clinical calipers | Progressed after >=1 prior platinum- and taxane-based regimen (ovarian/fallopian tube/primary peritoneal) | Extra-renal clear cell cancer: progressed after >=1 prior systemic regimen for advanced/metastatic disease | Age >=18 years | ECOG performance status 0-1 | Adequate organ and marrow function | Adequate thyroid function (TSH within normal range) | Resting oxygen saturation >=92% at rest","Prior therapy with nivolumab, anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 | Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C); endocrine therapy within 7 days | Not recovered from clinically significant adverse events to < grade 2 from prior therapies | Concurrent investigational agents | Known brain metastases | History of severe hypersensitivity reaction to any monoclonal antibody | Uncontrolled intercurrent illness (active infection requiring antibiotics, symptomatic CHF, unstable angina, serious arrhythmia, or significant psychiatric illness) | Pregnancy or breastfeeding | Other invasive malignancy within 3 years (exceptions for low-risk conditions as specified) | Prior chemotherapy within the last 3 years for cancers other than clear cell cancer | HIV infection not meeting: stable HAART, CD4 >350/µL, and undetectable viral load | Hepatitis B or C with detectable viral load or not definitively treated >=6 months | Active autoimmune disease or history likely to recur affecting vital organs or requiring immunosuppression | Systemic corticosteroids >10 mg prednisone equivalents daily or other immunosuppressive medications within 14 days prior to day 1 | Planned concomitant, non-protocol anti-cancer therapy | Grade >=2 peripheral neuropathy",Prior platinum- and taxane-based chemotherapy required (ovarian/fallopian tube/primary peritoneal); At least one prior systemic regimen required (extra-renal clear cell carcinoma); Washout: chemotherapy or radiotherapy >=4 weeks (>=6 weeks for nitrosoureas or mitomycin C); Washout: endocrine therapy >=7 days,ALL,A,"Disease and setting match (recurrent ovarian clear cell carcinoma), and she progressed after a prior platinum/taxane regimen as required; prior bevacizumab is allowed. Age/sex fit and no explicit exclusions (e.g., prior PD-1/CTLA-4) are evident; measurable disease and other labs/ECOG are unknown but not contradictory.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; BRCA1 positive; Optimal debulking surgery performed; Received adjuvant carboplatin + paclitaxel + bevacizumab; Cytology-positive malignant pleural effusion at 5 months post-adjuvant,(none),Carboplatin; Paclitaxel; Bevacizumab; Optimal debulking surgery,Stage III,,36,years,female,(none),CORRECT,A,"No hard exclusions. Disease matches (ovarian clear cell), setting is recurrent/metastatic, and patient progressed after a prior platinum/taxane regimen, satisfying line/prior anchor. Histology requirement aligns. Other requirements (measurable disease, ECOG, labs) are unknown and not contradictions per rubric. ≥2 core anchors match with no soft conflicts → A.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03375307,0.7561209201812744,Metastatic Urothelial Carcinoma,A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors With DNA-Repair Defects,PHASE2,18 years,Genitourinary Carcinoma (advanced/metastatic); Bladder Cancer (metastatic),Histologically confirmed non-prostate genitourinary (GU) cancer | Presence of cancer-associated genetic mutations per FoundationOne CDx per cohort definitions or TMB >= 10 mut/Mb | Measurable disease per RECIST 1.1 | Evidence of disease progression during or after at least one platinum-based chemotherapy regimen and/or an immune-checkpoint inhibitor | Age >= 18 years | ECOG performance status <= 1 (or Karnofsky >= 70%) | Able to tolerate oral medications; no gastrointestinal condition precluding absorption of olaparib | Negative pregnancy test for women of childbearing potential at screening and within 3 days prior to day 1 | Use of effective contraception during treatment and for required period after last dose | Provision of archival tumor sample or willingness to undergo mandatory screening biopsy (or liquid biopsy if tissue unavailable),"Prior treatment with olaparib or any PARP inhibitor | Myelodysplastic syndrome or acute myeloid leukemia, or baseline features suggestive of MDS/AML | Persistent toxicities >= CTCAE grade 2 from prior therapy (except alopecia or peripheral neuropathy) | Concurrent treatment with other investigational agents (per protocol during treatment phase) | Known brain metastases or spinal cord compression unless definitively treated and clinically stable for >= 28 days | Allergic reactions to compounds of similar chemical or biologic composition to olaparib | Current use of strong or moderate CYP3A inhibitors or inducers without adequate washout (>= 5 half-lives or 3 weeks, whichever is shorter) | Pregnancy or breastfeeding | Any chronic or concurrent acute liver disease | History of stroke, transient ischemic attack, or myocardial infarction within 6 months | Uncontrolled infection | Symptomatic congestive heart failure, unstable angina, or clinically significant cardiac arrhythmia | Unstable or untreated cardiac conditions or left ventricular ejection fraction < 50% | Uncontrolled diabetes mellitus | Psychiatric illness or social situation limiting compliance | Other severe medical or psychiatric condition or laboratory abnormality increasing risk or interfering with study | Immunocompromised state (e.g., HIV with detectable virus not on HAART) | Active hepatitis B or C infection | Other malignancy within 2 years except allowed low-risk cancers as specified | Systemic chemotherapy or radiotherapy (except palliative) within 2 weeks prior to study treatment | Major surgery within 2 weeks prior to starting study treatment without adequate recovery | Previous allogeneic bone marrow transplant or double umbilical cord blood transplantation","Progression during or after at least one platinum-based chemotherapy regimen required; Prior treatment with an immune-checkpoint inhibitor (atezolizumab, pembrolizumab, nivolumab, avelumab, or durvalumab) allowed and may qualify; Washout from chemotherapy >= 2 weeks before study treatment; Washout from monoclonal antibody therapy >= 4 weeks before study treatment",ALL,A,"Disease and setting match (metastatic urothelial carcinoma), and the patient has progressed after platinum chemotherapy and an immune-checkpoint inhibitor, meeting line-of-therapy requirements. The required genomic/TMB criterion is unknown from the provided data, making eligibility uncertain but not an exclusion.",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches. Stage/setting (metastatic) and line/prior exposure (progressed after platinum and ICI) both match core anchors. Required biomarker (DDR/TMB) status is unknown, which is not an exclusion and not a soft mismatch. Per decision procedure, ≥2 anchors match with no conflicts → A.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03390504,0.7831504344940186,Metastatic Urothelial Carcinoma,A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations,PHASE3,18 years,Urothelial Cancer,"Histologic transitional cell carcinoma of the urothelium (minor variant histology <50% allowed) | Metastatic or surgically unresectable urothelial cancer | Documented disease progression requiring a change in treatment prior to randomization | Cohort 1: Prior treatment with an anti–PD-(L)1 agent; no more than 2 prior lines of systemic therapy | Cohort 2: No prior treatment with an anti–PD-(L)1 agent; only 1 prior line of systemic therapy | Neoadjuvant or adjuvant chemotherapy with progression within 12 months counts as systemic therapy in the metastatic setting | Meets molecular eligibility by FGFR clinical trial assay | ECOG performance status 0–2 | Adequate bone marrow, liver, and renal function","Treatment with another investigational agent or participation in another therapeutic clinical study within 30 days prior to randomization | Active malignancy requiring treatment change in the last 24 months (exceptions: urothelial cancer, completely cured skin cancer, localized prostate cancer with Gleason 6 treated or under surveillance, or Gleason 3+4 treated >6 months with very low risk of recurrence) | Symptomatic central nervous system metastases | Prior treatment with an FGFR inhibitor | Known hypersensitivity or intolerance to erdafitinib or its excipients | Current central serous retinopathy or retinal pigment epithelial detachment of any grade | History of uncontrolled cardiovascular disease | Impaired wound healing capacity (e.g., skin/decubitus ulcers, chronic leg ulcers, known gastric ulcers, or unhealed incisions)",Cohort 1 requires prior anti–PD-(L)1 therapy; Cohort 1 allows up to 2 prior lines of systemic therapy; Cohort 2 prohibits prior anti–PD-(L)1 therapy; Cohort 2 allows only 1 prior line of systemic therapy; Neoadjuvant/adjuvant chemotherapy within 12 months of last dose counts as prior systemic therapy,ALL,A,"Disease and setting match (metastatic urothelial carcinoma), and prior exposure/line criteria fit Cohort 1 (prior PD-1 and ≤2 prior lines with progression). FGFR alteration is required but currently unknown; this is not an explicit exclusion.",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),INCORRECT,B,"A requires that any required biomarker be satisfied; here FGFR status is unknown. Stage/setting matches, but biomarker is unknown and line/prior details are not unequivocally aligned with the cohort rules (neoadjuvant counting is unclear vs the listed prior lines). With disease match and only one clearly confirmed core anchor (stage/setting), the correct grade is B, not A.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03547973,0.9586746692657471,Metastatic Urothelial Carcinoma,A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer,PHASE2,18 years,Metastatic Urothelial Cancer,"Age >= 18 years | ECOG performance status 0–1 | Adequate renal and hepatic function | Adequate hematologic parameters without transfusional support | Life expectancy >= 3 months | Cohorts 4 and 6: Measurable disease by RECIST 1.1 | Cohorts 1, 2, 3, 5: Creatinine clearance >= 30 mL/min | Cohort 4: No prior platinum-based chemotherapy in the metastatic or unresectable locally advanced setting | Cohort 4: Creatinine clearance >= 50 mL/min; if receiving cisplatin 70 mg/m2 Day 1 q21d, creatinine clearance >= 60 mL/min; if creatinine clearance 50–59 mL/min, receive split-dose cisplatin | Cohorts 4, 5, 6, 7: Archival tumor tissue (muscle-invasive or metastatic urothelial carcinoma) or biopsy of metastatic urothelial carcinoma | Cohort 5: Completed 4–6 cycles of gemcitabine + cisplatin with CR/PR/SD and treatment-free interval of 4–10 weeks | Cohort 6: Cisplatin-ineligible; no prior therapy for metastatic or unresectable locally advanced disease; CPI-naive or >12 months from completion of adjuvant therapy | Cohort 7: No prior systemic therapy for locally advanced or metastatic urothelial cancer (recurrence >12 months after curative therapy allowed) | Cohort 7: Measurable disease by RECIST 1.1","Pregnant or lactating | Active second malignancy | Known active hepatitis B or hepatitis C | Known active central nervous system metastases and/or carcinomatous meningitis | Other concurrent medical or psychiatric conditions that would preclude study participation | Prior anti-cancer monoclonal antibody within 4 weeks before Day 1 or unresolved > Grade 1 toxicities from prior therapy | Cohorts 3–6: Active autoimmune disease requiring systemic treatment in past 2 years | Cohorts 3–6: Receipt of a live vaccine within 30 days prior to first dose | Cohorts 3–6: History or evidence of interstitial lung disease or non-infectious pneumonitis | Cohort 3: Prior anti-PD-1/PD-L1 therapy | Cohort 4: Refractory to platinum in neoadjuvant/adjuvant setting (relapse <= 12 months after completion) | Cohorts 4, 5, 6: If prior checkpoint inhibitor, treatment-free interval must be >12 months between last dose and date of recurrence | Cohort 7: Prior anticancer therapy within 12 months before C1D1 or prior radiation within 2 weeks before C1D1 | Cohort 7: History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced or idiopathic pneumonitis, or active pneumonitis on screening CT | Cohort 7: Child-Pugh class B or C hepatic impairment | Cohort 7: Uncontrolled diabetes | Cohort 7: Active keratitis or corneal ulcerations | Cohort 7: Ongoing sensory or motor neuropathy Grade >= 2",Cohort 1: Prior platinum-containing therapy and prior anti-PD-1/PD-L1 therapy with progression/recurrence; Cohort 2: Platinum-ineligible for first-line metastatic disease and progression after first-line anti-PD-1/PD-L1 therapy; no prior platinum for recurrent/metastatic/advanced disease; Cohort 3: Prior platinum-containing therapy with progression/recurrence; Cohort 4: No prior platinum-based chemotherapy in the metastatic or unresectable locally advanced setting; Cohort 5: Completed 4–6 cycles of gemcitabine + cisplatin without progressive disease; Cohort 6: No prior therapy for metastatic or unresectable locally advanced disease; CPI-naive or >12 months since completion of adjuvant therapy; Cohort 7: No prior systemic therapy for locally advanced or metastatic disease (curative-intent therapy allowed if recurrence >12 months),ALL,A,Disease and setting match metastatic urothelial carcinoma. The patient fits Cohort 1 (prior platinum and PD-1 with progression) and has renal function consistent with cohorts requiring CrCl ≥30 mL/min; no explicit exclusions are evident.,Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),CORRECT,A,"Disease and metastatic setting match. Patient fits Cohort 1 (prior platinum and prior PD-1 with progression). Renal function (eGFR ~35) aligns with cohorts requiring CrCl ≥30 mL/min. No hard exclusions identified and no soft conflicts noted. Therefore ≥2 core anchors (stage/setting and line/prior) match, justifying grade A.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03866382,0.7714253067970276,Metastatic Urothelial Carcinoma,"A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)",PHASE2,18 years,Bladder Adenocarcinoma; Bladder Clear Cell Adenocarcinoma; Bladder Squamous Cell Carcinoma; Bladder Neuroendocrine Carcinoma; Bladder Small Cell Neuroendocrine Carcinoma; Urothelial Carcinoma; Micropapillary Urothelial Carcinoma; Plasmacytoid Urothelial Carcinoma; Giant Cell Urothelial Carcinoma; Lipid-Rich Urothelial Carcinoma; Nested Variant Urothelial Carcinoma; Lymphoepithelioma-Like Carcinoma; Large Cell Neuroendocrine Carcinoma; Chromophobe Renal Cell Carcinoma; Papillary Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Collecting Duct Carcinoma; Renal Medullary Carcinoma; Urachal Adenocarcinoma; Urethral Carcinoma; Urethral Clear Cell Adenocarcinoma; Penile Carcinoma; Prostate Small Cell Neuroendocrine Carcinoma; Malignant Testicular Leydig Cell Tumor; Malignant Testicular Sertoli Cell Tumor,"Metastatic disease with new or progressive lesions on imaging | At least one measurable lesion per RECIST v1.1 | For bone-only cohort: at least one bone lesion on bone scan/CT/MRI | Histologically confirmed metastatic small cell/neuroendocrine carcinoma of the bladder | Histologically confirmed metastatic bladder adenocarcinoma, urachal adenocarcinoma, or bladder/urethra clear cell adenocarcinoma (pure) | Histologically confirmed metastatic squamous cell carcinoma of the bladder (pure) | Histologically confirmed metastatic plasmacytoid urothelial carcinoma (>= ~50% plasmacytoid/discohesive) | Any penile cancer | Sarcomatoid renal cell carcinoma (predominantly ~50%, including rhabdoid) and unclassified high-grade RCC; malignant angiomyolipoma allowed | Other variant urothelial carcinomas (e.g., micropapillary >= ~50%, giant cell, lipid-rich, clear cell, nested), large cell neuroendocrine carcinoma, lymphoepithelioma-like carcinoma, mixed patterns; treatment-naive primary prostate small cell allowed; malignant testicular Sertoli or Leydig cell tumors; papillary and chromophobe RCC | Sarcomatoid urothelial carcinoma (predominantly ~50%) | Renal medullary carcinoma | Bone-only metastatic genitourinary tumors (non-prostate) | Renal collecting duct carcinoma (WHO definition) | Urethral carcinoma (any histology; if urothelial, isolated to urethra) | Availability of H&E slides from diagnostic tumor tissue for central review | Up to 2 prior systemic anticancer treatments allowed or treatment naive; small cell carcinoma should have received a platinum-based combination regimen; bone-only cohort must receive cisplatin-based chemotherapy if eligible | Age >= 18 years | Able to swallow oral tablets | Karnofsky performance status >= 80% | ANC >= 1,000/µL | Platelets >= 75,000/µL | Total bilirubin <= 1.5 x ULN (<= 3.0 mg/dL allowed with Gilbert syndrome) | AST/ALT <= 3 x ULN (<= 5 x ULN with liver metastases or Gilbert syndrome) | Creatinine <= 1.5 x ULN or creatinine clearance >= 40 mL/min/1.73 m2 | Hemoglobin >= 9 g/dL (PRBC transfusion allowed) | Serum albumin >= 3.2 g/dL | Lipase and amylase <= 2 x ULN and no clinical/radiologic pancreatitis | HIV-positive allowed if on stable HAART, CD4 > 350/µL, and viral load undetectable | Select stable autoimmune/rheumatologic conditions on topical therapy allowed; controlled endocrine deficiencies allowed; vitiligo allowed | Women of childbearing potential: negative pregnancy test within 7 days prior to registration | Recovery to baseline or CTCAE <= grade 1 from prior therapy toxicities (except alopecia, neuropathy, or non-clinically significant lab AEs) | Previously treated brain metastases eligible if asymptomatic and off steroids >= 2 weeks; baseline contrast brain imaging required if known brain metastases","Prior cabozantinib | Both prior MET/VEGF inhibitor exposure and prior PD-1/PD-L1/CTLA-4 therapy (sequentially or in combination) | Prior PD-1/PD-L1 or CTLA-4 therapy (except allowed for urothelial carcinoma cohorts D, H, J, L) | Active or acute diverticulitis, intra-abdominal abscess, or GI obstruction within 12 months | Pregnancy or breastfeeding | Cytotoxic chemotherapy or biologic agents within 2 weeks before first dose | Radiation therapy to lungs/mediastinum/abdomen within 4 weeks before first dose or with ongoing complications | Radiation to brain metastasis within 3 weeks (WBRT) or 2 weeks (SBRT) before first dose | Radiation to any other site within 2 weeks before first dose | Radionuclide treatment within 6 weeks before first dose | Small molecule kinase inhibitor within 14 days or 5 half-lives (whichever longer) before first dose | Hormonal therapy within 14 days or 5 half-lives (whichever longer) before first dose (GnRH agonists/antagonists allowed) | Other investigational agent within 14 days before first dose | Not recovered to baseline or CTCAE > grade 1 from prior therapy toxicities (except allowed conditions) | Active brain metastases or epidural disease requiring steroids within 2 weeks | Concomitant warfarin (except <= 1 mg/day); aspirin up to 325 mg/day, thrombin or factor Xa inhibitors, and LMWH permitted | Chronic concomitant strong CYP3A4 inducers or strong inhibitors | Clinically significant GI bleeding within 6 months | Hemoptysis >= 2.5 mL/day within 1 month | Signs of pulmonary hemorrhage within 3 months | Tumor invading major blood vessels | Tumor invading GI tract or endotracheal/endobronchial tumor within 28 days; rectal tumor masses | Congestive heart failure NYHA class III or IV | Uncontrolled hypertension (sustained BP > 150/90 mmHg) despite therapy within 7 days of first dose | QTcF > 500 ms (unless average of 3 repeat ECGs <= 500 ms) | History of congenital long QT syndrome | Within 6 months: unstable angina, clinically significant arrhythmias, stroke/TIA/ischemic event, myocardial infarction, or cardiomyopathy | Unresolved active peptic ulcer disease, acute diverticulitis/cholecystitis/cholangitis/appendicitis, or malabsorption within 28 days before first dose | Within 2 years: abdominal or genitourinary fistula, GI perforation, bowel or gastric outlet obstruction, or intra-abdominal abscess (must be fully resolved) | High fistula risk conditions (e.g., recent PEG tube placement) | Severe active infection requiring IV therapy within 14 days | Serious non-healing wound, ulcer, or bone fracture within 28 days | History of organ transplant or allogeneic stem cell transplant | Uncompensated hypothyroidism or thyroid dysfunction within 7 days (unless replacement started) | Major surgery within 3 months (or >= 6 weeks if completely healed) before first cabozantinib dose; minor surgery within 1 month (or 3 months if wound complications); wounds must be fully healed | Severe hypersensitivity to any monoclonal antibody | Active malignancy requiring systemic treatment within 2 years | Allergic reactions to compounds of similar chemical or biologic composition to cabozantinib, nivolumab, or ipilimumab | Active hepatitis B (HBsAg positive with detectable HBV DNA) or active hepatitis C infection | Active autoimmune disease or history with risk of recurrence requiring systemic immunosuppression (e.g., SLE, MS, myasthenia gravis, IBD, autoimmune hepatitis, TEN, Stevens-Johnson syndrome, antiphospholipid syndrome)","Up to 2 prior systemic anticancer treatments allowed; treatment naive allowed; Small cell carcinoma: prior platinum-based combination regimen required (neoadjuvant, adjuvant, or first line); Bone-only cohort: must receive standard cisplatin-based chemotherapy if cisplatin-eligible; Prior MET or VEGFR inhibitors allowed; No cytotoxic chemotherapy or biologic agents within 2 weeks before first dose; No radiation within protocol-specified windows before first dose (lungs/mediastinum/abdomen within 4 weeks; brain WBRT within 3 weeks or SBRT within 2 weeks; other sites within 2 weeks); No radionuclide therapy within 6 weeks before first dose; No small molecule kinase inhibitors within 14 days or 5 half-lives (whichever longer) before first dose; No hormonal therapy within 14 days or 5 half-lives (whichever longer) before first dose (GnRH agonists/antagonists allowed); No other investigational agents within 14 days before first dose; Toxicities from prior therapies recovered to baseline or CTCAE <= grade 1 (exceptions apply)",ALL,A,"Disease and metastatic setting match, and the patient’s prior therapies (two systemic regimens including PD-1) fit the trial’s allowance for urothelial carcinoma cohorts. Note: the patient’s eGFR 35 mL/min may not meet the trial’s creatinine clearance ≥ 40 mL/min requirement, which could affect eligibility.",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),INCORRECT,B,"A is too strong. While metastatic stage matches, the UC cohorts in this trial appear to require variant histology, making the required subtype unknown for this patient; moreover, prior PD-1 exposure is only allowed in certain UC cohorts, so line/prior compatibility is not clearly a match without confirming cohort eligibility. With exactly one clear core anchor (stage/setting) and no soft conflicts, the rubric points to B, not A. The low eGFR is not a hard exclusion under the rubric’s anchors.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT04003649,0.7128255367279053,Recurrent Glioblastoma,A Phase 1 Study to Evaluate IL13Rα2-Targeted Chimeric Antigen Receptor (CAR) T Cells Combined With Checkpoint Inhibition for Patients With Resectable Recurrent Glioblastoma,PHASE1,18 years,Glioblastoma (recurrent); Glioblastoma (refractory),"Age >= 18 years | ECOG <= 2 | Karnofsky >= 60% | Life expectancy >= 4 weeks | Histologically confirmed WHO grade IV glioblastoma or prior grade II/III glioma with progression consistent with grade IV glioblastoma after standard therapy | Relapsed/refractory measurable disease after standard therapy | >= 12 weeks after completion of front-line radiation therapy | IL13Ralpha2-positive tumor by IHC (H-score > 50) | WBC > 2000/µL or ANC >= 1000/µL (within 14 days prior to leukapheresis) | Platelets >= 75000/µL | Fasting blood glucose within ULN | Total bilirubin <= 1.5 x ULN | AST <= 2.5 x ULN | ALT <= 2.5 x ULN | Serum creatinine <= 1.6 mg/dL | Oxygen saturation >= 95% on room air | Seronegative for HIV Ag/Ab combo | Hepatitis C antibody negative or, if positive, HCV RNA negative | Hepatitis B surface antigen negative | Hepatitis A virus IgM antibody negative | Women of childbearing potential: negative pregnancy test | Agreement to use effective contraception during study and for at least 5 months after last nivolumab dose and/or 3 months after last CAR T cell cycle","Prior CTLA-4, PD-1, or PD-L1 inhibitor therapy | Steroid-dependent requiring > 6 mg dexamethasone per day at enrollment | Unresolved toxicities from prior therapy | History of or active autoimmune disease | Uncontrolled seizure activity or clinically evident progressive encephalopathy | History of allergic reactions to compounds similar to study agents | Active diarrhea | Clinically significant uncontrolled illness | Active infection requiring antibiotics | Known HIV, hepatitis B, or hepatitis C infection | Other active malignancy | Pregnant or breastfeeding | Any condition that contraindicates participation due to safety concerns per investigator | Inability to comply with study procedures",Completed standard therapy for glioblastoma; Radiographic progression after standard therapy; At least 12 weeks since completion of front-line radiation therapy,ALL,A,"Disease and setting match (recurrent GBM after standard therapy), with age and ECOG within trial limits and no conflicting exclusions (no prior PD-1/PD-L1). IL13Rα2 positivity is required but status is unknown; otherwise core anchors align.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),INCORRECT,C,"No hard exclusions. Disease and stage/line match, but the trial requires IL13Rα2-positive tumor and the patient’s IL13Rα2 status is unknown. Per rubric, A requires required biomarkers to be satisfied; with a required biomarker unknown, this remains uncertain rather than excellent, so grade C.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT04092270,0.9287134408950806,Recurrent Clear Cell Ovarian Carcinoma,A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC),PHASE1,18 years,Endometrial Endometrioid Adenocarcinoma (FIGO Grade 1); Endometrial Endometrioid Adenocarcinoma (FIGO Grade 2); Endometrial High Grade Endometrioid Adenocarcinoma; Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube High Grade Serous Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Ovarian High Grade Serous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Undifferentiated Carcinoma; Platinum-Sensitive Ovarian Carcinoma; Primary Peritoneal Carcinosarcoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Primary Peritoneal Transitional Cell Carcinoma; Primary Peritoneal Undifferentiated Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Ovarian Carcinosarcoma; Recurrent Ovarian Clear Cell Adenocarcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma; Recurrent Ovarian Low Grade Serous Adenocarcinoma; Recurrent Ovarian Mucinous Adenocarcinoma; Recurrent Ovarian Transitional Cell Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma,"Recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer (dose-escalation). | Expansion cohorts: recurrent or persistent low grade serous ovarian cancer (LGSOC) or high grade serous ovarian cancer (HGSOC). | Measurable disease per RECIST 1.1. | Prior therapy: at least one prior line of platinum-based chemotherapy required. | Prior therapy: unlimited additional lines of chemotherapy, targeted, biologic, or hormonal therapy allowed. | Washout: prior anti-cancer therapy discontinued >= 4 weeks, one cycle, or 5 half-lives (whichever is shortest) before study treatment. | Age >= 18 years. | Platinum-sensitive ovarian cancer eligible for dose expansion if PLD is appropriate. | ECOG performance status <= 2 (Karnofsky >= 60%). | Cardiac ejection fraction >= lower limit of normal. | Hemoglobin >= 9 g/dL. | Absolute neutrophil count >= 1,500/µL. | Platelets >= 100,000/µL. | Total bilirubin <= 1.5 x ULN. | AST/ALT <= 3 x ULN. | Alkaline phosphatase <= 2.5 x ULN. | Creatinine clearance > 30 mL/min. | HIV-infected patients eligible if on effective ART with undetectable viral load within 6 months. | Chronic hepatitis B eligible if viral load undetectable on suppressive therapy, if indicated. | Hepatitis C eligible if cured or on treatment with undetectable viral load. | Treated brain metastases eligible if no progression on follow-up imaging, off steroids, and clinically stable. | Women of childbearing potential: negative urine or serum pregnancy test within 72 hours prior to first dose. | Contraception required during treatment and for 6 months after last dose. | Prior or concurrent malignancy allowed if it will not interfere with assessment of safety or efficacy. | Cardiac risk assessment NYHA class 2B or better. | Availability of archival FFPE tissue (within past 36 months) for DNA/RNA analysis.","Eligible for available therapies known to confer clinical benefit (dose-escalation phase). | Inability to swallow or absorb oral medication (e.g., drainage PEG). | Prior anthracycline exposure for ovarian cancer (doxorubicin or pegylated liposomal doxorubicin). | Unresolved toxicities from prior therapy > grade 1 (except alopecia, thyroid dysfunction, or neuropathy). | Receipt of other investigational agents within 28 days prior to start of treatment. | Allergic reactions to compounds similar to peposertib or pegylated liposomal doxorubicin. | Unable to discontinue interacting medications or herbal supplements with peposertib (strong CYP3A4/5, CYP2C9, CYP2C19 modulators; narrow TI substrates of CYP3A4/5, CYP1A2, CYP2B6; narrow TI transport substrates of P-gp, BCRP, OCT1, OATP1B1, OATP1B3). | Unable to discontinue proton-pump inhibitors >= 5 days prior to treatment (calcium carbonate allowed). | Concurrent sorivudine or brivudine use. | Live attenuated vaccine within 30 days prior to peposertib dosing. | Uncontrolled intercurrent illness, including active infection. | Psychiatric illness or social situations limiting compliance. | Pregnant or breastfeeding. | Significant uncontrolled cardiac conduction abnormalities.","At least one prior line of platinum-based chemotherapy required.; Unlimited additional prior lines of chemotherapy, targeted therapy, biologic therapy, or hormonal therapy allowed.; Washout required: prior anti-cancer therapy stopped >= 4 weeks, one cycle, or 5 half-lives before study start (whichever is shortest).",FEMALE,A,"Recurrent clear cell ovarian carcinoma is explicitly included, and the patient is platinum-resistant with prior platinum therapy, female, age ≥18, and anthracycline-naive. No required biomarkers are needed and no explicit exclusions are identified from the provided data.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; BRCA1 positive; Optimal debulking surgery performed; Received adjuvant carboplatin + paclitaxel + bevacizumab; Cytology-positive malignant pleural effusion at 5 months post-adjuvant,(none),Carboplatin; Paclitaxel; Bevacizumab; Optimal debulking surgery,Stage III,,36,years,female,(none),CORRECT,A,"Disease matches explicitly (recurrent ovarian clear cell). Stage/setting (recurrent) and prior therapy (≥1 prior platinum) both match core anchors; no soft conflicts identified. The grader inferred anthracycline-naive, which is unnecessary but does not affect the A grade per rubric.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT04145115,0.7490242719650269,Recurrent Glioblastoma,A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma,PHASE2,18 years,"Glioblastoma (IDH-wildtype); Astrocytoma (IDH-mutant, grade 4); Secondary Glioblastoma; Diffuse Glioma","Histologically confirmed WHO grade 4 glioma at first or second recurrence, including secondary glioblastoma | Glioblastoma IDH-wildtype CNS WHO grade 4 per 2021 WHO criteria | Astrocytoma IDH-mutant CNS WHO grade 4 | Measurable disease on MRI with a bidimensionally measurable lesion >= 10 mm | Tumor tissue available from resection or biopsy of recurrent tumor within 28 days before pre-registration or planned within 28 days after pre-registration | Age >= 18 years | ECOG performance status <= 2 | Able to undergo brain MRI with contrast","Active autoimmune disease or history of autoimmune disease at risk for exacerbation | Prior treatment with checkpoint blockade therapies (anti-CTLA-4, anti-PD-1/PD-L1) | Prior bevacizumab | Prior laser ablation at the time of recurrent tumor tissue sampling (allowed if performed >= 4 months before sampling) | Requires > 4 mg dexamethasone beyond the perioperative period (> 2 weeks after surgery) | History of another active malignancy requiring treatment within the previous 2 years (except in situ cancers or basal/squamous cell skin cancers)",Prior laser ablation allowed if >= 4 months before recurrent tumor tissue sampling,ALL,A,"Recurrent IDH-wildtype glioblastoma after standard chemoradiation with ECOG 1 matches the trial’s disease, biomarker, and recurrent setting, and he has no disallowed prior checkpoint therapy or bevacizumab; age and sex are eligible. Measurable lesion size, recent recurrent-tumor tissue availability, and MRI-with-contrast ability are not provided and would need confirmation.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches (IDH-wildtype glioblastoma, recurrent). Core anchors: Stage/setting = recurrent (match); Line/prior = checkpoint-naïve and no bevacizumab (match); Biomarker/subtype = IDH-wildtype accepted (match). Unknowns (measurable lesion, recent tissue, MRI with contrast, exact recurrence count) do not create soft conflicts. Grade A is appropriate.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT04145622,0.7837072014808655,Castration-Resistant Prostate Cancer,"Phase I/II, Two-Part, Multicenter First-in-Human Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Subjects With Advanced Solid Malignant Tumors (IDeate-PanTumor01)",PHASE1/PHASE2,18 years,"Head and Neck Squamous Cell Carcinoma; Esophageal Squamous Cell Carcinoma; Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Bladder Cancer; Sarcoma; Endometrial Cancer; Melanoma; Prostate Cancer (castration-resistant, adenocarcinoma); Breast Cancer","ECOG performance status 0–1 | At least one measurable lesion per RECIST v1.1 on CT or MRI; lesions should not be from a previously irradiated site unless progression is documented | Adequate cardiac, hematopoietic, renal, and hepatic function | Adequate treatment washout period prior to study treatment | Pathologically confirmed advanced/unresectable or metastatic: head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, non-small cell lung cancer (squamous or adenocarcinoma), small cell lung cancer, bladder cancer, sarcoma, endometrial cancer, melanoma, adenocarcinoma castration-resistant prostate cancer, or breast cancer refractory/intolerant to standard therapy or without standard options | Expansion Cohort (2L ESCC): Disease progression after platinum-based therapy and an immune checkpoint inhibitor; maximum one prior line of systemic therapy for unresectable/metastatic ESCC","Prior treatment with a B7-H3–targeted agent, including ifinatamab deruxtecan | Prior discontinuation of an antibody-drug conjugate containing an exatecan derivative due to treatment-related toxicities | Multiple primary malignancies within 3 years, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, superficial GI tract tumors, and non-muscle invasive bladder cancer curatively resected by endoscopic surgery | Uncontrolled significant cardiovascular disease | Clinically severe pulmonary compromise, including underlying pulmonary disorders; autoimmune, connective tissue, or inflammatory disorders with potential pulmonary involvement; prior pneumonectomy; or requirement for supplemental oxygen | Uncontrolled infection requiring systemic therapy | Substance abuse or other medical conditions increasing safety risk or interfering with study participation or evaluation",Treatment washout required before study start; ESCC expansion: disease progression after platinum-based therapy; ESCC expansion: prior immune checkpoint inhibitor required; ESCC expansion: maximum one prior line of systemic therapy for unresectable/metastatic disease,ALL,A,"Disease matches (metastatic castration-resistant prostate cancer is included), and the patient has progressed on standard AR-targeted therapies, fitting the refractory setting. Age and sex are eligible, and there are no explicit exclusions noted; ECOG/measurable disease/organ function are unspecified but not conflicting.",Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches mCRPC cohort. Core anchors: Stage/setting (metastatic) matches and Line/prior (refractory to standard AR-targeted therapy) matches. No soft conflicts identified. Histology (adenocarcinoma) is not explicitly provided but not a hard exclusion and treated as neutral; other requirements (ECOG, measurable disease) are unknown and not part of core anchors. Thus A is appropriate per rubric.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT04388852,0.9547773003578186,Castration-Resistant Prostate Cancer,"DS3201 With Ipilimumab in Patients With Metastatic Aggressive Variant Prostate (AVPC), Urothelial (UC), and Renal Cell (RCC) Carcinomas",PHASE1,18 years,Aggressive Variant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma; Metastatic Urothelial Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma,"ECOG performance status 0-1 | Histologically or cytologically confirmed prostate carcinoma, urothelial carcinoma, or clear cell renal cell carcinoma; variant prostate histologies (small cell/neuroendocrine) permitted | Metastatic disease by CT/MRI and/or bone scan, or locally advanced not amenable to locoregional therapy | Prostate carcinoma: castration-resistant disease and maintain castrate testosterone (<= 50 ng/dL or <= 2.0 nM) throughout the study; small cell histology exempt from progression on prior ADT but must maintain castrate levels | Aggressive variant prostate carcinoma requires molecular signature: loss or mutation in at least 2 of TP53, RB1, PTEN by CLIA-certified testing | Renal cell carcinoma: progressive disease during or after at least one anti-angiogenic agent and one PD-1 or PD-L1 inhibitor | Urothelial carcinoma: progressive disease during or after at least one PD-1 or PD-L1 inhibitor and prior platinum chemotherapy or platinum-ineligible | AVPC patients may have received prior PD-1 or PD-L1 inhibitor but not required | Evidence of disease progression by RECIST; for AVPC, rising PSA per PCWG3 may qualify if AVPC molecular criteria met | Known brain metastases allowed if stable >= 4 weeks after local therapy, off steroids or on stable/decreasing dose <= 10 mg prednisone equivalent daily, and without confounding neurologic dysfunction | Recovery from prior surgery, radiotherapy, chemotherapy, or other anti-cancer therapy to baseline or <= grade 1 (other low-grade toxicities may be allowed if clinically insignificant) | Ability to swallow and retain oral medications | Disease site accessible for serial biopsies","Pregnant or lactating | Carcinomatous meningitis | Prior treatment with an EZH2 inhibitor | PD-1, PD-L1, PD-L2, or CTLA-4 inhibitor within 4 weeks prior to day 1 | Monoclonal antibody within 4 weeks prior to day 1 | Investigational drug within 2 weeks prior to day 1 | Chemotherapy within 2 weeks prior to day 1 | Radiation therapy or radionuclide therapy within 2 weeks prior to day 1 | Receipt of live virus vaccine within 30 days prior to day 1 | Untreated symptomatic spinal cord compression or brain metastases | History of immune-related adverse event leading to permanent discontinuation of prior immunotherapy | History of >= grade 3 immune-related adverse event within past 16 weeks, any grade 4 life-threatening irAE, or neurologic/ocular irAE of any grade with prior immunotherapy (endocrine AEs allowed if on stable replacement, no adrenal crisis, asymptomatic) | Active, known, or suspected autoimmune disease (exceptions: vitiligo, type 1 diabetes, residual hypothyroidism on replacement, psoriasis/eczema not requiring systemic treatment, or conditions not expected to recur) | Requires chronic systemic corticosteroids > 10 mg prednisone equivalents daily or other immunosuppressive medications (physiologic adrenal replacement > 10 mg allowed without active autoimmune disease; inhaled/intranasal/intra-articular/topical allowed) | History of interstitial lung disease, idiopathic pulmonary fibrosis, or active pneumonitis on screening CT | Clinically significant cardiovascular disease: MI or stroke within 6 months; unstable angina within 3 months; CHF NYHA class 3-4; clinically significant ventricular arrhythmias; uncontrolled hypertension (SBP >= 140 mmHg or DBP >= 90 mmHg); baseline ECG abnormalities including QTc > 470 msec, complete LBBB, ischemic ST-T changes, second- or third-degree AV block, or serious brady-/tachyarrhythmias | Active hepatitis B (positive HBsAg) or active hepatitis C (detectable HCV RNA) | Known HIV infection | Gastrointestinal disorder that negatively affects absorption (e.g., short bowel syndrome, severe diarrhea, TPN requirement) | Additional malignancy that is progressing, requires active treatment, or has >= 30% probability of recurrence within 24 months (exceptions: non-melanoma skin cancer after curative therapy, Ta urothelial carcinoma, stage 0 CLL) | Any other severe/uncontrolled medical condition that could compromise participation | Unwilling or unable to comply with the study protocol",Renal cell carcinoma: prior treatment with at least one anti-angiogenic agent; Renal cell carcinoma: prior treatment with a PD-1 or PD-L1 inhibitor; Urothelial carcinoma: prior treatment with a PD-1 or PD-L1 inhibitor; Urothelial carcinoma: prior platinum-based chemotherapy or platinum-ineligible; Prostate cancer: maintain castrate testosterone during study; Washout: PD-1/PD-L1/PD-L2 or CTLA-4 inhibitors within 4 weeks prior to day 1 not allowed; Washout: monoclonal antibody within 4 weeks prior to day 1 not allowed; Washout: investigational drug within 2 weeks prior to day 1 not allowed; Washout: chemotherapy within 2 weeks prior to day 1 not allowed; Washout: radiation or radionuclide therapy within 2 weeks prior to day 1 not allowed,ALL,A,"Disease matches (metastatic castration-resistant prostate carcinoma), and stage/setting plus prior-exposure compatibility align (AR-targeted therapy history is allowed; no prior checkpoint therapy reported). No explicit exclusions are apparent; the AVPC molecular signature applies only to that cohort and is not a known mismatch here.",Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches CRPC cohort. Core anchors: Stage/setting (metastatic CRPC) matches; Line/prior exposure compatible (prior AR-targeted therapy allowed, no disallowed IO reported). Biomarker requirement applies only to AVPC cohort; general CRPC cohort does not require it. No soft conflicts identified. Grade A is appropriate.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT04388852,0.9999872446060181,Metastatic Urothelial Carcinoma,"DS3201 With Ipilimumab in Patients With Metastatic Aggressive Variant Prostate (AVPC), Urothelial (UC), and Renal Cell (RCC) Carcinomas",PHASE1,18 years,Aggressive Variant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma; Metastatic Urothelial Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma,"ECOG performance status 0-1 | Histologically or cytologically confirmed prostate carcinoma, urothelial carcinoma, or clear cell renal cell carcinoma; variant prostate histologies (small cell/neuroendocrine) permitted | Metastatic disease by CT/MRI and/or bone scan, or locally advanced not amenable to locoregional therapy | Prostate carcinoma: castration-resistant disease and maintain castrate testosterone (<= 50 ng/dL or <= 2.0 nM) throughout the study; small cell histology exempt from progression on prior ADT but must maintain castrate levels | Aggressive variant prostate carcinoma requires molecular signature: loss or mutation in at least 2 of TP53, RB1, PTEN by CLIA-certified testing | Renal cell carcinoma: progressive disease during or after at least one anti-angiogenic agent and one PD-1 or PD-L1 inhibitor | Urothelial carcinoma: progressive disease during or after at least one PD-1 or PD-L1 inhibitor and prior platinum chemotherapy or platinum-ineligible | AVPC patients may have received prior PD-1 or PD-L1 inhibitor but not required | Evidence of disease progression by RECIST; for AVPC, rising PSA per PCWG3 may qualify if AVPC molecular criteria met | Known brain metastases allowed if stable >= 4 weeks after local therapy, off steroids or on stable/decreasing dose <= 10 mg prednisone equivalent daily, and without confounding neurologic dysfunction | Recovery from prior surgery, radiotherapy, chemotherapy, or other anti-cancer therapy to baseline or <= grade 1 (other low-grade toxicities may be allowed if clinically insignificant) | Ability to swallow and retain oral medications | Disease site accessible for serial biopsies","Pregnant or lactating | Carcinomatous meningitis | Prior treatment with an EZH2 inhibitor | PD-1, PD-L1, PD-L2, or CTLA-4 inhibitor within 4 weeks prior to day 1 | Monoclonal antibody within 4 weeks prior to day 1 | Investigational drug within 2 weeks prior to day 1 | Chemotherapy within 2 weeks prior to day 1 | Radiation therapy or radionuclide therapy within 2 weeks prior to day 1 | Receipt of live virus vaccine within 30 days prior to day 1 | Untreated symptomatic spinal cord compression or brain metastases | History of immune-related adverse event leading to permanent discontinuation of prior immunotherapy | History of >= grade 3 immune-related adverse event within past 16 weeks, any grade 4 life-threatening irAE, or neurologic/ocular irAE of any grade with prior immunotherapy (endocrine AEs allowed if on stable replacement, no adrenal crisis, asymptomatic) | Active, known, or suspected autoimmune disease (exceptions: vitiligo, type 1 diabetes, residual hypothyroidism on replacement, psoriasis/eczema not requiring systemic treatment, or conditions not expected to recur) | Requires chronic systemic corticosteroids > 10 mg prednisone equivalents daily or other immunosuppressive medications (physiologic adrenal replacement > 10 mg allowed without active autoimmune disease; inhaled/intranasal/intra-articular/topical allowed) | History of interstitial lung disease, idiopathic pulmonary fibrosis, or active pneumonitis on screening CT | Clinically significant cardiovascular disease: MI or stroke within 6 months; unstable angina within 3 months; CHF NYHA class 3-4; clinically significant ventricular arrhythmias; uncontrolled hypertension (SBP >= 140 mmHg or DBP >= 90 mmHg); baseline ECG abnormalities including QTc > 470 msec, complete LBBB, ischemic ST-T changes, second- or third-degree AV block, or serious brady-/tachyarrhythmias | Active hepatitis B (positive HBsAg) or active hepatitis C (detectable HCV RNA) | Known HIV infection | Gastrointestinal disorder that negatively affects absorption (e.g., short bowel syndrome, severe diarrhea, TPN requirement) | Additional malignancy that is progressing, requires active treatment, or has >= 30% probability of recurrence within 24 months (exceptions: non-melanoma skin cancer after curative therapy, Ta urothelial carcinoma, stage 0 CLL) | Any other severe/uncontrolled medical condition that could compromise participation | Unwilling or unable to comply with the study protocol",Renal cell carcinoma: prior treatment with at least one anti-angiogenic agent; Renal cell carcinoma: prior treatment with a PD-1 or PD-L1 inhibitor; Urothelial carcinoma: prior treatment with a PD-1 or PD-L1 inhibitor; Urothelial carcinoma: prior platinum-based chemotherapy or platinum-ineligible; Prostate cancer: maintain castrate testosterone during study; Washout: PD-1/PD-L1/PD-L2 or CTLA-4 inhibitors within 4 weeks prior to day 1 not allowed; Washout: monoclonal antibody within 4 weeks prior to day 1 not allowed; Washout: investigational drug within 2 weeks prior to day 1 not allowed; Washout: chemotherapy within 2 weeks prior to day 1 not allowed; Washout: radiation or radionuclide therapy within 2 weeks prior to day 1 not allowed,ALL,A,"Disease and setting match metastatic urothelial carcinoma, and the patient has progressed after PD-1 therapy with prior platinum exposure, meeting key cohort requirements. No explicit exclusion conflicts are identified from the provided information.",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),CORRECT,A,"No hard exclusions identified. Disease matches metastatic urothelial carcinoma. Stage/setting matches (metastatic), and line/prior exposure matches (prior PD-1 inhibitor and prior platinum). No soft conflicts evident from provided data. Therefore A is appropriate per rubric.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT04449549,0.7859668731689453,Recurrent Clear Cell Ovarian Carcinoma,Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel,PHASE2,18 years to 120 years,Granulosa Cell Ovarian Cancer; Clear Cell Ovarian Cancer; Anal Cancer; Ewing Sarcoma,Histologically confirmed rare solid tumor progressed on standard therapy known to prolong survival or with no standard treatment options | Measurable and evaluable disease | Age >= 18 years | ECOG performance status <=2 | Adequate organ and marrow function per protocol-defined labs | Completion of radiation therapy or major surgery >=3 weeks prior to enrollment | Completion of biologic therapy or chemotherapy >=5 half-lives or 3 weeks (whichever is shorter); 6 weeks for nitrosoureas or mitomycin C | >=2 weeks since prior Phase 0 (or equivalent) study drug | >=1 week from palliative radiation therapy to non-target lesions (after 2 cycles may be permitted at PI discretion) | Recovered to eligibility levels from prior therapy-related toxicity/adverse events | Women of childbearing potential and men agree to use adequate contraception during treatment and for 3 months after last dose | HIV-infected patients on effective antiretroviral therapy with undetectable viral load within 6 months are eligible; HIV viral load test within 28 days prior to enrollment,"QTcF interval >=450 msec at study entry or congenital long QT syndrome | Sensory or motor neuropathy >= Grade 2 | Concurrent treatment with other investigational agents | Primary CNS malignancy or symptomatic CNS metastases (exceptions for asymptomatic untreated or treated CNS disease meeting protocol criteria) | History of allergic reactions to compounds of similar chemical or biologic composition to study drugs | Uncontrolled intercurrent illness (e.g., serious untreated infection, symptomatic respiratory failure, congestive heart failure, unstable angina, significant arrhythmia, or psychiatric/social conditions limiting compliance) | Pregnancy or breastfeeding",Progressed on prior standard therapy known to prolong survival or no standard options available; Washout: radiation therapy or major surgery >=3 weeks before enrollment; Washout: biologic therapy or chemotherapy >=5 half-lives or 3 weeks (whichever is shorter); 6 weeks for nitrosoureas or mitomycin C; Washout: >=2 weeks since prior Phase 0 or equivalent study drug; Washout: >=1 week from palliative radiation therapy to non-target lesions; Recovery to eligibility levels from prior treatment-related toxicity,ALL,A,"Disease matches the trial’s clear cell ovarian cancer cohort, and the patient has recurrent disease after standard platinum/taxane/bevacizumab therapy, fitting the post-standard therapy setting. Age and sex meet eligibility, and no explicit exclusions are triggered by available data.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; BRCA1 positive; Optimal debulking surgery performed; Received adjuvant carboplatin + paclitaxel + bevacizumab; Cytology-positive malignant pleural effusion at 5 months post-adjuvant,(none),Carboplatin; Paclitaxel; Bevacizumab; Optimal debulking surgery,Stage III,,36,years,female,(none),CORRECT,A,"Disease matches (clear cell ovarian cancer cohort). Patient has recurrent disease after standard platinum/taxane/bevacizumab, satisfying post-standard therapy setting. Age/sex within bounds. No explicit exclusion identified. At least two core anchors match (stage/setting and line/prior), so A is appropriate.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT04592237,0.6147758960723877,Castration-Resistant Prostate Cancer,Randomized Phase II Study of Platinum-Taxane-Cetrelimab Induction Followed by Niraparib Plus or Minus Cetrelimab Maintenance in Men With Aggressive Variant Prostate Cancers,PHASE2,18 years,Aggressive Variant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Metastatic Prostate Neuroendocrine Carcinoma; Metastatic Prostate Small Cell Carcinoma; Stage IV Prostate Cancer,"Histologically or cytologically confirmed prostate carcinoma | Metastatic disease documented on imaging (bone scan, CT and/or MRI) | Meets at least one aggressive variant prostate carcinoma (AVPC) criterion | Histologically proven small cell (neuroendocrine) prostate carcinoma (AVPC criterion) | Exclusive visceral metastases (AVPC criterion) | Predominantly lytic bone metastases by x-ray or CT (AVPC criterion) | Bulky (>= 5 cm) lymphadenopathy or high-grade tumor mass in prostate/pelvis (AVPC criterion) | Low PSA (<= 10 ng/mL) at initial presentation or at symptomatic progression in the castrate-setting plus high-volume (>= 20) bone metastases (AVPC criterion) | Elevated LDH (>= 2 x ULN) or elevated CEA (>= 2 x ULN) without other etiologies (AVPC criterion) | Short interval (<= 180 days) to castration-resistant progression after initiation of hormonal therapy (AVPC criterion) | Loss or mutation in at least 2 of TP53, RB1, and PTEN by CLIA-certified testing, IHC and/or DNA sequencing (AVPC criterion) | Castration-resistant progression per RECIST without PSA rising to >= 1.0 ng/mL per PCWG3 (AVPC criterion) | Documented progressive disease by PSA progression (3 measurements >= 7 days apart with last >= 1.0 ng/mL), or new/increasing measurable disease (RECIST), or >= 2 new bone lesions (PCWG3), or increasing symptoms attributed to progression | Surgically or medically castrated with baseline testosterone <= 50 ng/dL | ECOG performance status <= 2 | Hemoglobin >= 10.0 g/dL (>= 8 g/dL if due to marrow infiltration) | Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1.0 x 10^9/L if due to marrow infiltration) | White blood cells (WBC) > 3 x 10^9/L (> 2 x 10^9/L if due to marrow infiltration) | Platelet count >= 100 x 10^9/L (>= 50 x 10^9/L if due to marrow infiltration) | Total bilirubin <= 1.5 x ULN (except Gilbert syndrome) | AST and ALT <= 2.5 x ULN (<= 5 x ULN with liver metastases) | Calculated creatinine clearance (Cockcroft-Gault) >= 30 mL/min | No features suggestive of MDS/AML on peripheral blood smear | Able to swallow study drugs whole (tablet/capsule)","Any prior treatment for CRPC with carboplatin, cisplatin, cabazitaxel, a PARP inhibitor, or an anti-PD-1/PD-L1 inhibitor | More than one prior line of chemotherapy | Unresolved toxicity from prior therapy > CTCAE grade 2 (except allowed ongoing LHRH therapy, bisphosphonates, or RANK ligand inhibitors) | Any unresolved CTCAE grade >= 2 toxicity from previous anti-cancer therapy (irreversible toxicities not expected to be exacerbated may be allowed) | History or current diagnosis of myelodysplastic syndrome or acute myeloid leukemia | Active uncontrolled infection | Active or symptomatic viral hepatitis or chronic liver disease | History of pneumonitis or extensive bilateral non-malignant lung disease | Another malignancy with >= 30% probability of recurrence within 24 months (except adequately treated non-melanoma skin cancer, curatively treated in-situ cervical cancer, or Ta urothelial carcinoma) | Serious underlying medical or psychiatric condition that would make study drug hazardous or confound adverse event interpretation (e.g., uncontrolled ventricular arrhythmia, recent myocardial infarction, superior vena cava syndrome, uncontrolled seizures, history of allogeneic transplant, primary immunodeficiency) | Unable to swallow oral medication or gastrointestinal disorders likely to interfere with absorption | Symptomatic uncontrolled brain metastases or spinal cord compression | Known hypersensitivity to niraparib, carboplatin, cabazitaxel, or anti-PD-1/PD-L1 inhibitors | Current or prior use of systemic immunosuppressive medication within 28 days before first cetrelimab dose (with specified corticosteroid exceptions) | Active or prior documented autoimmune or inflammatory disorders requiring systemic therapy (with specified exceptions such as vitiligo, alopecia, controlled hypothyroidism, certain inactive diseases, or celiac disease controlled by diet) | Receipt of live attenuated vaccine within 30 days prior to cetrelimab | Compulsory detention for treatment of psychiatric or physical illness",(none),MALE,A,"Stage/setting and prior-exposure requirements match (metastatic CRPC; no prior platinum, cabazitaxel, PARP, or PD-1/PD-L1). AVPC features are required but not provided; if he meets at least one AVPC criterion, he appears eligible.",Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),INCORRECT,C,"No hard exclusions. Stage/setting and prior-exposure anchors match (2 anchors). However, A requires required biomarker/subtype be satisfied when applicable; AVPC criterion is required and is unknown for this patient. With key required subtype unknown and no soft mismatches, the correct grade is C, not A.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT04847739,0.6389323472976685,Fistulizing Crohn's Disease,Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II),PHASE2,18 years to 70 years,Crohn's Disease; Perianal Fistula,Age 18-70 years | Crohn's disease diagnosed >=6 months | Single fistula tract with one internal and one external opening | Prior biologic or conventional therapy for fistula with failed response or documented intolerance,"Clinically significant medical conditions within 6 months compromising safety or compliance | Hepatitis B, hepatitis C, or HIV infection, or congenital/acquired immunodeficiencies | Participation in an investigational drug study within 30 days or investigational device study within 1 year involving rectum/vagina/fistula area or potentially interacting with study treatment | History of invasive cancer (including melanoma) within 5 years except localized skin cancers | Pregnant, attempting pregnancy, or breastfeeding | Allergy/hypersensitivity to aminoglycosides or contraindications to MR/MR contrast | History of clinically significant fat-directed autoimmunity | Genitourinary fistulization including rectovaginal fistula | Presence of an ileal anal pouch | Active, unresolved infection requiring parenteral antibiotics | Major gastrointestinal surgery within 3 months (stoma allowed) | Definitive surgical procedure for the target fistula or perianal procedure causing large soft tissue defect within 6 months | Compromised adipose harvest site (e.g., prior cool sculpting, local radiation, chemotherapy, recent tattoos, local infection) | Prior Cx601/Alofisel or other allogeneic/autologous stem-cell therapy within 6 months | Contraindications to local or general anesthesia or to adipose tissue collection | Horseshoe fistulas | Fistulas without an internal opening in anal canal or low rectum | Blind-ending sinus tracts (no external opening) | Branching fistulas (unless previously converted to a single tract) | More than one internal opening | Moderate or severe proctitis | Severe rectal mucosal fibrosis preventing securing of fistula plug cap | Any anatomical limitation preventing successful securing of the fistula plug cap | Moderately or greater active luminal Crohn's disease on colonoscopy | Use of systemic or rectal steroids for Crohn's disease within 2 weeks prior to screening/baseline | History of high-grade dysplasia, adenocarcinoma, or carcinoma in situ on colonoscopy within 5 years | Renal insufficiency: creatinine >1.8 mg/dL, eGFR <44 mL/min, or dialysis | Hemoglobin <8 g/dL | AST or ALT >2 x ULN | Unresolved abscess within the fistula tract | Coagulopathy (abnormal INR) or platelet count <75,000/µL | History of substance abuse interfering with protocol compliance",Failed prior biologic or conventional therapy for perianal fistula; No investigational drug within 30 days prior to screening; No investigational device implanted near fistula region within 1 year prior to screening; No systemic or rectal steroids within 2 weeks prior to screening/baseline; No prior Cx601/Alofisel or other stem-cell therapy within 6 months,ALL,A,"Disease and setting match perianal fistulizing Crohn’s; age and sex fit. He has failed prior biologics (infliximab, ustekinumab), satisfying prior-therapy requirements, and no explicit exclusion is triggered by the provided data.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),INCORRECT,D,"Disease matches and prior-therapy requirement matches, but there is a specific soft mismatch: the patient has moderate-to-severe luminal Crohn’s disease (CDAI 350), while the trial excludes moderately or greater active luminal disease (assessed by colonoscopy). Although not an explicit hard exclusion due to measurement modality, it is a clear stage/setting conflict, warranting D rather than A.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT05086692,0.7261306047439575,Recurrent Clear Cell Ovarian Carcinoma,"A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors",PHASE1/PHASE2,18 years,Acral Melanoma; Basal Cell Carcinoma; Bladder Cancer; Cervical Cancer; Clear Cell Renal Cell Carcinoma; Colorectal Cancer (MSI-H); Cutaneous Melanoma; Cutaneous Squamous Cell Carcinoma; Endometrial Cancer; Epithelial Ovarian Carcinoma; Esophageal Cancer; Fallopian Tube Cancer; Gastric Cancer; Gastroesophageal Junction Cancer; Merkel Cell Carcinoma; Mucosal Melanoma; Non-Small Cell Lung Cancer (non-squamous); Non-Small Cell Lung Cancer (squamous); Pancreatic Adenocarcinoma (MSI-H); Pleural Mesothelioma; Primary Peritoneal Cancer; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Cancer,Age >= 18 years | ECOG 0–1 | Histologically or cytologically confirmed locally advanced or metastatic solid tumor | Adequate organ function | Measurable disease per RECIST v1.1 | Life expectancy >= 12 weeks | Women of childbearing potential: negative pregnancy test at screening and within 72 hours before first dose | Women must not be breastfeeding | Use of highly effective contraception,"Prior systemic anti-cancer therapy within 4 weeks before start of treatment | Prior radiotherapy within 2 weeks before start of treatment | History of radiation pneumonitis | Radiation therapy to the lung > 30 Gy within 6 months before start of treatment | Participation in an investigational agent/device study within 4 weeks before start of treatment | Active central nervous system metastases or carcinomatous meningitis | Active malignancy other than the disease under treatment within the previous 3 years (except curable cancers) | Requirement for systemic corticosteroids > 10 mg prednisone equivalent daily or other immunosuppressive therapy within 7 days prior to treatment | Clinically significant active, known or suspected autoimmune disease or conditions exacerbated by immunotherapy | Severe pulmonary, cardiac, or other systemic disease | Known hepatitis B or hepatitis C virus infection | Pregnant or lactating or planning to become pregnant during the study | History of allogeneic tissue/solid organ transplant | Active infection requiring systemic therapy | Severe hypersensitivity to components of study drugs",Washout >= 4 weeks from prior systemic anti-cancer therapy (shorter interval may be considered for kinase inhibitors or short half-life drugs); Washout >= 2 weeks from prior radiotherapy; Washout >= 1 week for palliative radiotherapy (< 2 weeks of RT) to non-CNS disease; No radiation therapy to the lung > 30 Gy within 6 months prior to treatment; No participation in an investigational agent or device study within 4 weeks prior to treatment,ALL,A,"The trial includes epithelial ovarian carcinoma and targets advanced/metastatic disease, matching this patient's recurrent setting; prior platinum/taxane/bevacizumab is allowed with standard washout. No explicit exclusions are triggered; other requirements (ECOG, measurable disease) are unspecified rather than conflicting.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; BRCA1 positive; Optimal debulking surgery performed; Received adjuvant carboplatin + paclitaxel + bevacizumab; Cytology-positive malignant pleural effusion at 5 months post-adjuvant,(none),Carboplatin; Paclitaxel; Bevacizumab; Optimal debulking surgery,Stage III,,36,years,female,(none),CORRECT,A,"No hard exclusions. Disease matches (epithelial ovarian carcinoma includes clear cell). Stage/setting matches (recurrent/metastatic). Prior therapy/line compatible with only washout required and no prohibited exposures. No soft conflicts identified; other criteria (ECOG, measurable disease) are unknown, not mismatches. ≥2 core anchors match, so A is appropriate.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT05215574,0.7893915772438049,Metastatic Urothelial Carcinoma,A Phase 1 Dose Escalation/Dose Finding Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors,PHASE1,18 years,Bladder Urothelial Cancer; Breast Cancer; Cervical Cancer; Cholangiocarcinoma; Colorectal Carcinoma; Endocervical Cancer; Esophageal Cancer; Gastric Cancer; Melanoma; Mesothelioma; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Renal Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck,"Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy. | Adequate bone marrow, kidney and liver function. | Performance status of 0 or 1. | Acute effects of prior therapy resolved to baseline severity or CTCAE Grade 1 (except AEs not constituting a safety risk per investigator).",Prior treatment targeting ILT3. | Prior treatment targeting LAIR1.,Prior anticancer therapy permitted if acute effects have resolved to baseline or CTCAE Grade 1.,ALL,A,The trial includes metastatic urothelial/bladder cancer and allows prior therapies including PD-1; the patient’s metastatic setting and treatment history fit without disqualifying exclusions. ECOG and renal adequacy are unspecified for the patient and thus treated as neutral.,Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches (urothelial/bladder). Stage/setting (metastatic) matches and prior therapy/line is compatible for a phase 1 solid tumor trial. Biomarker not required; mets pattern not constrained. Renal function adequacy threshold is unspecified, so cannot infer a mismatch. Thus ≥2 core anchors match with no soft conflicts → A.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT05236036,1.0,Recurrent Glioblastoma,A Phase 1/1b Adaptive Dose Escalation Study of Mycophenolate Mofetil (MMF) in Combination With Standard of Care for Patients With Glioblastoma,PHASE1,18 years,Glioblastoma (IDH-wildtype); Recurrent Glioblastoma; Astrocytoma,"Histologically confirmed glioblastoma, IDH wild-type (IHC R132H negative or sequencing); astrocytoma with molecular features of GBM eligible | Newly diagnosed glioblastoma with prior surgical resection or biopsy; cohort-specific requirements per Group 1-3 | Group 2: Documented MGMT-unmethylated glioblastoma | Group S: Newly suspected or recurrent glioblastoma and scheduled for standard-of-care surgical resection or biopsy | Stable or decreasing corticosteroids at <= 8 mg dexamethasone daily for >= 7 days prior to registration | Age >= 18 years | Karnofsky performance status >= 70% | WBC >= 3,000/µL (within 14 days) | ANC >= 1,500/µL (within 14 days) | Hemoglobin >= 8 g/dL (within 14 days) | Platelets >= 100,000/µL (within 14 days) | Total bilirubin <= 2 x ULN (within 14 days) | AST/ALT <= 3 x ULN (within 14 days) | Creatinine <= 1.5 x ULN (within 14 days) | INR <= 1.5 x ULN (within 14 days) | PT/PTT <= 1.5 x ULN (within 14 days) | Females of childbearing potential: negative pregnancy test within 14 days prior to registration","Receiving other investigational agents (COVID-19 vaccine or treatment allowed) | Prior or concurrent malignancy that may interfere with study treatment or safety (per investigator discretion) | History of allergic reactions to temozolomide or mycophenolate mofetil or similar compounds | Spinal cord and diffuse leptomeningeal disease glioblastoma | Live vaccination within 2 weeks before initiation of MMF and/or TMZ | Current viral-vector based therapy | Uncontrolled epilepsy | Uncontrolled intercurrent illness | Concurrent malignancy outside of glioblastoma requiring tumor-directed treatment | Known hypoxanthine-guanine phosphoribosyltransferase (HGPRT) deficiency (e.g., Lesch-Nyhan or Kelley-Seegmiller syndromes) | Known concurrent shingles, herpes, or cytomegalovirus (CMV) infection | Known concurrent opportunistic fungal infection | Known concurrent or history of unexplained opportunistic infection | Known immunodeficiency that could predispose to opportunistic infections | Psychiatric illness or social conditions limiting compliance or compromising safety | Pregnant or nursing | Unable to swallow oral medication or conditions affecting absorption of oral medication | Known history of HIV, HBV, or HCV infection",Prior surgical resection or biopsy required for Groups 1-3; Group 1: Prior chemoradiation completed; Group 2: Surgical resection or biopsy only (no prior chemoradiation); Group 3: Surgical resection or biopsy only; Group S: Planned standard-of-care surgical resection or biopsy,ALL,A,"The patient has recurrent IDH-wildtype glioblastoma, matching the disease and biomarker requirements, and prior chemoradiation/temozolomide is compatible with trial cohorts. Age/sex fit; KPS, labs, steroid stability, and surgery planning are unknown but not conflicting.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),INCORRECT,B,"No hard exclusions. Disease and IDH-wildtype match. However, stage/setting is uncertain because the recurrent cohort appears to require planned surgery (Group S), which is not provided; Groups 1–3 seem for newly diagnosed. Line/prior compatibility for the applicable recurrent cohort is therefore unknown. Only one clear core anchor (biomarker) matches, so B is appropriate rather than A.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT05347095,0.6739141345024109,Fistulizing Crohn's Disease,"A Phase 3, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease",PHASE3,18 years,Perianal Crohn's Disease,"Diagnosis of Crohn's disease for >= 3 months | At least one active draining perianal fistula confirmed by screening MRI | Previously had inadequate initial response, loss of response, or intolerance to therapy from up to 2 classes of advanced drug therapies approved for Crohn's disease (e.g., infliximab, adalimumab, certolizumab pegol, vedolizumab or approved biosimilars) or a JAK inhibitor licensed for Crohn's disease (e.g., upadacitinib)","Very severe luminal Crohn's disease activity | History of rectovaginal fistulas, rectal and/or anal stenosis, stoma or functioning ostomy, undrained abscess/collections, colonic mucosal dysplasia or pre-cancerous lesions not removed, demyelinating disease, or systemic lupus erythematosus | Complications of Crohn's disease anticipated to require surgery or preclude fistula evaluation (e.g., symptomatic strictures/stenoses, short gut syndrome) | Any medical contraindications preventing study participation | History of ongoing, chronic, or recurrent enteral or systemic infectious disease","Prior exposure to up to 2 classes of advanced therapies for Crohn's disease (anti-TNF agents, vedolizumab, or JAK inhibitor such as upadacitinib); Documented inadequate response, loss of response, or intolerance to the above therapies",ALL,A,"Disease and setting match (active draining perianal fistula in Crohn's), and prior therapy exposure aligns (failed anti-TNF and another advanced class within the allowed up to 2 classes). Age/sex fit; MRI confirmation and absence of undrained abscess are unknown but not conflicting.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,A,No hard exclusions. Disease matches (perianal fistulizing Crohn’s). Stage/setting matches (active draining perianal fistula). Prior therapy exposure matches (failed anti-TNF and another advanced class; within up to two classes). Age/sex fit. Unknown MRI confirmation and abscess status are neutral per rubric. Thus ≥2 core anchors match with no soft conflicts → A. The grader’s reasoning aligns with the rubric.,,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT05394831,0.7731086015701294,Metastatic Non-Small Cell Lung Cancer,"A Phase 1/2, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of JIN-A02 in Patients With EGFR Mutant Advanced Non-small Cell Lung Cancer",PHASE1/PHASE2,18 years,Non-small Cell Lung Cancer (advanced/metastatic),"Age >= 18 years (>= 19 years in South Korea) | Pathologically confirmed advanced and/or metastatic non-small cell lung cancer with active EGFR mutation | Disease progression after standard therapy including an approved EGFR-TKI and/or up to 1 line of platinum-based chemotherapy | For Part C: prior approved EGFR-TKI active against T790M (e.g., osimertinib) required | Locally confirmed EGFR mutation by sponsor-approved test from tumor tissue and/or plasma ctDNA | Part A/B: EGFR C797S or EGFR T790M positive | Part C Cohort 1: EGFR C797S and T790M positive | Part C Cohort 2: EGFR C797S positive and T790M negative | Part C Cohort 3: EGFR T790M positive and C797S negative | Part C Cohort 4: any EGFR mutation with stable brain metastasis | Part C Cohort 5: EGFR-dependent mutation other than C797S or T790M | For Part C: at least one measurable lesion per RECIST v1.1 not previously irradiated | ECOG performance status 0–1 | Toxicities from prior therapy recovered to baseline or <= grade 1 (exceptions allowed for chronic <= grade 2 conditions per investigator) | Adequate bone marrow and organ function","NSCLC with mixed squamous histology or histologic transformation (e.g., transition to small cell lung cancer or epithelial–mesenchymal transition) | For Part A/B and Part C Cohort 4: uncontrolled CNS metastases, leptomeningeal disease, or need for steroid escalation within 28 days (unless stable after local CNS therapy per protocol timeframe) | EGFR-TKI treatment within 7 days before first dose | Systemic anticancer therapy within 14 days or 5 half-lives (whichever is shorter) before first dose | Limited field radiotherapy within 7 days or extended field chest radiotherapy within 14 days before first dose | Immunotherapy or other antibody therapy within 28 days before first dose | Not recovered from major surgery or its side effects within 28 days before first dose (excluding vascular access placement) | QTcF > 470 ms | Clinically significant and uncontrolled cardiac arrhythmia (e.g., type II second-degree or third-degree heart block) | Risk factors for QT prolongation or torsades de pointes (e.g., hypokalemia, congenital long QT, pertinent family history, or concomitant QT-prolonging drugs) | Uncontrolled hypertension: systolic blood pressure > 180 mmHg or diastolic blood pressure > 100 mmHg | Congestive heart failure NYHA class III–IV or hospitalization for heart failure within 6 months | Acute myocardial infarction or unstable angina within 6 months | Active second malignancy within 2 years (except adequately treated basal/squamous skin cancer or carcinoma in situ) | History/evidence of interstitial lung disease or steroid-requiring pneumonitis (COVID-19-related prior ILD may be eligible with approval) | Inability to swallow oral medication or significant gastrointestinal disorder causing malabsorption | Uncontrolled active infections including HIV, HBV, HCV, or tuberculosis | Known hypersensitivity to JIN-A02 or its components | History of drug abuse or unstable medical, mental, or social conditions interfering with study participation | Unable to comply with study procedures",Progression after an approved EGFR-TKI; Up to one prior line of platinum-based chemotherapy; For Part C: prior osimertinib (or another T790M-active EGFR-TKI) required,ALL,A,"Metastatic NSCLC with an active EGFR mutation (exon 19 deletion) matches the disease/biomarker requirements, and prior osimertinib exposure aligns with Part C. Progression status and brain metastasis stability are unspecified but not stated as conflicting.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches EGFR-mutant metastatic NSCLC. Core anchors: Stage/setting matches; Biomarker requirement (active EGFR mutation) matches. Line/prior progression requirement is unknown (not a soft mismatch). Brain metastasis stability is also unknown, not a soft mismatch. Thus ≥2 anchors match with no soft conflicts → A. The grader’s reasoning is acceptable.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT05465954,0.7280534505844116,Recurrent Glioblastoma,Efficacy and Safety Study of Neoadjuvant Efineptakin Alfa (NT-I7) and Pembrolizumab in Recurrent Glioblastoma,PHASE2,18 years,"Glioblastoma (recurrent, IDH-wildtype); Gliosarcoma (recurrent)","Age >= 18 years | WHO Grade IV IDH-wildtype glioblastoma or gliosarcoma with tissue-confirmed progressive or recurrent disease | Previously treated with maximal feasible resection or biopsy, radiation, and temozolomide | Enhancing mass on MRI amenable to resection or biopsy | ECOG performance status 0–1 | Karnofsky performance status >= 70","Life-threatening raised intracranial pressure requiring immediate surgery | Bevacizumab use within <= 4 months prior to registration | Live vaccine within <= 30 days prior to registration | Requirement for dexamethasone dose > 2 mg/day within <= 2 days prior to registration | Failure to recover from adverse events of prior major surgery within <= 28 days | Failure to recover from adverse events of prior radiation therapy within <= 14 days | Severe uncontrolled systemic illness or condition that would interfere with study assessments | Known HIV infection | Uncontrolled intercurrent illness (active infection, symptomatic CHF, unstable angina, cardiac arrhythmia, significant psychiatric or social illness) | Concurrent treatment with another investigational agent | Another active malignancy requiring systemic treatment within <= 1 year | Myocardial infarction within <= 6 months or congestive heart failure requiring maintenance therapy for life-threatening ventricular arrhythmias | Active autoimmune disease requiring systemic treatment within <= 2 years | Concurrent known active hepatitis B and active hepatitis C infection | Known active tuberculosis | History of (non-infectious) pneumonitis or interstitial lung disease that required steroids, or current pneumonitis/interstitial lung disease | Hypersensitivity to pembrolizumab or its excipients | Prior anti-PD-1/PD-L1/PD-L2 therapy within < 12 months prior to registration | History of allogeneic tissue/solid organ transplant",Prior maximal feasible resection or biopsy required; Prior radiation therapy required; Prior temozolomide required; No bevacizumab within 4 months prior to registration; No live vaccine within 30 days prior to registration; No major surgery within 28 days prior to registration; No radiation therapy within 14 days prior to registration; No prior anti-PD-1/PD-L1/PD-L2 therapy within 12 months prior to registration,ALL,A,"Recurrent IDH-wildtype glioblastoma after resection, radiation, and temozolomide with ECOG 1 matches the trial’s disease, setting, and prior-therapy requirements; age and sex are eligible and no exclusions (e.g., recent bevacizumab or prior PD-1) are indicated. Items like an enhancing lesion amenable to resection/biopsy and steroid dose are not provided and would need confirmation.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches (recurrent IDH-wildtype GBM). Core anchors: Stage/setting (recurrent) matches; Line/prior-exposure (prior surgery, RT, temozolomide; no prior PD-1) matches; required biomarker (IDH-wildtype) satisfied. No identified soft conflicts; unknowns like resectability/steroid dose are neutral. Grade A is appropriate.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT05681780,0.8000652194023132,Metastatic Non-Small Cell Lung Cancer,Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (CD40L TIL) for Patients With Oncogene-Driven Advanced Non-Small Cell Lung Cancer (NSCLC),PHASE1,18 years,Non-small Cell Lung Cancer (metastatic/recurrent),"Age >= 18 years | Stage IV or recurrent non-small cell lung cancer | Activating genomic alteration in EGFR, ALK, ROS1, or ERBB2 | ECOG performance status 0–1 | Expected survival >= 4 months | Progression after >= 1 prior line of systemic therapy for NSCLC | Prior appropriate targeted therapy for the relevant genomic alteration | Measurable disease (excluding lesion used for TIL harvest) prior to nivolumab start | Safely accessible tumor for TIL harvest by excisional biopsy expected to yield >= 1.5 cm3 of tissue (aggregate) | Brain metastases allowed if treated or clinically stable <= 10 mm or not requiring immediate CNS-specific therapy | Adequate organ and marrow function | DLCO >= 45% predicted within past 4 months | HIV: on effective ART >= 6 months with undetectable viral load and normal CD4 count | Chronic HBV: undetectable viral load on suppressive therapy if indicated and no overt cirrhosis | HCV: treated and cured, or on treatment with undetectable viral load and no overt cirrhosis | Prior or concurrent malignancy allowed if it will not interfere with safety or efficacy assessment","More than six prior lines of systemic therapy for NSCLC | Any prior PD-1 or PD-L1 inhibitor for metastatic NSCLC | Rapidly progressing tumors per investigator judgment | Active or prior documented autoimmune disease within the past 2 years (except allowed limited conditions with approval) | Active leptomeningeal or pachymeningeal metastases, or carcinomatous meningitis | Primary immunodeficiency | Chronic systemic steroid therapy or other immunosuppressive therapy within 7 days prior to enrollment (except allowed physiologic or topical/inhaled steroids) | Uncontrolled intercurrent illness (e.g., symptomatic congestive heart failure, unstable angina, significant arrhythmia other than AF/SVT, >= 85% carotid artery stenosis) | Unresolved >= grade 2 toxicity from prior anticancer therapy (unless irreversible and not expected to be exacerbated) | QTc >= 480 ms (Bazett) | Active systemic infection requiring intravenous antibiotics within 1 week prior to nivolumab | History of allogeneic organ transplant | Psychiatric illness or social situation limiting compliance | History of anaphylaxis to beta-lactam antibiotics",At least one prior line of systemic therapy for NSCLC required; Appropriate prior targeted therapy required for the relevant genomic alteration,ALL,A,"The patient has metastatic NSCLC with an activating EGFR exon 19 deletion, meeting the disease and biomarker requirements; age/ECOG fit and prior therapy (osimertinib) without PD-1 exposure aligns with trial expectations. Progression status and brain metastasis stability are unspecified but not explicit conflicts.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches. Core anchors: Stage/setting (metastatic) matches; required biomarker (EGFR exon 19) matches. Line/prior compatibility largely fits (≥1 prior line with appropriate targeted therapy; no PD-1), though progression status is unknown and brain mets stability is unknown—neither is a soft mismatch. With ≥2 anchors matched and no soft conflicts, grade A is appropriate. The grader’s reasoning aligns with the rubric.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT05920798,0.8471245765686035,Recurrent Clear Cell Ovarian Carcinoma,"MC220601, Folate Receptor Alpha Dendritic Cells (FRαDCs) Plus Pembrolizumab for Patients With Advanced Stage Ovarian Cancer (FRAPPE)",PHASE1/PHASE2,18 years,Ovarian Carcinoma (recurrent); Ovarian Clear Cell Adenocarcinoma (recurrent); Ovarian Endometrioid Adenocarcinoma (recurrent); Ovarian High Grade Serous Adenocarcinoma (recurrent); Ovarian Carcinosarcoma (recurrent); Fallopian Tube Carcinoma (recurrent); Fallopian Tube Clear Cell Adenocarcinoma (recurrent); Fallopian Tube Endometrioid Adenocarcinoma (recurrent); Fallopian Tube High Grade Serous Adenocarcinoma (recurrent); Fallopian Tube Carcinosarcoma; Primary Peritoneal Carcinoma (recurrent); Primary Peritoneal Clear Cell Adenocarcinoma (recurrent); Primary Peritoneal Endometrioid Adenocarcinoma (recurrent); Primary Peritoneal High Grade Serous Adenocarcinoma (recurrent); Primary Peritoneal Carcinosarcoma (recurrent),"Age >= 18 years | Histologically confirmed recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (high grade serous, endometrioid, or clear cell; mixed carcinomas/carcinosarcomas eligible if >= 50% high grade serous and/or endometrioid and/or clear cell) | Platinum-refractory, platinum-resistant, or platinum-sensitive recurrence | Measurable disease per RECIST v1.1 and/or CA-125-evaluable disease by GCIG | ECOG performance status 0-1 | Hemoglobin >= 8.5 g/dL | Absolute neutrophil count >= 1000/µL | Platelet count >= 75000/µL | Lymphocytes >= 300/µL | Monocytes >= 250/µL | Total bilirubin <= 1.5 x ULN (if Gilbert's, direct bilirubin <= ULN) | AST <= 3 x ULN | Creatinine clearance >= 30 mL/min","Pregnant or nursing | Persons of childbearing potential or able to father a child unwilling to use adequate contraception | Prior anti-PD-1 or anti-PD-L1 therapy for ovarian cancer | IV anti-cancer therapy <= 3 weeks or oral anti-cancer therapy <= 1 week prior to registration | Grade >= 2 ovarian cancer-related symptoms, or lesion > 5 cm (non-nodal long axis or nodal short axis), or disease likely to become symptomatic within 8 weeks | Significant comorbid illness that would interfere with study treatment or assessments | Uncontrolled HIV infection; HIV must be well controlled on ART with CD4 >= 350/µL and suppressed HIV RNA | Ongoing or active serious infection requiring systemic therapy | Current or prior immune-related pneumonitis or interstitial lung disease requiring steroids | Active autoimmune disease requiring systemic treatment within 2 years (except replacement therapy) | Active hepatitis B (unless on antivirals with undetectable HBV DNA) or active hepatitis C (unless successfully treated with undetectable HCV RNA) | Other active malignancy requiring palliative systemic therapy within 3 years or likely to require treatment in next 2 years (except non-melanoma skin cancer, papillary thyroid cancer not requiring therapy, or carcinoma in situ) | Myocardial infarction within 6 months or congestive heart failure requiring ongoing maintenance therapy for life-threatening ventricular arrhythmias | Systemic immunosuppressive medication within 7 days prior to registration (except permitted low-dose or inhaled steroids) | History of allogeneic stem cell transplant","Any number of prior therapies or maintenance regimens for ovarian cancer allowed; Eligible regardless of platinum status (platinum-refractory, -resistant, or -sensitive); Washout required: last IV anti-cancer therapy >= 3 weeks; last oral anti-cancer therapy >= 1 week before registration",FEMALE,A,"Recurrent clear cell ovarian carcinoma matches the trial disease; the study permits recurrent cases regardless of platinum status, any prior therapies, and requires no prior PD-1 (which the patient hasn’t received), with age/sex in range. Measurable/CA-125-evaluable disease and symptom/lesion size details are unspecified but no conflicts are evident.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; BRCA1 positive; Optimal debulking surgery performed; Received adjuvant carboplatin + paclitaxel + bevacizumab; Cytology-positive malignant pleural effusion at 5 months post-adjuvant,(none),Carboplatin; Paclitaxel; Bevacizumab; Optimal debulking surgery,Stage III,,36,years,female,(none),CORRECT,A,"No hard exclusions. Disease matches (recurrent clear cell ovarian carcinoma). Stage/setting matches (recurrent). Line/prior exposure compatible (any prior allowed; no prior PD-1). Required histology/subtype satisfied. Other criteria (measurable/CA-125, symptom/lesion size) are unknown and per rubric should not penalize. Therefore ≥2 core anchors match with no soft conflicts → A.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT06177964,0.7747989892959595,Recurrent Glioblastoma,Randomized Phase 2 Clinical Trial of Repeated Intratumoral and Cervical Perilymphatic Lerapolturev Injections Versus Lomustine in Recurrent Glioblastoma (GBM),PHASE2,18 years,"Glioblastoma (recurrent, supratentorial)","Age >= 18 years | Histopathologically confirmed recurrent supratentorial glioblastoma (WHO grade 4) | Karnofsky Performance Score >= 70% | Hemoglobin >= 9 g/dL prior to biopsy | Platelet count >= 100,000/µL prior to biopsy (unsupported) | Neutrophil count >= 1000/µL prior to biopsy | Creatinine <= 1.5 x ULN prior to biopsy | Total bilirubin <= 1.5 x ULN prior to biopsy (Gilbert's syndrome exception) | AST/ALT <= 2.5 x ULN | Prothrombin time and partial thromboplastin time <= 1.2 x ULN prior to biopsy | If on warfarin, INR < 2.0 prior to biopsy | Recurrent tumor presence confirmed by histopathology at time of biopsy prior to first lerapolturev infusion | Able to undergo brain MRI with and without contrast | Completed CDC-recommended poliovirus vaccination series and received IPV booster 1–6 weeks before lerapolturev (or evidence of anti-poliovirus immunity)","Pregnant or breastfeeding | Impending, life-threatening cerebral herniation syndrome | Active infection requiring IV therapy or unexplained febrile illness (Tmax > 99.5°F/37.5°C) | Known immunosuppressive disease or HIV infection | Severe heart disease (NYHA class III or IV) | Known lung disease (FEV1 < 50%) or uncontrolled diabetes mellitus | Known albumin allergy | History of agammaglobulinemia | Chemotherapy or bevacizumab within 4 weeks (nitrosourea within 6 weeks; metronomic daily etoposide or cyclophosphamide within 1 week) prior to study drug unless recovered from toxicities | Immunotherapy within 4 weeks prior to study drug unless recovered from toxicities | Tumor treating fields within 1 week prior to study drug | Less than 12 weeks from radiation therapy unless progression outside field, two progressive scans >= 4 weeks apart, or histopathologic confirmation | Failure to complete standard-of-care treatments including surgery and radiation (age-adjusted dosing) | If MGMT promoter methylated or unknown, lack of at least one prior chemotherapy regimen | Neoplastic lesions in brainstem, cerebellum, or spinal cord | Active multifocal disease, extensive subependymal disease, tumor crossing midline, or leptomeningeal disease | Dexamethasone > 4 mg/day within 2 weeks prior to first lerapolturev infusion | Worsening steroid myopathy | Prior unrelated malignancy requiring current active treatment (except cervical carcinoma in situ and adequately treated basal cell or squamous cell skin cancer) | Active autoimmune disease requiring systemic immunomodulatory treatment within the past 3 months | Known hypersensitivity to lomustine, dacarbazine, or components of lomustine","Maximal safe resection of recurrent tumor prior to study treatment; Completion of standard-of-care radiation therapy (age-adjusted dosing) prior to enrollment; If MGMT promoter methylated or unknown, at least one prior chemotherapy regimen required; Washout: chemotherapy or bevacizumab > 4 weeks (nitrosourea > 6 weeks; metronomic daily etoposide or cyclophosphamide > 1 week) before study drug; Washout: immunotherapy > 4 weeks before study drug; Washout: tumor treating fields > 1 week before study drug; Radiation therapy >= 12 weeks before study drug unless specified progression criteria met; Prior poliovirus vaccination series and IPV booster 1–6 weeks before lerapolturev",ALL,A,"Disease and setting match (recurrent GBM after standard chemoradiation), and prior therapy/exposure are compatible with trial requirements; age and sex are permitted. No explicit exclusions are triggered from available data, and no required biomarker constraints apply.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),CORRECT,A,"No hard exclusions. Disease and recurrent setting match. Prior standard chemoradiation aligns with line/prior requirements. Biomarker/subtype (supratentorial location) is unknown, not a mismatch. No soft conflicts identified. Thus ≥2 core anchors (stage/setting and line/prior) match → A is appropriate.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT06570798,0.7005309462547302,Rheumatoid Arthritis,"A Phase 2a, Open Label, Multicenter, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases",PHASE2,18 years to 75 years,Systemic Lupus Erythematosus (lupus nephritis); Rheumatoid Arthritis (refractory),"Subprotocols A/B: Systemic lupus erythematosus meeting 2019 EULAR/ACR classification criteria | Subprotocols A/B: Positive autoantibody at screening or documented history: ANA >= 1:80 or anti-dsDNA positive or anti-Smith positive | Subprotocols A/B: Active, biopsy-proven proliferative lupus nephritis class III or IV with/without class V features (2018 ISN/RPS) | Subprotocol A: Inadequate response, loss of response, or intolerance to >= 1 KDIGO-recommended therapy; UPCR >= 1.0 mg/mg | Subprotocol B: Inadequate response, loss of response, or intolerance to >= 2 KDIGO-recommended therapies; UPCR >= 1.0 mg/mg | Subprotocols A/B: If on background meds, stable doses prior to Day 1: prednisone <= 20 mg/day for 5 days; hydroxychloroquine <= 400 mg/day (or chloroquine/quinacrine) for 4 weeks; mycophenolate mofetil <= 3 g/day or mycophenolic acid <= 2160 mg/day for 2 weeks; azathioprine <= 2 mg/kg/day for 2 weeks | Subprotocol C: Rheumatoid arthritis meeting 2010 ACR/EULAR classification criteria | Subprotocol C: Active disease: DAS28-CRP > 3.2, >= 6 tender joints, and >= 6 swollen joints at screening | Subprotocol C: Refractory disease: prior treatment with >= 1 csDMARD and (>= 2 bDMARDs of different MOA OR >= 1 bDMARD and >= 1 tsDMARD) | Subprotocol C: Inadequate response despite >= 12 weeks of treatment with a csDMARD, bDMARD, or tsDMARD, or intolerance to these therapies","Subprotocols A/B: eGFR < 30 mL/min (MDRD) | Subprotocols A/B: Significant likely irreversible SLE-related organ damage (e.g., ESRD) | Subprotocols A/B: Acute, severe lupus flare during screening requiring immediate treatment | Subprotocols A/B: Prior kidney transplant or planned transplant during study treatment period | Subprotocols A/B: Other renal diseases that could interfere with lupus nephritis assessment (e.g., diabetic nephropathy) | Subprotocols A/B: Renal biopsy showing pure class V lupus nephritis | Subprotocol C: Other inflammatory joint disease history/current (non-RA) or significant systemic involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis, Felty's syndrome) | Subprotocol C: ACR Functional Class IV",Lupus nephritis: prior inadequate response/loss of response/intolerance to >= 1 (Subprotocol A) or >= 2 (Subprotocol B) KDIGO-recommended therapies; Rheumatoid arthritis: prior >= 1 csDMARD and >= 2 bDMARDs of different MOA OR >= 1 bDMARD and >= 1 tsDMARD; Rheumatoid arthritis: prior exposure >= 12 weeks to csDMARD/bDMARD/tsDMARD or documented intolerance; Allowed background medications if stable: prednisone <= 20 mg/day; hydroxychloroquine <= 400 mg/day (or chloroquine/quinacrine); mycophenolate mofetil <= 3 g/day or mycophenolic acid <= 2160 mg/day; azathioprine <= 2 mg/kg/day,ALL,A,"Disease matches the RA subprotocol, with active, refractory RA and prior MTX plus ≥2 bDMARDs of different MOA; age and sex are within limits, and CKD (eGFR 45) and resolved HBV are not excluded for the RA cohort. Tender/swollen joint counts and DAS28-CRP specifically are not provided, but active disease is documented.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,A,"No hard exclusions: disease (RA) included; age/sex fit; no explicit exclusion for CKD eGFR 45 or resolved HBV in RA cohort. Core anchors: Stage/setting (active, refractory RA) matches; Line/prior-exposure (csDMARD + ≥2 bDMARDs of different MOA) matches. Required RA activity details (DAS28-CRP, joint counts) are partially unknown but not a soft mismatch. Thus A is appropriate.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT06632418,0.6610082387924194,Fistulizing Crohn's Disease,A Randomized Controlled Trial Evaluating the Safety and Feasibility of the Recombinant Human Platelet-derived Growth Factor B (rhPDGF-BB)-enhanced Collagen Plug for Complex Perianal Fistula Healing,PHASE2,22 years,Anal Fistula; Complex Perianal Fistula,Single-tract perianal fistula not amenable to fistulotomy | Draining seton in place | Age >21 years,"Medical condition that compromises safety or ability to follow protocol per investigator | Genitourinary fistulization including rectovaginal fistulas | Presence of an ileal anal pouch | Major gastrointestinal surgery within 3 months | Prior perianal fistula surgery causing large soft tissue defect within 6 months | Horseshoe fistulas, no internal opening in anal canal/low rectum, blind-ending sinus tracts, branching fistulas (unless converted to single tract), >1 internal opening, moderate or severe proctitis, severe rectal mucosal fibrosis preventing securing of plug, or anatomical limitation to securing plug | Allergy to porcine collagen or yeast-derived products | Pregnant, breastfeeding, or planning pregnancy | Active infection at application site | Malignant neoplasms at application site | Prior radiation therapy at application site",(none),ALL,A,"The trial targets complex perianal fistula with a draining seton and age ≥22, which fits this 32-year-old male with active perianal fistula and seton. No exclusions or prior-therapy restrictions are triggered; single-tract status and other anatomic exclusions are unknown rather than conflicting.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),INCORRECT,C,"No hard exclusions identified (age and sex fit; disease is relevant given active perianal fistula). However, core anchors are largely unknown: Stage/setting specifics (e.g., not amenable to fistulotomy) and required anatomic subtype (single-tract) are unknown; line/prior exposure is not specified as required or restricted. Having a draining seton meets one required element but other required subtype features are unknown, so the biomarker/subtype anchor cannot be counted as matched. With 0 confirmed core anchor matches and no soft conflicts, the correct grade is C, not A.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT06660654,0.838748037815094,Recurrent Clear Cell Ovarian Carcinoma,"REJOICE-PanTumor01: A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants With Advanced/Metastatic Solid Tumors",PHASE2,18 years,Endometrial Cancer; Cervical Cancer; Clear Cell Ovarian Carcinoma; Endometrioid Ovarian Cancer (low grade); Serous Ovarian Cancer (low grade); Mucinous Ovarian Cancer; Urothelial Carcinoma; Clear Cell Renal Cell Carcinoma,"Age >= 18 years | At least 1 lesion not previously irradiated | Lesion amenable to biopsy and willingness to provide a pre-treatment biopsy | Measurable disease per RECIST 1.1 | Radiographic progression on or after the most recent line of systemic therapy | ECOG performance status 0–1 | Endometrial cancer: Pathologically or cytologically documented endometrial carcinoma (any histology) or carcinosarcoma, irrespective of MSI/MMR status | Endometrial cancer: Disease progression after 1–3 prior lines including platinum-based chemotherapy and an anti-PD-1–containing regimen (combined or sequential) in the advanced/metastatic setting | Cervical cancer: Pathologically or cytologically documented recurrent or persistent squamous, adenosquamous, or adenocarcinoma of the cervix | Cervical cancer: Disease progression after >=1 prior line of systemic therapy in the advanced or metastatic setting | Non-HGS ovarian cancer: Pathologically or cytologically documented unresectable or metastatic clear cell, low-grade endometrioid, low-grade serous, or mucinous ovarian cancer previously treated with >=1 prior line | Urothelial cancer: Pathologically or cytologically documented unresectable or metastatic urothelial carcinoma of bladder, renal pelvis, ureter, or urethra; histologic variants allowed if predominantly urothelial | Urothelial cancer: Relapsed/progressed after >=1 prior line (maximum 3) that contained anti-PD-(L)1 therapy in the perioperative or metastatic setting | ccRCC: Pathologically or cytologically documented unresectable or metastatic clear cell renal cell carcinoma | ccRCC: Previously treated with <=3 prior systemic regimens for advanced/metastatic RCC, including both a PD-(L)1 checkpoint inhibitor and a VEGF-TKI in sequence or combination","Clinically active brain metastases, spinal cord compression, or leptomeningeal carcinomatosis | Cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event within 6 months | Uncontrolled or significant cardiovascular disease | History of noninfectious ILD/pneumonitis requiring steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis on screening imaging | Clinically severe pulmonary compromise | Chronic steroid treatment >10 mg/day (with protocol-specified exceptions) | History of other active malignancy within 3 years, except those with negligible risk and treated with expected curative outcome | Unresolved toxicities from prior anticancer therapy (except alopecia) not resolved to <= Grade 1 or baseline per NCI-CTCAE v5.0 | Prior exposure to CDH6-targeted agents or to an ADC with an exatecan derivative topoisomerase I inhibitor (e.g., trastuzumab deruxtecan, datopotamab deruxtecan) | Ongoing uncontrolled systemic bacterial, fungal, or viral infection | Active or uncontrolled HIV, HBV, or HCV infection",Progression on or after the most recent line of systemic therapy; Endometrial cancer: 1–3 prior lines including platinum-based chemotherapy and an anti-PD-1–containing regimen; Cervical cancer: >=1 prior line of systemic therapy in advanced/metastatic setting; Non-HGS ovarian cancer: >=1 prior line of therapy; Urothelial cancer: >=1 prior line (max 3) including anti-PD-(L)1 therapy; ccRCC: <=3 prior systemic regimens including both a PD-(L)1 inhibitor and a VEGF-TKI,ALL,A,"Disease matches the clear cell ovarian carcinoma cohort, and the patient has recurrent/metastatic disease after prior systemic therapy (carboplatin/paclitaxel/bevacizumab), meeting stage/setting and prior-line requirements; age/sex also fit. Other requirements (RECIST-measurable disease, biopsy amenability, ECOG) are unknown but not conflicting.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; BRCA1 positive; Optimal debulking surgery performed; Received adjuvant carboplatin + paclitaxel + bevacizumab; Cytology-positive malignant pleural effusion at 5 months post-adjuvant,(none),Carboplatin; Paclitaxel; Bevacizumab; Optimal debulking surgery,Stage III,,36,years,female,(none),CORRECT,A,"No hard exclusions. Disease matches the clear cell ovarian cohort. Stage/setting aligns (recurrent/metastatic with malignant pleural effusion), and prior systemic therapy received with progression afterward meets line/prior requirements. Other criteria (measurable disease, biopsy, ECOG) are unknown, not conflicting. ≥2 core anchors match with no soft mismatches, so A is appropriate.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT06764771,0.8074948191642761,Recurrent Clear Cell Ovarian Carcinoma,A Phase 1/1b Open-label Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors,PHASE1,18 years,Clear-Cell Renal Cell Carcinoma; Clear-Cell Ovarian Cancer; Non-Small Cell Lung Cancer; Colorectal Cancer; Pancreatic Ductal Adenocarcinoma,"Age >= 18 years | Histologically confirmed locally advanced unresectable or metastatic solid tumor | Part 1A tumor types: clear-cell renal cell carcinoma, clear-cell ovarian cancer, non-small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma | Parts 2A, 1D, 2D: clear-cell renal cell carcinoma | Part 1B: solid tumors with KRAS G12C mutation | Part 2B: non-small cell lung cancer with KRAS G12C mutation | Parts 1C, 2C: colorectal cancer with KRAS G12C mutation | ECOG 0–1 | Measurable disease per RECIST v1.1","Untreated central nervous system metastases | Leptomeningeal metastasis | Impaired cardiac function or clinically significant cardiac disease | For adagrasib combination cohorts (Parts 1B, 1C, 2B, 2C): history of pneumonitis or interstitial lung disease | For adagrasib combination cohorts (Parts 1B, 1C, 2B, 2C): history of severe cutaneous adverse reactions including Stevens-Johnson syndrome or toxic epidermal necrolysis",(none),ALL,A,"Disease matches the clear-cell ovarian cancer cohort, and the patient has recurrent/metastatic setting after prior standard therapy, which is allowed; age and sex fit with no conflicting exclusions. Biomarker is not required for this cohort, and no disallowed prior exposures are noted.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; BRCA1 positive; Optimal debulking surgery performed; Received adjuvant carboplatin + paclitaxel + bevacizumab; Cytology-positive malignant pleural effusion at 5 months post-adjuvant,(none),Carboplatin; Paclitaxel; Bevacizumab; Optimal debulking surgery,Stage III,,36,years,female,(none),CORRECT,A,"No hard exclusions. Disease matches clear-cell ovarian cancer cohort. Stage/setting aligns (recurrent with malignant pleural effusion → metastatic). Prior therapies are compatible with a phase 1 study; no disallowed exposures. Biomarker not required for this cohort. At least two core anchors match (stage/setting and line/prior), with no soft mismatches. Grade A is appropriate.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT06784193,0.7955015897750854,Castration-Resistant Prostate Cancer,"A Phase 1 First-in-Human, Open-Label, Multicenter Study of OP-3136 in Adult Participants With Advanced or Metastatic Solid Tumors",PHASE1,18 years,Breast Cancer (ER+ HER2-); Prostate Cancer (castration-resistant metastatic); Non-Small Cell Lung Cancer (metastatic),Advanced or metastatic ER+ HER2- breast cancer (per cohort definitions) | Metastatic castration-resistant prostate cancer | Advanced or metastatic non-small cell lung cancer (Part 1 only) | Part 1A monotherapy: Unresectable or metastatic tumor with no life-prolonging options or intolerant/refractory to available therapies,"Prior therapy with a KAT6A/B inhibitor | Symptomatic visceral disease at risk of short-term life-threatening complications | Known active or symptomatic CNS metastases, carcinomatous meningitis, leptomeningeal disease, or spinal cord compression requiring CNS-directed therapy | CNS disease not clinically and radiologically stable for >= 2 months prior to first dose | Requirement for or current steroid therapy for CNS metastases | History of cerebrovascular disease, including transient ischemic attack, within 6 months prior to first dose | Impaired cardiac function or clinically significant cardiac disease within 6 months prior to first dose",ER+ HER2- mBC Part 1B/Part 2B (combo with fulvestrant): Progressed on or after >=1 prior line including endocrine therapy and a CDK4/6 inhibitor in the advanced/metastatic setting; ER+ HER2- mBC Part 1B/Part 2B (combo with fulvestrant): No more than 2 prior lines of endocrine therapy in the advanced/metastatic setting (Part 2B); no more than 3 prior lines of endocrine therapy with >=1 line combined with a CDK4/6 inhibitor (Part 1B); ER+ HER2- mBC Part 1B: No more than 1 prior line of chemotherapy or an antibody-drug conjugate in the advanced/metastatic setting; ER+ HER2- mBC Part 2A monotherapy: Up to 3 prior lines of endocrine therapy (one with a CDK4/6 inhibitor) and up to 1 prior line of chemotherapy or an antibody-drug conjugate; mCRPC Part 2A monotherapy: Up to 4 prior lines of systemic therapy for prostate cancer; mCRPC Part 2A monotherapy: Prior treatment must include an androgen receptor pathway inhibitor,ALL,A,"Disease and stage match mCRPC; the trial requires prior AR pathway inhibitor exposure, which the patient has (enzalutamide and abiraterone). Age and gender fit, and no explicit exclusions are triggered by available data.",Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),CORRECT,A,No hard exclusions. Disease matches mCRPC; stage/setting matches metastatic; line/prior exposure matches (prior AR pathway inhibitors present and within allowed prior lines is not contradicted). No identified soft conflicts (visceral mets are not documented as symptomatic). An A grade per rubric is appropriate.,,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT06860594,0.8228639364242554,Recurrent Glioblastoma,A Phase I Trial Combining Triapine With Radiation Therapy for Recurrent Glioblastoma or Astrocytoma,PHASE1,18 years,"Recurrent Glioblastoma, IDH-Wildtype; Recurrent Astrocytoma, IDH-Mutant; Recurrent Diffuse Midline Glioma","Histologically, molecularly, or cytologically confirmed recurrent astrocytic tumors: glioblastoma (IDH-wildtype) grade 2-4, astrocytoma (IDH-mutant) grade 2-4, or diffuse midline glioma (including pediatric-type H3K G34 or K27 mutant) | Tumor maximal diameter <= 6 cm | >= 6-month interval since last radiation therapy | Prior standard-dose radiation (approximately 59.4–60 Gy in 1.8–2 Gy fractions or equivalent) allowed | Non-standard RT dose or stereotactic radiosurgery allowed if new tumor outside prior field, histologic confirmation of tumor, or imaging consistent with true progression | Age >= 18 years | ECOG performance status <= 2 (Karnofsky >= 60%) | Absolute neutrophil count >= 1,500/µL | Hemoglobin >= 8 g/dL | Platelets >= 100,000/µL | Total bilirubin <= 1.5 x ULN | AST/ALT <= 3 x ULN | Creatinine <= 1.5 x ULN or GFR >= 50 mL/min | HIV-infected patients eligible if on effective ART with undetectable viral load within 6 months | Chronic HBV eligible if viral load undetectable on suppressive therapy | HCV eligible if treated and cured or on treatment with undetectable viral load | NYHA class II or better if cardiac risk factors or prior cardiotoxic therapy | Able to swallow whole capsules | Able to undergo MRI with contrast or adequate CT if MRI-incompatible | People of child-bearing potential: negative pregnancy test within 2 weeks of registration and agreement to use effective contraception during treatment and for 12 months after","Residual toxicities > grade 1 from prior anti-cancer therapy (except alopecia) | Concurrent treatment with other investigational agents | Concomitant medications known to induce methemoglobinemia (e.g., sulfonamides, nitrofurans, antimalarials such as primaquine or chloroquine, cyclophosphamide, ifosfamide) | History of allergic reactions to compounds similar to triapine | Known G6PD deficiency | Uncontrolled intercurrent illness or active infections making participation hazardous | Pregnancy or breastfeeding",Prior radiation therapy permitted; re-irradiation requires >= 6-month interval; Prior stereotactic radiosurgery permitted under protocol-defined criteria,ALL,A,"Disease and setting match (recurrent IDH‑wildtype glioblastoma post‑standard therapy), with age ≥18 and ECOG 1 meeting trial limits and no disallowed prior therapies; required biomarker is satisfied. Some criteria (tumor size ≤6 cm, ≥6 months since prior RT, labs) are unknown but not conflicting.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches (recurrent IDH-wildtype GBM) and stage/setting matches (recurrent). Required biomarker satisfied (IDH-wildtype). Line/prior exposure is compatible (prior RT/TMZ allowed). Unknowns like tumor size and interval since RT are not conflicts. Meets ≥2 core anchors without soft mismatches, so A is appropriate.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT06918808,0.7952461242675781,Fistulizing Crohn's Disease,A Phase 2a Study of Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product (DB-3Q) in Patients With Perianal Fistulizing Crohn's Disease,PHASE2,18 years to 75 years,Perianal Fistula (Crohn's Disease),"Age 18-75 years | Crohn's Disease diagnosed for >= 6 months prior to Day 1 | Single and/or multi-tract perianal fistula(s) with 2 or fewer openings that are actively draining | Failed at least one medical therapy within the last year (e.g., antibiotics, immunomodulators, monoclonal antibodies, or small molecule inhibitors) | Previous failed surgical intervention (including seton placement >= 2 weeks prior to screening) or not a candidate for/willing to undergo surgical intervention | Medical therapy for Crohn's Disease stable for >= 2 months prior to Day 1","Pregnant or breastfeeding | Woman of childbearing potential without a documented negative urine or serum pregnancy test | Active perianal abscess or infection at screening or Day 1 | Clinically significant medical conditions within 6 months before Day 1 that could compromise safety | Confirmed HIV infection | Confirmed Hepatitis B infection | Confirmed Hepatitis C infection | History of cancer, including melanoma, within 1 year of screening (except localized non-melanoma skin cancers) | History of colorectal cancer within 2 years of screening | Use of investigational therapy or treatment within 30 days prior to Day 1 | Unwilling to use medically acceptable contraception during the study",Failed at least one prior medical therapy for Crohn's Disease within the last year; Previous failed surgical intervention for perianal fistula or not a candidate/willing; Current Crohn's Disease medical therapy stable for >= 2 months prior to Day 1; No investigational therapy within 30 days prior to Day 1,ALL,A,"Disease and setting match perianal fistulizing Crohn’s with an actively draining fistula and seton; age/sex are within limits, and prior failures of infliximab and ustekinumab satisfy the requirement for failed medical therapy. No explicit exclusion (e.g., active abscess at screening) is documented in the patient profile.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,A,"No hard exclusions identified. Disease matches perianal fistulizing Crohn’s, and two core anchors match: stage/setting (active perianal fistula with seton) and line/prior exposure (failed prior biologics satisfying failed medical therapy). Other specifics (e.g., timing within last year, stability of therapy, number of fistula openings) are unknown, not mismatches. Grader’s A is appropriate.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT07087860,0.8715782165527344,Metastatic Urothelial Carcinoma,Randomized Phase II Rescuing Cancer Immunotherapy With Plasma Exchange in Bladder Cancer 1 (ReCIPE-B1),PHASE2,18 years,Bladder Urothelial Carcinoma (metastatic); Upper Tract Urothelial Carcinoma (metastatic),"Age >= 18 years | Histologically proven urothelial carcinoma of the bladder or upper urinary tract | Disease progressed despite prior enfortumab vedotin and pembrolizumab treatment (primary or secondary progression allowed) | Measurable disease per RECIST v1.1 | ECOG performance status 0-2 | Hemoglobin > 7.0 g/dL (within 30 days) | Platelet count >= 75,000/µL (within 30 days) | ALT <= 3.5 x ULN (within 30 days) | AST <= 3.5 x ULN (within 30 days) | Total bilirubin <= 3 x ULN (within 30 days) | Direct bilirubin <= 3 x ULN (within 30 days) | Estimated GFR >= 15 mL/min (within 30 days)","Pregnant | Breastfeeding | Persons of childbearing potential or able to father a child unwilling to use adequate contraception | Histologic variants/divergent differentiation including any neuroendocrine, micropapillary, or signet ring cell features | Active malignancy other than the study disease within 24 months (with specified exceptions) | Significant cardiovascular disease within 6 months (e.g., NYHA class >= III CHF, unstable angina, cardiac arrhythmia, myocardial infarction, ventricular fibrillation, Torsades de Pointes, cerebrovascular accident, transient ischemic attack) | Psychiatric illness or substance abuse that would limit compliance | Any condition that, in the investigator's opinion, would not be in the participant's best interest or could confound assessments",Prior enfortumab vedotin and pembrolizumab with documented progression,ALL,A,"Metastatic urothelial carcinoma with documented progression after enfortumab vedotin plus pembrolizumab matches the trial’s disease and required prior-exposure setting; age and sex are eligible. Renal function (eGFR 35 mL/min) meets the trial’s minimum (>=15), and no exclusions are apparent from the provided data.",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),CORRECT,A,"Disease matches metastatic urothelial carcinoma; stage/setting matches (metastatic) and line/prior-exposure matches (progressed after EV+pembrolizumab), giving ≥2 core anchors. No hard exclusions; eGFR 35 ≥15 meets trial criterion. Other eligibility items (ECOG, measurable disease, labs) are unknown and thus neutral. Grade A is appropriate.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT00692939,0.6685259342193604,Fistulizing Crohn's Disease,Autologous Stem Cell Transplantation with CD34-Selected Peripheral Blood Stem Cells (PBSC) in Pediatric and Adult Patients with Severe Crohn's Disease,PHASE1/PHASE2,10 years to 60 years,Crohn's Disease,"Age 10–60 years | Severe, refractory Crohn's Disease appropriate for stem cell transplant therapy | Prior surgery with severe recurrent disease despite aggressive maintenance therapy | Diffuse small bowel and colonic disease refractory to aggressive medical treatment and not eligible for surgery without high risk of short bowel syndrome or other contraindications to surgery | Persistently high disease activity: HBI > 6 or CDAI > 250 or PCDAI > 45, or moderate disease (HBI <= 6, CDAI < 250, PCDAI 30–45) requiring daily corticosteroids and aggressive medical treatment to maintain status | Resistant complications unresponsive to medical management (e.g., multiple enteric fistulas, enterovesicular or enterovaginal fistulas, severe perianal disease, debilitating arthritis, severe skin lesions such as pyoderma, severe bony complications such as aseptic necrosis or pathologic fractures) | Severe complications from medical therapy (e.g., pancreatitis from 6-mercaptopurine, colitis from 5-ASA, severe hypersensitivity to TNF-alpha inhibitors, anti-integrin agents, or anti-IL12/23 agents) | Stoma present is allowed | No surgical therapeutic option due to risk of short bowel syndrome or patient refusal | Harvey Bradshaw Index > 5, or CDAI > 250, or PCDAI > 30 | Platelet count > 100,000/µL | Absolute neutrophil count > 1500/µL | Creatinine <= 2.0 mg/dL | No history of coronary artery disease; LVEF >= 40% or shortening fraction >= 26% | FEV1/FVC >= 60% predicted; DLCO >= 60% predicted | Negative pregnancy test for females of childbearing potential | Agreement to use effective contraception during treatment and for up to 24 months after PBSC transplant or while on any medication that may harm a pregnancy","No prior adequate dosing of 6-mercaptopurine, 5-ASA products, and metronidazole | Sustained corticosteroid-free response to anti-TNF-alpha, anti-integrin, or anti-IL12/23 therapy after a 4-month course | Toxic megacolon | Intestinal perforation | Conjugated bilirubin > 2.0 mg/dL | Pregnancy or nursing | HIV seropositive, HTLV seropositive, HBsAg positive, or HCV RNA positive by PCR | Active infection within two weeks of mobilization and high-dose chemotherapy | Other significant medical problems or abnormal findings that increase risk, interfere with compliance, or impact data quality in the investigator's opinion","Prior adequate dosing of 6-mercaptopurine, 5-ASA products, and metronidazole required; Prior surgery allowed",ALL,B,"Disease and setting match: a 32-year-old with severe, refractory fistulizing Crohn's disease (CDAI 350) and perianal involvement fits the trial’s inclusion profile. However, eligibility requires prior adequate dosing of 6-mercaptopurine, 5-ASA, and metronidazole (not documented) and absence of active infection within two weeks, making prior-therapy and timing criteria uncertain.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,B,"No hard exclusions: disease, age, and sex match; required prior meds status is unknown, not a conflict. One core anchor clearly matches (severe/refractory setting). Line/prior exposure compatibility is uncertain, with no soft mismatch identified. Thus B is appropriate and the grader’s reasoning aligns with the rubric.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT02255383,0.6466730833053589,Rheumatoid Arthritis,Persona The Personalized Knee System TKA Outcomes Study: Prospective Multicenter Study of the Persona Knee System,NA,18 years to 75 years,Osteoarthritis; Rheumatoid Arthritis; Traumatic Arthritis; Polyarthritis; Avascular Necrosis of the Femoral Condyle,"Age 18-75 years | Severe knee pain/disability due to rheumatoid arthritis | Severe knee pain/disability due to osteoarthritis | Severe knee pain/disability due to traumatic arthritis | Severe knee pain/disability due to polyarthritis | Severe knee pain/disability due to collagen disorders | Severe knee pain/disability due to avascular necrosis of the femoral condyle | Post-traumatic loss of joint configuration (e.g., patellofemoral erosion/dysfunction or prior patellectomy) | Moderate valgus deformity | Moderate varus deformity | Moderate flexion deformity | Salvage of previously failed surgical attempts not including prior partial or total knee arthroplasty of the ipsilateral knee | Candidate for Persona fixed bearing knee components implanted per product labeling","Previous infection in the affected joint or other local/systemic infection that may affect the prosthetic joint | Insufficient bone stock on femoral or tibial surfaces | Skeletal immaturity | Neuropathic arthropathy | Osteoporosis compromising the affected limb | Loss of musculature or neuromuscular disease compromising the affected limb | Stable, painless arthrodesis in a satisfactory functional position | Severe instability due to absence of collateral ligament integrity | Rheumatoid arthritis with a skin ulcer or recurrent skin breakdown | Known or suspected sensitivity or allergy to implant materials | Pregnant | Prior partial or total knee arthroplasty of the ipsilateral knee",(none),ALL,B,"Disease and age match with no conflicts from prior therapies or biomarkers; however, the trial requires severe knee pain/disability and candidacy for total knee arthroplasty, which are not specified for this patient, leaving the key setting unknown.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),INCORRECT,C,"No hard exclusions. Disease matches but core anchors are unknown/not matched: stage/setting (TKA candidacy and severe knee pain) is unspecified; line/prior is irrelevant/unspecified; no biomarker or mets constraints. Age is not a core anchor. With 0 anchors matched and no soft conflicts, the correct grade is C, not B.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT02730338,0.6165587902069092,Castration-Resistant Prostate Cancer,"INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4): a Multicentre, Randomised, Controlled, Phase III Study",NA,18 years,Metastatic Prostate Cancer,Metastatic castration-resistant prostate cancer (mCRPC): adenocarcinoma with systemic metastatic disease despite castrate testosterone (<50 ng/dL). | mCRPC progression by measurable disease: >20% increase in sum of diameters or new lesion(s). | mCRPC progression by bone scan: new lesion(s) attributable to prostate cancer. | mCRPC progression by PSA: PSA >= 2 ng/mL with three rising values at least 1 week apart (PSA1 < PSA2 < PSA3). | mCRPC progression by PSMA PET/CT: new lesion(s) attributable to prostate cancer. | mCRPC treatment status category allowed: treatment-naive for mCRPC (<=4 weeks on approved therapies still considered naive). | mCRPC treatment status category allowed: on abiraterone/enzalutamide/apalutamide with stable or declining PSA after >=4 weeks. | mCRPC treatment status category allowed: PSA progression on abiraterone/enzalutamide/apalutamide if asymptomatic and no intent to start chemotherapy within 6 months. | mCRPC treatment status category allowed: prior first-line docetaxel/cabazitaxel or other approved chemotherapy for mCRPC if asymptomatic without evidence of progression. | mCRPC treatment status category allowed: progressed after first-line docetaxel/cabazitaxel and now on abiraterone/enzalutamide/apalutamide with stable or responding PSA; life expectancy >1 year. | Metastatic hormone-sensitive prostate cancer (mHSPC): high-risk (>=2 of: Gleason score >=8; >=3 bone lesions; measurable visceral lesions) or high-volume (visceral metastases and/or >=4 bone metastases with >=1 outside vertebral column/pelvis). | On androgen deprivation therapy during study or prior bilateral orchiectomy. | >=4 weeks since last major surgery and fully recovered. | Halabi Nomogram score < 1951 (low or intermediate risk). | Age >= 18 years. | ECOG performance status 0-1. | Medical clearance to undergo symptom-limited cardiopulmonary exercise test and vigorous aerobic and resistance training; able to complete an acceptable cardiopulmonary exercise test.,"Small cell neuroendocrine prostate cancer or features of small cell disease. | Known contraindications to high-intensity exercise (e.g., brain metastases; current congestive heart failure NYHA class II–IV; serious or non-healing wound, ulcer, or bone fracture; spinal cord compromise or instrumentation due to metastatic disease; peripheral neuropathy >= grade 3). | Serious cardiovascular events within 12 months (e.g., transient ischemic attack, cerebrovascular accident, myocardial infarction). | Uncontrolled hypertension (blood pressure >=160/90). | Engaging in vigorous aerobic exercise >60 minutes/week or structured resistance exercise >=2 days/week.",On androgen deprivation therapy during study or prior bilateral orchiectomy required.; Treatment-naive for mCRPC allowed (<=4 weeks on approved CRPC therapies considered naive).; On abiraterone or enzalutamide or apalutamide for mCRPC with stable or declining PSA allowed.; PSA progression on abiraterone/enzalutamide/apalutamide allowed if asymptomatic and no intent to start chemotherapy within 6 months.; Prior first-line docetaxel or cabazitaxel or other approved chemotherapy for mCRPC allowed if asymptomatic and without progression.; Progressed after first-line chemotherapy and now on abiraterone/enzalutamide/apalutamide with stable or responding PSA allowed; life expectancy >1 year.; >=4 weeks since last major surgery.,MALE,B,"Disease and stage match (male with metastatic castration-resistant prostate cancer), and prior abiraterone/enzalutamide exposure can be eligible under this protocol. However, key requirements (asymptomatic status, no near-term chemotherapy intent, ongoing ADT/castrate testosterone, ECOG and exercise clearance) are unspecified, so only one core anchor is clearly met.",Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),CORRECT,B,"No hard exclusions apply. Stage/setting (metastatic CRPC) clearly matches. Line/prior exposure is conditionally allowed but key qualifiers (asymptomatic, no near-term chemo, ongoing ADT, ECOG/exercise clearance) are unknown, so cannot be counted as a match. No soft mismatches identified. Exactly one core anchor match → Grade B per rubric.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT03389230,0.9556124806404114,Recurrent Glioblastoma,"Phase I Study of Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a HER2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients With Recurrent/Refractory Malignant Glioma",PHASE1,18 years to 75 years,Glioblastoma; Malignant Glioma; Recurrent Glioma; Refractory Glioma; WHO Grade III Glioma,"Histologically confirmed grade III or IV glioma, or prior grade II glioma with radiographic progression consistent with grade III or IV malignant glioma | Karnofsky performance status >= 60% | Life expectancy > 4 weeks | HER2 positive tumor by immunohistochemistry (>= 20%, 1+) confirmed by City of Hope Clinical Pathology | Appropriate venous access | Dexamethasone <= 2 mg TID on the day of PBMC collection | At least 2 weeks since last targeted agent, chemotherapy, or radiation before PBMC collection (PI discretion for locally delivered CSF investigational agents) | Creatinine < 1.6 mg/dL | White blood cell count > 2,000/µL or absolute neutrophil count > 1,000/µL | Platelets >= 100,000/µL | INR < 1.3 | Total bilirubin < 1.5 mg/dL | ALT and AST <= 2 x ULN | Released cryopreserved CAR T cell product available | No supplemental oxygen required to keep saturation > 95% and no progressive chest X-ray abnormalities | No history of CHF NYHA class III–IV, cardiomyopathy, myocarditis, or MI within 6 months; if risk factors present, EKG and echocardiogram within 42 days prior to registration | If new cardiac symptoms or cardiotoxic exposures: cardiac consultation, CPK, and troponin deem fit for study | Afebrile (<= 38.5 C), negative blood cultures within 48 hours prior to infusion, and no signs of meningitis | Serum creatinine < 1.8 mg/dL at infusion eligibility | Serum total bilirubin and transaminases <= 2 x ULN at infusion eligibility | Platelets > 100,000/µL (if 75,000–99,999/µL, may proceed after transfusion with post-transfusion >= 100,000/µL) | Dexamethasone <= 2 mg TID during CAR T cell therapy | Washouts before CAR T infusion: >= 6 weeks since nitrosourea; >= 23 days since temozolomide; >= 4 weeks since other non-nitrosourea cytotoxic chemotherapy; >= 2 weeks since last targeted agent (>= 4 weeks for bevacizumab)","Requires supplemental oxygen to maintain saturation > 95% and not expected to resolve within 2 weeks | History of CHF NYHA class III–IV within 6 months, cardiomyopathy, myocarditis, or MI; or significant cardiotoxic exposures without appropriate cardiac evaluation | Requires dialysis | Uncontrolled seizure activity and/or clinically evident progressive encephalopathy | Other active malignancies | Severe infection under treatment or recovering from major surgery until recovery is complete | Uncontrolled illness including ongoing or active infection | Known active hepatitis B or hepatitis C infection | Confirmed HIV positivity within 4 weeks of enrollment | Inability to understand the study or its risks/benefits (unless a legal guardian consents)","At least 2 weeks since last targeted therapy, chemotherapy, or radiation before PBMC collection; At least 6 weeks since nitrosourea chemotherapy before CAR T infusion; At least 23 days since temozolomide before CAR T infusion; At least 4 weeks since other non-nitrosourea cytotoxic chemotherapy before CAR T infusion; At least 2 weeks since last targeted agent before CAR T infusion (at least 4 weeks for bevacizumab)",ALL,B,"Recurrent glioblastoma matches the trial’s disease and setting, and age/sex are within range. However, the trial requires HER2-positive tumor by IHC (not provided for this patient) and washout/lab details are unknown, so only one core anchor is firmly met.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),CORRECT,B,"No hard exclusions. Disease and recurrent setting match. Required HER2 biomarker is unknown, which blocks an A. No soft mismatches identified. While washout/lab details aren’t core anchors, even without them the appropriate grade remains B given biomarker uncertainty.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT04196257,0.7107007503509521,Recurrent Clear Cell Ovarian Carcinoma,A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients With Advanced or Recurrent Solid Tumors,PHASE1,18 years,Solid Tumor; Ovarian Epithelial Carcinoma; Endometrial Cancer; Fallopian Tube Neoplasm; Peritoneal Cancer,"Age >= 18 years | Advanced or recurrent solid tumor not a candidate for regimens known to confer clinical benefit | ECOG 0–1 | Willing to undergo pre-treatment and post-treatment biopsies (if applicable) | Dose expansion: recurrent or persistent epithelial ovarian, primary peritoneal, fallopian tube, or endometrial tumor and suitable for single-agent paclitaxel | Endometrial cancer eligible histologies include endometrioid, serous, undifferentiated, clear cell, mixed epithelial, adenocarcinoma NOS, mucinous, squamous cell, transitional cell, mesonephric | Ovarian tumor eligible histologies include high-grade serous, endometrioid, clear cell, squamous, transitional (Brenner), mixed epithelial-stromal, undifferentiated or other epithelial | Uterine carcinosarcoma and other uterine sarcomas are not eligible | Estimated life expectancy > 3 months | Measurable disease per RECIST v1.1 | At least one target lesion per RECIST v1.1; previously irradiated lesions are non-target unless progression or biopsy confirms persistence >= 90 days after RT | Adequate bone marrow, hepatic, renal, neurologic, and coagulation function per protocol thresholds | Prior docetaxel allowed | Dose expansion: prior paclitaxel allowed if no progression on therapy and no relapse within 6 months after completing therapy; persistent disease at completion of primary paclitaxel is not eligible | Free of active infection requiring antibiotics (except uncomplicated UTI) | Discontinue hormonal therapy directed at the tumor >= 2 weeks before first dose | Discontinue other prior anti-tumor therapy, including immunologic agents, >= 4 weeks before first dose (6 weeks for nitrosoureas or mitomycin C)","Dose expansion: low-grade serous ovarian carcinoma or mucinous ovarian carcinoma | Dose expansion: use of strong inhibitor, inducer, or substrate of both CYP3A4 and CYP2C8 within 2 weeks before investigational drug | Prior bone marrow or hematopoietic stem cell transplant | Concurrent treatment with other investigational agents | Pregnant or breastfeeding | CNS disease including primary brain tumor, uncontrolled seizures, any brain metastases, or cerebrovascular accident/transient ischemic attack/subarachnoid hemorrhage within 6 months | Within 6 months: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, cerebrovascular accident, or transient ischemic attack | Uncontrolled significant cardiovascular conditions (e.g., unstable angina, NYHA class III–IV heart failure, uncontrolled sustained hypertension, clinically significant arrhythmia) or QTcF > 470 msec | Active symptomatic pleural or pericardial effusion | Ineligible for MRI or history of allergic reaction to gadolinium contrast | History of >= Grade 3 hypersensitivity to paclitaxel, docetaxel, or products mixed in Cremophor EL or Tween 80 | Unresolved > CTCAE Grade 1 toxicity from prior therapy (excluding alopecia) | Substance abuse or medical/psychological/social conditions that may interfere with study participation | HIV infection with CD4+ T-cell count < 350 cells/µL or clinically active hepatitis B or C | Major surgery, open biopsy, dental extractions or other dental surgery with open wound, or significant traumatic injury within 28 days before first dose; placement of vascular access device or core biopsy within 7 days before registration | Dose expansion: ineligible or unable to receive paclitaxel","Prior docetaxel allowed; Prior paclitaxel allowed if no progression on therapy and no relapse within 6 months after completing therapy; persistent disease at completion of primary paclitaxel is not eligible; Discontinue hormonal therapy directed at the tumor >= 2 weeks before first dose; Discontinue prior anti-tumor therapy, including immunologic agents, >= 4 weeks before first dose (6 weeks for nitrosoureas or mitomycin C)",ALL,B,"Recurrent clear cell ovarian carcinoma fits the trial’s disease scope and recurrent/advanced setting. Potential issues include relapse within 6 months of paclitaxel (which may preclude the paclitaxel-based expansion cohort) and the malignant pleural effusion if symptomatic, but these are not definitive hard exclusions.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; BRCA1 positive; Optimal debulking surgery performed; Received adjuvant carboplatin + paclitaxel + bevacizumab; Cytology-positive malignant pleural effusion at 5 months post-adjuvant,(none),Carboplatin; Paclitaxel; Bevacizumab; Optimal debulking surgery,Stage III,,36,years,female,(none),CORRECT,B,"No hard exclusions are definitive (pleural effusion symptom status unknown; age/sex/disease match). Stage/setting clearly matches recurrent/advanced. Line/prior exposure is a potential mismatch only for the paclitaxel expansion cohort (relapse within 6 months), but other cohorts may still be viable and “not a candidate for standard regimens” is unknown. With exactly one clear core anchor match and no confirmed soft conflicts, B is appropriate.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT04214392,0.7626396417617798,Recurrent Glioblastoma,A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for Patients With MMP2+ Recurrent or Progressive Glioblastoma,PHASE1,18 years,Glioblastoma (recurrent); Malignant Glioma (recurrent); WHO Grade II Glioma (recurrent); WHO Grade III Glioma (recurrent),"Karnofsky performance status >= 60% | ECOG <= 2 | Life expectancy >= 4 weeks | Histologically confirmed grade IV glioblastoma, or prior grade II/III malignant brain tumor with radiographic progression consistent with grade IV glioblastoma | Relapsed/progressive measurable disease after standard therapy and >= 12 weeks after completion of frontline radiation therapy | MMP2-positive tumor by IHC (>= 20% moderate/high staining) | No known contraindications to leukapheresis, steroids, or tocilizumab | WBC > 2000/µL or ANC >= 1000/µL (pre-leukapheresis) | Platelets >= 75,000/µL (pre-leukapheresis) | Hemoglobin >= 8 g/dL (pre-leukapheresis) | Total bilirubin <= 1.5 x ULN (pre-leukapheresis) | AST <= 2.5 x ULN (pre-leukapheresis) | ALT <= 2.5 x ULN (pre-leukapheresis) | Serum creatinine <= 1.6 mg/dL (pre-leukapheresis) | Oxygen saturation >= 95% on room air (pre-leukapheresis) | Seronegative for HIV Ag/Ab combo | Women of childbearing potential: negative pregnancy test | Females and males of childbearing potential agree to effective contraception or abstinence during study and for >= 3 months after last dose","Prior bevacizumab within 3 months before enrollment | Not recovered from toxicities of prior therapy | Uncontrolled seizure activity and/or clinically evident progressive encephalopathy | History of allergic reactions to compounds of similar composition to study agent | Active diarrhea | Clinically significant uncontrolled illness | Active infection requiring antibiotics | Known HIV, hepatitis B, or hepatitis C infection | Other active malignancy | Pregnant or breastfeeding | Any condition that, in the investigator's judgment, contraindicates participation due to safety concerns | Participant may be unable to comply with study procedures",Prior standard therapy required; >= 12 weeks since completion of frontline radiation therapy,ALL,B,"Disease and setting match (recurrent GBM after standard therapy; ECOG 1; age eligible), but the required MMP2-positivity is unknown and the >=12 weeks since frontline radiation criterion is not confirmed, so full eligibility cannot be established.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),CORRECT,B,"No hard exclusions. Disease and recurrent setting match. Line/prior exposure compatibility is uncertain due to the >=12 weeks post-RT requirement being unconfirmed, and the required MMP2 biomarker status is unknown (precludes A). With exactly one clear core anchor (stage/setting) and no soft mismatches, B is appropriate.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT04704544,0.7276947498321533,Rheumatoid Arthritis,Effectiveness of Tele-rheumatology for Delivering High Quality Rheumatology Care During the COVID-19 Crisis,NA,18 years,Rheumatic Disease,"Diagnosis of rheumatic disease (e.g., rheumatoid arthritis, systemic lupus erythematosus)","Unstable rheumatic disease requiring in-person visits (e.g., recent diagnosis of severe lupus nephritis) | Expected need for in-office procedures (e.g., joint injection) | Lack of access to a phone",(none),ALL,B,"Rheumatoid arthritis is included under the trial’s rheumatic diseases, age/sex are eligible, and there are no prior-therapy restrictions. Suitability for tele-rheumatology (stability/need for in-person procedures) is not specified, so no soft conflict is identified.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),INCORRECT,C,"Disease matches and no hard exclusions. However, none of the CORE ANCHORS are clearly matched: stage/setting not specified, line/prior-exposure not stated (cannot assume no restrictions), no required biomarkers, and no mets pattern relevance. With 0 anchors matched and no soft conflict, the correct grade is C. The grader incorrectly treated the absence of prior-therapy info as a match and assigned B.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT04768972,0.7257431149482727,Amyotrophic Lateral Sclerosis,"A Phase 1-3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION363 in Amyotrophic Lateral Sclerosis Patients With Fused in Sarcoma Mutations (FUS-ALS)",PHASE3,10 years,Amyotrophic Lateral Sclerosis (FUS-mutated),Age >= 10 years with signs or symptoms consistent with ALS | Confirmed pathogenic or likely pathogenic FUS genetic mutation by certified laboratory | Slow vital capacity (upright) >= 50% predicted OR if < 50% predicted: age 10–30 years AND ALS symptom onset within 12 months | Stable dose of edaravone for >= 28 days before Day 1 and willingness to continue | Stable dose of riluzole for >= 28 days before Day 1 and willingness to continue | Stable dose of sodium phenylbutyrate/taurursodiol combination for >= 28 days before Day 1 and willingness to continue | Stable dose of sodium phenylbutyrate for >= 28 days before Day 1 and willingness to continue | Stable dose of tauroursodeoxycholic acid for >= 28 days before Day 1 and willingness to continue | Stable concomitant medications and nutritional support for >= 1 month prior to Day 1 | Not pregnant or lactating; agrees to protocol-specified contraception or is surgically sterile/postmenopausal | Has an informant/caregiver able to provide accurate information; participants < 18 years have a reliable trial partner >= 18 years who can attend visits,"Requires permanent ventilation (> 22 hours/day for > 21 consecutive days) and/or tracheostomy | Pathogenic or likely pathogenic genetic variant for ALS-FTD spectrum other than FUS | Positive test for HIV | Positive test for HCV unless treated and HCV RNA negative for >= 6 months post-treatment | Positive test for HBV surface antigen unless on nucleotide/nucleoside analogue treatment | Clinically significant abnormalities in medical history or physical exam (e.g., recent acute coronary syndrome within 3 months; major surgery within 2 months) | Uncontrolled hypertension (blood pressure > 160/100 mm Hg) | Malignancy within 1 year except adequately treated basal/squamous cell skin cancer or cervical carcinoma in situ; other curatively treated cancers without recurrence for >= 6 months may be eligible per investigator | Obstructive hydrocephalus | Significant brain or spinal disease interfering with LP, CSF circulation, or safety assessment (e.g., tumors, subarachnoid hemorrhage, raised ICP, spinal stenosis/curvature, Chiari malformation, syringomyelia, tethered cord, Ehlers-Danlos, Marfan) | Concurrent participation in another interventional clinical study | Previous or current treatment with an oligonucleotide (including siRNA, tofersen) | Treatment with another investigational drug/biologic/device within 1 month before Screening or 5 half-lives, whichever is longer | History of gene therapy, cell transplantation, or experimental brain surgery | Anticipated need for antiplatelet or anticoagulant therapy that cannot be safely paused around LP (low-dose aspirin <= 100 mg/day as monotherapy permitted) | Any other condition that makes the participant unsuitable or could interfere with participation per investigator",Stable dose of edaravone for >= 28 days prior to Day 1; Stable dose of riluzole for >= 28 days prior to Day 1; Stable dose of sodium phenylbutyrate/taurursodiol combination for >= 28 days prior to Day 1; Stable dose of sodium phenylbutyrate for >= 28 days prior to Day 1; Stable dose of tauroursodeoxycholic acid for >= 28 days prior to Day 1; Stable concomitant medications and nutritional support for >= 1 month prior to Day 1,ALL,B,"ALS diagnosis, age/sex, and prior therapy (riluzole) are compatible, but the trial requires a confirmed pathogenic FUS mutation and the patient’s FUS status is not provided, making the key biomarker fit uncertain.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,B,No hard exclusions: ALS matches disease scope; sex/age within bounds; required FUS mutation is unknown (not a mismatch). Core anchors: Line/prior exposure compatible (match); Stage/setting not specifically defined (unknown); Biomarker unknown; Mets pattern N/A. Exactly one anchor matches → B. Grader’s reasoning aligns.,,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT04913337,0.7970306873321533,Metastatic Non-Small Cell Lung Cancer,A Phase 1/2 Dose Escalation/Expansion Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies,PHASE1/PHASE2,18 years,Breast Cancer; Cervical Cancer; Cholangiocarcinoma; Colorectal Cancer; Endocervical Cancer; Esophageal Cancer; Gastric Cancer; Glioblastoma; Melanoma; Mesothelioma; Non Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Ductal Adenocarcinoma; Renal Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck,"Histologically or cytologically confirmed locally advanced or metastatic solid tumor malignancy. | Progressed on or was intolerant to all available therapies known to confer clinical benefit appropriate for the tumor type, or refused standard-of-care treatments perceived to have marginal clinical benefit. | Adequate bone marrow, kidney, and liver function. | Performance status 0 or 1. | Acute effects of prior therapy resolved to baseline or CTCAE Grade 1 (except AEs not constituting a safety risk by investigator judgment).",Prior treatment targeting ILT2 and/or ILT4 or targeting HLA-G.,Received and progressed on or were intolerant to prior standard therapies known to confer clinical benefit for their tumor type.; Refusal of standard-of-care treatments perceived to have marginal clinical benefit is allowed.; Acute toxicities from prior therapy resolved to baseline or <= Grade 1 before enrollment.,ALL,B,"Disease (NSCLC) and metastatic setting match, age/sex/ECOG fit, and there are no explicit exclusions. However, the trial requires progression on or intolerance to available standard therapies (or refusal), and the patient is currently on osimertinib with no documented progression, making line-of-therapy eligibility uncertain.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,B,"No hard exclusions. Disease and metastatic setting clearly match (1 core anchor). Line/prior exposure requirement (post-progression or intolerance/refusal) is not confirmed from the patient data and should be treated as unknown per rubric, not a soft mismatch. With exactly one anchor match and no soft conflicts, grade B is appropriate. The grader’s reasoning aligns with this.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT05355701,0.8058992028236389,Metastatic Non-Small Cell Lung Cancer,"A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS",PHASE1,16 years,Glioma; Melanoma; Non-Small-Cell Lung Cancer; Thyroid Cancer,"Advanced or metastatic solid tumor, including primary brain tumor | Qualifying BRAF alteration: V600 or non-V600 Class II/Class III in tumor tissue and/or ctDNA | Disease progression during or after last prior treatment with no satisfactory alternative options (Parts 1 and 2) | Tumor-specific cohorts (melanoma, colorectal cancer) must have received prior approved therapies",Brain metastasis >4 cm | Ongoing systemic anti-cancer therapy or small molecule therapeutics at start of study treatment | History or current evidence of retinal vein occlusion (for participants who may receive binimetinib) | Concurrent neuromuscular disorder associated with elevated creatine kinase (for participants who may receive binimetinib),Progression on or after prior therapy required (Parts 1–2); Prior approved therapies required for melanoma and colorectal cancer cohorts,ALL,B,"Disease and stage match (metastatic NSCLC; age/sex within range). However, the trial requires a qualifying BRAF alteration and progression after prior therapy—both are not documented for this patient—so key eligibility elements are uncertain.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,B,"No hard exclusions: disease matches NSCLC; age/sex allowed. Stage/setting matches (metastatic). Required BRAF alteration and progression status are unknown, and brain mets size unknown, so other core anchors are not confirmed. Exactly one core anchor match without soft conflicts → B. Grader’s reasoning aligns with rubric.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT05394675,0.7714447379112244,Metastatic Non-Small Cell Lung Cancer,"A Phase 1, First-in-Human Study of DS-9606a in Patients With Tumor Types Known to Express Claudin-6 (CLDN6)",PHASE1,18 years,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Germ Cell Tumor; Endometrial Cancer; Pancreatic Adenocarcinoma; Non-Squamous Non-Small Cell Lung Cancer; Gastric Cancer,"Age >= 18 years | ECOG performance status 0–1 | Archived tumor tissue available (mandatory in Part A); germ cell tumor patients without archived samples may be allowed with approval | Left ventricular ejection fraction >= 50% | Adequate bone marrow and organ function | Life expectancy >= 3 months | Adequate treatment washout prior to study start | Dose Escalation: Histologically or cytologically confirmed locally advanced or metastatic solid tumors including ovarian cancer (including fallopian tube and primary peritoneal), germ cell tumors, uterine/endometrial cancers, pancreatic adenocarcinoma, non-squamous non-small cell lung cancer, or gastric cancer | Dose Escalation: Disease progression after standard therapies for metastatic disease known to confer benefit, or intolerant to or refuse standard treatment | Dose Expansion: Histologically or cytologically confirmed locally advanced or metastatic ovarian cancer | Dose Expansion: Provide archived tumor sample if available or mandatory pre-treatment and on-treatment tumor biopsies if not clinically contraindicated","History or presence of central nervous system metastases unless treated >= 4 weeks prior, with no CNS progression and no chronic corticosteroids within 2 weeks before treatment | Other invasive malignancy within 2 years, except certain non-invasive or curatively treated localized malignancies with low risk of recurrence | Myocardial infarction or unstable angina within 6 months before study treatment | Symptomatic congestive heart failure (NYHA class II–IV) or serious cardiac arrhythmia requiring treatment | QTcF > 470 ms | History of interstitial lung disease/pneumonitis requiring corticosteroids, current ILD/pneumonitis, or suspected ILD/pneumonitis on screening imaging | Uncontrolled infection requiring ongoing or long-term therapy | Known active hepatitis or uncontrolled hepatitis B or C infection",Progressed after standard therapies for metastatic disease or intolerant/refuse standard treatment; Treatment washout period required,ALL,B,"Stage/setting matches (metastatic NSCLC) with eligible age and ECOG 0. However, non-squamous histology, progression after standard therapy, CLDN6 status, and treated/stable brain metastases are not documented, so eligibility is uncertain.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,B,"No hard exclusions are confirmed. Stage/setting (metastatic) matches. Line/prior requirement (post-standard progression), non-squamous histology, CLDN6 status, and treated/stable brain mets are all unknown, not mismatches. With exactly one core anchor match and no soft conflicts, B is appropriate.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT05843578,0.6491439938545227,Fistulizing Crohn's Disease,"A Phase 2a, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AGMB-129 in Patients With Fibrostenotic Crohn's Disease",PHASE2,18 years,Crohn's Disease (fibrostenotic),"Diagnosis of ileal or ileocolonic Crohn's disease established >=3 months prior to screening | At least one terminal ileum stricture confirmed by MRE meeting criteria: localized luminal narrowing <=50% vs adjacent bowel, bowel wall thickening >=25%, and either prestenotic dilation >=3 cm or nonpassable with adult colonoscope | Tolerable obstructive symptoms with screening S-PRO severity score >=2 and not expected to require hospitalization, dilation, surgery, or additional therapy during the study | Stable background therapy for Crohn's disease and agree to maintain during the study","History or current diagnosis of ulcerative colitis, indeterminate colitis, ischemic colitis, NSAID-induced colitis, idiopathic colitis, radiation colitis, microscopic colitis, colonic mucosal dysplasia, or untreated bile acid malabsorption | Crohn's disease-related complications (e.g., extensive small bowel resection, ileorectal anastomosis, proctocolectomy, short bowel syndrome, ostomy or stoma, ileoanal pouch, inactive fistulae in or adjacent to an ileal stricture, anal/perianal stricture, active intra-abdominal or perianal abscess not appropriately treated, abscess related to the stricture, toxic megacolon, very severe inflammation, or deep ulceration in the colon or terminal ileum) | Ileitis not associated with Crohn's disease (e.g., infectious, spondyloarthropathy-associated, ischemic) | Endoscopic balloon dilation or surgical treatment of the same small bowel stricture within 6 months prior to screening | Receiving cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil within 8 weeks of screening | Janus kinase inhibitor therapy within 4 weeks of screening | Requiring continued treatment with systemic medications that are sensitive CYP3A4/5 substrates with a narrow therapeutic index or strong inhibitors of aldehyde oxidase or xanthine oxidase | Current or history of vasculitis, valvulopathy, large vessel disorder, or major abnormalities on cardiac echocardiography with Doppler","Stable background therapy for Crohn's disease required and maintained during the study; No cyclosporine, tacrolimus, sirolimus, or mycophenolate within 8 weeks before screening; No Janus kinase inhibitor therapy within 4 weeks before screening",ALL,B,"Crohn’s disease and age/sex match, and prior biologic failures are allowed, but the trial requires a terminal ileum stricture with obstructive symptoms (fibrostenotic phenotype), which is not documented for this patient with fistulizing perianal disease; thus eligibility is uncertain without evidence of a qualifying stricture.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,B,"No hard exclusions identified. Disease (Crohn’s) and age/sex match; prior biologic exposure is compatible. The required fibrostenotic/ileal stricture phenotype is not documented, which is unknown rather than a clear soft mismatch per the rubric. Thus exactly one core anchor (line/prior compatibility) matches with no soft conflicts → Grade B.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT06311578,0.816875696182251,Metastatic Non-Small Cell Lung Cancer,"Phase 1 Study of Intratumoral Administration of JNJ-87704916, an Oncolytic Virus, as Monotherapy and in Combination for Advanced Solid Tumors",PHASE1,18 years,Solid Tumor (advanced/metastatic); Non-Small Cell Lung Cancer (metastatic or locally advanced),Advanced or metastatic solid tumor with no available standard of care therapy (Part 1) | Histologically or cytologically confirmed metastatic or locally advanced non-small cell lung cancer (Part 2) | At least 1 injectable tumor | ECOG performance status 0–1 | Negative pregnancy test if of childbearing potential | Thyroid function laboratory values within normal range,"Active central nervous system involvement (primary CNS tumors, metastases, or leptomeningeal disease) with limited exceptions | Prior history of, or active, significant herpetic infections (e.g., herpetic keratitis or encephalitis) or active herpetic infections requiring ongoing systemic antiviral therapy | Active infection requiring systemic anti-infective therapy within 7 days prior to first dose or chronic use of anti-infective agents | History of solid organ or hematologic stem cell transplantation | Known HIV infection or other immunodeficiency syndrome | History of Grade >=3 toxicity with prior immunotherapy or requirement of anti-TNF or anti-IL-6 agents to manage prior immunotherapy adverse events | History of allergy to protein-based therapies or significant drug allergy (e.g., anaphylaxis, hepatotoxicity, immune-mediated thrombocytopenia or anemia)",Exhausted all available standard of care therapy (Part 1),ALL,B,"Disease and metastatic setting match (NSCLC, metastatic; ECOG 0), and no line-of-therapy restrictions conflict with prior osimertinib. However, the trial requires an injectable lesion and excludes active CNS disease—both unknown for this patient—so only one core anchor clearly matches.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,B,"No hard exclusions apply (active CNS status and injectable lesion are unknown). Disease and metastatic setting clearly match. Line/prior exposure requirements for the NSCLC cohort are not specified, so other anchors are unknown rather than matches. With exactly one clear core anchor match and no soft conflicts, B is appropriate.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06835283,0.6440473794937134,Dementia,Sequential Accelerated ITBS / Remote tDCS for Treatment of Neuropsychiatric Symptoms in Alzheimer's Disease: A Pilot Study,NA,65 years to 85 years,Alzheimer Disease; Alzheimer Disease-related Dementia,Age 60–85 years | Clinical diagnosis of mild to moderate Alzheimer disease or related dementia | Clinically significant neuropsychiatric symptoms with NPI-Q domain score >= 2 in at least one domain | MMSE score 15–23,"Contraindication to MRI | Contraindication to iTBS or tDCS (e.g., seizure disorder, severe cardiovascular disease, history of brain surgery, or cortical stroke near stimulation site) | Current alcohol or substance use disorder | Neuropsychiatric symptoms severe enough to preclude safe and effective intervention (e.g., agitation or aggression) | Unstable coexisting medical condition that may interfere with the protocol or increase risk",Psychotropic medications allowed if stable for >= 4 weeks,ALL,B,"Disease and stage align (moderate dementia consistent with trial’s mild–moderate AD/related dementia), age 68 and MMSE 19 meet inclusion, and no disqualifying exclusions are known. However, the required neuropsychiatric symptom criterion (NPI-Q ≥2) is not provided, so one key eligibility anchor is unknown.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,B,"No hard exclusions. Disease aligns (AD/related dementia acceptable for unspecified dementia), age and MMSE fit, and stage/setting matches. Other core anchors (line/prior, biomarkers, mets) are non-applicable/unknown. Exactly one core anchor match → B. The mention of NPI-Q is not a core anchor but its unknown status doesn’t change the grade.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT06915012,0.6914706230163574,Rheumatoid Arthritis,A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Impact of Biophoton Therapy on Chronic Severe Arthritis Pain,NA,18 years to 80 years,Arthritis,Age 18-80 years | Chronic severe arthritis pain for >=3 months | Current VAS pain rating >=5/10,"Untreated psychiatric disturbances that would affect participation | Ventilator dependence | Implantable electronic devices (e.g., pacemaker, deep brain stimulator) | Severe comorbid conditions that could interfere with study activities (e.g., severe chronic pulmonary disease, uncontrolled seizures, acute or chronic infectious illness, severe diabetes, kidney failure, end-of-life prognosis) | Active infectious disease (e.g., COVID-19) | Pregnancy",(none),ALL,B,"Disease and demographics fit and the trial imposes no restrictions on prior therapies, matching one core anchor. However, required pain inclusion criteria (chronic severe arthritis pain ≥3 months and VAS ≥5/10) are not documented, and her comorbidities do not trigger explicit exclusions.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,B,"No hard exclusions apply (arthritis umbrella includes RA; age/sex fit; no explicit comorbidity exclusion). Only one core anchor clearly matches (prior-exposure compatibility). Stage/setting (pain severity/criteria) is unknown rather than a mismatch, so B is appropriate.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT01961986,0.685097336769104,Rheumatoid Arthritis,"Rotator Cuff Sparing Total Arthroplasty - A Prospective, Randomized Clinical Trial",NA,21 years,Inflammatory Arthritis; Osteoarthritis,Indicated for shoulder joint replacement | Age >= 21 years | Expected survival >= 2 years beyond surgery,Prior arthroplasty in the affected shoulder | Significant deformity of the proximal humerus requiring a custom implant or consideration of osteotomy of the shaft and/or tuberosity | Significant medial erosion of the glenoid with the lateral edge of the humeral head medial to the lateral rim of the acromion | Significant injury to the brachial plexus | Pregnant or lactating,(none),ALL,C,"The trial targets inflammatory arthritis and the patient meets broad age/sex criteria, so the disease matches. However, it specifically requires being indicated for shoulder joint replacement, which is unknown for this patient, and there are no applicable line-of-therapy or biomarker requirements to establish additional core anchor matches.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,C,"No hard exclusions apply. RA falls under trial’s “Inflammatory Arthritis,” so disease matches. Stage/setting (indicated for shoulder arthroplasty) is unknown, and there are no applicable line/prior or biomarker anchors; no soft mismatches identified. Thus 0 core anchors match → Grade C. Grader’s reasoning and grade are appropriate.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT02038140,0.6365199685096741,Rheumatoid Arthritis,Prospective Post Market Clinical Follow-Up (PMCF) Study of the Zimmer® Trabecular Metal™ Total Ankle,NA,18 years,Degenerative Arthritis; Post-traumatic Arthritis; Rheumatoid Arthritis,"Age > 18 years | Skeletally mature | Eligible for primary or revision total ankle arthroplasty for degenerative arthritis, rheumatoid arthritis, or post-traumatic arthritis","Ankle arthrodesis with malleolar exeresis compromising the affected limb | Severe neurological disease affecting the limb | Severe vascular disease affecting the limb | Loss of musculature or neuromuscular compromise affecting the limb | Severe instability, maltracking, or misalignment of the tibia and talus uncorrectable by surgery | Local or systemic infection that may affect the prosthetic joint | Previous history of infection in the affected joint | Pregnant | Insufficient bone stock or bone quality to fix components (e.g., osteoporosis, Charcot disease) | Known sensitivity or allergic reaction to implanted materials",(none),ALL,C,"Disease (rheumatoid arthritis) matches and age/sex are within trial parameters. However, the trial requires eligibility for total ankle arthroplasty, and the patient’s ankle involvement/surgical candidacy and other limb-specific criteria are unknown.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,C,"No hard exclusions apply. Disease matches, age/sex acceptable. Core anchors: stage/setting (ankle arthroplasty eligibility) is unknown, others not applicable/unknown, yielding 0 matches and no soft conflict. Grade C is appropriate and reasoning is sound.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT02442297,0.7249960899353027,Recurrent Glioblastoma,Phase I Study of Intracranial Injection of T Cells Expressing HER2-specific Chimeric Antigen Receptors (CAR) in Subjects With HER2-Positive Tumors of the Central Nervous System (iCAR),PHASE1,3 years,Brain Tumor (recurrent/refractory),Recurrent or refractory HER2-positive primary CNS tumor or HER2-positive tumor metastatic to the CNS (procurement) | Karnofsky/Lansky score >= 60 (procurement) | Recurrent or refractory HER2-positive primary CNS tumor or HER2-positive solid tumor metastatic to the CNS (treatment) | HER2 positivity by IHC or RT-PCR; IHC >= grade 1 and >= 1+ intensity | Intracranial catheter in place | Age >= 3 years | Life expectancy >= 6 weeks | Karnofsky/Lansky score >= 60 | Bilirubin <= 3 x ULN | AST <= 5 x ULN | ALT <= 5 x ULN | Serum creatinine <= 2 x ULN (age-adjusted) | Hemoglobin >= 7.0 g/dL | Oxygen saturation >= 90% on room air | Available autologous transduced T lymphocytes with >= 15% HER2 CAR expression and >= 20% killing of HER2-positive targets | Recovered from tumor resection with stable neurological deficits for >= 1 week prior to treatment | Off other investigational antineoplastic therapy for 2 weeks prior to CAR T-cell infusion | Temozolomide allowed up to 48 hours pre-infusion | Dexamethasone allowed up to 2 mg/day if medically indicated,Diagnosis of diffuse intrinsic pontine glioma (DIPG) (procurement) | Bulky tumors causing midline shift and/or signs of impending herniation (procurement) | Known HIV positivity (procurement) | Severe intercurrent infection (treatment) | Known HIV positivity (treatment) | Pregnant or lactating (treatment) | History of hypersensitivity reactions to murine protein-containing products (treatment) | Diagnosis of diffuse intrinsic pontine glioma (DIPG) (treatment) | Dexamethasone dose > 2 mg/day or equivalent (treatment),Off other investigational antineoplastic therapy >= 2 weeks before infusion; Temozolomide permitted up to 48 hours pre-infusion; Dexamethasone <= 2 mg/day permitted if medically indicated,ALL,C,"The trial targets recurrent/refractory primary CNS tumors and is compatible with the patient's recurrent glioblastoma and prior standard therapy. However, the required HER2-positive status (and intracranial catheter) are not documented for this patient, so eligibility is uncertain.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),INCORRECT,B,"No hard exclusions: age/sex align, disease category (recurrent CNS tumor) matches, and HER2 status is unknown (should not trigger F). At least one core anchor clearly matches (stage/setting: recurrent). Prior exposure is compatible and not disallowed, but even conservatively counting only stage/setting yields exactly one anchor → B. The grader’s C underweights the clear stage/setting match and improperly penalizes unknown HER2/catheter (not a core anchor).",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT02469662,0.755436360836029,Rheumatoid Arthritis,Retrospective and Prospective Clinical Outcomes Study of the Zimmer® Nexel™ Total Elbow,NA,18 years,Acute Comminuted Elbow Articular Fracture; Rheumatoid Arthritis (advanced); Joint Ankylosis; Bilateral Joint Ankylosis (non-septic); Elbow Instability (bone loss); Degenerative Arthritis; Elbow Joint Destruction; Joint Instability; Loss of Joint Motion; Post-traumatic Arthritis; Post-traumatic Lesion,Age >= 18 years | Candidate for primary or revision total elbow arthroplasty | Elbow joint destruction compromising daily living | Post-traumatic lesions contributing to elbow instability | Bone loss contributing to elbow instability | Ankylosed joints including bilateral ankylosis from non-septic causes | Advanced rheumatoid arthritis with incapacitating pain | Post-traumatic arthritis with incapacitating pain | Degenerative arthritis with incapacitating pain | Instability or loss of motion when joint or soft tissue damage precludes reliable osteosynthesis | Acute comminuted articular fracture of elbow joint surfaces (including 13-C3 distal humerus fractures),"Active or repeated local infection at the surgical site | Current major infection distant from the operative site | History of prior sepsis | Paralysis or dysfunctional neuropathy at the elbow joint | Significant ipsilateral hand dysfunction | Excessive scarring near the surgical site preventing adequate soft tissue coverage | Daily activities that place significant stress on an implanted device (heavy labor, torsional stress, competitive sports) | Known alcohol or drug abuse | Known pregnancy",(none),ALL,C,"Disease (rheumatoid arthritis) matches and age/sex fit, but the trial requires candidacy for total elbow arthroplasty/advanced elbow involvement, which is unknown for this patient. No explicit exclusions are triggered.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,C,"No hard exclusions. Disease (RA) is included, but key stage/setting requirement (candidate for total elbow arthroplasty/advanced elbow involvement) is unknown, and other anchors are not applicable/unknown. With 0 anchors matched and no soft conflicts, C is appropriate.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT02658279,0.9180995225906372,Recurrent Glioblastoma,"A Proof-of-Concept, Pilot Study of Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype",NA,18 years,Recurrent Malignant Glioma,"Histologically confirmed malignant glioma | WHO grade IV glioblastoma or variants | WHO grade III anaplastic astrocytoma or oligodendroglial tumor | WHO grade II glioma with contrast enhancement on MRI | Recurrent tumor after prior therapy including at least radiation therapy and one cytotoxic chemotherapy | Hypermutator phenotype defined as >=30 nonsynonymous somatic mutations by CLIA-certified NGS (or per PI approval, mutation in mismatch repair gene or other hypermutator-associated genes, or presence of microsatellite instability) | Age >= 18 years | >=12 weeks since prior radiation therapy unless histopathologic confirmation of recurrence or new enhancement outside radiation field | >=4 weeks since last investigational agent or any other treatment prior to first dose of pembrolizumab | Recovered to <= Grade 1 from adverse events of prior therapy | Karnofsky performance status >= 70 | Adequate organ function | Negative pregnancy test for females of childbearing potential | Agreement to use effective contraception","Requirement for escalating or chronic supraphysiologic corticosteroids (>10 mg/day prednisone equivalent) for disease control at registration | Prior treatment with anti-CTLA-4, anti-PD-1, anti-PD-L1, or anti-PD-L2 agents | Hypersensitivity to pembrolizumab or its excipients | Immunodeficiency including HIV/AIDS | Active hepatitis B or active hepatitis C infection | Known history of active tuberculosis | Additional malignancy that is progressing or requires active treatment (except certain skin cancers or in situ cervical cancer) | Active autoimmune disease requiring systemic treatment in the past 2 years | History or evidence of active non-infectious pneumonitis | Active infection requiring systemic therapy | Pregnant or breastfeeding | Unable to undergo brain MRI | Live vaccine within 30 days before start of study therapy | Prior treatment with bevacizumab",Must have received prior radiation therapy; Must have received at least one prior cytotoxic chemotherapy; >=12 weeks since prior radiation therapy unless pathologic confirmation of recurrence or new enhancement outside radiation field; >=4 weeks since last investigational agent or any other treatment; Recovered to <= Grade 1 from prior therapy adverse events; Prior surgical resection for recurrence allowed,ALL,C,"Stage/setting and prior therapy requirements match (recurrent GBM after radiation and cytotoxic temozolomide). However, the trial requires a hypermutator phenotype (e.g., >=30 nonsynonymous mutations or MSI/MMR alteration), which is not provided for this patient, making eligibility uncertain.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),CORRECT,C,"No hard exclusions. Disease matches; stage/setting and prior therapy anchors match. However, a required biomarker (hypermutator phenotype) is unknown, so A cannot be assigned. With no soft mismatches identified, C is appropriate per rubric.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT02868567,0.7655721306800842,Amyotrophic Lateral Sclerosis,"A Multicenter, 18-week Open Label Safety and Efficacy Trial of Dalfampridine in Primary Lateral Sclerosis",PHASE1,18 years to 99 years,Primary Lateral Sclerosis; Amyotrophic Lateral Sclerosis (UMN-predominant),Age 18-99 years | Diagnosis of upper motor neuron disease compatible with primary lateral sclerosis or UMN-predominant ALS with only UMN features in at least 2 body regions | Electromyography within 3 months showing minimal or no evidence of lower motor neuron disease | Time from symptom onset > 18 months | No previous allergy to dalfampridine | No current or prior exposure to any therapeutic agent targeting PLS or ALS within 30 days of enrollment | Forced vital capacity (FVC) >= 60% of predicted | Stable dose of riluzole or not taken riluzole for at least 30 days | Impaired walking with Hauser walking index 2-6 | Mini-Mental State Examination score > 22 | Women of childbearing potential must use effective contraception during treatment and for 3 months after,"Clinically significant liver disease | Clinically significant renal disease | Peripheral neuropathy | Serious peripheral vascular disease | Hereditary spastic paraplegia | Positive C9orf72 mutation | Positive SPG4 mutation | Active cancer within the previous 2 years except treated basal cell carcinoma of the skin | Use of any experimental drug within 30 days prior to enrollment | History of seizures | History of brain surgery | Presence of brain implants | Metallic implants above the neck | Cardiac pacemaker | Cochlear implant | Piercing or body modification above the neck | History of transcranial magnetic stimulation-related complications or side effects | Tinnitus | Moderate or severe renal impairment (creatinine clearance <= 50 mL/min) | Botulinum toxin administered to lower extremities within 6 months prior to screening or expected during the study | Allergy to pyridine-containing substances or inactive ingredients of dalfampridine | History of drug or alcohol abuse within the past year | Clinically significant abnormal laboratory values | Pregnant, breastfeeding, or attempting to become pregnant | Any condition that, in the investigator’s opinion, increases risk or interferes with study compliance",No therapeutic agents targeting PLS or ALS within 30 days before enrollment; Riluzole allowed only if on a stable dose or not taken for at least 30 days before enrollment,ALL,C,"ALS could fit the trial’s UMN-predominant ALS cohort, but key requirements (UMN-only features/EMG, symptom onset >18 months, and Hauser walking index 2–6) are unknown. Age and FVC meet criteria and riluzole may be allowed if on a stable dose, with no explicit exclusions identified.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,C,"No hard exclusions apply. Disease category (ALS) aligns with the trial’s ALS (UMN-predominant) cohort but required UMN-only features/EMG are unknown. Stage/setting not defined; line/prior-exposure compatibility with riluzole is uncertain (stability not provided); other requirements (symptom onset >18 months, Hauser index) are unknown. Thus 0 core anchors clearly match and no soft mismatch is identified, supporting grade C.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT03283878,0.6045668125152588,Rheumatoid Arthritis,"Perioperative Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty: A Prospective, Randomized, Open-label, Controlled Multi-center Trial",PHASE4,18 years,Knee Osteoarthritis; Inflammatory Arthritis; Avascular Necrosis; Posttraumatic Arthritis,"Age >= 18 years | No open wounds on operative leg | Elective total knee arthroplasty for posttraumatic arthritis, osteoarthritis, avascular necrosis, or inflammatory arthritis | No active infection in the operative leg or joint",Age <= 18 years | Pregnancy | Psychiatric disorder that precludes safe participation | Emergent or urgent total knee arthroplasty for traumatic injury | Active infection in the operative leg or joint | Severe dementia | Suspicion of illicit drug abuse | ASA score 5–6 | Use of topical antibiotic powder or antibiotic beads in the surgical wound | Intra-operative antibiotic re-dosing outside protocol or without excessive blood loss (<1500 mL) | History of prior native septic knee arthritis,(none),ALL,C,"Rheumatoid arthritis fits the trial’s 'inflammatory arthritis' disease category, and age/sex are within bounds. However, the trial is specifically for patients undergoing elective total knee arthroplasty, which is unknown for this patient, leaving stage/setting and other core anchors insufficient to confirm a match.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,C,"No hard exclusions apply (disease category matches as inflammatory arthritis; age/sex within bounds). The key stage/setting requirement—undergoing elective total knee arthroplasty—is unknown, not a clear mismatch. With no other anchors matched and no soft conflicts identified, grade C per rubric is appropriate. The grader’s reasoning reflects this.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT03724136,0.7121427655220032,Dementia,Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study,NA,18 years,Alzheimer Disease; Autism Spectrum Disorder; CADASIL; Chronic Traumatic Encephalopathy; Mixed Dementia; Huntington's Dementia; LATE (limbic-predominant age-related TDP-43 encephalopathy); Lewy Body Dementia; Parkinson-Dementia Syndrome; Traumatic Brain Injury; Vascular Dementia; Wernicke-Korsakoff Syndrome,"Documented cognitive impairment or a diagnosis associated with cognitive impairment (e.g., Alzheimer's disease, autism spectrum disorder) | If on current medical therapy for the condition, be stable and unlikely to have reversal of impairment from ongoing treatment | Investigator judges potential for improvement with BMSC and minimal procedural risk | Age >= 18 years | Medically stable and cleared by a primary care practitioner for the procedure",Not medically stable or at significant health risk to undergo the procedure | Pregnant or planning pregnancy within 3 months post treatment | Investigator deems BMSC collection/treatment poses significant risk to general health or neurologic function,(none),ALL,C,"The study enrolls adults with documented cognitive impairment, matching the patient's moderate dementia, and there are no age/sex or biomarker restrictions that conflict. However, the protocol provides no specific stage/setting or prior-therapy requirements, leaving core anchors beyond disease match essentially unknown.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,C,"No hard exclusions apply (age/sex OK; disease fits broad cognitive impairment criteria; no required biomarkers). Trial does not specify stage/setting or line/prior exposure, yielding 0 clear CORE ANCHOR matches and no soft mismatches. Grade C is appropriate.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT03726554,0.5769773125648499,Rheumatoid Arthritis,Comprehensive Reverse Shoulder: Porous Augmented Glenoid Baseplate and Mini Humeral Tray Post-Market Clinical Follow-up Study,NA,18 years,Shoulder Arthropathy; Rotator Cuff Deficiency; Shoulder Osteoarthritis; Post-Traumatic Arthritis; Rheumatoid Arthritis,Age >= 18 years | Anatomically and structurally suited to receive the implants | Functional deltoid | Grossly deficient rotator cuff with severe arthropathy | Previously failed shoulder joint replacement with a grossly deficient rotator cuff,Osteoporosis | Metabolic disorder that may impair bone formation | Osteomalacia | Distant foci of infection that may spread to the implant site | Rapid joint destruction | Marked bone loss | Bone resorption on radiograph,(none),ALL,C,"Disease matches (rheumatoid arthritis) and age/sex fit, but the trial specifically targets candidates for reverse shoulder arthroplasty with gross rotator cuff deficiency and severe shoulder arthropathy, which are not documented for this patient. Prior therapy/exposure requirements are not specified for this surgical study, so core anchors are largely unknown.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,C,"No hard exclusions apply (disease includes RA; age/sex ok; no explicit exclusions triggered). Core anchors are unknown: stage/setting (surgical shoulder pathology) not documented; line/prior not applicable; required clinical features (rotator cuff deficiency/severe shoulder arthropathy) unknown. With disease match and anchors unknown/no soft mismatch, grade C is appropriate.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT04684602,0.5959930419921875,Dementia,"Evaluation of the Safety, Tolerability and Efficacy of Regenerative Therapy for the Treatment of Various Chronic and Acute Conditions",PHASE1/PHASE2,18 years,Autoimmune Disease; Cardiovascular Disorder; Diabetes Complication; Integumentary Disease; Musculoskeletal Disorder; Neurodegenerative Disorder; Neurologic Disorder; Pulmonary Disorder; Sexual Dysfunction; Urologic Disorder; Viral Illness,Age >= 18 years,Active or recent malignancy within 2 years | Pregnancy or breastfeeding,(none),ALL,C,"The patient’s condition (dementia, a neurodegenerative/neurologic disorder) fits the trial’s broad disease categories and age/sex/exclusions are compatible. However, the trial provides no specific stage/setting, line-of-therapy, or biomarker requirements to establish core anchor matches, leaving anchors effectively unknown.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,C,"No hard exclusions apply (dementia fits neurodegenerative/neurologic categories; age/sex OK; no conflicting exclusions). Core anchors are largely unspecified: stage/setting unknown, line/prior unknown, no required biomarkers, no mets constraints. With 0 known anchor matches and no soft mismatches, grade C per rubric. The grader’s reasoning aligns with this.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT04754087,0.8256611824035645,Rheumatoid Arthritis,"Global, Multicenter, and Prospective Post-Market Clinical Follow-Up Study of the G7 Acetabular System With Vivacit-E and Longevity Highly Crosslinked Polyethylene (HXLPE) Liners & Instrumentation",NA,18 years,Hip Avascular Necrosis; Hip Degenerative Joint Disease; Hip Fracture; Hip Osteoarthritis; Hip Rheumatoid Arthritis,"Adult with full skeletal maturity | Indicated for noninflammatory degenerative joint disease (including osteoarthritis and avascular necrosis) | Rheumatoid arthritis of the hip | Correction of functional deformity of the hip | Treatment of non-union, femoral neck fracture, or trochanteric fractures of the proximal femur with head involvement unmanageable by other techniques | Revision procedure where other treatment or devices have failed","Osteoporosis that may limit ability to support total hip arthroplasty | Metabolic disorder that may impair bone formation | Osteomalacia | Infection, sepsis, osteomyelitis, or distant foci of infection that may spread to the implant site | Rapid joint destruction, marked bone loss, or bone resorption on imaging | Vascular insufficiency, muscular atrophy, or neuromuscular disease | Current alcohol or drug abuse | Neurologic disorder with inability or unwillingness to follow directions | Pregnancy",(none),ALL,C,"The trial targets patients undergoing hip arthroplasty for hip-specific conditions including rheumatoid arthritis of the hip, but the patient’s profile does not specify hip involvement or a surgical indication. No hard exclusions (age/sex) are triggered, and other core anchors (stage/setting, prior exposure) are unknown.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,C,"No hard exclusions are definitively triggered. The trial requires hip-specific RA/surgical indication, which is not stated for the patient, so this is unknown rather than a soft mismatch. Core anchors (stage/setting and required subtype) are unknown; line/prior is irrelevant. With 0 clear anchor matches and no soft conflicts, C is appropriate.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT06560411,0.5705716609954834,Amyotrophic Lateral Sclerosis,Evaluation of Automatic Expiratory Positive Airway Pressure (Auto-EPAP) for Management of Upper Airway Obstruction During Non-Invasive Ventilation With Vivo 45 LS,NA,18 years,Chronic Obstructive Pulmonary Disease; Neuromuscular Disease; Obesity Hypoventilation Syndrome; Obstructive Sleep Apnea,Age >= 18 years | Documented respiratory failure with sleep hypoventilation and historical transcutaneous CO2 (PtCO2) increase >= 10 mmHg and/or daytime hypercapnia > 45 mmHg | Currently using non-invasive positive pressure ventilation for 1 month | Apnea-hypopnea index >= 5/hr | EPAP settings reviewed within <= 12 months,"Non-compliance with NIV (use < 4 hours/night) | Pregnant | On oxygen therapy >= 5 L/min | Invasive interface (e.g., tracheostomy) | Acute exacerbation within the last 3 months resulting in hospitalization | Acutely ill, medically complicated, or medically unstable | NIV therapy medically contraindicated | Surgery of the upper airway, nose, sinus, or middle ear within the previous 90 days | Untreated non-obstructive sleep disorders (e.g., insomnia, periodic limb movement syndrome, restless legs syndrome) | Severe bullous lung disease | Recurrent pneumothorax or pneumomediastinum | Cerebrospinal fluid leak | Recent cranial surgery or trauma",Currently using non-invasive ventilation for 1 month,ALL,C,"ALS fits the trial's neuromuscular disease cohort and the patient meets age/sex criteria. However, required features—documented sleep hypoventilation with hypercapnia, AHI ≥ 5, and current non-invasive ventilation use for ≥1 month—are not reported, so eligibility on key anchors is uncertain.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,C,"No hard exclusions. ALS falls under the trial’s neuromuscular disease category; age/sex fit. Key inclusion requirements (NIV use ≥1 month, AHI ≥5, documented sleep hypoventilation/hypercapnia) are unknown, not mismatches. With 0 confirmed core anchor matches and no soft conflicts, C is appropriate.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT07138898,0.6021736860275269,Rheumatoid Arthritis,Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty,PHASE2,18 years,Rheumatoid Arthritis; Psoriatic Arthritis; Ankylosing Spondylitis; Systemic Lupus Erythematosus; Juvenile Idiopathic Arthritis; Spondyloarthritis; Polymyalgia Rheumatica; Giant Cell Arteritis; Vasculitis; Granulomatosis With Polyangiitis; Dermatomyositis; Polymyositis; Inflammatory Bowel Disease-Associated Arthritis,"Age >= 18 years | Diagnosis of rheumatic disease (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, juvenile idiopathic arthritis, spondyloarthritis, polymyalgia rheumatica, giant cell arteritis, vasculitis, granulomatosis with polyangiitis, dermatomyositis, polymyositis, inflammatory bowel disease-associated arthritis) | On active immunosuppression for >= 3 months prior to scheduled surgery | Scheduled for elective total shoulder arthroplasty",Active infection | Active malignancy | Shoulder arthroplasty indication is fracture or tumor | Pregnancy or breastfeeding | Severe systemic lupus erythematosus with marked activity,On active immunosuppression for >= 3 months,ALL,C,"Disease (RA) and age/sex match, but it’s unknown whether the patient is scheduled for elective total shoulder arthroplasty or has been on active immunosuppression ≥3 months, both required by the trial. No explicit exclusions are identified from the available data.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,C,"No hard exclusions apply. Disease matches, but key required setting (scheduled elective total shoulder arthroplasty) and active immunosuppression ≥3 months are unknown, yielding 0 core anchor matches without soft conflicts. Grade C is appropriate per rubric.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT00365157,0.8184962272644043,Metastatic Urothelial Carcinoma,A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency,PHASE1/PHASE2,18 years,Urothelial Carcinoma (advanced/metastatic),"Locally advanced or metastatic urothelial cancer not amenable to surgical treatment | Histologically or cytologically confirmed urothelial tract carcinoma | Measurable disease (>= 20 mm by conventional imaging or >= 10 mm by spiral CT) | Up to two prior lines of chemotherapy for recurrent/advanced disease allowed | Received at least one platinum-based chemotherapy for recurrent/advanced disease | For a specified cohort, prior tubulin inhibitor therapy required (e.g., paclitaxel, docetaxel, or vinblastine) | Women with or without prior therapy eligible | Life expectancy > 6 months | ECOG performance status 0-2 or Karnofsky >= 60% | Absolute neutrophil count >= 1,000/µL | Platelets >= 100,000/µL | Hemoglobin >= 9 g/dL | Total bilirubin <= 1.5 x ULN | AST/ALT <= 2.5 x ULN | Renal function: creatinine <= 1.5 x ULN or creatinine clearance >= 60 mL/min, or moderate/severe renal dysfunction with creatinine clearance >= 20 mL/min","Concurrent treatment with other investigational agents | Unstable or untreated brain metastases | Uncontrolled intercurrent illness (including active infection, symptomatic congestive heart failure, unstable angina, clinically significant arrhythmia, or psychiatric illness/social conditions limiting compliance) | Pregnant or breastfeeding | HIV-positive on combination antiretroviral therapy | HIV-positive with CD4+ <= 500/mm3 | Prior therapy with eribulin | Symptomatic uremia, uncontrolled edema, or unstable serum electrolytes not stabilized prior to enrollment","Prior platinum-based chemotherapy for recurrent/advanced disease required; Up to two prior lines of chemotherapy for recurrent/advanced disease allowed; Prior tubulin inhibitor required for a specified cohort (e.g., paclitaxel, docetaxel, vinblastine)",ALL,D,"Stage and population match (metastatic urothelial carcinoma; renal function ≥20 mL/min), but the trial requires prior platinum-based chemotherapy specifically for recurrent/advanced disease, which the patient has not received (only neoadjuvant platinum).",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),CORRECT,D,"No hard exclusions. Disease and stage match. There is a clear soft mismatch on the Line/prior-exposure anchor: the trial requires prior platinum specifically for recurrent/advanced disease, while the provided prior therapies show only neoadjuvant platinum and EV+pembrolizumab in the metastatic setting. That warrants a D per rubric.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT02122185,0.8481891751289368,Recurrent Clear Cell Ovarian Carcinoma,"A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction With Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal Cancer",PHASE2,18 years,Ovarian Epithelial Cancer (Stage III–IV); Fallopian Tube Cancer (Stage III–IV); Primary Peritoneal Cancer (Stage III–IV); Ovarian Serous Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Clear Cell Carcinoma; Ovarian Mixed Epithelial Carcinoma; Ovarian Undifferentiated Adenocarcinoma; Brenner Tumor,"Age >= 18 years | ECOG performance status <= 2 | Leukocytes >= 3,000/µL | Absolute neutrophil count >= 1,500/µL | Platelets >= 100,000/µL | Total bilirubin <= 1 x ULN (Gilbert syndrome allowed) | AST <= 2.0 x ULN | ALT <= 2.0 x ULN | Creatinine <= 1 x ULN or creatinine clearance >= 60 mL/min | Fasting blood glucose <= 126 mg/dL or nonfasting glucose <= 140 mg/dL | Histologically confirmed carcinoma consistent with ovarian, fallopian tube, or primary peritoneal carcinoma | Stage III or IV disease with gross macroscopic residual disease after primary debulking surgery | For planned neoadjuvant chemotherapy: cytology or biopsy showing adenocarcinoma and CA-125 > 250 or CA-125:CEA ratio > 25 or CA-125 <= 250 with no evidence of GI cancer; presumed stage III or IV based on carcinomatosis/effusions/ascites | Agreement to receive 6–8 cycles of an allowed standard chemotherapy regimen as specified | Women of child-bearing potential agree to use effective non-hormonal contraception during the study","Known diabetes mellitus or fasting glucose > 126 mg/dL or random glucose > 140 mg/dL | Current use of metformin, sulfonylureas, thiazolidinediones, or insulin | Use of other investigational agents | Comorbidities with expected survival < 2 years unrelated to ovarian cancer | Concurrent active invasive malignancy or prior malignancy with > 30% risk of recurrence within 2 years | Allergy to metformin or compounds of similar composition | NYHA class III or IV heart failure | History of any acidosis | Alcoholic liver disease | Habitual intake of >= 3 alcoholic beverages per day | Uncontrolled intercurrent illness (e.g., active major infection, unstable angina, symptomatic CHF, significant arrhythmia, psychiatric illness limiting compliance) | Pregnant or nursing | Mucinous adenocarcinoma or borderline tumors | Planned intraperitoneal chemotherapy | Neoadjuvant chemotherapy without planned interval debulking surgery (assuming adequate response) | Planned chemotherapy regimens not specified in the protocol | Participation in other interventional trials to reduce ovarian cancer recurrence or planned off-protocol maintenance therapy (e.g., paclitaxel or bevacizumab)",(none),FEMALE,D,"Disease histology matches, but the trial requires stage III/IV patients in the upfront setting with gross residual disease after primary debulking and agreement to receive 6–8 cycles of specified first-line chemotherapy, whereas the patient has recurrent disease after completing adjuvant carboplatin/paclitaxel/bevacizumab. This represents a stage/setting and line-of-therapy mismatch.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; BRCA1 positive; Optimal debulking surgery performed; Received adjuvant carboplatin + paclitaxel + bevacizumab; Cytology-positive malignant pleural effusion at 5 months post-adjuvant,(none),Carboplatin; Paclitaxel; Bevacizumab; Optimal debulking surgery,Stage III,,36,years,female,(none),CORRECT,D,"No hard exclusion applies (disease, age, sex match; no explicit exclusion triggered; unknowns are neutral). There is a clear stage/setting and line-of-therapy mismatch since the trial is for upfront stage III/IV with gross residual and planned first-line chemo, while the patient is recurrent post-adjuvant with optimal debulking. That warrants a D per the rubric.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT02266745,0.8315225839614868,Castration-Resistant Prostate Cancer,"A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts",PHASE2,18 years,Metastatic Castration-Resistant Prostate Cancer,"Male >= 18 years of age | Histologically or cytologically confirmed adenocarcinoma of the prostate | Metastatic castration-resistant prostate cancer with documented metastatic lesions on bone scan or CT/MRI | Received at least three prior intended life-prolonging therapies for metastatic disease | ECOG 0-1 | Progressive disease by RECIST v1.1 or PCWG3 or by informative tumor markers | Adequate organ function | If known history of brain metastases, disease must be stable",Cytotoxic chemotherapy within 21 days prior to initiation of study drug | Immunomodulatory drug therapy within 14 days prior to initiation of study drug | Anti-neoplastic hormonal therapy within 14 days prior to initiation of study drug | Immunosuppressive therapy within 14 days prior to initiation of study drug | Corticosteroids within 14 days prior to initiation of study drug | Growth factor treatment within 14 days prior to initiation of study drug | Inadequate bone marrow reserve | Radiotherapy within 14 days prior to baseline | Radiotherapy to >25% of active bone marrow | Major surgery within 28 days prior to initiation of study drug,At least three prior intended life-prolonging therapies for metastatic disease; Washout: cytotoxic chemotherapy >= 21 days before study drug; Washout: immunomodulatory drugs >= 14 days before study drug; Washout: anti-neoplastic hormonal therapy >= 14 days before study drug; Washout: immunosuppressive therapy >= 14 days before study drug; Washout: corticosteroids >= 14 days before study drug; Washout: growth factors >= 14 days before study drug; Washout: radiotherapy >= 14 days before baseline; Washout: major surgery >= 28 days before study drug,MALE,D,"Disease and setting match (metastatic castration-resistant prostate cancer). However, the trial requires ≥3 prior intended life-prolonging therapies for metastatic disease, and only two are documented (abiraterone, enzalutamide), making the patient likely ineligible unless an additional qualifying prior therapy is confirmed.",Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),INCORRECT,B,"Disease and metastatic setting match. The grader labeled a soft mismatch on line/prior exposure by counting only two prior life-prolonging therapies and ignoring leuprolide. Given the provided data lists three prior therapies and the trial’s wording does not exclude ADT from “intended life-prolonging therapies,” this anchor is at least unknown rather than a clear mismatch. With one clear anchor match (stage/setting) and no confirmed soft conflicts, the rubric points to B, not D.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT03170960,0.9999558329582214,Castration-Resistant Prostate Cancer,A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors,PHASE1,18 years,Castration-Resistant Prostate Cancer; Colorectal Cancer; Differentiated Thyroid Cancer; Endometrial Cancer; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Head and Neck Cancer; Hepatocellular Carcinoma; Lower Esophageal Cancer; Non-Small Cell Lung Cancer; Ovarian Cancer; Renal Cell Carcinoma; Triple Negative Breast Cancer; Urothelial Carcinoma,"Histologically or cytologically and radiologically confirmed inoperable, locally advanced, metastatic, or recurrent solid tumor per cohort definitions | Measurable disease per RECIST 1.1 | Tumor tissue available (archival or recent biopsy) | Recovery to baseline or <= Grade 1 from prior treatment toxicities unless clinically nonsignificant/stable on supportive therapy | Age >= 18 years | ECOG performance status 0–1 | Adequate organ and marrow function | Use of effective contraception if of childbearing potential or sexually active | Negative pregnancy test for females of childbearing potential","Prior treatment with cabozantinib or immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1, anti-PD-L1, anti-PD-L2) except in specified cohorts (5, 7, 9, 11, 17, 19, 20) | Known brain metastases or cranial epidural disease unless adequately treated and stable for >= 4 weeks prior to first dose | Concomitant anticoagulation with oral anticoagulants | Systemic steroid therapy >10 mg daily prednisone equivalent or other immunosuppressive therapy within 2 weeks prior to first dose | Receipt of a live attenuated vaccine within 30 days before first dose | Uncontrolled significant intercurrent or recent illness, including active or history of autoimmune disease or immune deficiency | Interstitial lung disease (idiopathic pulmonary fibrosis, organizing pneumonia) or pneumonitis | Active infection requiring systemic treatment | HIV infection or AIDS-related illness | Acute or chronic hepatitis B or C infection | Positive test for tuberculosis | Moderate to severe hepatic impairment (Child-Pugh B or C) | Pregnant or lactating | Allergy or hypersensitivity to components of study treatments | Another malignancy diagnosed within 2 years prior to first dose","Prior platinum-based chemotherapy for urothelial carcinoma (specific cohorts); Up to one prior VEGFR-targeting TKI allowed for non–clear cell RCC (Expansion Cohort 10); No prior systemic anticancer therapy required for selected cohorts (e.g., clear cell RCC, HCC, PD-L1 positive NSCLC); Progression after prior immune checkpoint inhibitor required for selected UC and NSCLC cohorts; Prior EGFR-targeting TKI with subsequent progression required for EGFR-mutant NSCLC cohort; Prior systemic chemotherapy containing fluoropyrimidine with oxaliplatin or irinotecan required for CRC cohort; At least one prior systemic therapy required for TNBC cohort; Platinum-resistant or refractory OC after up to two prior lines; At least one prior systemic therapy required for EC cohort; Prior enzalutamide and/or abiraterone for metastatic CRPC (specific cohort); Exactly one prior novel hormonal therapy for mCRPC cohorts; Prior docetaxel for mCRPC required in a specific cohort",ALL,D,"Disease and metastatic setting match, but the mCRPC cohorts in this trial specify exactly one prior novel hormonal therapy; the patient has received both abiraterone and enzalutamide, making eligibility unlikely though not an explicit hard exclusion.",Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),CORRECT,D,"No hard exclusions apply (disease, age, sex match; no prior ICI/Cabozantinib noted). Stage/setting matches metastatic. However, the trial’s mCRPC cohorts specify exactly one prior novel hormonal therapy, while the patient has received both abiraterone and enzalutamide, creating a clear line/prior soft mismatch. This warrants a D per the rubric.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT03517969,0.9290853142738342,Castration-Resistant Prostate Cancer,"A Phase 2 Study of M6620 (VX-970, Berzosertib) in Combination With Carboplatin Compared With Docetaxel in Combination With Carboplatin in Metastatic Castration-Resistant Prostate Cancer",PHASE2,18 years,Castration-Resistant Prostate Cancer (metastatic),"Histologically or cytologically confirmed prostate cancer with progressive disease (rising PSA or radiographic progression) | Metastatic disease on imaging and castrate testosterone < 50 ng/dL | Baseline PSA >= 2.0 ng/mL or measurable disease per RECIST 1.1 | Maintain castrate state (LHRH/GnRH therapy if no orchiectomy unless intolerant) | At least 2 prior treatments for castration-resistant prostate cancer | Prior progression or intolerance to at least one secondary hormonal therapy (e.g., abiraterone, enzalutamide, apalutamide, darolutamide, etc.) | Prior progression or intolerance to taxane-based chemotherapy | ECOG performance status <= 1 | Leukocytes >= 3,000/µL | Absolute neutrophil count >= 1,500/µL | Hemoglobin >= 9 g/dL | Platelets >= 150,000/µL | Total bilirubin <= 1.5 x ULN (except Gilbert syndrome) | AST <= 2.5 x ULN (<= 5 x ULN if liver metastases) | ALT <= 2.5 x ULN (<= 5 x ULN if liver metastases) | Creatinine clearance >= 40 mL/min | Prior treatment with mTOR inhibitors, TKIs, or biologic therapies allowed | Prior treatment with PARP inhibitors permitted | Lesion amenable to image-guided core biopsy for NGS prior to cycle 1 day 1 (may be waived per PI if required)","Chemotherapy or radiotherapy within 4 weeks prior to cycle 1 day 1 (6 weeks for nitrosoureas or mitomycin C) | Oral antineoplastic agents (including oral hormonal agents, PARP inhibitors, oral experimental agents) not discontinued >= 14 days prior to cycle 1 day 1 | Residual toxicities > grade 1 from prior therapy (except grade 2 anorexia, alopecia, neuropathy, or fatigue) | Concurrent treatment with other investigational agents | Known brain metastases or leptomeningeal disease | History of allergic reactions to compounds similar to berzosertib or carboplatin | Use of ototoxic or nephrotoxic medications that cannot be discontinued >= 7 days before first carboplatin dose and during study | Concomitant strong CYP3A4 inhibitors or inducers prohibited with berzosertib | Uncontrolled intercurrent illness (e.g., active infection, symptomatic CHF, unstable angina, significant arrhythmia, significant psychiatric illness) | Pregnant or nursing women | HIV-positive with detectable viral load and/or CD4 count <= 300/µL, or on interacting antiretroviral therapy | Prior platinum-containing regimen or prior ATR inhibitor for prostate cancer","Progression or intolerance to at least one secondary hormonal therapy required; Progression or intolerance to taxane-based chemotherapy required; Prior mTOR inhibitors, TKIs, or biologic therapies allowed; Prior PARP inhibitors permitted; Washout: chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to cycle 1 day 1 not allowed; Washout: oral antineoplastic agents discontinued >= 14 days prior to cycle 1 day 1",MALE,D,"Stage/setting matches metastatic castration-resistant prostate cancer and prior secondary hormonal therapy is met, but the trial requires prior progression or intolerance to taxane-based chemotherapy, which is not documented in the patient's history.",Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),INCORRECT,B,"No hard exclusions. Disease matches and stage/setting clearly match. The trial’s requirement for prior taxane chemotherapy is UNKNOWN for the patient (not documented), and per rubric unknowns should not be treated as mismatches. Thus there’s exactly one confirmed core anchor match and no soft conflicts → Grade B, not D.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT03737994,0.8366274833679199,Metastatic Non-Small Cell Lung Cancer,A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol,PHASE2,18 years,Non-Squamous Non-Small Cell Lung Cancer (metastatic),"Histologically or cytologically confirmed stage IV ALK-positive non-squamous NSCLC | ALK rearrangement demonstrated by FDA-approved assay (FISH or IHC) or by NGS | Willing and able to undergo a fresh biopsy or provide recent post-progression biopsy with sufficient tissue | Progressive disease per RECIST 1.1 after exactly one second-generation ALK inhibitor (ceritinib, alectinib, ensartinib, or brigatinib) | Prior crizotinib allowed; the second-generation ALK inhibitor must be the last treatment before enrollment | No prior chemotherapy except one prior cycle at initial metastatic diagnosis without progression; adjuvant/neoadjuvant chemotherapy allowed if last dose >12 months before enrollment | ANC >= 1500/µL within 28 days prior to Step 2 | Platelets >= 100000/µL within 28 days prior to Step 2 | Creatinine clearance >= 60 mL/min within 28 days prior to Step 2 | Total bilirubin <= 1.5 x ULN within 28 days prior to Step 2 (except Gilbert's syndrome) | AST <= 2.5 x ULN within 28 days prior to Step 2 (<= 5 x ULN with liver metastases) | ALT <= 2.5 x ULN within 28 days prior to Step 2 (<= 5 x ULN with liver metastases) | Asymptomatic treated or untreated brain metastases allowed; measurable extracranial target lesion required if brain metastases present; stable/decreasing steroids for >= 7 days | ECOG performance status 0-2 | Acute effects of prior therapy resolved to baseline or CTCAE <= 1 (except alopecia, hearing loss) | Able to take oral medications","Prior lorlatinib (third-generation ALK inhibitor) | Major surgery within 2 weeks before study entry | Palliative radiotherapy (< 10 fractions) within 48 hours before study entry | Stereotactic/small field brain irradiation within 1 week before study entry | Whole brain or other palliative radiotherapy within 2 weeks before study entry | Dose of next-generation ALK inhibitor (ceritinib, alectinib, ensartinib, lorlatinib) within 5 days before Step 2; brigatinib within 7 days before Step 2 | History of interstitial lung disease or interstitial fibrosis (including pneumonitis, obliterative bronchiolitis, pulmonary fibrosis) | Active inflammatory gastrointestinal disease or conditions affecting absorption (e.g., Crohn's disease, ulcerative colitis), chronic diarrhea, symptomatic diverticular disease | Clinically significant cardiovascular disease (e.g., uncontrolled hypertension, NYHA class 3 heart failure, unstable angina, poorly controlled arrhythmia, recent MI within 6 months) | Active and clinically significant bacterial, fungal, or viral infection | Active or chronic pancreatitis | Other serious illness or organ dysfunction that could compromise safety or study drug evaluation | Planned receipt of other investigational agents during therapy | Active malignancy other than ALK-positive NSCLC within 2 years, except specified adequately treated cancers | No chemotherapy and/or immunotherapy allowed after Step 1 registration | Pregnant or breastfeeding","Progression after one second-generation ALK inhibitor required (ceritinib, alectinib, ensartinib, or brigatinib); Prior crizotinib allowed; No prior lorlatinib allowed; No prior chemotherapy except one cycle at initial metastatic diagnosis without progression; Prior adjuvant or neoadjuvant chemotherapy allowed if last dose > 12 months before enrollment; No chemotherapy or immunotherapy permitted after Step 1 registration",ALL,D,"Stage and setting match and brain metastases are allowed, but the trial requires ALK-positive NSCLC with progression after exactly one second-generation ALK inhibitor. The patient has EGFR exon 19 disease treated with osimertinib and no ALK inhibitor exposure documented, so the line-of-therapy requirement is not met.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,D,"No hard exclusion applies: disease category (NSCLC) matches, age/sex ok, ALK status is unknown (cannot assume negative). However, there is a clear soft mismatch on line-of-therapy/prior exposure because the trial requires progression after exactly one second-generation ALK inhibitor, and the patient has only received osimertinib (EGFR TKI). Per rubric, a specific soft mismatch on a core anchor yields D. The grader’s reasoning aligns with this.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT03926520,0.7645418643951416,Dementia,Effect and Safety of Electroconvulsive Therapy Plus Usual Care for the Acute Management of Severe Agitation in Dementia,NA,40 years,Alzheimer Dementia; Vascular Dementia; Frontotemporal Dementia; Dementia with Lewy Bodies,"Diagnosis of Alzheimer's dementia per NIA-AA criteria | Diagnosis of vascular dementia with MRI evidence of microvascular ischemic disease and no clinical/radiologic evidence of stroke | Diagnosis of frontotemporal dementia | Diagnosis of dementia with Lewy bodies | Mini-Mental State Examination (MMSE) <= 15 | Cohen-Mansfield Agitation Inventory (CMAI) threshold for severe agitation as specified | At least one failed pharmacological intervention to manage behavioral symptoms | Medically stable for safe ECT based on physical exam, urinalysis, and serum chemistries (and brain imaging when indicated) | Comprehension of English | Authorized legal representative able and willing to provide informed consent | Age >= 40 years","Current co-morbid delirium by Confusion Assessment Method (CAM) or clinical diagnosis | Vascular dementia due to stroke (abrupt onset, step-wise decline, MRI evidence of hemorrhagic/embolic stroke, or exam consistent with current/prior stroke) | Schizophrenia | Bipolar disorder | Schizoaffective disorder | Active substance use disorder within the past 6 months | Treatment with ECT, transcranial magnetic stimulation, or vagal nerve stimulation within the past 3 months",At least one failed pharmacological intervention for behavioral symptoms,ALL,D,"The trial requires severe agitation with MMSE ≤15 and at least one failed pharmacologic intervention for behavioral symptoms; the patient has MMSE 19 and no prior behavioral therapy documented. Disease subtype and agitation severity are not specified, though age and sex fit.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),INCORRECT,F,"Hard exclusions apply: the trial requires MMSE ≤15 (patient MMSE is 19) and at least one failed pharmacologic intervention for behavioral symptoms (patient has none). These are required criteria the patient definitively lacks, triggering F. The grader identified these issues but incorrectly issued D instead of F.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT04220021,0.7088781595230103,Amyotrophic Lateral Sclerosis,"A Single-Center, Open Label Study to Assess the Safety and Tolerability of Metformin in Subjects With C9orf72 Amyotrophic Lateral Sclerosis Over 24 Weeks of Treatment",PHASE2,18 years to 80 years,Amyotrophic Lateral Sclerosis (C9orf72-positive),"Probable or definite ALS per Revised El Escorial criteria | C9orf72 repeat expansion positive (ALS/FTD) | Able to take oral diet, pills, and liquids; FOIS >= 4 | No known allergy to barium sulfate or metformin | Currently taking or previously taken metformin | Females of childbearing potential: negative urine pregnancy test prior to VFSS exams","FOIS <= 3 | Does not carry the C9orf72 hexanucleotide repeat expansion | Clinically significant liver disease, renal disease, or other exclusionary medical condition | Pregnant, attempting to become pregnant, or breastfeeding | Active cancer within the previous 2 years (except treated basal cell carcinoma of the skin) | Use of any investigational drug within 30 days prior to enrollment or within 5 half-lives, whichever is longer | eGFR < 30 mL/min/1.73 m2 | Hepatic impairment: serum aminotransferases > 5 x ULN or evidence of liver dysfunction (e.g., elevated bilirubin) | Use of potentially hepatotoxic drugs (e.g., allopurinol, methyldopa, sulfasalazine) | Clinically significant abnormal laboratory values per investigator | Implanted electrical device or metallic clips contraindicating MRI",Current or prior metformin use allowed,ALL,D,"The trial requires participants to be currently taking or to have previously taken metformin, but the patient has no documented metformin exposure. C9orf72-positive status and FOIS/swallowing ability are not reported, so those remain uncertain rather than exclusions.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,D,"No hard exclusions apply (age, sex, disease match; C9orf72 status unknown, not a hard fail). There is a clear soft mismatch on the Line/prior-exposure anchor because the trial requires current or prior metformin use and the patient has none. Other requirements (C9orf72+, FOIS) are unknown. Thus D is correct.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT04225117,0.7794124484062195,Metastatic Non-Small Cell Lung Cancer,"An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)",PHASE2,18 years,Breast Cancer (HR+/HER2-); Triple Negative Breast Cancer; Squamous Non-Small Cell Lung Cancer; Non-squamous Non-Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Esophageal Adenocarcinoma; Esophageal Squamous Cell Carcinoma,"Adult per local regulations | Measurable disease by RECIST 1.1 | Archival tumor tissue available or agree to biopsy (unless unsafe) | ECOG performance status 0–1 | Baseline labs meet protocol thresholds | Evidence of progression on or after last regimen | Locally advanced or metastatic disease not amenable to curative treatment | Cohort 1 (HR+/HER2- breast cancer): Histologically/cytologically confirmed HR+/HER2- and not a candidate for further hormonal therapy (ER and/or PR >= 1% per ASCO/CAP) | Cohort 1: Prior taxane or anthracycline in neoadjuvant/adjuvant or advanced setting | Cohort 1: >=1 prior standard cytotoxic regimen in advanced setting and <=2 prior cytotoxic lines in advanced setting; progressed/relapsed or discontinued for toxicity; prior endocrine and/or CDK inhibitor therapy with progression/toxicity (CDK inhibitor not required) | Cohort 2 (TNBC): Histologically/cytologically confirmed TNBC (ER-/PR- <1%, HER2 0–1+ or 2+ and FISH negative) | Cohort 2: Prior taxane or anthracycline; >=1 prior standard cytotoxic regimen in advanced setting and <=2 prior cytotoxic lines; prior anti-PD-1/PD-L1 per guidelines with progression/toxicity or contraindicated | Cohort 3 (Squamous NSCLC): Histologically/cytologically confirmed squamous NSCLC; mixed histology allowed if no neuroendocrine component; actionable mutations allowed if treated and progressed/toxic | Cohort 3: Progressed/relapsed or discontinued due to toxicity after 1 platinum-based regimen for advanced disease; <=2 prior cytotoxic lines in advanced setting; prior anti-PD-1/PD-L1 per guidelines with progression/toxicity or contraindicated | Cohort 4 (Non-squamous NSCLC): Histologically/cytologically confirmed non-squamous NSCLC; mixed histology allowed if no neuroendocrine component; actionable mutations allowed if treated and progressed/toxic | Cohort 4: Progressed/relapsed or discontinued due to toxicity after 1 platinum-based regimen for advanced disease; <=2 prior cytotoxic lines in advanced setting; prior anti-PD-1/PD-L1 per guidelines with progression/toxicity or contraindicated | Cohort 5 (Head and neck cancer, 2L+): Histologically/cytologically confirmed head and neck cancer of oral cavity, oropharynx, hypopharynx, or larynx (non-nasopharyngeal) | Cohort 5: Progressed/relapsed or discontinued due to toxicity after 1 platinum-based regimen for advanced disease; <=2 prior cytotoxic lines; prior anti-PD-1/PD-L1 per guidelines with progression/toxicity or contraindicated | Cohorts 6–8 (Gastric/GEJ/esophageal): Histologically/cytologically confirmed gastric, GEJ, or esophageal cancer; progressed/relapsed or discontinued due to toxicity after 1 platinum-based regimen for advanced disease; <=2 prior cytotoxic lines; HER2+ must have received HER2-directed therapy; prior anti-PD-1/PD-L1 per guidelines with progression/toxicity or contraindicated | Cohort 9 (1L HNSCC): Histologically/cytologically confirmed HNSCC of oral cavity, oropharynx, hypopharynx, or larynx (non-nasopharyngeal) | Cohort 9: Recurrent or metastatic and incurable by local therapy | Cohort 9: PD-L1 CPS >= 1 by local or central IHC | Cohort 9: No prior systemic therapy for recurrent/metastatic disease (allowed if >6 months since completion of systemic therapy given for locally advanced disease); prior PD-1/PD-L1 in curative setting allowed if >=12 months since last dose | Cohort 9: ANC >= 1.5 x 10^9/L | Cohort 9: INR or PT and aPTT <= 1.5 x ULN (unless on therapeutic anticoagulation) | Cohort 9: For oropharynx tumors, HPV status by p16 testing available","Preexisting sensory or motor neuropathy >= Grade 2 | Active CNS metastases unless clinically stable >=6 weeks, on <=20 mg/day prednisone equivalent if needed, no new/enlarged lesions, and no leptomeningeal disease | Ongoing clinically significant toxicity >= Grade 2 from prior therapy (except alopecia) | Ongoing >= Grade 3 immunotherapy-related hypothyroidism or panhypopituitarism; history of immunotherapy-related colitis, uveitis, myocarditis or pneumonitis; or immunotherapy-related AEs requiring >20 mg/day prednisone equivalent | Uncontrolled diabetes within 3 months (HbA1c >= 8% or 7% to <8% with diabetes symptoms) | Prior treatment with enfortumab vedotin or other MMAE-based ADCs | Second malignancy within 3 years or residual disease from prior malignancy (exceptions apply) | Active systemic infection requiring treatment; active hepatitis B or C; known HIV infection | Recent significant cardiovascular event within 6 months (stroke/TIA, unstable angina, MI, or NYHA III–IV heart failure) | Major surgery within 4 weeks before first dose | Prior radiotherapy, chemotherapy, biologics, investigational agents, or immunotherapy not completed >= 2 weeks before first dose | Known hypersensitivity to enfortumab vedotin or CHO cell products/excipients | Active keratitis or corneal ulcerations (adequately treated superficial punctate keratitis allowed) | Any condition that makes the subject unsuitable for study participation | Cohort 9: Disease progression within 6 months of completing curative systemic therapy for locoregionally advanced HNSCC | Cohort 9: Prior allogeneic tissue/solid organ transplant | Cohort 9: Severe hypersensitivity (>= Grade 3) to pembrolizumab or its excipients | Cohort 9: History of non-infectious pneumonitis/ILD requiring steroids or current pneumonitis/ILD | Cohort 9: Idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced/idiopathic pneumonitis, or active pneumonitis on screening CT | Cohort 9: Life expectancy < 3 months or rapidly progressing disease per investigator | Cohort 9: Active autoimmune disease requiring systemic treatment in past 2 years (specified exceptions allowed) | Cohort 9: Active infection requiring systemic therapy | Cohort 9: Prior anti-PD-1/PD-L1 therapy in the recurrent/metastatic setting (if given as curative therapy, must be >= 1 year since last dose) | Cohort 9: Live vaccine within 30 days before start of therapy | Cohort 9: Active tuberculosis",Breast cancer (HR+/HER2- or TNBC): Prior taxane or anthracycline in neoadjuvant/adjuvant or advanced setting; Breast cancer HR+: >=1 prior cytotoxic regimen in advanced setting; <=2 prior cytotoxic lines; progression after endocrine therapy and/or CDK inhibitor (CDK inhibitor not required); TNBC: >=1 prior cytotoxic regimen in advanced setting; <=2 prior cytotoxic lines; prior anti-PD-1/PD-L1 with progression/toxicity or contraindicated; Squamous and non-squamous NSCLC: Progressed/relapsed or toxic after 1 platinum-based regimen for advanced disease; <=2 prior cytotoxic lines; prior anti-PD-1/PD-L1 with progression/toxicity or contraindicated; actionable mutations treated with targeted therapy if present; Head and neck cancer (2L+): Progressed/relapsed or toxic after 1 platinum-based regimen; <=2 prior cytotoxic lines; prior anti-PD-1/PD-L1 with progression/toxicity or contraindicated; Gastric/GEJ/esophageal: Progressed/relapsed or toxic after 1 platinum-based regimen; <=2 prior cytotoxic lines; HER2+ must have received HER2-directed therapy; prior anti-PD-1/PD-L1 with progression/toxicity or contraindicated; All cohorts: Prior anti-cancer therapies completed >= 2 weeks before first dose,ALL,D,"Disease and metastatic setting match, and age/ECOG fit. However, the NSCLC cohorts require prior progression after at least one platinum-based regimen and prior PD-1/PD-L1 therapy (≤2 prior cytotoxic lines), which the patient lacks (only on osimertinib), making a line/prior-therapy mismatch; CNS stability is also unknown.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,D,"Disease and metastatic setting match, but the trial’s NSCLC cohorts require prior platinum-based chemotherapy and prior PD-1/PD-L1 therapy with progression/toxicity, which the patient lacks. That is a clear soft mismatch on the line/prior-exposure anchor, warranting D. No hard exclusions are definitively triggered; CNS stability is unknown, not an exclusion.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT04969315,0.9614568948745728,Castration-Resistant Prostate Cancer,"Phase I/II First-in-Human Study of TT-10 (PORT-6), an Adenosine 2A Receptor Antagonist, and PORT-7, an Adenosine 2B Receptor Antagonist, as Single Agents and in Combination in Participants With Advanced Selected Solid Tumors",PHASE1/PHASE2,18 years,Castrate-Resistant Prostate Cancer; Colorectal Cancer; Endometrial Cancer; Head and Neck Squamous Cell Carcinoma; Non-Small Cell Lung Cancer; Ovarian Cancer; Renal Cell Carcinoma,"Histologically or cytologically confirmed advanced solid tumors per cohort definitions | RCC: locally advanced or metastatic with >=2 prior systemic regimens including VEGF-targeted therapy and checkpoint inhibitor therapy | CRPC: metastatic disease with prior second-generation hormonal agent and a taxane-based chemotherapy | SCCHN: advanced/metastatic, incurable by surgery or radiotherapy, progressed during/after platinum-based chemotherapy and/or checkpoint inhibitor therapy | NSCLC: metastatic, intolerant or resistant to standard therapy or no standard therapy available | CRC: metastatic, intolerant or resistant to standard therapy or no standard therapy available | Endometrial Cancer: metastatic, intolerant or resistant to standard therapy or no standard therapy available | Ovarian Cancer: metastatic, intolerant or resistant to standard therapy or no standard therapy available | ECOG 0–1 | Measurable disease per RECIST 1.1; CRPC may enroll with non-measurable disease if screening PSA >= 2.0 ng/mL with sponsor approval | Adequate hematologic, hepatic, and renal function | Consent to baseline biopsy or provision of recent archival tissue as specified | Able to swallow capsules","Major surgery within 4 weeks prior to screening | Active CNS metastases; treated/stable off corticosteroids allowed; leptomeningeal metastases excluded | Prior radiotherapy within 2 weeks of start; 1-week washout permitted for palliative radiotherapy (<= 2 weeks) to non-CNS disease | Prior anti-cancer therapy within 4 weeks (2 weeks for short-acting TKIs); unresolved treatment-related toxicities > Grade 1 | HIV infection | HBsAg positive unless on antiviral therapy >= 4 weeks with undetectable HBV viral load; must remain on therapy per guidelines | History of HCV infection unless curatively treated with undetectable viral load at screening | Requires immunosuppressive therapy including systemic steroids >= 10 mg prednisone equivalent daily or other immunosuppressants/biologics | Requires strong inhibitors or inducers of CYP3A4, CYP2C9, or CYP2C19 | Requires drugs that modify gastric pH (PPIs or H2 blockers); antacids allowed with dose separation | Ongoing systemic bacterial, fungal, or viral infection | Live vaccine within 6 weeks of first dose (mRNA COVID-19 vaccines permitted) | Baseline QTcF > 470 ms (average of triplicate) | Prior surgery or gastrointestinal dysfunction that may affect drug absorption (e.g., gastric bypass, gastrectomy) | Pregnant or breastfeeding | Concurrent active malignancy other than non-melanoma skin cancer, carcinoma in situ of the cervix, or prostate intraepithelial neoplasia | Past medical history of interstitial lung disease, drug-induced interstitial lung disease, or radiation pneumonitis requiring steroids; or clinically active interstitial lung disease | History of peptic ulcer or gastrointestinal bleed within 6 months | History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring treatment within 6 months | Unstable or severe uncontrolled medical condition that increases study risk",RCC: prior >= 2 systemic regimens including VEGF-targeted therapy and checkpoint inhibitor therapy; CRPC: prior second-generation hormonal therapy and taxane-based chemotherapy; SCCHN: prior platinum-based chemotherapy and/or checkpoint inhibitor with progression; NSCLC/CRC/Endometrial/Ovarian Cancer: intolerant or resistant to standard therapy or no standard therapy available; Washout from prior anti-cancer therapy >= 4 weeks (>= 2 weeks for short-acting TKIs) before start; Washout from radiotherapy >= 2 weeks (>= 1 week for short palliative courses <= 2 weeks),ALL,D,"Disease and metastatic setting match, but the CRPC cohort requires prior taxane-based chemotherapy in addition to a second-generation hormonal agent. The patient has only received abiraterone/enzalutamide without a taxane, making a line-of-therapy mismatch and likely ineligibility.",Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),CORRECT,D,"No hard exclusions apply. Disease and metastatic setting match, but the CRPC cohort requires prior taxane chemotherapy, which the patient lacks per provided prior_therapies, creating a clear line-of-therapy soft mismatch. Thus D is appropriate.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT06483334,0.7762960195541382,Metastatic Urothelial Carcinoma,"A Phase 1/2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab, as Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER-U04): Substudy 04C",PHASE1/PHASE2,18 years,Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma,Histologically documented locally advanced or metastatic urothelial carcinoma | Archival or newly obtained tumor tissue adequate for biomarker evaluation (prefer newly obtained if feasible) | Adverse events from prior anticancer therapy recovered to <= Grade 1 or baseline (endocrine AEs allowed if adequately treated) | Part 1: Prior platinum-based chemotherapy for la/mUC | Part 1: <= 2 prior lines of therapy for la/mUC (platinum-based chemotherapy followed by avelumab maintenance counts as 2 lines) | Part 2: No prior systemic therapy for la/mUC,"Additional malignancy that is progressing or required active treatment within the past 3 years | Active central nervous system metastases or carcinomatous meningitis | Peripheral neuropathy Grade >= 2 | History of severe dry eye syndrome, severe Meibomian gland disease, blepharitis, or corneal disease that prevents/delays corneal healing | Active inflammatory bowel disease requiring immunosuppressive medication or prior history of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, chronic diarrhea) | Uncontrolled significant cardiovascular or cerebrovascular disease, or serious cardiovascular/cerebrovascular events within 6 months | Active keratitis or corneal ulcerations (superficial punctate keratitis allowed if adequately treated) | History of uncontrolled diabetes | Received an investigational agent or used an investigational device within 4 weeks prior to study intervention | Received a live or live-attenuated vaccine within 30 days prior to first dose | Part 2: Diagnosis of immunodeficiency or receiving chronic systemic steroids or other immunosuppressive therapy within 7 days before first dose (inhaled/topical steroids permitted; physiologic replacement allowed for adrenal insufficiency) | Part 2: Active autoimmune disease requiring systemic treatment in past 2 years except replacement therapy | Human immunodeficiency virus infection with history of Kaposi's sarcoma and/or Multicentric Castleman's Disease | Active hepatitis B or hepatitis C virus infection | History of noninfectious pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease | Active infection requiring systemic therapy | Part 2: History of allogeneic tissue/solid organ transplant | Not adequately recovered from major surgery or ongoing surgical complications",Part 1: Prior platinum-based chemotherapy required for la/mUC; Part 1: <= 2 prior lines of therapy for la/mUC; Part 2: No prior systemic therapy for la/mUC,ALL,D,"Stage matches metastatic urothelial carcinoma, but Part 1 requires prior platinum-based chemotherapy specifically for locally advanced/metastatic disease (patient’s platinum was neoadjuvant only), and Part 2 requires no prior systemic therapy for la/mUC (patient has received EV+pembrolizumab).",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),CORRECT,D,"Stage matches mUC, but the patient’s prior therapy history does not fit either trial part: lacks prior platinum for la/mUC (Part 1) and has prior systemic therapy for la/mUC (disqualifies Part 2). This is a clear soft mismatch on the line/prior-exposure anchor, so D per rubric. No hard exclusion applies.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06937229,0.5847024917602539,Dementia,"A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-3)",PHASE3,55 years to 90 years,Alzheimer Disease (agitation),Completed study CN012-0023 or CN012-0024 per protocol | One identified caregiver with approximately 10 hours/week or more contact,"Clinically significant cardiovascular (e.g., untreated or unstable hypertension, clinically significant tachycardia), pulmonary, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any condition that could jeopardize participant safety or study validity in the investigator’s opinion",(none),ALL,D,"This is an open-label extension that only enrolls participants who completed CN012-0023 or CN012-0024, which is not documented for this patient, so prior-exposure requirements are likely not met. Age and sex fit, but AD-specific agitation and caregiver availability are not established.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),INCORRECT,F,"Hard exclusion applies: trial targets Alzheimer’s disease (agitation) while the patient’s disease is listed only as Dementia, not AD. Per rubric, disease mismatch → F. The grader instead gave D based on unknown prior trial completion and agitation/caregiver status, which should be treated as unknowns, not soft mismatches.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT07048457,0.8283476829528809,Metastatic Urothelial Carcinoma,A Phase II Study of Consolidative Local Therapy in Patients With Locally Advanced or Oligo-metastatic Urothelial Carcinoma (la/mUC) Following Treatment Response to Systemic Therapy With or Without Metastasis-directed Radiotherapy,PHASE2,18 years,Urothelial Carcinoma (locally advanced); Urothelial Carcinoma (oligo-metastatic),"Age >= 18 years | ECOG performance status 0–1 | Surgical candidate for extirpative surgery of primary site with bilateral pelvic lymph node dissection and urinary diversion | If applicable, surgical candidate for resection of non-irradiated metastatic lesion(s) | Histologically confirmed urothelial carcinoma, locally advanced or oligo-metastatic (<= 5 distinct metastatic lesions) | Variant histology < 50% with urothelial carcinoma predominant | Received first-line enfortumab vedotin-based systemic therapy started >= 3 months prior to surgery and total treatment duration <= 6 months | Most recent restaging scan shows stable disease, partial response, or complete response by investigator-assessed RECIST v1.1","Systemic anti-cancer therapy within 3 weeks prior to surgery | Radiotherapy within 2 weeks prior to surgery | Positive pregnancy test or breastfeeding | History of central nervous system or leptomeningeal metastases | Concurrent medical, surgical, or psychiatric condition that may confound study interpretation or prevent completion of study procedures | Any medical condition posing undue risk to participation per investigator judgment",First-line enfortumab vedotin-based systemic therapy initiated >= 3 months before surgery; total duration <= 6 months; Metastasis-directed radiotherapy allowed,ALL,D,"The trial requires patients who have responded (SD/PR/CR) to first-line enfortumab vedotin–based therapy and are candidates for consolidative surgery of the primary site; this patient progressed on EV+pembrolizumab and has already had a cystectomy with progression after second-line therapy, mismatching the stage/setting and line/prior-therapy requirements.",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),INCORRECT,F,"Hard exclusions apply: the trial requires response (SD/PR/CR) to first-line enfortumab vedotin–based therapy and candidacy for consolidative extirpative surgery of the primary site. The patient progressed on EV+pembrolizumab and already had a cystectomy, definitively lacking required stage/setting criteria. Under the rubric, failing required stage/setting is a hard exclusion → F, not D.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT00329043,0.6337130069732666,Castration-Resistant Prostate Cancer,A Phase II Neoadjuvant Trial of Sunitinib Malate (SU011248) Plus Hormonal Ablation for Patients Who Have High Risk Localized Prostate Cancer and Will Undergo Prostatectomy,PHASE2,Not specified,Prostate Cancer,"Histologically confirmed adenocarcinoma of the prostate deemed resectable (ductal adenocarcinoma included). | Low anesthetic risk for radical prostatectomy and intent to undergo prostatectomy after neoadjuvant therapy. | High-risk disease: cT3 or Gleason 8–10, or cT2b–c with PSA >= 10 ng/mL and Gleason 7 (AJCC 1992). | ECOG performance status 0–1. | Adequate bone marrow, hepatic, and renal function.","Small cell or sarcomatoid carcinoma of the prostate. | Clinical or radiological evidence of metastatic disease. | Receiving ketoconazole as prior hormonal therapy. | Prior chemotherapy or experimental agents for prostate cancer. | Active infection that could worsen or be affected by investigational therapy. | NYHA class III/IV heart failure, unstable angina, stroke/TIA, pulmonary embolism, or myocardial infarction within 6 months. | Uncontrolled severe hypertension (>= 140/90 despite medication). | Uncontrolled diabetes mellitus. | Oxygen-dependent lung disease. | Known chronic liver disease or HIV infection. | Second malignancy (excluding non-melanoma skin cancer) unless disease-free for 3 years. | Ongoing therapeutic-dose warfarin (low-dose <= 2 mg/day for DVT prophylaxis allowed); low molecular weight heparin allowed. | Overt psychosis, mental disability, incompetence to consent, or history of non-compliance.",Prior hormonal therapy up to 2 months permitted.,MALE,F,"This neoadjuvant trial requires resectable high-risk localized prostate cancer and explicitly excludes any metastatic disease. The patient has metastatic castration-resistant prostate cancer with liver and bone metastases, which directly violates the trial’s exclusion criteria.",Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),CORRECT,F,"Explicit exclusion: the trial excludes any metastatic disease, and the patient has metastatic castration-resistant prostate cancer. This is a hard exclusion per rubric, so F is correct. The grader’s reasoning correctly identified this factor.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT00499330,0.8164030909538269,Metastatic Non-Small Cell Lung Cancer,A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer,PHASE3,18 years,Non-Small Cell Lung Cancer,Peripheral lung nodule <= 2 cm on preoperative CT located in the outer third of the lung | Tumor location suitable for either lobar or sublobar resection | ECOG 0–2 | Age >= 18 years | Histologic confirmation of non-small cell lung cancer | Pathologic N0 status by intraoperative frozen section with required nodal stations negative,"Pure ground glass opacity lesion | Pathologically confirmed N1 or N2 disease | Prior malignancy within 3 years other than non-melanoma skin cancer, superficial bladder cancer, or cervical carcinoma in situ | Prior chemotherapy or radiation therapy for this malignancy | Evidence of locally advanced or metastatic disease",(none),ALL,F,"The trial explicitly excludes patients with locally advanced or metastatic disease and requires resectable, node-negative NSCLC; the patient has de novo metastatic NSCLC with multiple metastases. This is a hard exclusion.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"The trial explicitly excludes patients with evidence of locally advanced or metastatic disease; the patient has de novo metastatic NSCLC. This is a hard exclusion, so F is correct. The grader’s reasoning appropriately identified the exclusion.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT00565851,0.7941914796829224,Recurrent Clear Cell Ovarian Carcinoma,"A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)",PHASE3,18 years,Ovarian Carcinoma (recurrent); Fallopian Tube Carcinoma (recurrent); Primary Peritoneal Carcinoma (recurrent),"Candidate for cytoreductive surgery when applicable per protocol/randomization plan | Histologic epithelial ovarian, primary peritoneal, or fallopian tube carcinoma, recurrent | Eligible epithelial histologies include serous, endometrioid, mucinous, clear cell, transitional cell, undifferentiated, malignant Brenner tumor, mixed epithelial, or adenocarcinoma NOS | Complete response to front-line platinum-taxane therapy (>=3 cycles) | Treatment-free interval without progression >=6 months after completion of front-line chemotherapy (platinum and taxane) | Maintenance biologic or hormonal therapy allowed if recurrence >6 months and >=4 weeks since last biologic infusion | Clinically evident recurrent disease | Measurable disease per RECIST with at least one lesion: >=20 mm by conventional imaging/MRI/CT or >=10 mm by spiral CT | ANC >=1500/µL | Platelets >=100000/µL | Creatinine <=1.5 x ULN | Total bilirubin <=1.5 x ULN | AST <=2.5 x ULN | Alkaline phosphatase <=2.5 x ULN | Urine protein-to-creatinine ratio <1.0 mg/dL (if receiving bevacizumab) | ECOG 0–2","More than one prior chemotherapy regimen (maintenance not counted as a separate regimen) | Concurrent immunotherapy or radiotherapy | Prior radiotherapy to any portion of the abdominal cavity or pelvis | Prior secondary cytoreductive surgery for recurrent disease | Requirement for parenteral hydration or nutrition with evidence of partial bowel obstruction or perforation | Prior chemotherapy for other abdominal or pelvic tumors (except ovarian, fallopian tube, primary peritoneal) | Synchronous or prior primary endometrial cancer unless all met: stage <= IB; no more than superficial myometrial invasion without vascular/lymphatic invasion; no poorly differentiated subtypes (papillary serous, clear cell, FIGO grade 3) | Uncontrolled infection | Severe uncontrolled comorbid medical conditions limiting compliance or increasing risk | Peripheral neuropathy >= grade 2 | History of hypersensitivity to carboplatin and/or paclitaxel unless successfully desensitized | Hypersensitivity to CHO cell products or other recombinant antibodies (applies to bevacizumab recipients) | Pregnant or breastfeeding; inadequate contraception | Other invasive malignancy within 5 years (except non-melanoma skin cancer) or prior cancer therapy contraindicating protocol therapy | Active bleeding or high-risk bleeding conditions/coagulopathy (applies to bevacizumab recipients) | CNS disease (including brain metastases), uncontrolled seizures, or stroke within 5 years (applies to bevacizumab recipients) | Significant cardiovascular disease, including conduction abnormalities (PR >0.24 s or 2nd/3rd-degree AV block), uncontrolled hypertension (systolic >150 mmHg or diastolic >90 mmHg), myocardial infarction/cardiac arrhythmia/unstable angina within 6 months, NYHA class >= II heart failure, serious arrhythmia requiring medication, peripheral vascular disease grade >= II, or cerebrovascular accident within 6 months (applies to bevacizumab recipients) | Major surgery, open biopsy, dental extractions/procedures resulting in open wound, or significant traumatic injury within 28 days before treatment; vascular access device placement or core biopsy within 7 days before treatment",Complete response to front-line platinum-taxane therapy (>=3 cycles) required; Treatment-free interval >=6 months from completion of front-line platinum and taxane chemotherapy; Front-line therapy may have included bevacizumab; Maintenance cytotoxic chemotherapy must be discontinued >=6 months before documentation of recurrence; Maintenance biological or hormonal therapy allowed if recurrence >6 months and >=4 weeks since last biologic infusion,FEMALE,F,"Trial requires platinum-sensitive recurrent disease with a treatment-free interval ≥6 months after front-line platinum-taxane therapy; the patient recurred at 5 months post-adjuvant, a definitive mismatch with the required setting.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; BRCA1 positive; Optimal debulking surgery performed; Received adjuvant carboplatin + paclitaxel + bevacizumab; Cytology-positive malignant pleural effusion at 5 months post-adjuvant,(none),Carboplatin; Paclitaxel; Bevacizumab; Optimal debulking surgery,Stage III,,36,years,female,(none),CORRECT,F,"The trial explicitly requires platinum-sensitive recurrence (treatment-free interval ≥6 months post front-line platinum-taxane). The patient recurred at 5 months, definitively lacking the required setting. This is a hard exclusion per the rubric, so F is correct.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT00611585,1.0,Rheumatoid Arthritis,"Birmingham Hip Resurfacing System (BHR) Post Approval Study: A Prospective, Multi-Centered Study of the Birmingham Hip Resurfacing System",NA,21 years to 75 years,Osteoarthritis; Traumatic Arthritis; Avascular Necrosis; Hip Dysplasia; Rheumatoid Arthritis,Age >= 21 years | Skeletally mature | Requires primary hip resurfacing due to osteoarthritis | Requires primary hip resurfacing due to traumatic arthritis | Requires primary hip resurfacing due to avascular necrosis | Requires primary hip resurfacing due to hip dysplasia | Requires primary hip resurfacing due to rheumatoid arthritis,"Active infection or sepsis | Vascular insufficiency severe enough to compromise implant stability or postoperative recovery | Muscular atrophy severe enough to compromise implant stability or postoperative recovery | Neuromuscular disease severe enough to compromise implant stability or postoperative recovery | Female of child-bearing age | Bone stock inadequate to support the device | Moderate to severe renal insufficiency | Known or suspected metal hypersensitivity | Immunosuppressed state (e.g., AIDS) or receiving high doses of corticosteroids | Psychological or neurological conditions precluding participation | Severely overweight",(none),ALL,F,"The trial explicitly excludes patients with moderate to severe renal insufficiency, and this patient has moderate chronic kidney disease (eGFR 45). Additionally, the trial requires a need for primary hip resurfacing, which is not established in the patient profile.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Correct: The trial explicitly excludes patients with moderate to severe renal insufficiency, and the patient has moderate CKD (eGFR 45), which is a hard exclusion. The additional note about hip resurfacing need is unknown and not required for the F decision.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT00716066,0.5575029253959656,Amyotrophic Lateral Sclerosis,"High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases",PHASE2,up to 71 years,Central Nervous System Vasculitis; Rasmussen Encephalitis; Autoimmune Peripheral Neuropathy; Autoimmune Cerebellar Degeneration; Gait Ataxia With Late-Onset Polyneuropathy; Stiff-Person Syndrome; Chronic Inflammatory Demyelinating Polyneuropathy; Myasthenia Gravis; Lambert-Eaton Myasthenic Syndrome; HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis; Opsoclonus Myoclonus Syndrome; Neuromyelitis Optica; Multiple Sclerosis,"Diagnosis of a severe autoimmune disorder of the central or peripheral nervous system | Central Nervous System Vasculitis | Rasmussen Encephalitis | Autoimmune Peripheral Neuropathy | Autoimmune Cerebellar Degeneration | Gait Ataxia With Late-Onset Polyneuropathy (GALOP) | Stiff-Person Syndrome | Chronic Inflammatory Demyelinating Polyneuropathy | Myasthenia Gravis | Lambert-Eaton Myasthenic Syndrome | HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis | Opsoclonus Myoclonus Syndrome | Neuromyelitis Optica | Multiple Sclerosis | Meets diagnostic criteria for one of the specified severe neurological autoimmune disorders | Age <= 70 years | Evidence of disease activity (e.g., gadolinium-enhancing MRI or clinical progression) | Failed at least 2 lines of standard therapy",Age >= 71 years | Pregnancy or plans to become pregnant within 1 year | HIV positive | Severe pulmonary dysfunction: DLCO < 60% or requires supplemental oxygen | Oxygen saturation < 92% on room air (if unable to perform PFTs) | Uncontrolled malignant arrhythmias | Congestive heart failure NYHA class III–IV | Left ventricular ejection fraction < 50% | Estimated GFR (creatinine or iothalamate clearance) < 50 mL/min/1.73 m2 | AST/ALT > 3 x ULN | Direct bilirubin > 2.5 mg/dL on two repeated tests | Active uncontrolled infection | Lack of compliance with prior medical care | Life expectancy limited by illness other than neurological condition | Evidence of myelodysplasia | Active malignancy (except localized basal or squamous cell skin cancer),Failed >=2 lines of standard therapy,ALL,F,"The trial targets specific autoimmune neurologic diseases (e.g., MS, NMO, CIDP) and does not include amyotrophic lateral sclerosis. Although age and sex fit, the disease mismatch is a hard exclusion.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,F,"Disease mismatch hard exclusion applies: the trial targets specific autoimmune neurologic diseases (MS, NMO, CIDP, etc.) and does not include ALS. Therefore grade F is correct regardless of other factors.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT01134614,0.7159545421600342,Recurrent Glioblastoma,A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma,PHASE2,18 years,Advanced Melanoma; Metastatic Melanoma; Recurrent Melanoma; Unresectable Melanoma; Cutaneous Melanoma (Stage III); Cutaneous Melanoma (Stage IV),Measurable disease per RECIST | <=1 prior systemic therapeutic regimen for unresectable stage III or IV melanoma (adjuvant therapies excluded from this count) | Histologic diagnosis of metastatic melanoma (FNA cytology alone for unknown primary not acceptable) | Not pregnant or breast-feeding | No HIV infection | No active hepatitis B infection | No active or chronic hepatitis C infection | ECOG performance status 0-1 | WBC >= 2000/µL | ANC >= 1500/µL | Platelets >= 100000/µL | Hemoglobin >= 8 g/dL | Creatinine <= 3.0 x ULN | AST <= 2.5 x ULN | ALT <= 2.5 x ULN | Bilirubin <= 3.0 x ULN (except Gilbert's syndrome),"History of central nervous system metastases | History of other malignancy within 2 years except adequately treated basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix | History of autoimmune disease (except treated, stable autoimmune thyroiditis) | Underlying medical or psychiatric condition that makes study drug hazardous or obscures adverse event interpretation (e.g., frequent diarrhea) | Receipt of non-oncology vaccine for prevention of infectious diseases within 28 days before or after any ipilimumab dose | Prior treatment with ipilimumab, CD137 agonists, or CTLA-4 inhibitors/agonists | Concurrent systemic steroids required (inhaled/topical steroids permitted) | Concurrent therapy with IL-2, interferon, or other non-study immunotherapy regimens | Concurrent cytotoxic chemotherapy | Concurrent immunosuppressive agents | Concurrent other investigational therapies","<=1 prior systemic regimen for unresectable stage III or IV melanoma (adjuvant therapies allowed); Discontinue immunotherapy, cytotoxic chemotherapy, immunosuppressive agents, investigational therapies, and chronic systemic corticosteroids >=4 weeks before randomization",ALL,F,"Disease mismatch: the trial is exclusively for advanced melanoma, while the patient has recurrent glioblastoma. This triggers a hard exclusion.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),CORRECT,F,"The trial targets advanced/metastatic melanoma, while the patient has recurrent glioblastoma. This is a hard disease mismatch per the rubric, warranting an immediate F. The grader’s reasoning and grade are correct.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT01171898,0.8099497556686401,Castration-Resistant Prostate Cancer,"An Open-Label, Phase 1/2, Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Patients With Progressive Advanced Castration-Resistant Prostate Cancer",PHASE1/PHASE2,18 years,Prostate Cancer (castration-resistant),Histologically or cytologically confirmed prostate cancer | Non-metastatic CRPC with PSA >= 8 ng/mL (within 3 months) | Non-metastatic CRPC with PSA doubling time <= 10 months | Progressive metastatic CRPC by PSA progression | Progressive metastatic CRPC by radiographic progression | Ongoing androgen deprivation therapy with a GnRH analog/inhibitor or orchiectomy | Serum testosterone <= 50 ng/dL | ECOG 0-1 | Life expectancy >= 3 months | Prior abiraterone therapy >= 6 months before progression (post-abiraterone cohort),"Distant metastases including CNS, vertebral, or meningeal involvement (for non-metastatic cohort) | Brain metastases or untreated spinal cord compression | Prior treatment with enzalutamide (MDV3100) | Prior treatment with abiraterone | Prior treatment with ketoconazole | Concurrent treatment with medications known to have seizure potential | Concurrent corticosteroids (must taper off as soon as possible if already on) | QTc > 450 msec | History of seizure or condition predisposing to seizure | Severe or uncontrolled systemic disease | HIV infection",Ongoing androgen deprivation therapy required; Prior abiraterone therapy >= 6 months required for post-abiraterone cohort,MALE,F,"The trial explicitly excludes patients with prior enzalutamide, which this patient has received. It also lists prior abiraterone as an exclusion.",Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),CORRECT,F,"The trial explicitly excludes prior enzalutamide, which the patient has received—a hard exclusion per rubric. Even though abiraterone is inconsistently listed (excluded vs. required in a cohort), the enzalutamide exclusion alone mandates grade F. The grader’s conclusion is correct.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT01247207,1.0,Duchenne Muscular Dystrophy,"An Open-Label, Safety Study for Ataluren (PTC124) Patients With Nonsense Mutation Dystrophinopathy",PHASE3,Not specified,Duchenne Muscular Dystrophy,Prior exposure to ataluren in a PTC study or is an affected nmDBMD sibling of a participant who completed the placebo-controlled portion. | Fertile men sexually active with women of childbearing potential must use barrier contraception during treatment and for 50 days after the last dose.,"Exposure to another investigational drug within 1 month prior to start of study treatment. | Eligibility for another ataluren clinical trial that is actively enrolling participants. | Positive Hepatitis B core antibody or Hepatitis C antibody at screening (for ataluren-naive participants or those with a treatment gap of 1 year). | Known hypersensitivity to ataluren or its excipients. | Ongoing intravenous aminoglycoside or intravenous vancomycin therapy. | Ongoing uncontrolled medical or surgical condition, ECG findings, or laboratory abnormality that could adversely affect safety or follow-up.",Prior exposure to ataluren in a PTC study or treatment plan required (or affected nmDBMD sibling of an eligible participant).; No investigational drug within 1 month before starting study treatment.,MALE,F,"The trial is restricted to nonsense mutation dystrophinopathy (nmDMD) and requires prior ataluren exposure or being an affected nmDBMD sibling; the patient has a DMD exon 49-50 deletion (not a nonsense mutation) and no ataluren exposure, which is a required biomarker/prior-exposure mismatch.",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,"The trial requires nonsense mutation dystrophinopathy (nmDMD), while the patient has a DMD exon 49-50 deletion (not a nonsense mutation). This is a required biomarker/subtype mismatch, which is a hard exclusion → F. The grader’s reasoning and grade align with the rubric.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT01247207,0.5278329849243164,Amyotrophic Lateral Sclerosis,"An Open-Label, Safety Study for Ataluren (PTC124) Patients With Nonsense Mutation Dystrophinopathy",PHASE3,Not specified,Duchenne Muscular Dystrophy,Prior exposure to ataluren in a PTC study or is an affected nmDBMD sibling of a participant who completed the placebo-controlled portion. | Fertile men sexually active with women of childbearing potential must use barrier contraception during treatment and for 50 days after the last dose.,"Exposure to another investigational drug within 1 month prior to start of study treatment. | Eligibility for another ataluren clinical trial that is actively enrolling participants. | Positive Hepatitis B core antibody or Hepatitis C antibody at screening (for ataluren-naive participants or those with a treatment gap of 1 year). | Known hypersensitivity to ataluren or its excipients. | Ongoing intravenous aminoglycoside or intravenous vancomycin therapy. | Ongoing uncontrolled medical or surgical condition, ECG findings, or laboratory abnormality that could adversely affect safety or follow-up.",Prior exposure to ataluren in a PTC study or treatment plan required (or affected nmDBMD sibling of an eligible participant).; No investigational drug within 1 month before starting study treatment.,MALE,F,"Disease mismatch: the trial targets Duchenne muscular dystrophy (nonsense mutation dystrophinopathy), while the patient has amyotrophic lateral sclerosis. This is a hard exclusion.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,F,"Correct: There is a hard exclusion due to disease mismatch (trial targets Duchenne muscular dystrophy; patient has ALS). Per rubric, this mandates an F regardless of other factors.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT01688492,0.7812774181365967,Castration-Resistant Prostate Cancer,A Phase 2 Study Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer,PHASE1/PHASE2,18 years,"Prostate Cancer (castration-resistant, metastatic)","Chemotherapy- and immunotherapy-naive metastatic castration-resistant prostate cancer | Age >= 18 years | Histologically or cytologically confirmed adenocarcinoma of the prostate | Castrate serum testosterone <= 50 ng/dL | Ongoing androgen deprivation therapy with a GnRH analogue or prior bilateral orchiectomy | Metastatic disease on imaging; if lymph node-only metastasis, at least one node >= 2 cm in diameter | Progressive disease at study entry per PCWG2 by PSA and/or radiographic criteria | Karnofsky performance status >= 80% | Estimated life expectancy >= 6 months | Toxicities from prior therapy resolved to <= Grade 1 or baseline or deemed irreversible and stable | Able to swallow study drug and comply with study requirements","History of another malignancy within the previous 5 years other than nonmelanoma skin cancer | Absolute neutrophil count < 1500/µL | Platelet count < 75000/µL | Hemoglobin < 9 g/dL | Serum bilirubin >= 1.5 x ULN or, with Gilbert's disease, >= 3 mg/dL | AST or ALT >= 2.5 x ULN (<= 5 x ULN allowed with known liver metastases) | Creatinine > 2 mg/dL | Albumin < 3.0 g/dL | Potassium <= 3.5 mEq/L | Clinically significant cardiovascular disease (myocardial infarction within 6 months, uncontrolled angina within 3 months, NYHA class 3 or 4 heart failure, uncontrolled hypertension with SBP > 160 mmHg or DBP > 95 mmHg) | Major surgery or radiation therapy within 4 weeks of enrollment | Treatment with antiandrogens (bicalutamide, flutamide, nilutamide) within 4 weeks of enrollment | History of progression of prostate cancer while receiving ketoconazole | Prior use or participation in a trial of androgen synthesis inhibitors (e.g., abiraterone, TAK-700, TAK-683, TAK-448), chemotherapy, or immunologic agents (immune modulators, cytokines, vaccines, antibody-delivered chemotherapy) | Known allergy to any study compounds | Uncontrolled or significant medical condition that would make participation hazardous in the investigator's opinion | Autoimmune disease (e.g., inflammatory bowel disease, rheumatoid arthritis, systemic sclerosis, systemic lupus erythematosus, autoimmune vasculitis, motor neuropathy of autoimmune origin) | Known or suspected brain metastasis or untreated leptomeningeal disease | Active infection or other medical condition making prednisone use contraindicated | Active or symptomatic viral hepatitis or chronic liver disease | Disease limited to regional pelvic lymph nodes only | Use of hematopoietic growth factors within 7 days or blood transfusions within 28 days prior to screening labs",Chemotherapy-naive required; Immunotherapy-naive required; Ongoing androgen deprivation therapy required; Antiandrogens discontinued >= 4 weeks before enrollment; No major surgery or radiation therapy within 4 weeks before enrollment; No hematopoietic growth factors within 7 days and no blood transfusions within 28 days before screening labs,MALE,F,"The trial explicitly excludes prior use of androgen synthesis inhibitors (e.g., abiraterone); the patient previously received abiraterone (Zytiga), making them ineligible despite disease match.",Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),CORRECT,F,"The trial explicitly excludes prior use of androgen synthesis inhibitors (e.g., abiraterone), and the patient previously received abiraterone. This is a hard exclusion, so grade F is correct.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT01708954,0.8649299144744873,Metastatic Non-Small Cell Lung Cancer,"A Randomized Phase II Trial of Erlotinib, Cabozantinib, or Erlotinib Plus Cabozantinib as 2nd or 3rd Line Therapy in Patients With EGFR Wild-Type NSCLC",PHASE2,18 years,Non-Small Cell Lung Cancer (metastatic),"Non-small cell lung carcinoma confirmed cytologically or histologically | Predominant non-squamous histology; small cell components excluded | Stage IV or recurrent disease by AJCC 7th edition | Measurable disease per RECIST v1.1 | Tumor tissue available for MET IHC testing | One to two prior lines of chemotherapy for advanced disease | Any prior chemotherapy completed per required washout | Discontinued investigational agents >= 4 weeks before registration | Recovered to baseline or CTCAE v4.0 <= grade 1 from prior therapy toxicities (except alopecia and non-clinically significant AEs) | Brain metastases status meeting protocol criteria (stable if present); baseline brain imaging per protocol | Radiation-related toxicities resolved to <= grade 1 | ECOG performance status 0-2 | Anticipated life expectancy > 3 months | Acceptable bone marrow, renal, and hepatic function within 2 weeks prior to registration | QTcF <= 500 ms within 28 days before registration | Able to swallow tablets | Step 2: Radiographic progressive disease after >= 2 courses on Arm A or Arm B | Step 2: Registered within 4 weeks of last dose from Step 1 | Step 2: ECOG performance status 0-2 | Step 2: Recovered to baseline (pre-Step 1) or CTCAE v4.0 <= grade 1 from prior therapy toxicities","Insufficient tumor pathology material (tumor block or 10 unstained slides) for required testing | Prior erlotinib or other EGFR tyrosine kinase inhibitor therapy | Prior VEGFR tyrosine kinase inhibitor therapy | Prior MET tyrosine kinase inhibitor therapy or MET monoclonal antibody | Radiation therapy to thoracic cavity, abdomen, or pelvis within 3 months; to bone or brain within 14 days; or to any other site within 28 days prior to registration | Clinically significant gastrointestinal bleeding within 6 months | Hemoptysis >= 2.5 mL within 3 months | Other signs of pulmonary hemorrhage within 3 months | Tumor invading the gastrointestinal tract or endotracheal/endobronchial tumor within 28 days prior to registration | Cavitating pulmonary lesion(s) within 28 days prior to registration | Tumor in contact with, invading, or encasing major blood vessels within 28 days prior to registration | History of major thrombotic events (deep vein thrombosis or pulmonary embolism) within 6 months | Therapeutic anticoagulation or antiplatelet therapy (except low-dose aspirin <= 81 mg/day and prophylactic LMWH) | Concomitant strong CYP3A4 inducers | Congestive heart failure NYHA class III or IV | Uncontrolled hypertension | History of congenital long QT syndrome | Unstable angina within 6 months | Clinically significant cardiac arrhythmias within 6 months | Stroke or transient ischemic attack or other ischemic event within 6 months | Myocardial infarction within 6 months | Gastrointestinal disorders with high risk of perforation or fistula | High risk of fistula including PEG tube placement within 3 months | Uncontrolled, significant intercurrent or recent illness | Prior malignancy within 2 years requiring systemic treatment or currently active | Pregnant or breastfeeding | HIV infection on antiretroviral therapy | Chronic active hepatitis B | Step 2: Intervening anticancer treatment or major surgery between Step 1 and Step 2 (except palliative bone radiation finished >= 2 weeks before Step 2 registration) | Step 2: Central nervous system progression | Step 2: Intercurrent illness or complication limiting ability to safely tolerate erlotinib plus cabozantinib",Required: 1-2 prior lines of chemotherapy for advanced NSCLC; Prior adjuvant chemotherapy allowed if > 12 months before first-line systemic therapy (otherwise counts as one line); Discontinue investigational agents >= 4 weeks before registration,ALL,F,The trial is for EGFR wild-type NSCLC and explicitly excludes prior EGFR TKI therapy; the patient has an EGFR exon 19 mutation and has been treated with osimertinib.,Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"The trial requires EGFR wild-type and excludes prior EGFR TKI therapy; the patient has EGFR exon 19 mutation and has received osimertinib. These are hard exclusions, so F is correct.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT01892397,0.7134679555892944,Recurrent Glioblastoma,Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma,NA,18 years,Atypical Meningioma (recurrent); Anaplastic Meningioma (recurrent),"Histologically proven recurrent WHO grade II (atypical) or grade III (anaplastic) supratentorial meningioma | Radiographic evidence of progression by MRI (or CT if MRI contraindicated) within 14 days of registration | Stable or decreased dose of steroids for >=5 days prior to baseline imaging | Recovered from effects of recent resection; start treatment >=28 days after surgery | Measurable disease >=1 cm x 1 cm contrast-enhancing lesion | Prior radiotherapy for meningioma required; interval >4 weeks from completion with subsequent progression documented | Confirmation of true progression (not radiation necrosis) required after prior brachytherapy or stereotactic radiosurgery (via PET/MR-perfusion/MR-spectroscopy or surgery) | Age >=18 years | Karnofsky performance status >=60% | >=4 weeks from any radiation, stereotactic radiosurgery, conventional surgery, or chemotherapy | Life expectancy >=3 months | Neurofibromatosis patients eligible; other CNS tumors allowed if stable for >=6 months","History of other cancer unless in complete remission off therapy for >=3 years (except non-melanoma skin cancer or cervical carcinoma in situ) | Concomitant use of investigational drugs | Concurrent treatment on another therapeutic clinical trial | Pregnancy or breastfeeding | Implanted active medical device (e.g., pacemaker, defibrillator, deep brain stimulator, vagus nerve stimulator) or significant arrhythmia | Evidence of increased intracranial pressure (midline shift >5 mm, clinically significant papilledema, vomiting/nausea, or reduced consciousness) | Infratentorial meningioma without a concurrent growing supratentorial target lesion | Coagulopathy: PT or APTT >1.5 x ULN (if not on anticoagulation) | Thrombocytopenia: platelets <100 x 10^3/µL | Neutropenia: ANC <1 x 10^3/µL | Severe acute infection | Skull defect with missing bone | Ventricular shunt or catheter | Intracranial foreign body (e.g., bullet fragment)","Prior radiotherapy for meningioma required; No limit on number of prior surgeries, radiotherapy treatments, radiosurgery treatments, or chemotherapy; Washout >=4 weeks from any radiation treatment, stereotactic radiosurgery, conventional surgery, or chemotherapy before study entry; Start treatment >=28 days after surgery with recovery from surgical effects",ALL,F,"Disease mismatch hard exclusion: the trial enrolls recurrent atypical/anaplastic meningioma, while the patient has recurrent IDH-wildtype glioblastoma.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),CORRECT,F,"Disease mismatch is a hard exclusion: the trial targets recurrent atypical/anaplastic meningioma, while the patient has recurrent IDH-wildtype glioblastoma. Therefore F is correct.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT01946204,0.7799389958381653,Castration-Resistant Prostate Cancer,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer",PHASE3,18 years,Prostate Cancer (non-metastatic castration-resistant),"Histologically or cytologically confirmed prostate adenocarcinoma without neuroendocrine or small cell features | High risk for metastasis defined as PSA doubling time <= 10 months during continuous ADT | Castration-resistant prostate cancer on continuous ADT with 3 PSA rises >= 1 week apart and last PSA > 2 ng/mL | Maintain castrate levels of testosterone within 4 weeks prior to randomization and throughout the study | Bone-sparing agents allowed if on stable doses for >= 4 weeks prior to randomization | Washout from first-generation anti-androgen (e.g., bicalutamide, flutamide, nilutamide) for >= 4 weeks with PSA progression after washout | >= 4 weeks since 5-alpha reductase inhibitors, estrogens, and any other anti-cancer therapy prior to randomization | >= 4 weeks since major surgery or radiation therapy prior to randomization | ECOG performance status 0 or 1 | Resolution of acute toxicities from prior therapy or surgery to Grade <= 1 or baseline before randomization | Adequate organ function per protocol-defined criteria | No growth factors or blood transfusions within 4 weeks before hematology labs for eligibility","Confirmed distant metastases, including CNS, vertebral, or meningeal involvement | Symptomatic local or regional disease requiring medical intervention | Prior treatment with second-generation anti-androgens | Prior treatment with CYP17 inhibitors | Prior treatment with radiopharmaceutical agents or any other investigational agent for non-metastatic castration-resistant prostate cancer | Prior chemotherapy for prostate cancer except if given in the adjuvant or neoadjuvant setting | History of seizure or condition predisposing to seizure | Concurrent therapy with protocol-defined excluded medications | Any prior malignancy within 5 years except adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or cancer in situ in complete remission | Severe or unstable angina within 6 months prior to randomization | Myocardial infarction within 6 months prior to randomization | Symptomatic congestive heart failure within 6 months prior to randomization | Arterial or venous thromboembolic events within 6 months prior to randomization | Clinically significant ventricular arrhythmias within 6 months prior to randomization | Uncontrolled hypertension | Gastrointestinal disorder affecting absorption | Active infection | Any other condition that would impair the patient's ability to comply with study procedures",Continuous ADT required; Washout from first-generation anti-androgens >= 4 weeks with PSA progression after washout; >= 4 weeks since 5-alpha reductase inhibitors or estrogens; >= 4 weeks since any other anti-cancer therapy; >= 4 weeks since major surgery; >= 4 weeks since radiation therapy; Bone-sparing agents allowed if stable for >= 4 weeks,MALE,F,"The trial is for non-metastatic (M0) CRPC and explicitly excludes patients with confirmed distant metastases; this patient has metastatic disease (liver and bone). It also excludes prior treatment with second-generation anti-androgens and CYP17 inhibitors, which the patient has received (enzalutamide and abiraterone).",Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),CORRECT,F,"The trial explicitly excludes patients with confirmed distant metastases and prior second-generation anti-androgen or CYP17 inhibitor therapy; the patient has metastatic disease and received enzalutamide and abiraterone. These are hard exclusions, so F is correct.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT01962415,0.7642838358879089,Rheumatoid Arthritis,"A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation",PHASE2,2 months to 55 years,Primary Immunodeficiency; Congenital Bone Marrow Failure Syndrome; Inherited Metabolic Disorder; Hereditary Anemia; Crohn's Disease; Inflammatory Bowel Disease; Juvenile Rheumatoid Arthritis; Systemic Juvenile Idiopathic Arthritis,"Availability of a suitable graft: 4/6–6/6 HLA matched related or unrelated UCB unit with total nucleated cells >= 3 x 10^7/kg (or double units each >= 2 x 10^7/kg) or 8/8 or 7/8 HLA allele-matched unrelated donor bone marrow or peripheral blood progenitor graft | Serum creatinine <= 2.0 mg/dL | Creatinine clearance >= 50 mL/min | ALT <= 4 x ULN | AST <= 4 x ULN | Cardiac function adequate: shortening fraction > 26% or ejection fraction > 40% or > 80% of normal for age | Pulmonary function: FEV1/FVC >= 50% predicted for age | Pulmonary function: DLCO (hemoglobin-corrected) >= 50% predicted (adults, if obtainable) | Resting pulse oximetry >= 92% on room air | HIV negative | Negative pregnancy test if pubertal and/or menstruating | Non-malignant disorder amenable to HSCT, including primary immunodeficiency syndromes (e.g., SCID with NK activity, Omenn, BLS, CID, CVID, Wiskott-Aldrich, leukocyte adhesion deficiency, CGD, X-linked hyper IgM, IPEX, Chediak-Higashi, ALPS, HLH, lymphocyte signaling defects) | Congenital bone marrow failure syndromes (e.g., dyskeratosis congenita, congenital amegakaryocytic thrombocytopenia, osteopetrosis) | Inherited metabolic disorders (e.g., mucopolysaccharidoses [Hurler, Hunter], leukodystrophies [Krabbe, metachromatic leukodystrophy, X-linked adrenoleukodystrophy, HDLS], alpha mannosidosis, Gaucher disease) | Hereditary anemias (e.g., thalassemia major, sickle cell disease with qualifying complications, Diamond-Blackfan anemia, other congenital transfusion-dependent anemias) | Inflammatory conditions (e.g., Crohn's disease/Inflammatory Bowel Disease)","Allogeneic hematopoietic stem cell transplant within the previous 6 months | Active malignancy or myelodysplastic syndrome | Severe acquired aplastic anemia | Uncontrolled bacterial, viral, or fungal infection with progression of clinical symptoms despite therapy | Pregnancy or nursing | Poorly controlled pulmonary hypertension | Any condition that precludes serial follow-up",(none),ALL,F,"Disease mismatch: the trial targets juvenile rheumatoid arthritis/systemic JIA and other non-malignant disorders, not adult rheumatoid arthritis. Additionally, the trial requires creatinine clearance ≥50 mL/min, and the patient’s eGFR of 45 suggests this renal criterion would not be met.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Disease mismatch is a hard exclusion: the trial targets juvenile RA/systemic JIA and other non-malignant disorders, not adult rheumatoid arthritis. That alone warrants F. The noted renal function shortfall (CrCl ≥50 vs eGFR 45) further supports ineligibility but isn’t needed for the hard exclusion decision.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT02003924,0.7789888381958008,Castration-Resistant Prostate Cancer,"PROSPER: A MULTINATIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER",PHASE3,18 years,Prostate Cancer (nonmetastatic castration-resistant),"Histologically or cytologically confirmed prostate adenocarcinoma without neuroendocrine, signet cell, or small cell features | Ongoing androgen deprivation therapy with GnRH agonist/antagonist or prior bilateral orchiectomy | Testosterone <= 50 ng/dL at screening | Progressive disease on androgen deprivation therapy at enrollment | PSA >= 2 ng/mL (central) | PSA doubling time <= 10 months | No prior or present evidence of metastatic disease | Asymptomatic prostate cancer | ECOG performance status 0–1 | Estimated life expectancy >= 12 months","Prior cytotoxic chemotherapy | Hormonal therapy or biologic therapy for prostate cancer (other than approved bone-targeting agents and GnRH therapy) within 4 weeks of randomization | Investigational agent within 4 weeks of randomization | Known or suspected brain metastasis or active leptomeningeal disease | History of another invasive cancer within 3 years of randomization | Absolute neutrophil count < 1000/µL | Platelet count < 100,000/µL | Hemoglobin < 10 g/dL | Total bilirubin >= 1.5 x ULN | Creatinine > 2 mg/dL | Albumin < 3.0 g/dL | History of seizure or condition predisposing to seizure | Clinically significant cardiovascular disease | Gastrointestinal disorder affecting absorption | Major surgery within 4 weeks of randomization | Hypersensitivity to enzalutamide or capsule components (including Labrasol, butylated hydroxyanisole, butylated hydroxytoluene) | Any concurrent disease, infection, or comorbidity that interferes with participation or data interpretation",Ongoing androgen deprivation therapy with GnRH agonist/antagonist or prior bilateral orchiectomy required; Washout >= 4 weeks since hormonal/biologic therapy for prostate cancer or any investigational agent,MALE,F,"The trial requires nonmetastatic CRPC with no evidence of metastatic disease, while the patient has metastatic CRPC with liver and bone metastases—an explicit setting mismatch.",Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),CORRECT,F,"Trial explicitly requires nonmetastatic CRPC (no evidence of metastases); patient has metastatic CRPC with liver/bone mets. This is a required stage/setting mismatch, which is a hard exclusion per rubric → F. The grader’s reasoning aligns with this.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT02020070,0.7313702702522278,Castration-Resistant Prostate Cancer,"A Phase 2 Study Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy",PHASE2,18 years,Prostate Cancer (metastatic castration sensitive),"Age >= 18 years | Histologically confirmed adenocarcinoma of the prostate | Newly diagnosed metastatic prostate cancer (Cohort A) | Castration-sensitive disease | <= 10 bony metastatic lesions allowed (biopsy-proven lesions without clear bone imaging permitted) | Distant metastatic lymph nodes allowed; regional pelvic lymph nodes count as metastasis if > 1.5 cm short axis | Medically fit for radical prostatectomy (Cohort A) | Karnofsky performance status 80-100 | WBC >= 2000/µL | ANC >= 1000/µL | Platelets >= 75000/µL | Creatinine <= 2.0 x ULN | AST <= 2.5 x ULN | ALT <= 2.5 x ULN | Bilirubin <= 1.5 x ULN (Gilbert's syndrome allowed if total bilirubin < 3.0 mg/dL) | Negative HIV, Hepatitis B, and Hepatitis C screening tests | No more than 5 months of prior androgen deprivation therapy; no prior primary local therapy (radiation or surgery) to the prostate (Cohort A) | Biochemical recurrence after radical prostatectomy with progressive disease defined by rising PSA (>= 50% increase to >= 1 ng/mL based on >= 3 determinations >= 1 week apart) or PSA doubling time <= 12 months (Cohort B) | Prior prostate radiotherapy allowed (Cohort B)","Other malignancy within 5 years (except adequately treated basal/squamous cell skin cancer or superficial bladder cancer) | Major surgery within 4 weeks of enrollment | Prior radiation therapy to the prostate (Cohort A); prior palliative radiation to metastatic sites allowed | > 5 months of prior hormonal therapy for prostate cancer | Use of megestrol acetate or anti-androgen within 2 weeks of enrollment | Use of 5-alpha reductase inhibitor within 2 weeks of enrollment | Prior ketoconazole, abiraterone, or enzalutamide for prostate cancer | Current or prior investigational therapies for prostate cancer | Prior chemotherapy administered with intent to treat prostate cancer | Concomitant therapy with any other experimental drug | Autoimmune disease (e.g., inflammatory bowel disease, rheumatoid arthritis, scleroderma, systemic lupus erythematosus, autoimmune vasculitis) | Motor neuropathy of autoimmune origin (e.g., Guillain-Barre syndrome, myasthenia gravis) | Medical or psychiatric condition that would make ipilimumab hazardous or obscure adverse event interpretation (e.g., frequent diarrhea) | Underlying heart conditions rendering patient ineligible for surgery (Cohort A) | Non-oncology vaccine therapy within 1 month before or after any dose of ipilimumab (inactivated vaccines allowed) | Prior treatment with ipilimumab, CTLA-4 inhibitor/agonist, or CD137 agonist | Concomitant or prior IL-2, interferon, or other non-study immunotherapy regimens | Immunosuppressive agents or chronic systemic corticosteroids within 6 weeks of study entry | Visceral metastatic disease (Cohort B) | > 3 cycles of intermittent androgen deprivation therapy (Cohort B) | History of acute diverticulitis, intra-abdominal abscess, gastrointestinal obstruction, or abdominal carcinomatosis",<= 5 months of prior androgen deprivation therapy allowed (Cohort A); No prior primary local therapy to the prostate (radiation or surgery) required (Cohort A); Prior prostate radiotherapy allowed (Cohort B); <= 3 cycles of intermittent androgen deprivation therapy allowed (Cohort B); No washout required for GnRH analogs; 2-week washout required for megestrol acetate or anti-androgens; 2-week washout required for 5-alpha reductase inhibitors,MALE,F,"The trial targets castration-sensitive prostate cancer (newly diagnosed metastatic or biochemically recurrent), whereas the patient has metastatic castration-resistant disease. Additionally, the trial explicitly excludes prior abiraterone or enzalutamide, both of which the patient received.",Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),CORRECT,F,"Hard exclusions apply: the trial requires castration-sensitive disease (patient is castration-resistant) and explicitly excludes prior abiraterone or enzalutamide, both of which the patient received. Therefore F is correct.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT02101788,0.7825309038162231,Recurrent Clear Cell Ovarian Carcinoma,A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer,PHASE2/PHASE3,18 years,Ovarian Low-Grade Serous Carcinoma (recurrent); Primary Peritoneal Low-Grade Serous Carcinoma (recurrent),"Age >= 18 years | Recurrent low-grade serous ovarian or peritoneal carcinoma (including invasive micropapillary serous carcinoma or invasive grade I serous carcinomas) after initial diagnosis of low-grade serous disease | Recurrent low-grade serous carcinoma after initial diagnosis of serous borderline ovarian or peritoneal carcinoma | Prospective pathology confirmation of low-grade serous carcinoma prior to study entry | Measurable disease per RECIST 1.1 with required lesion size; imaging within 28 days prior to registration | At least 4 weeks since any major surgery | Progression/recurrence after at least one platinum-based chemotherapy regimen | Unlimited number of prior therapy regimens allowed | Hormonal therapy for malignancy discontinued >= 1 week prior to registration | Chemotherapy and radiation therapy discontinued >= 4 weeks prior to registration | Investigational agents discontinued >= 28 days prior to registration | Women of childbearing potential and men agree to use highly effective contraception during treatment and for 6 months after last dose; negative serum pregnancy test within 14 days prior to randomization; not breastfeeding | Ability to understand and sign informed consent | GOG performance status 0 or 1 | Able to swallow and retain oral medication; no clinically significant GI abnormalities that may alter absorption | All prior treatment-related toxicities <= grade 1 (except alopecia) at randomization | Left ventricular ejection fraction >= lower limit of normal by ECHO or MUGA | Serum creatinine <= 1.5 mg/dL or creatinine clearance >= 50 mL/min | Total bilirubin <= 1.5 x ULN | ALT <= 2.5 x ULN | AST <= 2.5 x ULN | Albumin >= 2.5 g/dL | PT and APTT <= 1.5 x ULN | Absolute neutrophil count >= 1500/µL | Platelet count >= 100000/µL | Hemoglobin >= 9.0 g/dL | If letrozole selected: patient must be postmenopausal (bilateral oophorectomy or >= 5 years after spontaneous menopause, or postmenopausal LH/FSH if within 5 years or hysterectomy without oophorectomy); discontinue HRT before letrozole","Chemotherapy or radiotherapy within 4 weeks prior to entry (6 weeks for nitrosoureas or mitomycin C) or unresolved toxicities from prior therapy > grade 1 | Use of other investigational drugs within 28 days (or five half-lives, whichever shorter; minimum 14 days) before first dose | Index lesion previously irradiated must have progressed post-radiation to be measurable | Prior therapy with MEK, KRAS, or BRAF inhibitors | Concurrent use of other anticancer agents or investigational agents | Concurrent use of herbal supplements (e.g., St. John's wort, kava, ephedra, ginkgo biloba, DHEA, yohimbe, saw palmetto, ginseng) | Known leptomeningeal or brain metastases or spinal cord compression | Bowel obstruction or GI conditions affecting absorption (malabsorption, inability to swallow, major gastric or bowel resection) | History of interstitial lung disease or pneumonitis | Previous or current malignancy at other sites, except curatively treated in-situ cervix or non-melanoma skin cancer, or cancers without relapse for 5 years | Active HBV or HCV infection (chronic or cleared HBV/HCV allowed); HIV-positive patients on antiretroviral therapy not eligible | Hypersensitivity to trametinib, related compounds, excipients, dimethyl sulfoxide (DMSO), or Cremophor EL (Cremophor exclusion relevant only if paclitaxel is the only available agent and patient randomized to control) | Cardiovascular risk: LVEF < LLN, QTcB >= 480 msec, clinically significant uncontrolled arrhythmias (except controlled AF > 30 days), ACS/MI/unstable angina, coronary angioplasty or stenting within 6 months, NYHA class >= II heart failure, refractory hypertension (SBP > 140 mmHg and/or DBP > 90 mmHg despite therapy), intracardiac defibrillator or permanent pacemaker, known cardiac metastases | History or risk of retinal vein occlusion | Serious/unstable medical or psychiatric disorder that could interfere with safety or compliance | Concomitant medications that prolong QT interval required | Pregnant or nursing",Progression after at least one platinum-based chemotherapy regimen required; Unlimited prior therapy regimens allowed; Hormonal therapy for malignancy discontinued >= 1 week before registration; Chemotherapy and radiation therapy discontinued >= 4 weeks before registration; Investigational agents discontinued >= 28 days before registration; At least 4 weeks since major surgery before registration,FEMALE,F,"The trial is restricted to recurrent low-grade serous ovarian or peritoneal carcinoma, whereas the patient has clear cell ovarian carcinoma. This histology mismatch is a hard disease exclusion.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; BRCA1 positive; Optimal debulking surgery performed; Received adjuvant carboplatin + paclitaxel + bevacizumab; Cytology-positive malignant pleural effusion at 5 months post-adjuvant,(none),Carboplatin; Paclitaxel; Bevacizumab; Optimal debulking surgery,Stage III,,36,years,female,(none),CORRECT,F,"The trial is specifically for recurrent low-grade serous ovarian or peritoneal carcinoma, while the patient has clear cell ovarian carcinoma. This is a disease/histology mismatch, which is a hard exclusion per the rubric, warranting an F. Other factors are irrelevant once a hard exclusion is present.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT02127398,0.5249025821685791,Fistulizing Crohn's Disease,Fecal Microbiota Transplantation in Refractory Clostridium Difficile Colitis,PHASE2,18 years,Clostridium Difficile Colitis,Age >18 years | Three or more episodes of Clostridium difficile colitis within the previous 12 months,"Absolute neutrophil count < 500 cells/mm3 | Active infection at other sites requiring ongoing antibacterial therapy (antiviral or antifungal therapy acceptable) | Current or planned cytotoxic chemotherapy within 14 days of fecal transplantation date | Life expectancy < 180 days | Diagnosis of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis) | Inability to swallow capsules | Indwelling nasogastric, orogastric, gastrostomy, or jejunostomy tube | History of partial or total gastrectomy | Short gut syndrome requiring total parenteral nutrition | Pregnancy | Documented intestinal parasite infection without documentation of appropriate treatment",(none),ALL,F,"Disease mismatch: the trial targets recurrent Clostridium difficile colitis, not fistulizing Crohn's disease, and it explicitly excludes patients with inflammatory bowel disease (e.g., Crohn's).",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,F,"Hard exclusions apply: (1) Disease mismatch (trial targets C. difficile colitis, not Crohn’s); (2) Explicit exclusion of inflammatory bowel disease including Crohn’s. Therefore F is correct.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT02171104,0.5825443863868713,Amyotrophic Lateral Sclerosis,"MT2013-31: Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis Following Conditioning With Busulfan (Therapeutic Drug Monitoring), Fludarabine +/- ATG",PHASE2,up to 55 years,Acyl-CoA Oxidase Deficiency; Adrenoleukodystrophy (cerebral); Alpha-mannosidosis; Alpha-methylacyl-CoA Racemase Deficiency; Aspartylglucosaminuria; D-Bifunctional Enzyme Deficiency; Fucosidosis; Globoid Cell Leukodystrophy; Glycoprotein Metabolic Disorders; Hereditary Leukoencephalopathy With Axonal Spheroids; Hunter Syndrome; Hurler Syndrome; Infantile Refsum Disease; Inherited Metabolic Disorders; Maroteaux Lamy Syndrome; Metachromatic Leukodystrophy; Mitochondrial Neurogastrointestinal Encephalopathy; Mucopolysaccharidosis Disorders; Multifunctional Enzyme Deficiency; Neonatal Adrenoleukodystrophy; Niemann-Pick B; Niemann-Pick C Subtype 2; Peroxisomal Disorders; Recessive Leukodystrophies; Severe Osteopetrosis; Sly Syndrome; Sphingolipidoses; Sphingomyelin Deficiency; Zellweger Syndrome,"Age 0–55 years | Adequate graft available | Adequate organ function | MPS IH (Hurler syndrome) | MPS II (Hunter syndrome) with no or minimal symptomatic neurologic disease but expected neurologic phenotype | MPS VI (Maroteaux-Lamy syndrome) | MPS VII (Sly syndrome) | Alpha-mannosidosis | Fucosidosis | Aspartylglucosaminuria | Globoid cell leukodystrophy | Metachromatic leukodystrophy | Niemann-Pick disease type B (sphingomyelin deficiency) | Niemann-Pick C subtype 2 | Adrenoleukodystrophy (cerebral involvement) | Zellweger syndrome | Neonatal adrenoleukodystrophy | Infantile Refsum disease | Acyl-CoA oxidase deficiency | D-bifunctional enzyme deficiency | Multifunctional enzyme deficiency | Alpha-methylacyl-CoA racemase deficiency (AMACRD) | Mitochondrial neurogastrointestinal encephalopathy (MNGIE) | Severe osteopetrosis | Hereditary leukoencephalopathy with axonal spheroids (CSF1R mutation) | Other life-threatening lysosomal, peroxisomal or similar inherited disorders with white matter disease or neurologic manifestations where transplantation is rational (e.g., Wolman disease, GM1 gangliosidosis, I-cell disease, Tay-Sachs disease, Sandhoff disease) | Voluntary written consent","Pregnancy | Prior myeloablative chemotherapy within 4 months of start of conditioning | Uncontrolled bacterial, fungal, or viral infection including HIV | Active Aspergillus or other mold infection within 30 days",(none),ALL,F,"Disease mismatch: the trial targets inherited metabolic disorders/severe osteopetrosis, not ALS. Additionally, the patient is 62 years old, exceeding the trial’s maximum age of 55.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,F,Hard exclusions apply: the trial diseases do not include ALS (disease mismatch) and the patient is older than the trial’s maximum age (55). Either factor alone yields F. The grader’s reasoning and grade are correct.,,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT02257528,0.7344746589660645,Recurrent Clear Cell Ovarian Carcinoma,"A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer",PHASE2,18 years,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Recurrent Cervical Carcinoma; Cervical Cancer (stage IV),"Histologically confirmed squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix that is persistent, recurrent, or metastatic with documented progression and not amenable to curative therapy. | Measurable disease per RECIST 1.1. | At least one target lesion per RECIST 1.1; lesions in previously irradiated fields are non-target unless progression is documented or biopsy confirms persistence >=90 days after radiation. | Recovery from adverse effects of prior surgery, radiotherapy, or chemotherapy. | Exactly one prior systemic chemotherapy regimen for persistent, recurrent, or metastatic cervical carcinoma. | Performance status 0 or 1. | ANC >= 1,500/µL. | Platelets >= 100,000/µL. | Creatinine <= 1.5 x ULN or creatinine clearance >= 40 mL/min. | Bilirubin <= 1.5 x ULN. | AST <= 3 x ULN. | ALT <= 3 x ULN.","Prior therapy with nivolumab, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, or other agents targeting T-cell co-stimulation or immune checkpoint pathways. | History of severe hypersensitivity reaction to any monoclonal antibody. | Prior invasive malignancy (except non-melanoma skin cancer) unless disease-free for >=3 years. | Uncontrolled intercurrent illness including active infection, symptomatic congestive heart failure, unstable angina, significant arrhythmia, or psychiatric/social conditions limiting compliance. | Pregnant or breastfeeding. | Known brain or leptomeningeal metastases unless treated with no MRI evidence of progression for >=4 weeks and no requirement for systemic corticosteroids >10 mg/day prednisone equivalents for >=2 weeks. | Known HIV infection or AIDS. | Positive hepatitis B surface antigen or positive hepatitis C RNA indicating acute or chronic infection. | Active autoimmune disease or history of autoimmune disease that might recur, affect vital organ function, or require immunosuppressive treatment (exceptions include vitiligo, type I diabetes, residual hypothyroidism on replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur). | Systemic corticosteroids >10 mg/day prednisone equivalents or other immunosuppressive medications within 14 days prior to study drug (topical, inhaled, ocular, intra-articular, intranasal, and physiologic replacement doses allowed). | Active or recent gastrointestinal conditions including diverticulitis, intra-abdominal abscess, abdominal/pelvic fistula, gastrointestinal perforation, gastrointestinal obstruction, or requirement for parenteral hydration/nutrition.","Exactly one prior systemic chemotherapy regimen for persistent/recurrent/metastatic cervical cancer is required.; Chemotherapy, biologic/targeted agents, and immunologic agents must be discontinued >=3 weeks before registration.; Investigational agents must be discontinued >=30 days before registration.; Prior radiation therapy must be completed >=4 weeks before registration.; Major surgery must be completed >=4 weeks before registration.",FEMALE,F,"Disease mismatch: the trial enrolls cervical cancer (persistent/recurrent/metastatic), while the patient has recurrent clear cell ovarian carcinoma, which is not included.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; BRCA1 positive; Optimal debulking surgery performed; Received adjuvant carboplatin + paclitaxel + bevacizumab; Cytology-positive malignant pleural effusion at 5 months post-adjuvant,(none),Carboplatin; Paclitaxel; Bevacizumab; Optimal debulking surgery,Stage III,,36,years,female,(none),CORRECT,F,"The trial targets cervical cancers only; the patient has recurrent clear cell ovarian carcinoma. This is a hard disease mismatch per rubric, warranting an F. The grader’s reasoning correctly identified the key exclusion.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT02291523,0.5655512809753418,Fistulizing Crohn's Disease,The Effect of Therapeutic Fecal Transplant on the Gut Microbiome in Children With Ulcerative Colitis,PHASE1,7 years to 21 years,Ulcerative Colitis,Age 7-21 years with diagnosed ulcerative colitis | Mild to moderate disease per PUCAI score 10-64 | Clinical need for colonoscopy,"Known resistance to steroid therapy, immunomodulators, and biologics | Current steroid dose >0.5 mg/kg/day (maximum 20 mg) | Recent dose change within 4 weeks of biologics, 5-ASA, steroids, or immunomodulators | Allergy or intolerance to mesalamine or 5-ASA products | Evidence of infectious colitis | Concurrent infections requiring antimicrobial therapy | Received probiotic preparations within 4 weeks prior to randomization | Pregnancy or breastfeeding | Significant renal dysfunction | Significant liver dysfunction | Congenital or acquired immunodeficiency | Immunosuppressed due to conditions other than ulcerative colitis (e.g., neoplastic disease or organ transplantation) | Received or receiving chemotherapy | Diagnosed with HIV | Unable to give informed consent/assent","Stable dosing of biologics, 5-ASA, steroids, or immunomodulators for >= 4 weeks prior to randomization; No probiotic preparations within 4 weeks prior to randomization",ALL,F,"Disease mismatch: the trial is for ulcerative colitis, while the patient has fistulizing Crohn's disease. Additionally, the patient is 32 years old, outside the trial's 7–21-year age range.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,F,Disease mismatch (Crohn’s vs ulcerative colitis) and age outside the trial’s 7–21 range are hard exclusions. F is correct per rubric.,,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT02315027,0.5399202704429626,Amyotrophic Lateral Sclerosis,Intrathecal Autologous Mesenchymal Stem Cell Therapy in Multiple System Atrophy (MSA) - Effect of Dose and Natural History,PHASE1/PHASE2,30 years to 80 years,Multiple System Atrophy,Age 30-80 years | Diagnosis of multiple system atrophy (MSA) per Gilman 2000 criteria (probable MSA-P or MSA-C) | Autonomic testing supportive of MSA: CASS >=5 or TST% >=25% | Less than 4 years from documented MSA diagnosis | Anticipated survival >=3 years | Able to provide informed consent | Mini-Mental State Examination (MMSE) >24,"Women of childbearing potential not using acceptable contraception | Clinically significant or unstable medical/surgical condition that may affect safety or results | Congestive heart failure | Recent myocardial infarction (<6 months) | Cardiopulmonary disease | Severe, uncontrolled hypertension | Thrombocytopenia (<50,000/µL) | Severe anemia (<8 g/dL) | Immunocompromised state | Liver disease | Kidney disease (creatinine >2.3 mg/dL) | Uncontrolled diabetes mellitus (HbA1c >10%) | Alcoholism | Amyloidosis | Uncontrolled hypothyroidism | History of sympathectomy | Unstable peripheral neuropathies | Concurrent systemic or local infection (including near spinal injection site) | Orthopedic problems compromising mobility or activities of daily living | Cerebrovascular accident | Exposure to neurotoxic or neuroactive drugs | Drug-induced parkinsonism (e.g., neuroleptics, alpha-methyldopa, reserpine, metoclopramide) | Malignant neoplasms | Use of investigational products within 60 days prior to baseline | Medications affecting autonomic function unless withdrawn 48 hours prior (e.g., midodrine, anticholinergics, alpha/beta adrenergic antagonists); fludrocortisone up to 0.2 mg/day permitted | Diseases with features of Parkinson's disease (e.g., diffuse Lewy body disease, progressive supranuclear palsy, essential tremor, hereditary olivopontocerebellar atrophy, postencephalitic parkinsonism) | Dementia (DSM-IV); MMSE must be >24 | History of electroconvulsive therapy | History of brain surgery for Parkinson's disease | Contraindication to MRI (e.g., MRI-incompatible pacemaker)","No investigational products within 60 days prior to baseline; Hold medications affecting autonomic function (e.g., midodrine, anticholinergics, alpha/beta blockers) 48 hours before autonomic evaluations; fludrocortisone up to 0.2 mg/day permitted",ALL,F,"The trial is for Multiple System Atrophy and requires an MSA diagnosis, while the patient has amyotrophic lateral sclerosis (ALS); this disease mismatch is a hard exclusion.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,F,"Disease mismatch: trial requires Multiple System Atrophy while patient has ALS. This is a hard exclusion per rubric, so F is correct.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT02362438,0.5513969659805298,Amyotrophic Lateral Sclerosis,A Phase I Study of Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy,PHASE1,3 years to 99 years,Giant Axonal Neuropathy,Age >= 3 years | Genetic diagnosis of Giant Axonal Neuropathy with pathogenic variants on both GAN alleles | Willingness to undergo a nerve biopsy at baseline and at 12 months after treatment | Use of barrier contraception post-dose (men for 6 months; women 3–6 months) and urine hCG testing for women of childbearing potential,"Pregnant or lactating | Forced vital capacity <= 50% predicted (if age >= 5 years) | Ventilator dependence including daytime assisted ventilation | Current clinically significant infections requiring systemic treatment, including HIV, hepatitis A/B/C, varicella zoster virus, or HTLV-1 | Prior history of bacterial meningitis | Unwilling to undergo lumbar puncture at baseline and during follow-up | Clinically significant echocardiogram abnormality | Clinically significant electrocardiogram abnormality | History of brain or spinal cord disease that would interfere with lumbar puncture procedures, CSF circulation, or safety assessments | Presence of an implanted CSF shunt or implanted CNS catheter | Any prior participation in a study with a gene therapy vector or prior stem cell transplantation | Participation in an IND/IDE or equivalent clinical study within the past 6 months | Chemotherapy, radiotherapy, or other immunosuppressive therapy within the past 30 days | Immunizations of any kind within the month prior to the study | Current use of medications that could increase intracranial pressure (e.g., levothyroxine, vitamin A, oral contraceptives, tetracycline, acetazolamide) | Known sensitivity or adverse reaction to anesthetic medications likely to be used | Giant Axonal Neuropathy without quantifiable weakness or functional loss | Evidence of cardiomyopathy or other cardiac disease that would make participation unsafe | History of diabetes or clinically significant abnormality of glucose tolerance test or fasting blood glucose | Positive purified protein derivative test for tuberculosis | Platelet count < 100,000/µL | Total white blood cell count < 3,000/µL or > 12,000/µL | Hemoglobin < 10 g/dL | Abnormal prothrombin time or partial thromboplastin time | Abnormal liver function tests (> 1.5 x ULN or > 2 x baseline) | Abnormal pancreatic enzymes (> 1.5 x ULN or > 2 x baseline) | Renal impairment: urinary protein concentration >= 0.2 g/L on 2 consecutive tests | Failure to thrive (significant weight percentile decline or weight < 3rd percentile for age/sex) | Anticipated need for major surgery in the next 12–18 months | Ongoing medical condition that would interfere with study conduct or assessments",(none),ALL,F,"Disease mismatch: the trial is for Giant Axonal Neuropathy with required genetic confirmation, while the patient has ALS. This triggers a hard exclusion.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,F,"Disease mismatch is a hard exclusion. The trial targets Giant Axonal Neuropathy, while the patient has ALS. The grader correctly applied the rubric and assigned F based on disease mismatch.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT02432963,0.7823978066444397,Metastatic Non-Small Cell Lung Cancer,A Phase I Study of a p53MVA Vaccine in Combination With Pembrolizumab,PHASE1,18 years,Non-Small Cell Lung Carcinoma; Head and Neck Squamous Cell Carcinoma; Hepatocellular Carcinoma; Renal Cell Carcinoma; Melanoma; Bladder Carcinoma; Soft Tissue Sarcoma; Triple-Negative Breast Carcinoma; Colorectal Carcinoma; Pancreatic Carcinoma,"Advanced (unresectable) solid tumors from predefined histologies (NSCLC, head and neck squamous cell carcinoma, hepatocellular carcinoma, renal cell carcinoma, melanoma, bladder carcinoma, soft tissue sarcoma, triple-negative breast cancer, colorectal carcinoma displaying microsatellite instability, or pancreatic cancer) | Failed or intolerant to at least one line of standard therapy or refusal of standard treatment | ECOG performance status <= 2 (Karnofsky >= 60%) | Absolute neutrophil count >= 1500/µL | Platelets >= 100000/µL | Hemoglobin > 9 g/dL | Creatinine clearance >= 50 mL/min or serum creatinine <= 1.6 mg/dL | Total bilirubin <= 1.5 x ULN | AST <= 3 x ULN (<= 5 x ULN with liver metastasis) | ALT <= 3 x ULN (<= 5 x ULN with liver metastasis) | Confirmed TP53 involvement: TP53 overexpression by IHC (>= 10% tumor cells) or TP53 mutation by tumor mutational analysis","Concurrent investigational agents or radiation therapy | Pregnant or breastfeeding | Known brain metastasis | Radiotherapy within 4 weeks prior to study entry | Prior exposure to anti-PD-1 or anti-PD-L1 therapy | History of allergy to egg proteins | Unresolved adverse events from prior therapy > 4 weeks | Concurrent use of systemic corticosteroids (nasal, inhaled, adrenal replacement, and topical allowed) | History of immunodeficiency including organ grafts or HIV infection | Active autoimmune disease or condition requiring systemic corticosteroids (exceptions: vitiligo, type 1 diabetes mellitus) | History of severe immune-mediated adverse reactions with ipilimumab (grade 4 toxicity requiring > 10 mg/day prednisone or equivalent for > 12 weeks) | History of cardiac disease or abnormal screening ECG (excluding 1st degree bundle branch block, sinus bradycardia, sinus tachycardia, or non-specific T wave changes) or serum troponin >= grade 2 | Investigator-assessed inability to comply with safety monitoring","At least one prior line of standard therapy failed or intolerant, or refusal of standard treatment",ALL,F,"The trial explicitly excludes patients with known brain metastases, which this patient has. Additionally, required TP53 involvement and prior failure of standard therapy are not documented.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"The trial explicitly excludes patients with known brain metastases, and the patient has brain metastases on MRI, triggering a hard exclusion. Other requirements like TP53 involvement and prior failure are undocumented and should not drive the F, but the brain metastasis exclusion alone warrants F.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT02446600,0.8972036242485046,Recurrent Clear Cell Ovarian Carcinoma,"A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",PHASE3,18 years,Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Tumor; Ovarian Seromucinous Carcinoma; Ovarian Serous Tumor; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma; Recurrent Primary Peritoneal Carcinoma,"Platinum-sensitive recurrent high-grade serous or high-grade endometrioid ovarian, primary peritoneal, or fallopian tube cancer; other high-risk histologies (clear cell, mixed epithelial, undifferentiated, or transitional cell) allowed if deleterious germline BRCA1 or BRCA2 mutation is present | Platinum-sensitive disease: > 6 months since last platinum and complete clinical response to prior platinum; no progression through prior platinum therapy | Measurable disease by RECIST 1.1 OR evaluable disease with CA-125 doubled from nadir and > 2 x ULN | Prior chemotherapy must have included a first-line platinum-based regimen; unlimited prior platinum-based regimens in the recurrent setting allowed | Up to 1 prior non-platinum-based line in the recurrent setting allowed; prior hormonal therapy does not count toward this limit | ECOG performance status 0–2 (Karnofsky >= 60%) | Able to swallow and retain oral medications; no gastrointestinal illness precluding absorption | Blood pressure <= 140/90 mmHg on up to three antihypertensive medications; able and willing to record daily BP | Toxicities from prior therapy resolved to <= grade 1 (except alopecia); long-standing stable grade 2 neuropathy may be allowed (will not receive carboplatin/paclitaxel if randomized to that arm) | Adequately controlled thyroid function; TSH within normal limits without symptoms of thyroid dysfunction | Women of childbearing potential: negative pregnancy test and agreement to use two reliable forms of contraception | Age >= 18 years","Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to starting treatment, or unresolved toxicities from prior therapy > grade 1 | Hormonal therapy within 2 weeks prior to study entry (except raloxifene for bone health) | Concurrent investigational agents or investigational trial participation within 4 weeks | Medications that may markedly affect renal function (e.g., vancomycin, amphotericin, pentamidine) | Prior treatment affecting the VEGF pathway (e.g., thalidomide, sunitinib, pazopanib, sorafenib, nintedanib) in the recurrent setting; upfront bevacizumab allowed | Prior PARP inhibitor | CA-125–only disease without RECIST 1.1 measurable or otherwise evaluable disease | Untreated or symptomatic brain metastases, spinal cord compression, or leptomeningeal disease; treated brain metastases must be radiographically stable >= 6 months and asymptomatic | Strong CYP3A4 inhibitors or inducers; strong UGT/P-gp modulators should be used with caution | History of gastrointestinal perforation; abdominal fistula unless healed and no evidence for >= 6 months and low risk of recurrence | Intra-abdominal abscess within 3 months | Current signs/symptoms of bowel obstruction or within 3 months prior to starting study drugs | Dependency on IV hydration or total parenteral nutrition | Other invasive malignancy unless meeting specified curatively treated exceptions and disease-free >= 3 years | Myocardial infarction within 6 months, unstable angina, clinically significant ECG abnormalities, or NYHA class III/IV heart failure | Left ventricular ejection fraction below institutional normal or < 55% if no institutional threshold | History of stroke or transient ischemic attack within 6 months | Any prior hypertensive crisis or hypertensive encephalopathy | Clinically significant peripheral or other vascular disease (including aortic aneurysm or dissection) | Major surgery, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib | Uncontrolled intercurrent illness (active infection, symptomatic CHF, unstable angina, significant arrhythmia other than controlled AF, or psychiatric/social conditions limiting compliance) | Pregnancy or breastfeeding | Known HIV-positive status | Use of complementary or alternative medicines (natural herbal products or folk remedies) | Features suggestive of myelodysplastic syndrome or acute myelogenous leukemia on smear or marrow (if evaluated) | Prior allogeneic bone marrow transplant or double umbilical cord blood transplantation",Required prior first-line platinum-based chemotherapy (with or without IV consolidation); Unlimited prior platinum-based regimens in the recurrent setting allowed; Up to 1 prior non-platinum-based line in the recurrent setting allowed; Prior hormonal therapy allowed and does not count toward non-platinum limit; Washout: chemotherapy or radiotherapy >= 4 weeks (>= 6 weeks for nitrosoureas or mitomycin C) before study treatment; Washout: hormonal therapy >= 2 weeks before study entry,FEMALE,F,"The trial requires platinum-sensitive recurrence (>6 months from last platinum), but the patient recurred at 5 months, which fails this mandatory inclusion criterion. While clear cell histology is allowed with deleterious germline BRCA1/2 (germline status not specified), the <6-month platinum-free interval is a hard exclusion.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; BRCA1 positive; Optimal debulking surgery performed; Received adjuvant carboplatin + paclitaxel + bevacizumab; Cytology-positive malignant pleural effusion at 5 months post-adjuvant,(none),Carboplatin; Paclitaxel; Bevacizumab; Optimal debulking surgery,Stage III,,36,years,female,(none),CORRECT,F,"Trial mandates platinum-sensitive recurrence (>6 months since last platinum). Patient recurred at 5 months, definitively lacking the required setting, which is a hard exclusion per rubric. Germline BRCA status is unknown and should not trigger F, but the platinum-sensitivity requirement alone justifies F.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT02621424,0.7123395800590515,Dementia,Repetitive Transcranial Magnetic Stimulation for Dementia,NA,55 years to 99 years,Alzheimer's Disease; Mild Cognitive Impairment,"Age >= 55 years | Diagnosed with mild cognitive impairment or dementia likely due to Alzheimer's disease | Ability to obtain motor threshold during screening | If on prescription cognition medication, dose stable for >= 4 weeks prior to randomization","Prior exposure to repetitive transcranial magnetic stimulation or electroconvulsive therapy | Unable to safely withdraw from medications that substantially increase seizure risk >= 2 weeks before treatment | Cardiac pacemaker or cochlear implant | Implanted deep brain stimulation device or metal in the brain | Current substance abuse (excluding caffeine or nicotine) | Active current suicidal intent or plan | Current or prior seizure disorder | Traumatic brain injury within the last 2 months | Participation in another concurrent interventional clinical trial | Known current psychosis | Current or prior mass lesion, cerebral infarct, or other active CNS disease increasing seizure risk | Not fluent in English or severe hearing impairment impairing comprehension",Cognition medications allowed if dose stable for >= 4 weeks prior to randomization; Washout of medications that increase seizure risk for >= 2 weeks before treatment,ALL,F,"The trial enrolls only mild cognitive impairment or dementia likely due to Alzheimer's disease, but the patient's disease is listed as unspecified dementia (not AD/MCI). Age and sex fit, but this disease mismatch is a hard exclusion.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,"Disease mismatch is a hard exclusion. The trial enrolls AD or MCI (dementia likely due to AD), while the patient’s listed disease is unspecified dementia with biomarkers arguing against AD. Thus F is appropriate without needing anchor assessment.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT02627443,0.7144074440002441,Recurrent Clear Cell Ovarian Carcinoma,"Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer",PHASE1,18 years,High Grade Serous Ovarian Carcinoma; Endometrioid Ovarian Carcinoma; Primary Peritoneal Carcinoma; Fallopian Tube Carcinoma,"Histologically confirmed high grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube malignancy that is metastatic and not curable | Measurable disease by RECIST: >= 20 mm by conventional imaging or >= 10 mm by spiral CT/MRI/clinical calipers | Expansion cohort: archival tumor tissue available and willingness for baseline and on-treatment biopsies | Platinum-sensitive disease in first or second recurrence (recurrence > 6 months after last platinum therapy) | No more than two prior platinum-based regimens | ECOG performance status <=2 (Karnofsky >=60%) | Life expectancy > 6 months | Leukocytes >= 3,000/µL | Absolute neutrophil count >= 1,500/µL | Platelets >= 100,000/µL | Total bilirubin within normal limits | AST/ALT <= 2 x ULN | Creatinine within normal limits or creatinine clearance >= 50 mL/min | Negative serum pregnancy test for females of childbearing potential","Platinum-resistant disease or beyond second platinum-sensitive recurrence | Chemotherapy or radiotherapy within 4 weeks prior to enrollment or unresolved > grade 1 toxicities (except alopecia; peripheral neuropathy <= grade 1 allowed) | Prior exposure to gemcitabine | Concurrent treatment with other investigational agents | Known brain metastases | History of allergic reactions to compounds similar to berzosertib, carboplatin, or gemcitabine | Concomitant use of strong CYP3A4 inhibitors or inducers | Uncontrolled intercurrent illness (e.g., active infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, significant psychiatric illness) | Pregnant or breastfeeding | Li-Fraumeni syndrome | Addition of bevacizumab to study treatment not allowed",Platinum-sensitive recurrence (first or second) required; No more than two prior platinum-based regimens; Prior PARP inhibitor allowed; Prior bevacizumab allowed; Washout >= 4 weeks since chemotherapy or radiotherapy,FEMALE,F,"Disease mismatch: the trial enrolls high-grade serous or endometrioid ovarian cancers (plus primary peritoneal/fallopian tube), not clear cell ovarian carcinoma. Additionally, the patient’s recurrence at 5 months indicates platinum-resistant disease, while the trial requires platinum-sensitive recurrence.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; BRCA1 positive; Optimal debulking surgery performed; Received adjuvant carboplatin + paclitaxel + bevacizumab; Cytology-positive malignant pleural effusion at 5 months post-adjuvant,(none),Carboplatin; Paclitaxel; Bevacizumab; Optimal debulking surgery,Stage III,,36,years,female,(none),CORRECT,F,"Correct: The trial restricts histology to high-grade serous/endometrioid (plus primary peritoneal/fallopian tube), excluding clear cell—disease mismatch is a hard exclusion. Additionally, recurrence at 5 months after platinum indicates platinum-resistant disease, which is explicitly excluded. F is appropriate.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT02659241,0.7141554355621338,Recurrent Clear Cell Ovarian Carcinoma,A Pilot Study of Wee1 Inhibition Induction Prior to Tumor Reductive Surgery in Ovarian Cancer,EARLY_PHASE1,18 years,Ovarian High Grade Serous Carcinoma; Fallopian Tube High Grade Serous Carcinoma; Primary Peritoneal High Grade Serous Carcinoma,"Presumed advanced-stage high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma | Medically able to undergo primary cytoreductive surgery 13-28 days after starting study drug | No prior therapy for high-grade serous ovarian, fallopian tube, or primary peritoneal carcinoma | Able to swallow and tolerate oral medications; no GI illness precluding absorption | Absolute neutrophil count >= 1,500/µL | Hemoglobin >= 9 g/dL | Platelets >= 100,000/µL | Total bilirubin <= 1.5 x ULN | AST <= 2.5 x ULN | ALT <= 2.5 x ULN | Creatinine clearance > 50 mL/min | Creatinine < 1.5 x ULN | ECOG performance status 0-1","Prior treatment for ovarian, fallopian tube, or primary peritoneal cancer | Current receipt of other investigational agents or additional anti-cancer agents | Active CNS disease other than neurologically stable, treated brain metastases | Other active cancers (exceptions: certain stage I, in-situ, or prior non-melanoma skin cancers) | Major surgery within 28 days or minor surgery within 7 days before starting treatment | Significant symptom burden including large volume ascites, pain requiring narcotics, or dyspnea on exertion | Myocardial infarction within 6 months, symptomatic CHF (NYHA > class II), unstable angina, or unstable arrhythmia | QTc > 470 msec or congenital long QT syndrome | Use of moderate to strong CYP3A4 inhibitors/inducers or sensitive/narrow therapeutic index CYP3A4 substrates that cannot be discontinued (including aprepitant/fosaprepitant) | Herbal preparations prohibited (e.g., St. John's wort, kava, ephedra, ginkgo, DHEA, yohimbe, saw palmetto, ginseng) and avoidance of grapefruit/exotic citrus during study | Known hypersensitivity to study treatment components | Pregnant or breast-feeding | Severe or uncontrolled systemic diseases (e.g., severe hepatic impairment, interstitial lung disease, uncontrolled chronic renal disease), serious active infection, uncontrolled hypertension (>= 140/90), active bleeding diathesis, or active infection including hepatitis B, hepatitis C, or HIV | Investigator deems patient unsuitable or unlikely to comply | Statin use (e.g., atorvastatin) prohibited due to BCRP inhibition","No prior therapy for high-grade serous ovarian, fallopian tube, or primary peritoneal carcinoma",FEMALE,F,"Disease mismatch: the trial enrolls only high-grade serous ovarian/fallopian tube/primary peritoneal carcinoma, while the patient has clear cell ovarian carcinoma. Additionally, the trial requires no prior therapy, but the patient has received carboplatin, paclitaxel, and bevacizumab.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; BRCA1 positive; Optimal debulking surgery performed; Received adjuvant carboplatin + paclitaxel + bevacizumab; Cytology-positive malignant pleural effusion at 5 months post-adjuvant,(none),Carboplatin; Paclitaxel; Bevacizumab; Optimal debulking surgery,Stage III,,36,years,female,(none),CORRECT,F,"Trial restricts to high-grade serous disease while patient has clear cell—hard disease mismatch. Trial also excludes any prior therapy; patient received adjuvant chemo/bevacizumab. Both are hard exclusions, so F is correct.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT02690558,0.7811114192008972,Metastatic Urothelial Carcinoma,Phase II Single Arm Study of Gemcitabine and Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer,PHASE2,18 years,Urothelial Bladder Cancer,"Age >= 18 years | ECOG performance status 0–1 | Histologically confirmed urothelial carcinoma of the bladder (mixed histology allowed if component of urothelial carcinoma; excludes pure small cell, pure adenocarcinoma, pure squamous) | Clinical stage T2–T4a N0/X M0 urothelial carcinoma | Medically appropriate candidate for radical cystectomy and planning to receive cystectomy | No prior systemic cytotoxic chemotherapy for urothelial carcinoma (prior intravesical chemotherapy permitted) | Adequate organ function per protocol laboratory criteria | Life expectancy > 3 months","Participation in another investigational study or use of an investigational device within 4 weeks prior to first dose | Immunodeficiency or systemic steroid/immunosuppressive therapy within 7 days prior to first dose (except allowed prophylactic antiemetic steroids, inhaled/topical steroids) | Active tuberculosis | Hypersensitivity to pembrolizumab or its excipients | Prior monoclonal antibody therapy within 4 weeks prior to Day 1 or not recovered to <= Grade 1 from prior adverse events | Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to Day 1 or not recovered to <= Grade 1 from prior adverse events | Additional malignancy that is progressing or requires active treatment (except certain skin cancers or in situ cervical cancer after curative therapy) | Active autoimmune disease requiring systemic treatment within the past 2 years | Interstitial lung disease or active, non-infectious pneumonitis | Active infection requiring systemic therapy | Pregnant or breastfeeding, or planning conception/fathering during study and for 120 days after last dose | Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibodies | Prior radiation therapy to the bladder for urothelial carcinoma | Known HIV infection | Active hepatitis B or hepatitis C infection | Clinically relevant hearing impairment > Grade 2 | Live vaccine within 30 days prior to first dose","No prior systemic cytotoxic chemotherapy for urothelial carcinoma; No prior checkpoint inhibitor therapy (anti-PD-1/PD-L1/PD-L2, anti-CD137, anti-CTLA-4); Washout >= 4 weeks from prior monoclonal antibody therapy; Washout >= 2 weeks from prior chemotherapy, targeted therapy, or radiation therapy; No prior radiation therapy to the bladder for urothelial carcinoma; No investigational agents/devices within 4 weeks prior to first dose",ALL,F,"Explicit exclusions apply: the trial prohibits prior PD-1 therapy and prior systemic cytotoxic chemotherapy, while the patient received pembrolizumab and gemcitabine/cisplatin. Additionally, the trial is neoadjuvant for non-metastatic (M0) candidates pre-cystectomy, whereas the patient has metastatic disease post-cystectomy.",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),CORRECT,F,"The trial has explicit exclusions for prior PD-1/PD-L1 therapy and prior systemic cytotoxic chemotherapy, both of which the patient has received (pembrolizumab and gemcitabine/cisplatin). These are hard exclusions per the rubric, warranting an F. The grader correctly identified these and also noted the neoadjuvant M0 setting mismatch, though the hard exclusions alone are sufficient.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT02795052,0.5280157327651978,Duchenne Muscular Dystrophy,Neurologic Bone Marrow Derived Stem Cell Treatment Study,NA,18 years,Amyotrophic Lateral Sclerosis; Alzheimer Disease; CADASIL; Cerebral Hemorrhage; Cerebral Infarction; Cerebral Ischemia; Chronic Traumatic Encephalopathy; Cognitive Impairment; Dementia; Diabetic Neuropathy; Frontotemporal Dementia; Lewy Body Disease; Lewy Body Variant of Alzheimer Disease; Multiple System Atrophy; Neuropathy; Parkinson Disease; Progressive Supranuclear Palsy; Stroke; Traumatic Brain Injury,"Documented functional damage to the central or peripheral nervous system unlikely to improve with current standard of care | >= 6 months since disease onset | If on pharmacologic or surgical therapy, clinically stable and unlikely to have reversal of neurologic damage from that therapy | Investigator assessment that there is potential for improvement with BMSC and minimal risk from the procedure | Age > 18 years | Medically stable and able to be cleared by a primary care practitioner for the procedure",Not medically stable or at significant risk to health from undergoing the procedure | Pregnant at the time of treatment or planning pregnancy within 3 months post-treatment,Current pharmacologic or surgical therapy allowed if stable,ALL,F,"The trial does not include Duchenne Muscular Dystrophy among eligible diseases and requires participants to be ≥18 years old, while the patient is 11.",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,"Disease mismatch (Duchenne Muscular Dystrophy not among trial diseases) and age below minimum (11 < 18) are hard exclusions, so F is appropriate. The grader correctly identified both issues.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT02812420,0.8375187516212463,Metastatic Urothelial Carcinoma,"A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Neoadjuvant Chemotherapy",EARLY_PHASE1,18 years,Bladder Urothelial Carcinoma; Infiltrating Bladder Urothelial Carcinoma (micropapillary variant); Infiltrating Bladder Urothelial Carcinoma (plasmacytoid variant); Infiltrating Bladder Urothelial Carcinoma (sarcomatoid variant); Renal Pelvis Urothelial Carcinoma; Infiltrating Renal Pelvis Urothelial Carcinoma (sarcomatoid variant); Ureter Urothelial Carcinoma; Urethral Urothelial Carcinoma,"Transurethral resection of bladder tissue (TURBT) performed at MD Anderson Cancer Center | Histologic proof of urothelial cancer (bladder, renal pelvis, ureter, or urethra); upper tract urothelial carcinoma included | Muscle-invasive disease (e.g., cT2-3aN0M0) or tumor not completely removed at TURBT, or requiring cystectomy/applicable surgery | High-risk features not candidates for traditional neoadjuvant chemotherapy: micropapillary, sarcomatoid, or plasmacytoid features | High-risk feature: 3-dimensional mass on exam under anesthesia | High-risk feature: lymphovascular invasion | High-risk feature: hydronephrosis (unless deemed not due to tumor) | High-risk feature: high-grade tumors of the ureter or renal pelvis with radiographic mass on CT or MRI | High-risk feature: direct invasion of prostatic stroma or vaginal wall (cT4a) | Candidates for but refusing conventional chemotherapy may be eligible | No prior exposure to immunotherapy such as anti-CTLA-4, anti-PD-1, or anti-PD-L1 antibodies (vaccines excluded) | ECOG performance status 0–1 | Adequate organ and marrow function without transfusions or growth factor support within 28 days prior to first dose | Hemoglobin >= 9 g/dL | Absolute neutrophil count >= 1,000/µL | Platelet count >= 100,000/µL | Total bilirubin <= 1.5 x ULN (Gilbert's syndrome allowed up to 3.0 mg/dL) | Cisplatin ineligible due to renal dysfunction, hearing impairment, comorbidities, or refusal; examples include GFR < 60 mL/min, CHF NYHA class III or higher, peripheral neuropathy grade >= 2, ECOG PS >= 2, impaired hearing, or patient refusal | Contraception required for females of childbearing potential through 180 days after final dose | Contraception required for nonsterilized males through 90 days after final dose","Concurrent enrollment in another clinical trial (unless in follow-up or observational) | Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer | Investigational anticancer therapy within 28 days prior to first dose | Major surgical procedure within 28 days prior to first dose or not recovered from prior surgery | Unresolved toxicities from prior anticancer therapy > grade 1 (except alopecia and specified labs); irreversible toxicities not expected to be exacerbated may be allowed | Known or suspected autoimmune disease including inflammatory bowel disease, rheumatoid arthritis, systemic sclerosis, systemic lupus erythematosus, or autoimmune vasculitis | Systemic corticosteroids > 10 mg prednisone equivalents daily or other immunosuppressive medications within 14 days prior to first dose (inhaled/adrenal replacement allowed) | History of primary immunodeficiency | Prior organ allograft | Active hepatitis B or hepatitis C infection | Known HIV infection or AIDS | Receipt of live attenuated vaccine within 28 days prior to first dose (and not during study or for 180 days after last dose) | Pregnant or lactating | Uncontrolled intercurrent illness including active infection, current pneumonitis, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, interstitial lung disease, or significant psychiatric/social conditions limiting compliance | Other invasive malignancy within 2 years except certain in situ or non-melanoma skin cancers surgically cured | Evidence of metastatic urothelial carcinoma | Known allergy or hypersensitivity to study drug formulations | Currently on dialysis",>=28 days since prior investigational anticancer therapy,ALL,F,"Explicit exclusions apply: the trial excludes patients with metastatic urothelial carcinoma and those with prior PD-1/PD-L1/CTLA-4 therapy, while the patient has metastatic disease and previously received pembrolizumab.",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),CORRECT,F,"The trial explicitly excludes patients with metastatic urothelial carcinoma and requires no prior PD-1/PD-L1/CTLA-4 therapy. The patient has metastatic disease and prior pembrolizumab, so hard exclusions apply → F. The grader correctly identified these conflicts.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT02818920,0.7922804355621338,Metastatic Non-Small Cell Lung Cancer,"Pembrolizumab Prior to Surgery for Stage 1B, 2 or 3A Non-small Cell Lung Cancer (NSCLC): A Phase II Study",PHASE2,18 years,Non-small Cell Lung Cancer,"Histologically or cytologically confirmed non-small cell lung cancer | Clinical stage IB (>= 3 cm), stage IIA/IIB, or stage IIIA (N0-2) amenable to surgical resection | Primary tumor >= 3 cm | Deemed a surgical candidate | ECOG performance status 0–1 | No active invasive malignancy in the past 2 years other than non-melanoma skin cancer; in-situ cancers allowed | Age >= 18 years | Negative pregnancy test for females of childbearing potential within 48 hours prior to initial study procedures | Measurable disease per RECIST 1.1 | Post-operative predicted FEV1 > 40% predicted | Post-operative predicted DLCO > 40% predicted | Adequate organ function","Treatment within the last 30 days with an investigational drug or use of an investigational device within 4 weeks of first dose | Known history of active tuberculosis | Hypersensitivity to pembrolizumab or any of its excipients | Concurrent administration of any other anti-tumor therapy | Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent | Known active hepatitis B or active hepatitis C infection | Active infection requiring antibiotics, antifungal, or antiviral therapy | History of or evidence of active, non-infectious pneumonitis | Known history of HIV infection | Active autoimmune disease requiring systemic treatment in the past 2 years | Autoimmune motor neuropathy (e.g., Guillain-Barre syndrome, myasthenia gravis) | Systemic steroid therapy or other immunosuppressive therapy within 7 days prior to first dose | Known additional invasive malignancy that is progressing or requires active treatment (exceptions for certain skin cancers and in situ cervical cancer) | Pregnant or breastfeeding, or planning to conceive/father children during treatment and for 120 days after last dose | Major surgery (other than definitive lung cancer surgery) within 2 weeks prior to study | Receipt of non-oncology vaccine within 30 days before or after any dose of pembrolizumab (inactivated injectable influenza vaccines allowed; live attenuated intranasal vaccines not allowed) | History of myocardial infarction within 6 months, uncontrolled arrhythmia, symptomatic angina, active ischemia, or uncontrolled heart failure | History of interstitial lung disease | Inability to comply with study procedures | Prisoners or subjects involuntarily detained",(none),ALL,F,"The trial requires resectable stage IB–IIIA NSCLC for neoadjuvant pembrolizumab, whereas the patient has de novo metastatic (stage IV) disease; this is a definitive required stage/setting mismatch.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"The trial requires resectable stage IB–IIIA NSCLC (neoadjuvant setting), while the patient has de novo metastatic (stage IV) disease. Per rubric, a required stage/setting the patient definitively lacks is a HARD EXCLUSION → F. Age/sex/disease type otherwise match, but the hard exclusion governs. The grader’s reasoning aligns.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT03023540,0.5812726020812988,Amyotrophic Lateral Sclerosis,"International, Multi-center, Open Label, Follow-up Extension Study Assessing the Long-term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A",PHASE3,17 years to 67 years,Charcot-Marie-Tooth Disease Type 1A,Female patients agree to use an approved method of birth control during the study,"Clinically significant change in health status that would prevent participation or completion | Use of unauthorized concomitant treatments (e.g., baclofen, naltrexone, sorbitol [pharmaceutical form], opioids, levothyroxine, and potentially neurotoxic drugs such as amiodarone, chloroquine, or cancer drugs that can induce peripheral neuropathy)",(none),ALL,F,"Disease mismatch: the trial targets Charcot-Marie-Tooth Disease Type 1A, while the patient has amyotrophic lateral sclerosis (ALS). This is a hard exclusion regardless of other factors.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,F,"Disease mismatch is a hard exclusion: the trial targets Charcot-Marie-Tooth Disease Type 1A, while the patient has ALS. The grader correctly assigned F based on the rubric.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03036098,0.8525841236114502,Metastatic Urothelial Carcinoma,"A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab, or With Standard of Care Chemotherapy, Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer",PHASE3,18 years,Urothelial Cancer (metastatic),"Histological or cytological evidence of metastatic or surgically inoperable transitional cell carcinoma of the urothelium (renal pelvis, ureter, bladder, or urethra) | No prior systemic chemotherapy for metastatic or surgically inoperable urothelial cancer | ECOG performance status 0 or 1","Disease suitable for local therapy with curative intent | Serious or uncontrolled medical disorder that may increase risk or interfere with study participation or interpretation | Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibodies, or other agents targeting T-cell co-stimulation or checkpoint pathways",(none),ALL,F,"The trial excludes participants with prior anti–PD-1/PD-L1 or CTLA-4 therapy, and the patient received pembrolizumab (anti–PD-1) for metastatic disease. The trial also requires no prior systemic therapy for metastatic disease, whereas the patient has progressed after second-line therapy.",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),CORRECT,F,"The trial explicitly excludes prior PD-1/PD-L1/CTLA-4 therapy and requires no prior systemic therapy for metastatic disease. The patient received pembrolizumab (PD-1) and prior systemic therapy for metastatic disease, triggering hard exclusions. The grader correctly assigned F and cited the key reasons.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT03067181,0.7122465968132019,Recurrent Clear Cell Ovarian Carcinoma,A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors,PHASE3,Not specified,Germ Cell Tumor; Malignant Germ Cell Tumor; Extracranial Germ Cell Tumor; Malignant Ovarian Teratoma; Ovarian Embryonal Carcinoma; Ovarian Yolk Sac Tumor; Ovarian Choriocarcinoma; Testicular Seminoma; Testicular Embryonal Carcinoma; Testicular Yolk Sac Tumor; Testicular Choriocarcinoma; Extragonadal Embryonal Carcinoma; Testicular Mixed Choriocarcinoma and Embryonal Carcinoma; Testicular Mixed Choriocarcinoma and Teratoma; Testicular Mixed Choriocarcinoma and Yolk Sac Tumor,"Low risk stratum: no age limit | Standard risk 1: age < 11 years at enrollment | Standard risk 2: age >= 11 and < 25 years at enrollment | Low risk arms: newly diagnosed stage I germ cell tumor | Standard risk arms: newly diagnosed malignant germ cell tumor (stage II or higher) | Histologic confirmation of primary extracranial germ cell tumor required unless markedly elevated tumor markers (AFP >= 500 ng/mL or HCG >= 500 IU/L) with imaging consistent with GCT and biopsy not feasible/urgent therapy needed | Low risk ovarian immature teratoma: ovarian site; any stage/grade; pure or mixed immature/mature teratoma; may contain microscopic foci of yolk sac tumor (< 3 mm); AFP <= 1,000 ng/mL; beta-HCG normal; all ages | Low risk stage I non-seminoma MGCT: ovarian, testicular, or extragonadal; must contain yolk sac tumor, embryonal carcinoma, or choriocarcinoma (pure or mixed); all ages | Low risk stage I seminoma MGCT: testicular; histology only seminoma (may contain immature/mature teratoma); all ages | Standard risk 1: ovarian, testicular, or extragonadal; COG stage II–IV or FIGO IC–IV; must contain yolk sac tumor, embryonal carcinoma, or choriocarcinoma; age < 11 years | Standard risk 2 ovarian: COG stage II, III, III-X or FIGO IC–III; must contain yolk sac tumor, embryonal carcinoma, or choriocarcinoma; age >= 11 and < 25 years | Standard risk 2 testicular: COG stage II–IV, AJCC II–III, IGCCC good risk; must contain yolk sac tumor, embryonal carcinoma, or choriocarcinoma; post-op AFP < 1,000 ng/mL, beta-HCG < 5,000 IU/mL, LDH < 3 x ULN; age >= 11 and < 25 years | ECOG performance status 0–3 (Karnofsky for > 16 years; Lansky for <= 16 years) | Organ function requirements apply only to chemotherapy recipients (SR1 and SR2) | Adequate renal function: creatinine clearance or GFR >= 70 mL/min/1.73 m^2 within 7 days prior to enrollment or age/sex-specific serum creatinine threshold | Total bilirubin <= 2 x ULN (unless due to Gilbert's disease, malignant liver involvement, or vanishing bile duct syndrome) | AST and ALT < 3 x ULN (unless due to Gilbert's disease, malignant liver involvement, or vanishing bile duct syndrome) | Absolute neutrophil count >= 750/µL and platelets >= 75,000/µL within 7 days prior to enrollment | Standard risk arms: medically fit for protocol treatment with no contraindications to chemotherapy | AYA-HEARS substudy: age >= 11 and < 25 years; fluent in English; prior cisplatin- or carboplatin-based chemotherapy for any malignancy; followed for care at specified participating institutions","Stage I testicular cancer with prior primary retroperitoneal lymph node dissection | Pure ovarian or extragonadal dysgerminoma/seminoma | Pure mature teratoma | Pure immature teratoma with AFP >= 1000 ng/mL | Poor-risk germ cell tumor (age >= 11 years with COG stage IV ovarian, COG stage II–IV extragonadal, or IGCCC intermediate/poor-risk testicular) | Primary central nervous system germ cell tumor | Germ cell tumor with somatic malignant transformation | Spermatocytic seminoma | Prior systemic therapy for the current cancer diagnosis | Prior radiation therapy (except CNS irradiation for brain metastases in SR1 patients) | Significant pre-existing respiratory disease contraindicating bleomycin (ineligible for standard risk chemotherapy arms) | Pregnancy (for patients receiving chemotherapy) | Lactation with intent to breastfeed (for patients receiving chemotherapy) | Sexually active patients of reproductive potential not agreeing to effective contraception during study participation (for patients receiving chemotherapy)",No prior systemic therapy for current cancer diagnosis; No prior radiation therapy (except CNS irradiation for brain metastases in SR1 patients); Prior cisplatin- or carboplatin-based chemotherapy for another malignancy required for AYA-HEARS substudy eligibility,ALL,F,"The trial targets germ cell tumors (e.g., ovarian yolk sac, embryonal, choriocarcinoma), not epithelial clear cell ovarian carcinoma. Additionally, the patient is 36 with prior systemic therapy for the current diagnosis, which conflicts with the trial’s newly diagnosed/age-restricted cohorts.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; BRCA1 positive; Optimal debulking surgery performed; Received adjuvant carboplatin + paclitaxel + bevacizumab; Cytology-positive malignant pleural effusion at 5 months post-adjuvant,(none),Carboplatin; Paclitaxel; Bevacizumab; Optimal debulking surgery,Stage III,,36,years,female,(none),CORRECT,F,"Hard exclusion applies: disease mismatch (trial is for germ cell tumors; patient has clear cell ovarian carcinoma). Additionally, the trial explicitly excludes prior systemic therapy for the current diagnosis, which the patient had. F is appropriate.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT03120624,0.7592718005180359,Recurrent Clear Cell Ovarian Carcinoma,"Phase I Trial of Intravenous Administration of Vesicular Stomatitis Virus Genetically Engineered to Express Thyroidal Sodium Iodide Symporter (NIS) and Human Interferon Beta (hIFNb), in Patients With Metastatic or Recurrent Endometrial Cancer",PHASE1,18 years,Endometrial Carcinoma (recurrent); Endometrial Adenocarcinoma (recurrent); Endometrial Clear Cell Adenocarcinoma (recurrent); Endometrial Endometrioid Adenocarcinoma (recurrent); Endometrial Serous Adenocarcinoma (recurrent); Endometrial Undifferentiated Carcinoma (recurrent); Endometrial Mixed Cell Adenocarcinoma (recurrent); Uterine Carcinosarcoma (recurrent); Uterine Corpus Cancer (stage IV),"Stage IVA–IVB or recurrent endometrial carcinoma | Eligible histologies: endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, carcinosarcoma, adenocarcinoma NOS | Group A only: largest tumor diameter <= 5 cm (no maximum for Group B) | Life expectancy >= 12 weeks | ECOG performance status 0–2 | Prior chemotherapy, targeted therapy, external beam radiation, and/or hormonal therapy allowed if last treatment >= 4 weeks before registration | Vaginal brachytherapy may have been given at any time prior to registration","Availability of and patient acceptance of curative therapy | Active infection requiring treatment within 5 days prior to registration | Active or latent tuberculosis or hepatitis | Known untreated or symptomatic brain metastases | Chemotherapy < 4 weeks prior to registration | Targeted biologic therapy < 4 weeks prior to registration | Immunotherapy < 4 weeks prior to registration | Any prior viral or gene therapy | External beam radiotherapy < 4 weeks prior to registration | NYHA class III or IV heart failure, symptomatic coronary artery disease, or uncontrolled arrhythmias (atrial fibrillation or SVT) | Active CNS disorder, seizure disorder, known CNS disease, or neurologic symptoms | HIV infection, other immunodeficiency, or immunosuppression | History of hepatitis B or C or chronic hepatitis | Concurrent chemotherapy, immunotherapy, radiotherapy, or other investigational therapy | Treatment with systemic corticosteroids (excluding topical or inhaled) | Household contact with infants <= 15 months old or with known immunodeficiency | Pregnancy, nursing, or unwillingness to use effective contraception | Any condition deemed by the investigator to negatively impact treatment safety | Ongoing immunotherapy-related adverse events > grade 1 | Receipt of a live virus vaccine within 2 months prior to registration",Any number of prior chemotherapy regimens allowed; Any number of prior targeted therapies allowed; Prior external beam radiation therapy allowed; Prior hormonal therapy allowed; Last systemic treatment must be >= 4 weeks before registration; Vaginal brachytherapy may have been given at any time,FEMALE,F,"The trial is limited to metastatic or recurrent endometrial/uterine cancers, while the patient has recurrent clear cell ovarian carcinoma. This disease mismatch is a hard exclusion.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; BRCA1 positive; Optimal debulking surgery performed; Received adjuvant carboplatin + paclitaxel + bevacizumab; Cytology-positive malignant pleural effusion at 5 months post-adjuvant,(none),Carboplatin; Paclitaxel; Bevacizumab; Optimal debulking surgery,Stage III,,36,years,female,(none),CORRECT,F,"Disease mismatch: the trial is for endometrial/uterine cancers, while the patient has recurrent clear cell ovarian carcinoma. This is a hard exclusion per rubric, so F is correct.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT03123835,0.6027411222457886,Fistulizing Crohn's Disease,Outcome Analysis of Endoluminal Therapies for Gastrointestinal Conditions Compared to Current Treatment Paradigms,NA,18 years to 80 years,Achalasia; Gastric Fistula; Gastric Nec; Marginal Ulcer; Stenosis; Weight Gain After Primary Weight Loss Surgery,Age 18-80 years | Meets criteria for surgery for benign and/or malignant gastrointestinal pathology | Gastroesophageal reflux disease | Achalasia | Barrett's esophagus | Post-bariatric surgery conditions | Other gastrointestinal and postsurgical disorders,Adults unable to consent | Does not meet inclusion criteria or does not qualify for endoluminal treatment paradigms,(none),ALL,F,"Disease mismatch: the trial targets conditions like achalasia, GERD, Barrett’s esophagus, and post-bariatric issues, not Crohn’s disease or perianal fistulizing Crohn’s disease. Although age/sex fit, the patient’s disease is not included.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,F,"Disease mismatch is a hard exclusion. The trial targets achalasia/GERD/post-bariatric and related GI conditions, not Crohn’s disease or perianal fistulizing Crohn’s. Thus F is correct regardless of age/sex fit.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT03162432,0.6691051721572876,Fistulizing Crohn's Disease,High Dose Interval Vitamin D Supplementation in Patients With IBD Receiving Remicade,PHASE3,7 years to 25 years,Crohn Disease; Ulcerative Colitis,Existing diagnosis of inflammatory bowel disease | Age 0–25 years | Serum 25-OH vitamin D level 15–29 ng/mL within the last 8 weeks with no changes in vitamin D supplementation in the interim,"Pregnant | History of underlying kidney disease | History of granulomatous disease | Inability to take oral vitamin D | History of hypercalcemia | History of hypercalciuria | Currently taking an anti-epileptic medication | History of pre-existing liver disease (excluding primary sclerosing cholangitis, non-alcoholic fatty liver disease, or steatohepatitis)",(none),ALL,F,"The patient is 32 years old, which is outside the trial's eligible age range of 7–25 years. This age window conflict is a hard exclusion.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,F,"Age 32 exceeds trial maximum age of 25, which is a hard exclusion per the rubric. Grader correctly assigned F based on age window conflict.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT03199469,0.6317780017852783,Duchenne Muscular Dystrophy,"ASPIRO: A Phase 1/2/3, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Efficacy of AT132, an AAV8-Delivered Gene Therapy in X-Linked Myotubular Myopathy (XLMTM) Patients",PHASE2/PHASE3,up to 5 years,X-Linked Myotubular Myopathy,"Diagnosis of X-Linked Myotubular Myopathy with a genetically confirmed MTM1 mutation | Male | Age < 5 years at dosing | Requires mechanical ventilatory support | Part 1: Requires some mechanical ventilatory support (from full-time invasive to noninvasive CPAP/BiPAP during sleep) | Part 2: Requires invasive mechanical ventilatory support 20–24 hours/day at screening (confirmed by daytime polysomnography) | If requiring invasive mechanical ventilation, fitted with or willing to be fitted with a cuffed tracheostomy tube for some respiratory assessments | Ventilator PEEP < 8 cm H2O at screening | France: Weight >= 4.8 kg","Participation in an interventional study designed to treat X-Linked Myotubular Myopathy | Born < 35 weeks gestation and not term by corrected age | Positive AAV8 neutralizing antibody above protocol-specified titer threshold | Recent surgery (< 3 months before Day 1) or planned surgery that may confound data collection during the first 48 weeks | Clinically important condition other than X-Linked Myotubular Myopathy in the opinion of the investigator | Clinically significant underlying liver disease | Current clinically important respiratory infection or other active infection | Received pyridostigmine or any medication to treat X-Linked Myotubular Myopathy within 3 months before Day 1 | Received immune-modulating agents within 3 months before Day 1 (inhaled corticosteroids allowed); concomitant chronic medications must be stable for at least 4 weeks before dosing | Contraindication to prednisolone | Contraindication to study drug or its ingredients | Previous scoliosis repair surgery/procedure, or planned/expected scoliosis repair in the 12 months following Day 1 (Part 2) | Contractures, scoliosis, or other condition limiting potential to achieve unassisted sitting (Part 2) | Able to sit without assistance for at least 30 seconds at screening (Part 2) | Clinically important condition including CTCAE v4.03 Grade >= 2 anemia (< 10 g/dL hemoglobin) | Contraindication to ursodiol (ursodeoxycholic acid) | France: Prior diagnosis or history of cardiac arrhythmias, myocarditis, or any other cardiac disease | France: Contraindication to general anesthesia and to muscle biopsy procedures",Washout >= 3 months for pyridostigmine or any XLMTM-targeted medication before Day 1; Washout >= 3 months for immune-modulating agents before Day 1 (inhaled corticosteroids allowed); Concomitant chronic medications stable for >= 4 weeks before dosing,MALE,F,"The trial targets X-linked myotubular myopathy with a required MTM1 mutation and age <5 years, while the patient has Duchenne muscular dystrophy with a DMD exon 49-50 deletion and is 11 years old. This constitutes a disease mismatch and age/biomarker requirement conflicts, which are hard exclusions.",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,"Disease mismatch (Duchenne Muscular Dystrophy vs XLMTM) is a hard exclusion per rubric, and patient is also over the trial’s age limit (<5 years). The grader correctly assigned F and identified the key hard exclusions.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT03199469,0.5380009412765503,Amyotrophic Lateral Sclerosis,"ASPIRO: A Phase 1/2/3, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Efficacy of AT132, an AAV8-Delivered Gene Therapy in X-Linked Myotubular Myopathy (XLMTM) Patients",PHASE2/PHASE3,up to 5 years,X-Linked Myotubular Myopathy,"Diagnosis of X-Linked Myotubular Myopathy with a genetically confirmed MTM1 mutation | Male | Age < 5 years at dosing | Requires mechanical ventilatory support | Part 1: Requires some mechanical ventilatory support (from full-time invasive to noninvasive CPAP/BiPAP during sleep) | Part 2: Requires invasive mechanical ventilatory support 20–24 hours/day at screening (confirmed by daytime polysomnography) | If requiring invasive mechanical ventilation, fitted with or willing to be fitted with a cuffed tracheostomy tube for some respiratory assessments | Ventilator PEEP < 8 cm H2O at screening | France: Weight >= 4.8 kg","Participation in an interventional study designed to treat X-Linked Myotubular Myopathy | Born < 35 weeks gestation and not term by corrected age | Positive AAV8 neutralizing antibody above protocol-specified titer threshold | Recent surgery (< 3 months before Day 1) or planned surgery that may confound data collection during the first 48 weeks | Clinically important condition other than X-Linked Myotubular Myopathy in the opinion of the investigator | Clinically significant underlying liver disease | Current clinically important respiratory infection or other active infection | Received pyridostigmine or any medication to treat X-Linked Myotubular Myopathy within 3 months before Day 1 | Received immune-modulating agents within 3 months before Day 1 (inhaled corticosteroids allowed); concomitant chronic medications must be stable for at least 4 weeks before dosing | Contraindication to prednisolone | Contraindication to study drug or its ingredients | Previous scoliosis repair surgery/procedure, or planned/expected scoliosis repair in the 12 months following Day 1 (Part 2) | Contractures, scoliosis, or other condition limiting potential to achieve unassisted sitting (Part 2) | Able to sit without assistance for at least 30 seconds at screening (Part 2) | Clinically important condition including CTCAE v4.03 Grade >= 2 anemia (< 10 g/dL hemoglobin) | Contraindication to ursodiol (ursodeoxycholic acid) | France: Prior diagnosis or history of cardiac arrhythmias, myocarditis, or any other cardiac disease | France: Contraindication to general anesthesia and to muscle biopsy procedures",Washout >= 3 months for pyridostigmine or any XLMTM-targeted medication before Day 1; Washout >= 3 months for immune-modulating agents before Day 1 (inhaled corticosteroids allowed); Concomitant chronic medications stable for >= 4 weeks before dosing,MALE,F,"Disease mismatch: the study is for X-linked myotubular myopathy, not ALS. Additionally, the patient’s age (62) is outside the trial’s <5-year age limit.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,F,Disease mismatch (ALS vs XLMTM) and age outside trial limit (<5 years vs 62) are hard exclusions. The grader correctly applied the rubric and assigned F.,,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03237780,0.7901102304458618,Metastatic Urothelial Carcinoma,"A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination With Atezolizumab Compared to Atezolizumab Alone in Subjects With Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-Based Treatment is Not an Option",PHASE2,18 years,Urothelial Carcinoma of Bladder; Urothelial Carcinoma of Renal Pelvis; Urothelial Carcinoma of Ureter; Urothelial Carcinoma of Urethra,"Age >= 18 years | Histologically or cytologically confirmed locally advanced/unresectable and/or metastatic transitional cell urothelial carcinoma of the renal pelvis, ureter, urinary bladder, or urethra | Measurable disease per RECIST 1.1 | Post-radiotherapy lesions must show progression to be targetable | Archival or newly obtained invasive tumor tissue available for biomarker analysis; sequential biopsies at baseline and 6 weeks if safe | PD-L1 status determined centrally (SP142) available before randomization | New, progressive or recurrent disease during or within 12 months of platinum therapy, or first-line cisplatin-ineligible due to creatinine clearance < 60 mL/min, grade >= 2 hearing loss, and/or ECOG 2 | Up to two prior lines of chemotherapy for advanced disease allowed | Adequate recovery from prior anti-neoplastic treatment toxicities (generally <= grade 1; exceptions: any grade alopecia, grade 2 neuropathy, any grade hearing loss) | Brain metastases allowed if treated or stable, asymptomatic, and off steroids >= 28 days | Life expectancy >= 12 weeks | ECOG performance status 0-2 (Karnofsky >= 60%) | HIV-positive allowed if on stable HAART without CYP3A4 inducers/inhibitors, no need for opportunistic infection prophylaxis, CD4 > 250 cells/µL, and undetectable HIV viral load","Prior allogeneic bone marrow transplantation or prior solid organ transplantation | Chemotherapy within 3 weeks prior to cycle 1 day 1 | Radiotherapy or targeted therapy within 2 weeks prior to cycle 1 day 1 (6 weeks for nitrosoureas or mitomycin C) | Not recovered from prior therapy adverse events beyond allowable exceptions | Prior treatment with anti-PD-1 or anti-PD-L1 agents or prior eribulin | Prior anti-CTLA-4 unless >= 12 weeks from first dose, > 6 weeks from last dose, and no history of severe immune-related adverse events | Investigational agent within 4 weeks prior to cycle 1 day 1 | Systemic immunostimulatory agents (e.g., IFN-alpha, IL-2) within 6 weeks prior to cycle 1 day 1 | Systemic immunosuppressive medications within 2 weeks prior to cycle 1 day 1 (exceptions for acute low-dose use, inhaled steroids, mineralocorticoids) | Bisphosphonate therapy for symptomatic hypercalcemia | Requirement for RANKL inhibitor (e.g., denosumab) that cannot be discontinued before atezolizumab | Primary CNS malignancy or symptomatic CNS metastases | Hypersensitivity to Chinese hamster ovary cell products, humanized antibodies, fusion proteins, or eribulin | Additional malignancy that is progressing or requires active treatment (exceptions: certain skin cancers or in situ cancers in remission >= 2 years) | Congestive heart failure > NYHA class III | Unstable angina or myocardial infarction within 6 months | Serious cardiac arrhythmia | QTcF > 450 ms or risk factors/medications predisposing to torsade de pointes | Autoimmune disease requiring systemic treatment in past 2 years | Clinically significant illness requiring medical treatment within 8 weeks or clinically significant infection within 4 weeks of dosing | History of organ allograft | Active hepatitis B (HBsAg positive) or active hepatitis C infection (PCR positive) | Clinically significant liver disease (active hepatitis, cirrhosis, fatty liver, inherited liver disease) | History or risk of autoimmune diseases (e.g., SLE, RA, IBD, vasculitis, multiple sclerosis) unless meeting specified exceptions | Idiopathic pulmonary fibrosis, pneumonitis (including drug-induced), organizing pneumonia, or active pneumonitis on screening CT | Active tuberculosis | Severe infections within 4 weeks prior to cycle 1 day 1 | Signs or symptoms of infection within 2 weeks prior to cycle 1 day 1 | Oral or IV antibiotics within 2 weeks prior to cycle 1 day 1 (except prophylactic use) | Major surgery within 28 days prior to cycle 1 day 1 or anticipated during the study | Live attenuated vaccine within 4 weeks before cycle 1 day 1 or planned during treatment and up to 5 months after last atezolizumab dose | Uncontrolled intercurrent illness that would limit compliance | Pregnant or breastfeeding",Progression during or within 12 months of platinum-based therapy or first-line cisplatin-ineligible status; Up to two prior lines of chemotherapy for advanced disease allowed; No chemotherapy within 3 weeks before cycle 1 day 1; No radiotherapy or targeted therapy within 2 weeks before cycle 1 day 1 (6 weeks for nitrosoureas or mitomycin C); No investigational agents within 4 weeks before cycle 1 day 1; No systemic immunostimulatory agents within 6 weeks before cycle 1 day 1; No systemic immunosuppressive medications within 2 weeks before cycle 1 day 1 (with specified exceptions); Prior anti-CTLA-4 allowed with washout (>= 12 weeks from first dose and > 6 weeks from last dose) and no severe immune-related adverse events,ALL,F,"Explicit exclusion: the trial excludes any prior anti-PD-1/PD-L1 therapy, and the patient received pembrolizumab. Although the disease and setting match, this prior exposure makes the patient ineligible.",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),CORRECT,F,"The trial explicitly excludes patients with prior anti-PD-1/PD-L1 therapy, and the patient received pembrolizumab. This is a hard exclusion, so grade F is correct despite disease and setting alignment.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT03310905,0.6114654541015625,Fistulizing Crohn's Disease,Abdominal Wall Transplantation for the Reconstruction of Abdominal Wall Defects as Adjunct to Abdominal Solid Organ Transplantation,NA,18 years to 65 years,Abdominal Wall Defect; Abdominal Wall Fistula; Abdominal Wall Hernia; Abdominal Wall Injury; Bowel Transplant Failure; Liver Transplant Failure; Kidney Transplant Failure,Age 18-65 years | Able and willing to provide informed consent | For combined procedures: eligible for the non-vascularized composite allograft organ transplant at the center | Negative serum pregnancy test within 48 hours prior to transplant (women of childbearing potential),Active malignancy or history of malignancy that precludes transplantation | Pregnancy | Medical contraindications to general anesthesia | Ongoing substance abuse or history of untreated substance abuse,(none),ALL,F,"Disease mismatch: the trial targets abdominal wall defects/fistulas in the context of abdominal wall/solid organ transplantation, not fistulizing Crohn's disease or perianal fistulas. Therefore, the patient's condition is not included in the trial's disease scope.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,F,"Disease mismatch applies: the trial targets abdominal wall defects/fistulas and transplant-related conditions, not Crohn’s disease or perianal fistulas. This triggers a hard exclusion → F. The grader’s reasoning aligns with the rubric.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03473743,0.8215529322624207,Metastatic Urothelial Carcinoma,"A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Various Regimens of Erdafitinib in Subjects With Metastatic or Locally Advanced Urothelial Cancer",PHASE1/PHASE2,18 years,Urothelial Carcinoma (metastatic or locally advanced),"Histologic urothelial carcinoma (transitional cell); variant histologies allowed (glandular, squamous, sarcomatoid, micropapillary) | Metastatic or locally advanced disease | Measurable disease by RECIST v1.1 at baseline | Phase 1b erdafitinib + cetrelimab cohort: any number of prior therapy lines for metastatic disease allowed | Phase 1b erdafitinib + cetrelimab + platinum cohort: no prior systemic therapy for metastatic disease | Renal function to receive platinum: creatinine clearance >30 mL/min for carboplatin eligibility and >60 mL/min for cisplatin eligibility (Cockcroft-Gault) | Phase 2: no prior systemic therapy for metastatic disease and cisplatin-ineligible (ECOG 0-1 with at least one: CrCl <60 mL/min, grade >=2 neuropathy, grade >=2 hearing loss; or ECOG 2) | ECOG performance status as follows: Phase 1b erdafitinib + cetrelimab cohort ECOG 0-2; Phase 1b platinum cohort ECOG 0-1 for cisplatin and 0-2 for carboplatin; Phase 2 ECOG 0-2","Investigational agent or therapeutic clinical study participation within 30 days prior to Cycle 1 Day 1 | Phase 1b: prior nitrosoureas or mitomycin C within 6 weeks | Phase 1b erdafitinib + cetrelimab cohort: chemotherapy within 3 weeks of Cycle 1 Day 1 | Phase 1b platinum cohort and Phase 2: prior neoadjuvant/adjuvant chemotherapy allowed only if last dose >12 months before recurrence and no discontinuation due to drug-related toxicity | Prior PD-1, PD-L1, or PD-L2 therapy (exceptions: neoadjuvant/adjuvant >12 months without toxicity leading to discontinuation; PD-1 for non–muscle-invasive bladder cancer allowed) | Active malignancy requiring concurrent therapy other than urothelial cancer | Symptomatic central nervous system metastases",Phase 1b erdafitinib + cetrelimab cohort: any number of prior systemic therapy lines allowed for metastatic disease; Phase 1b erdafitinib + cetrelimab + platinum cohort: no prior systemic therapy for metastatic disease; Phase 2: no prior systemic therapy for metastatic disease (cisplatin-ineligible); Prior neoadjuvant/adjuvant chemotherapy allowed if last dose >12 months before recurrent disease and no discontinuation due to drug-related toxicity; Washout: investigational agents within 30 days prohibited; Washout: nitrosoureas or mitomycin C within 6 weeks prohibited (Phase 1b); Washout: chemotherapy within 3 weeks prohibited (Phase 1b erdafitinib + cetrelimab cohort),ALL,F,"Explicit exclusion: the trial disallows prior PD-1/PD-L1 therapy (except limited adjuvant/NMIBC), and the patient received pembrolizumab for metastatic disease. Despite disease and stage matching, this prior exposure makes the patient ineligible.",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),CORRECT,F,"The trial’s exclusion criteria explicitly disallow prior PD-1/PD-L1 therapy except limited adjuvant/NMIBC contexts. The patient received pembrolizumab for metastatic disease, triggering a hard exclusion. Disease, age, and sex otherwise match, but the explicit exclusion mandates grade F. The grader’s reasoning aligns with the rubric.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03474107,0.7917110323905945,Metastatic Urothelial Carcinoma,"An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)",PHASE3,18 years,Urothelial Carcinoma (locally advanced or metastatic),"Histologically or cytologically confirmed urothelial carcinoma of the bladder, renal pelvis, ureter, or urethra (including squamous differentiation or mixed types). | Radiographic progression or relapse during or after PD-1/PD-L1 checkpoint inhibitor for locally advanced or metastatic disease (progression after discontinuation due to toxicity allowed). | Received a platinum-containing regimen (cisplatin or carboplatin) in metastatic/locally advanced, neoadjuvant, or adjuvant setting; if adjuvant/neoadjuvant, progression within 12 months of completion. | Radiologically documented metastatic or locally advanced disease at baseline not amenable to curative resection. | ECOG 0–1. | ANC >= 1500/µL. | Platelet count >= 100000/µL. | Hemoglobin >= 9 g/dL. | Total bilirubin <= 1.5 x ULN (<= 3 x ULN with Gilbert's disease). | ALT <= 2.5 x ULN. | AST <= 2.5 x ULN. | Creatinine clearance >= 30 mL/min.","Preexisting sensory or motor neuropathy grade >= 2. | Active central nervous system metastases (allowed if treated and clinically stable >= 6 weeks, no new or enlarged lesions, no leptomeningeal disease, and on <= 20 mg/day prednisone equivalent if steroids required). | Ongoing clinically significant toxicity grade >= 2 from prior therapy (except alopecia; <= grade 2 hypothyroidism or panhypopituitarism on replacement allowed). | Ongoing immunotherapy-related colitis, uveitis, or pneumonitis, or requirement for high-dose steroids > 20 mg/day prednisone equivalent. | Prior treatment with enfortumab vedotin or other MMAE-based antibody-drug conjugates. | Prior chemotherapy for urothelial cancer including all available control-arm agents (docetaxel and paclitaxel ± vinflunine depending on region). | More than 1 prior chemotherapy regimen for locally advanced or metastatic urothelial cancer (including adjuvant or neoadjuvant if recurrence within 12 months). | History of another malignancy within 3 years (exceptions include nonmelanoma skin cancer, certain localized prostate cancer, and carcinoma in situ completely resected). | Active systemic infection requiring antimicrobial therapy. | Active hepatitis B or active hepatitis C infection. | Known HIV infection. | Cerebrovascular event (stroke or TIA), unstable angina, myocardial infarction, or NYHA class III–IV heart failure within 6 months. | Radiotherapy or major surgery within 4 weeks before first dose. | Chemotherapy, biologics, investigational agents, or immunotherapy not completed >= 2 weeks before first dose. | Hypersensitivity to enfortumab vedotin or to biopharmaceuticals produced in CHO cells. | Hypersensitivity to docetaxel (including polysorbate 80), paclitaxel (including macrogolglycerol ricinoleate 35), or vinflunine (including other vinca alkaloids). | Active keratitis or corneal ulceration. | Other underlying medical condition that would impair ability to receive or tolerate treatment and follow-up. | Uncontrolled diabetes mellitus within 3 months (HbA1c >= 8% or HbA1c 7% to < 8% with polyuria or polydipsia).","Prior PD-1/PD-L1 checkpoint inhibitor required for locally advanced or metastatic disease.; Prior platinum-containing regimen (cisplatin or carboplatin) required in metastatic/locally advanced, neoadjuvant, or adjuvant setting.; No more than 1 prior chemotherapy regimen for locally advanced or metastatic urothelial cancer.; Washout: radiotherapy or major surgery completed >= 4 weeks before first dose.; Washout: chemotherapy, biologics, investigational agents, or immunotherapy completed >= 2 weeks before first dose.",ALL,F,"The trial explicitly excludes prior treatment with enfortumab vedotin, which the patient has received. Therefore the patient is ineligible.",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),CORRECT,F,"The trial explicitly excludes patients with prior enfortumab vedotin, which the patient received (EV + pembrolizumab). This is a hard exclusion per the rubric, so an F is correct.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT03482479,0.615860641002655,Rheumatoid Arthritis,Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis,PHASE2,18 years,Giant Cell Arteritis; Takayasu Arteritis; Polyarteritis Nodosa; Granulomatosis With Polyangiitis; Microscopic Polyangiitis; Eosinophilic Granulomatosis With Polyangiitis,"Diagnosis of giant cell arteritis, Takayasu arteritis, polyarteritis nodosa, granulomatosis with polyangiitis, microscopic polyangiitis, or eosinophilic granulomatosis with polyangiitis per specified criteria | PROMIS Global Physical Health normalized score <= 40 at baseline | Vasculitis in remission or very low disease activity (Physician Global Assessment 0–1) for >= 12 weeks | Stable immunosuppressive therapy (including prednisone) related to vasculitis for >= 12 weeks | No change in medications in the past 12 weeks made with the expectation of improving pain, fatigue, or mood | No plan to change medication or non-pharmacologic treatment regimen likely to affect pain, fatigue, mood, or vasculitis activity during the next 12 weeks | Age >= 18 years","Change in any medication related to control of vasculitis, pain, fatigue, or mood within the past 12 weeks | Use of another investigational agent within 30 days of enrollment | Current use of any opioid agonist including tramadol or buprenorphine/naloxone | Change in vasculitis activity in the past 12 weeks (change in Physician Global Assessment > 1) | Baseline PROMIS Global Physical Health normalized score > 40 | New major medical problem or surgery in the past 12 weeks | Pregnancy or breastfeeding | Schizophrenia or bipolar disorder | Poorly controlled depression or anxiety (PHQ-9 >= 20) | Liver cirrhosis | Significant kidney disease (GFR < 30 mL/min)",Stable immunosuppressive therapy (including prednisone) allowed if stable for >= 12 weeks; >= 30-day washout from other investigational agents,ALL,F,"Disease mismatch: the trial targets specific vasculitides (e.g., GCA, GPA, MPA), while the patient has rheumatoid arthritis.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Correct: The patient has rheumatoid arthritis, while the trial includes only specific vasculitides. This is a hard disease mismatch per the rubric, warranting an immediate F.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03520491,0.8204485177993774,Metastatic Urothelial Carcinoma,A Pilot Study to Evaluate the Safety of Neoadjuvant Nivolumab Alone or in Combination With Ipilimumab for Cisplatin-Ineligible Patients With Muscle Invasive Bladder Cancer (CA209-9DJ),PHASE2,18 years,"Bladder Cancer (urothelial, muscle-invasive); Upper Tract Urothelial Carcinoma","Histologically confirmed urothelial carcinoma of the bladder; variant histology allowed if predominantly urothelial. | Muscle-invasive bladder cancer (Cohorts 1–3): cT2–T4a cN0 cM0 by cystoscopy and imaging; cT4a with prostatic stromal invasion eligible without cystoscopic muscle invasion. | Upper tract urothelial carcinoma (Cohort U): High-grade urothelial carcinoma of ureter or renal pelvis with T2–T4a N0/x M0 and positive selective urinary cytology; hydronephrosis associated with tumor considered invasive; variant histology allowed if predominantly urothelial. | Cisplatin-ineligible: Creatinine clearance >= 30 mL/min and < 60 mL/min, or grade >= 2 hearing loss, or grade >= 2 peripheral neuropathy. | Availability of tumor block or 30 unstained slides from diagnosis of muscle-invasive disease (fewer allowed per PI discretion). | Karnofsky performance status >= 70%. | Medically appropriate candidate for radical cystectomy. | Age >= 18 years. | Baseline laboratory values meet protocol thresholds.","Prior systemic chemotherapy for urothelial cancer. | Prior immune checkpoint inhibitor therapy for non–muscle-invasive bladder cancer. | Prior bladder-directed radiotherapy (Cohorts 1–3). | Active autoimmune disease excluding permitted conditions (e.g., type 1 diabetes, residual hypothyroidism on replacement, certain skin disorders not requiring systemic therapy, asymptomatic autoantibodies, or conditions not expected to recur). | Systemic corticosteroids > 10 mg/day prednisone equivalent or other immunosuppressive medications within 14 days of first dose (except inhaled/topical/adrenal replacement). | Unstable angina. | NYHA class II or greater congestive heart failure. | Myocardial infarction within 6 months. | Stroke within 6 months. | Bleeding diathesis or coagulopathy (therapeutic anticoagulation allowed if on stable dose). | Major surgical procedure within 28 days prior to study (TURBT permitted). | Serious, non-healing wound, ulcer, or bone fracture. | Another active malignancy within 2 years, except definitively treated early-stage cancers with negligible risk of recurrence. | Prior therapy targeting T-cell co-stimulation/checkpoint pathways (e.g., anti–PD-1, anti–PD-L1, anti–PD-L2, anti–CTLA-4, anti–CD137); prior IL-2 permitted. | Intravesical BCG within 6 weeks of treatment. | Positive hepatitis B surface antigen or positive hepatitis C RNA/antibody indicating infection. | Known HIV infection or AIDS. | History of severe hypersensitivity to monoclonal antibodies or study drug components. | Pregnant or breastfeeding. | Women of childbearing potential not using acceptable contraception during treatment and for at least 23 weeks after last dose. | Male subjects unwilling to use contraception during treatment and for at least 31 weeks after last dose.",Intravesical BCG allowed with washout >= 6 weeks,ALL,F,"Ineligible: the trial is a neoadjuvant study for non-metastatic muscle-invasive bladder cancer, while the patient has metastatic disease after second-line therapy. Additionally, the protocol explicitly excludes prior systemic chemotherapy and prior PD-1/PD-L1 therapy, both of which the patient has received (gemcitabine/cisplatin and pembrolizumab).",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),CORRECT,F,"Correct F. The trial requires non-metastatic, neoadjuvant setting (cT2–T4a N0 M0, cystectomy candidate), which the patient definitively lacks (metastatic post–second-line). Additionally, explicit exclusions of prior systemic chemotherapy and prior PD-1 therapy apply. Multiple hard exclusions → F per rubric.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT03520751,0.5397878885269165,Amyotrophic Lateral Sclerosis,Phase I/IIa Trial Evaluating scAAV1.tMCK.NTF3 for Treatment of Charcot-Marie-Tooth Neuropathy Type 1A (CMT1A),PHASE1/PHASE2,18 years to 35 years,Charcot-Marie-Tooth Neuropathy Type 1A,Age 18–35 years | Diagnosis of Charcot-Marie-Tooth Neuropathy Type 1A | 1.5 Mb duplication at 17p11.2 inclusive of the PMP22 gene | Weakness of ankle dorsiflexion muscle with full ROM against gravity and able to stand on heels >=3 seconds | Abnormal nerve conduction velocities,"Active viral infection (HIV, Hepatitis B, Hepatitis C, herpesvirus, or adenovirus) | Ongoing immunosuppressive therapy or immunosuppressive therapy within 6 months (e.g., corticosteroids, cyclosporine, tacrolimus, methotrexate, cyclophosphamide, intravenous immunoglobulin) | Persistent leukopenia or leukocytosis (WBC <=3.5 K/µL or >=15 K/µL) | Absolute neutrophil count <1.5 K/µL | AAV1 binding antibody titer >=1:50 | Circulating anti-NT-3 antibody titer >=1:50 | Investigational medication within 30 days before study drug | GGT >3 x ULN | Total bilirubin >=3.0 mg/dL | Creatinine >=1.8 mg/dL | Hemoglobin <8 g/dL or >18 g/dL | Ankle contractures or prior surgeries preventing proper muscle strength testing | Pregnancy or lactation | Limb surgery within the past 6 months | Severe infection (e.g., pneumonia, pyelonephritis, meningitis) within 4 weeks before gene transfer | Concomitant illness or chronic drug treatment that creates unnecessary risks for gene transfer, per investigator judgment",No investigational medication within 30 days before study drug,ALL,F,"Disease mismatch: the trial targets Charcot-Marie-Tooth neuropathy type 1A (with PMP22 duplication), while the patient has ALS. Additionally, the patient is 62 years old, exceeding the trial’s 18–35 age window.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,F,"Correct: Disease mismatch (ALS vs CMT1A) is a hard exclusion; additionally, the patient’s age (62) is outside the trial’s 18–35 window—another hard exclusion. Either triggers an F.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT03523858,0.5266870260238647,Amyotrophic Lateral Sclerosis,"An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients With Progressive Multiple Sclerosis",PHASE3,18 years to 65 years,Progressive Multiple Sclerosis,Definite diagnosis of progressive multiple sclerosis (per McDonald 2010 PPMS or Lublin 2014 PMS criteria) | EDSS <= 6.5 at screening | Documented disability progression independent of relapse within the prior 2 years | Meets at least one predefined criterion for relapse-independent disability progression in the last 2 years,"Relapsing-remitting multiple sclerosis at screening | Inability to complete MRI | Gadolinium intolerance | Other neurological disorder present | Pregnancy | Lactation | Concomitant disease requiring chronic systemic corticosteroids or immunosuppressants | History or active primary or secondary immunodeficiency | Lack of peripheral venous access | Significant or uncontrolled somatic disease | Active infection not resolved before first infusion | Severely immunocompromised state | Active malignancy or under active surveillance for recurrence | History of progressive multifocal leukoencephalopathy (PML) | Positive hepatitis B screening | CD4 count <250/µL | ANC <1.0 x 10^3/µL | AST or ALT >= 3 x ULN with total bilirubin > 2 x ULN or clinical jaundice | Hypersensitivity to ocrelizumab or excipients | Prior ocrelizumab treatment | Prior B-cell targeted therapies (e.g., atacicept, tabalumab, belimumab, ofatumumab, obinutuzumab); rituximab allowed only if last dose >6 months before infusion, discontinued for AE or immunogenicity, and B cells above LLN | Any prior alemtuzumab, total body irradiation, or bone marrow transplantation | Prior natalizumab without PML exclusion per algorithm | Contraindications or intolerance to oral or IV corticosteroids (including IV methylprednisolone) | Systemic corticosteroid therapy within 4 weeks prior to screening | Required vaccines not completed >=6 weeks before first infusion; avoid live vaccines during treatment and follow-up until B-cell repletion | Prior daclizumab, ozanimod, or fingolimod within 8 weeks | Prior siponimod within 2 weeks | Fampridine/dalfampridine or other symptomatic MS treatment unless on a stable dose >=30 days before screening | Prior natalizumab within 12 weeks | Prior teriflunomide within 12 weeks unless accelerated elimination performed | Prior azathioprine, cyclophosphamide, mycophenolate mofetil, or methotrexate within 12 weeks | Investigational agent within 24 weeks or 5 half-lives (whichever is longer) or experimental MS procedures | Prior mitoxantrone, cyclosporine, or cladribine within 96 weeks | Teriflunomide within the last 2 years unless plasma <0.02 mg/L or accelerated elimination performed","No prior ocrelizumab; No prior B-cell targeted therapies (atacicept, tabalumab, belimumab, ofatumumab, obinutuzumab); prior rituximab allowed if last dose >6 months, stopped for AE/immunogenicity, and B cells > LLN; No prior alemtuzumab, total body irradiation, or bone marrow transplant; No natalizumab unless PML excluded per algorithm; washout >=12 weeks; No systemic corticosteroids within 4 weeks prior to screening; Complete required vaccinations >=6 weeks before first infusion; avoid live vaccines during treatment and follow-up until B-cell repletion; No daclizumab, ozanimod, or fingolimod within 8 weeks; No siponimod within 2 weeks; Fampridine/dalfampridine or other symptomatic MS treatments must be on stable dose >=30 days before screening; No teriflunomide within 12 weeks unless accelerated elimination (cholestyramine or activated charcoal) performed; No azathioprine, cyclophosphamide, mycophenolate mofetil, or methotrexate within 12 weeks; No investigational agents within 24 weeks or 5 half-lives (whichever longer); No mitoxantrone, cyclosporine, or cladribine within 96 weeks; If teriflunomide within last 2 years, require plasma <0.02 mg/L or accelerated elimination before screening",ALL,F,"Disease mismatch: the trial is for progressive multiple sclerosis, while the patient has amyotrophic lateral sclerosis (ALS), which is not included.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,F,"Disease mismatch is a hard exclusion: trial targets progressive multiple sclerosis, patient has ALS. F is appropriate per rubric.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT03531645,0.71271812915802,Recurrent Clear Cell Ovarian Carcinoma,A Pilot Phase II Study of Neoadjuvant Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma,PHASE2,18 years,Low-Grade Serous Ovarian Carcinoma; Primary Peritoneal Carcinoma; Fallopian Tube Carcinoma,"Stage III or IV low-grade serous ovarian, primary peritoneal, or fallopian tube carcinoma deemed unlikely to be optimally cytoreduced and recommended for neoadjuvant therapy | Histologic diagnosis confirmed by surgical or core biopsy | Measurable disease by RECIST v1.1 | Women aged >= 18 years | ECOG performance status 0–1 | Resolution of acute toxic effects of prior therapy or surgery to CTCAE v4.03 grade <= 1 | Pre/perimenopausal women amenable to treatment with goserelin","Pregnant or breastfeeding | Serious preexisting medical conditions precluding participation (e.g., interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, history of major gastric or small bowel resection, Crohn's disease, ulcerative colitis, or baseline grade >= 2 diarrhea) | Current use of potent CYP3A4 inhibitors or inducers | Current use of drugs known to prolong the QT interval | Another malignancy within 3 years except adequately treated basal or squamous cell skin cancer or carcinoma in situ of the cervix | Previous chemotherapy or hormonal therapy for ovarian cancer | Known hepatitis B, hepatitis C, or HIV infection | Inability or unwillingness to swallow pills | Active infection requiring IV antibiotics or other uncontrolled intercurrent illness requiring hospitalization | History of syncope of cardiovascular etiology, ventricular arrhythmia, or sudden cardiac arrest | Prior hematopoietic stem cell or bone marrow transplantation | Coagulation abnormalities or anticoagulant therapy precluding intramuscular injections | Hypersensitivity to fulvestrant or abemaciclib or their excipients | Pre/perimenopausal women with hypersensitivity to GnRH agonists",Resolution of prior therapy or surgical toxicities to CTCAE v4.03 grade <=1,FEMALE,F,"Disease mismatch: the trial enrolls low‑grade serous ovarian (or related) carcinomas, while the patient has clear cell ovarian carcinoma. The study also targets a neoadjuvant, treatment‑naïve setting and excludes prior ovarian chemotherapy, which the patient has received.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; BRCA1 positive; Optimal debulking surgery performed; Received adjuvant carboplatin + paclitaxel + bevacizumab; Cytology-positive malignant pleural effusion at 5 months post-adjuvant,(none),Carboplatin; Paclitaxel; Bevacizumab; Optimal debulking surgery,Stage III,,36,years,female,(none),CORRECT,F,"Hard exclusion applies: disease mismatch (clear cell vs low‑grade serous) and explicit exclusion of any prior ovarian chemotherapy, which the patient has received. The grader correctly assigned F and cited appropriate reasons.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT03542383,0.597878098487854,Dementia,Treatment of Memory Disorders in Gulf War Illness With High Definition Transcranial Direct Cortical Stimulation,NA,45 years to 78 years,Gulf War Illness; Memory Disorder,Right-handed,History of dementia | Moderate to severe traumatic brain injury | Brain tumor | Present or past drug abuse | Stroke | Cerebrovascular abnormalities in the brain | Parkinson's disease | Huntington's disease | Multiple sclerosis | Amphetamines use | Levodopa use | Carbamazepine use | Sulpiride use | Pergolide use | Lorazepam use | Rivastigmine use | Dextromethorphan use | D-cycloserine use | Flunarizine use | Ropinirole use | Citalopram use | Cardiac pacemaker | Implanted medication pump | Severe heart disease | Metal objects in or near the head that cannot be safely removed,(none),ALL,F,"The trial explicitly excludes individuals with a history of dementia, which the patient has. This is a hard exclusion regardless of other factors.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,"The trial explicitly excludes participants with a history of dementia, which the patient has. This is a hard exclusion per the rubric, warranting an immediate F regardless of other factors. The grader’s reasoning and grade are correct.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT03570931,0.5509370565414429,Amyotrophic Lateral Sclerosis,A Prospective Open-label Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy,PHASE2/PHASE3,18 months to 10 years,Infantile Neuroaxonal Dystrophy,Age 18 months to 10 years | Medical history consistent with classic infantile neuroaxonal dystrophy (onset of symptoms between 6 months and 3 years) | Homozygous for PLA2G6 deficiency (variant alleles may be mixed heterozygotes) | Impairment in at least 2 assessed categories at baseline,"Received treatment with other experimental therapies within the last 30 days prior to the first dose | Requiring mechanical ventilation, other than positive air pressure support for sleep apnea | Life expectancy < 1 year | Diagnosis of atypical neuroaxonal dystrophy (ANAD)",Washout >= 30 days from other experimental therapies before first dose,ALL,F,"Hard exclusion: the trial targets infantile neuroaxonal dystrophy (not ALS) and restricts age to 18 months–10 years, while the patient is 62.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,F,Disease mismatch (ALS vs Infantile Neuroaxonal Dystrophy) and age window conflict (62 years vs 18 months–10 years) are both hard exclusions. Grade F is correct and reasoning is appropriate.,,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03582475,0.7540104389190674,Metastatic Urothelial Carcinoma,Phase Ib Trial of Pembrolizumab (MK-3475) With Platinum-Based Chemotherapy in Small Cell/Neuroendocrine Cancers of Urothelium and Prostate,PHASE1,18 years,Small Cell Bladder Carcinoma; Small Cell Urethral Carcinoma; Small Cell Ureter Carcinoma; Small Cell Prostate Carcinoma; Prostate Neuroendocrine Neoplasm,"Histologically confirmed locally advanced or metastatic small cell cancer of the bladder, urethra, or upper urinary tract, or primary small cell/neuroendocrine prostate cancer | Measurable disease per RECIST 1.1 | Archival or newly obtained tumor tissue available (FFPE preferred) | ECOG performance status 0–1 | Adequate hematologic and organ function per protocol labs","Disease suitable for curative local therapy | Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, or other T-cell co-regulatory agents (e.g., CTLA-4, OX40, CD137) | Prior systemic anticancer therapy within 4 weeks before first dose or unresolved toxicities > grade 1 (except <= grade 2 neuropathy) | Major surgery without adequate recovery prior to study treatment | Radiotherapy within 2 weeks before start of study treatment (1-week washout allowed for palliative <= 2 weeks non-CNS radiation) | Live vaccine within 30 days before first dose | Participation in another investigational study or use of an investigational device within 4 weeks before first dose | Immunodeficiency or chronic systemic steroids > 10 mg prednisone equivalent daily or other immunosuppressive therapy within 7 days before first dose | Another active malignancy requiring treatment within the past 3 years (except certain skin cancers or carcinoma in situ) | Active CNS metastases or carcinomatous meningitis (previously treated stable brain metastases allowed without steroids) | Severe hypersensitivity to pembrolizumab | Active autoimmune disease requiring systemic treatment within the past 2 years | History of pneumonitis requiring steroids or current pneumonitis | Active infection requiring systemic therapy | Known HIV infection | Active hepatitis B or active hepatitis C infection | Active tuberculosis | Pregnant or breastfeeding","Cohort 1: No prior systemic chemotherapy for locally advanced/metastatic urothelial carcinoma; prior platinum-based chemotherapy allowed if recurrence > 12 months after completion; Cohort 2: No prior systemic chemotherapy for primary small cell prostate cancer; prior platinum-based chemotherapy allowed if recurrence > 12 months after completion; Cohort 2: Prior mCRPC treatments allowed, including up to 2 prior chemotherapy agents if > 6 months since last dose (docetaxel used twice counts as 1 therapy); Cohort 2: Ongoing androgen deprivation therapy with up to 2 second-generation hormonal agents (e.g., abiraterone, enzalutamide) permitted; Cohort 2: Ongoing bone-targeted therapy (denosumab or zoledronic acid) permitted; Cohort 2: Prior sipuleucel-T allowed if completed > 4 weeks before enrollment; Washout: No systemic anticancer therapy (including investigational agents) within 4 weeks before first dose; Washout: No radiotherapy within 2 weeks before start (1-week washout allowed for palliative <= 2 weeks non-CNS)",ALL,F,"Disease mismatch: the trial requires small cell/neuroendocrine bladder/urothelial/prostate cancer, while the patient has metastatic urothelial carcinoma without small cell histology. Additionally, the trial excludes prior PD-1 therapy and the patient received pembrolizumab.",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),CORRECT,F,Correct: Hard exclusions apply. The trial targets small cell/neuroendocrine variants (disease mismatch with metastatic urothelial carcinoma) and explicitly excludes prior PD-1 therapy; the patient received pembrolizumab. Either alone warrants an F.,,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03601455,0.7949587106704712,Metastatic Urothelial Carcinoma,"Phase II Study of Radiation Therapy and Anti-PD-L1 Checkpoint Inhibitor (Durvalumab) With or Without Anti-CTLA-4 Inhibition (Tremelimumab) in Patients With Unresectable, Locally Advanced, or Metastatic Urothelial Bladder Cancer That Are Ineligible or Refusing Chemotherapy",PHASE2,18 years,Urothelial Bladder Cancer (unresectable or metastatic),"cT2–T4 or metastatic (N+ or M+) urothelial bladder cancer; mixed histology allowed if predominantly urothelial. | Localized disease: patient refuses cystectomy or is not an ideal cystectomy candidate. | If metastatic: intact, symptomatic bladder tumor appropriate for palliative bladder RT. | Measurable metastatic disease per RECIST v1.1 (>=1 non-irradiated lesion; longest diameter >=10 mm or lymph node short axis >=15 mm). | ECOG performance status 0–1. | Life expectancy >= 12 weeks. | Ineligible for or refusal of cisplatin-based chemotherapy (CrCl < 60 mL/min, CTCAE grade >=2 hearing loss, CTCAE grade >=2 peripheral neuropathy, NYHA class III heart failure, or other investigator-determined reason). | Provision of archived tumor tissue within 12 months or willingness to undergo pre-treatment fresh tumor biopsy; additional older archival tissue requested if available. | Hemoglobin >= 9.0 g/dL. | ANC >= 1500/µL. | Platelets >= 100000/µL. | Total bilirubin <= 1.5 x ULN (Gilbert syndrome allowed per physician). | AST/ALT <= 2.5 x ULN (<= 5 x ULN if liver metastases). | Creatinine clearance > 30 mL/min (Cockcroft-Gault or 24-hour collection). | Women of childbearing potential: negative pregnancy test; or non-reproductive potential as defined.","ECOG performance status >=2. | Prior cystectomy or definitive radiotherapy to the bladder. | Active or prior autoimmune or inflammatory disorders (e.g., myasthenia gravis, autoimmune hepatitis, SLE, rheumatoid arthritis, IBD, sarcoidosis, vasculitis, multiple sclerosis) with specified exceptions. | HIV infection, active hepatitis B or active hepatitis C (exceptions for resolved/past HBV and HCV RNA-negative). | History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced or idiopathic pneumonitis, or active pneumonitis on screening imaging. | Prior radiation therapy to the abdomen or pelvis, including bladder, prostate, or rectum. | Concurrent systemic chemotherapy, biologic, or hormonal therapy for cancer treatment (non-cancer hormonal therapy allowed). | Major surgery within 28 days before first dose (biopsy and TURBT allowed). | Another primary malignancy not meeting allowed exceptions. | QTcF >= 470 ms or clinically significant ECG abnormalities. | Current or prior immunosuppressive medication within 14 days before first dose (with specified corticosteroid exceptions). | History of primary immunodeficiency. | History of allogeneic organ transplant. | Hypersensitivity to durvalumab, tremelimumab, or their combination/excipients. | Uncontrolled intercurrent illness (e.g., infection, CHF, uncontrolled hypertension, unstable angina, arrhythmia, active PUD/gastritis, bleeding diathesis, psychiatric/social conditions limiting compliance). | Active infection including tuberculosis. | History of leptomeningeal carcinomatosis. | Receipt of live attenuated vaccine within 30 days before study entry or within 30 days of receiving study drugs. | Brain metastases or spinal cord compression unless stable, asymptomatic, and off steroids for >=14 days prior to treatment. | Uncontrolled seizures. | Pregnant or breastfeeding; unwilling to use effective contraception for the required period.",Prior systemic therapies allowed with washout >= 45 days,ALL,F,"The trial explicitly excludes patients with prior cystectomy, and this patient underwent cystectomy. Additionally, the metastatic cohort requires an intact symptomatic bladder tumor for palliative RT, which the patient lacks.",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),CORRECT,F,"Correct F: The trial’s exclusion criteria list prior cystectomy, which the patient has—a hard exclusion. Additionally, the metastatic cohort requires an intact symptomatic bladder tumor for palliative RT, which the patient lacks. Either point warrants F per rubric.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT03613116,0.5806409120559692,Dementia,Phase II RCT of High-dose Vitamin D Supplements in Older Adults,PHASE2,65 years to 90 years,Mild Cognitive Impairment; Alzheimer Disease (mild); Vitamin D Deficiency,"Age 65-90 years | Serum 25-hydroxyvitamin D < 20 ng/mL at screening | Fluent in English or Spanish | Willingness to be randomized to high-dose vs standard-dose vitamin D | Education-adjusted Montreal Cognitive Assessment (MOCA) score 12-30 at baseline | Consensus clinical diagnosis of No Cognitive Impairment, Mild Cognitive Impairment, or mild Alzheimer disease dementia | No Cognitive Impairment subgroup: MOCA >= 23 if education > 12 years or MOCA > 20 if education < 12 years | No Cognitive Impairment subgroup: CDR global usually 0; CDR may be 0.5 if Petersen MCI criteria not met and CDR-Sum of Boxes < 1.0 | Mild Cognitive Impairment subgroup: Amnestic MCI (single- or multiple-domain) with standardized memory scores > 1.5 SDs below average | Mild Cognitive Impairment subgroup: Global CDR = 0.5 | Mild Cognitive Impairment subgroup: MOCA > 20 if education > 12 years or MOCA > 17 if education < 12 years | Mild Alzheimer disease dementia subgroup: Probable or possible Alzheimer disease | Mild Alzheimer disease dementia subgroup: Global CDR = 1 | Mild Alzheimer disease dementia subgroup: MOCA > 15 if education > 12 years or MOCA > 12 if education < 12 years | Stable doses (> 6 weeks) of Alzheimer disease therapies (e.g., donepezil, memantine) permitted with no planned dose changes during the trial","Inadequate vision, hearing, or literacy to complete psychometric testing | Albumin < 3.3 g/dL | Alanine aminotransferase > 2 x ULN | Bilirubin > 2 x ULN | Aspartate aminotransferase > 3 x ULN | Serum creatinine > 1.7 mg/dL | Glomerular filtration rate < 40 mL/min/1.73 m2 | Hypercalcemia | Current serious or unstable medical illness that could interfere with safe participation or life expectancy < 4 years | History of recurrent renal stones | Unable to undergo MRI scanning | History of osteoporosis with screening 25-hydroxyvitamin D < 12 ng/mL | History of chronic psychiatric illness (e.g., schizophrenia, bipolar disorder) | Major depression within the last 2 years or current GDS > 6 | Recent suicide attempt or suicidal ideation | Serious infectious disease affecting the brain within 5 years | Head trauma within 5 years with > 10 minutes loss of consciousness or persistent cognitive deficit | Chronic alcohol or drug abuse/dependence within the past 5 years | Primary or recurrent malignant disease within the last 5 years (except resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or non-metastatic prostate cancer with normal PSA post-treatment) | Poor venous access precluding multiple blood draws | Regular use of benzodiazepines | Regular use of antipsychotics | Regular use of narcotics | Regular use of cholinesterase inhibitors (non-stable dosing) | Regular use of memantine (non-stable dosing) | Regular use of anti-epileptic drugs | Planned changes in doses of CNS-active medications during the trial | Plans to change dosage of any vitamin supplement during the study (unless to treat a documented deficiency) | Current participation in a clinical trial involving experimental Alzheimer disease therapies | Pregnancy or planning pregnancy during the trial | Inability to swallow oral capsules | History of multiple strokes | More than two incidental infarcts on structural MRI",Stable acetylcholinesterase inhibitor therapy >= 6 weeks allowed; Stable memantine therapy >= 6 weeks allowed; Stable SSRI or SNRI antidepressant doses allowed,ALL,F,"The trial only includes participants with no impairment, MCI, or mild Alzheimer disease dementia, whereas the patient has moderate-stage dementia (MMSE 19), a required stage mismatch. The trial also requires vitamin D deficiency (<20 ng/mL), which is not documented.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,"F is appropriate due to hard disease/cohort mismatch: the trial only enrolls no impairment/MCI/mild Alzheimer’s dementia, while the patient has moderate dementia—no trial cohort fits. Age/sex are fine; vitamin D deficiency is required but unknown and should not drive F. The grader’s rationale correctly focused on the stage/cohort exclusion, yielding F.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT03639701,0.5396581888198853,Duchenne Muscular Dystrophy,Deoxythymidine and Deoxycytidine Treatment for Thymidine Kinase 2 (TK2) Deficiency,PHASE1/PHASE2,Not specified,Thymidine Kinase 2 Deficiency; Mitochondrial DNA Depletion Syndrome 2 (myopathic),Genetically confirmed TK2 deficiency | Symptomatic due to TK2 deficiency | Single-gene disease; absence of polygenic disease | Hematocrit within normal range for age,Clinical history of bleeding or abnormal PT/PTT | Hepatic insufficiency with LFTs > 2 x ULN | Renal insufficiency requiring dialysis | Concurrent inborn error of metabolism (other than TK2 deficiency) | Severe end-organ hypoperfusion secondary to cardiac failure resulting in lactic acidosis,(none),ALL,F,"This study enrolls patients with genetically confirmed TK2 deficiency, while the patient has Duchenne muscular dystrophy with a DMD exon 49-50 deletion. Therefore, there is a disease mismatch (hard exclusion).",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,"The patient has Duchenne muscular dystrophy, while the trial is for TK2 deficiency. This is a disease mismatch, which is a hard exclusion per the rubric. The grader correctly assigned F and identified the correct rationale.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT03661645,0.5917590260505676,Rheumatoid Arthritis,Post-operative Methylprednisolone Taper Course for Orthopedic Surgery,PHASE4,18 years to 95 years,Upper Extremity Fracture; Hip Osteoarthritis; Knee Osteoarthritis; Carpal Tunnel Syndrome; Upper Extremity Tendon Injury; Upper Extremity Arthritis,"Undergoing surgery for an upper extremity fracture | Undergoing total shoulder arthroplasty or reverse shoulder arthroplasty | Undergoing surgery for upper extremity arthritis | Undergoing release for upper extremity compressive neuropathies (e.g., carpal tunnel) | Undergoing procedures for upper extremity tendon pathologies (e.g., tendon repair) | Undergoing total hip arthroplasty for osteoarthritis of the hip | Undergoing total knee arthroplasty for osteoarthritis of the knee | Age 18 to 95 years",Concurrent significant injuries to other bones or organs | Local infection | Minors or vulnerable subjects | Allergy to glucocorticoids | Daily use of glucocorticoids | Chronic opioid use prior to injury | Severe heart disease (NYHA 2) | Renal failure | Liver dysfunction | Active peptic ulcer disease | Diabetic neuropathy | Rheumatoid arthritis | Neurological diseases potentially influencing pain perception | Psychiatric diseases potentially influencing pain perception | Pregnancy | Pre-existing immunosuppression | Non-compliance risk per investigator judgment,(none),ALL,F,"The trial targets orthopedic surgical conditions and explicitly excludes patients with rheumatoid arthritis. The patient has rheumatoid arthritis, triggering a hard exclusion.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Trial explicitly excludes rheumatoid arthritis, which the patient has. Additionally, disease mismatch exists since the trial targets orthopedic surgical conditions, not RA. Hard exclusion applies → F.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT03671148,0.7093204259872437,Rheumatoid Arthritis,"A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE 2)",PHASE3,18 years,Psoriatic Arthritis,Clinical diagnosis of psoriatic arthritis with symptom onset >= 6 months before screening | Meets CASPAR criteria for psoriatic arthritis at screening | Active disease: >= 5 tender joints (68-joint count) and >= 5 swollen joints (66-joint count) at screening and baseline | Diagnosis of active plaque psoriasis with >= 1 plaque of >= 2 cm diameter or nail changes consistent with psoriasis at screening | Inadequate response or intolerance to biologic therapy(ies) or conventional synthetic DMARD therapy(ies),Investigator deems participant unsuitable for the study | Known hypersensitivity to risankizumab,Prior biologic therapy with inadequate response or intolerance; Prior conventional synthetic DMARD therapy with inadequate response or intolerance,ALL,F,"Disease mismatch: the trial enrolls psoriatic arthritis, while the patient has rheumatoid arthritis. This constitutes a hard exclusion.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,Disease mismatch is a hard exclusion per rubric (trial: psoriatic arthritis; patient: rheumatoid arthritis). The grader correctly assigned F based on this.,,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT03719859,0.6041219830513,Rheumatoid Arthritis,Multicenter Randomized Trial of Home vs. Physical Therapist-Directed Rehabilitation for Reverse Total Shoulder Arthroplasty,NA,Not specified,Rotator Cuff Tear Arthropathy; Shoulder Arthritis,Reverse total shoulder arthroplasty for cuff tear arthropathy | Reverse total shoulder arthroplasty for massive irreparable rotator cuff tear with pseudoparalysis | Reverse total shoulder arthroplasty for primary osteoarthritis,Non-reverse total shoulder arthroplasty | Reverse total shoulder arthroplasty for fracture | Tendon transfers as part of reverse total shoulder arthroplasty | Revision reverse total shoulder arthroplasty | Cognitive deficits limiting ability to follow directions,Reverse total shoulder arthroplasty,ALL,F,"Disease mismatch: the trial targets patients undergoing reverse total shoulder arthroplasty for rotator cuff tear arthropathy/shoulder osteoarthritis, not rheumatoid arthritis.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Disease mismatch is a hard exclusion. Trial targets reverse total shoulder arthroplasty indications (rotator cuff tear arthropathy/shoulder osteoarthritis), not rheumatoid arthritis. F is appropriate.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT03723655,0.531043529510498,Duchenne Muscular Dystrophy,A Long-Term Safety Extension Study of Mavacamten (MYK-461) in Adults With Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE),PHASE2/PHASE3,18 years,Hypertrophic Cardiomyopathy; Non-obstructive Hypertrophic Cardiomyopathy; Obstructive Hypertrophic Cardiomyopathy,Body weight > 45 kg | Adequate acoustic windows for transthoracic echocardiograms | Left ventricular ejection fraction >= 50% at rest by core lab echocardiography | Safety laboratory parameters within normal limits,"Electrocardiogram abnormality posing safety risk (e.g., second-degree atrioventricular block type II) | History of syncope or sustained ventricular tachyarrhythmia with exercise since parent study end-of-study visit | History of resuscitated sudden cardiac arrest or appropriate implantable cardioverter-defibrillator discharge for life-threatening ventricular arrhythmia since parent study end-of-study visit (anti-tachycardia pacing allowed) | Current treatment with disopyramide or ranolazine within 14 days prior to screening or planned during the study | Acute or serious comorbid condition (e.g., major infection or hematologic, renal, metabolic, gastrointestinal, or endocrine dysfunction) that could interfere with participation or assessments | Clinically significant malignant disease developed since enrollment in the parent study | Participation in another interventional clinical trial with an investigational drug or device within 30 days prior to screening or <5 half-lives of the prior investigational product (whichever is longer), except MAVERICK-HCM or EXPLORER-HCM",(none),ALL,F,"Disease mismatch: the trial targets hypertrophic cardiomyopathy, while the patient has Duchenne muscular dystrophy. Additionally, the patient is 11 years old, below the trial’s minimum age of 18.",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,"There are hard exclusions: disease mismatch (trial targets hypertrophic cardiomyopathy, patient has Duchenne muscular dystrophy) and age window conflict (trial min age 18 vs patient 11). Under the rubric, any hard exclusion yields F. The grader’s reasoning correctly identified these factors.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT03725007,0.5699001550674438,Rheumatoid Arthritis,"An Open-Label Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis",PHASE1,2 years to 17 years,Juvenile Idiopathic Arthritis (polyarticular course),"Total body weight >=10 kg at screening | Diagnosis of polyarticular-course JIA (RF-positive or RF-negative polyarticular JIA, extended oligoarticular JIA, or systemic JIA with active arthritis and without active systemic features) with history of arthritis affecting >=5 joints within first 6 months of disease (for extended oligoarticular JIA: <=4 joints within first 6 months and >4 joints thereafter) | >=5 active joints at screening (swollen joints not due to deformity, or limitation of movement with pain on motion and/or tenderness; limitation of movement present in at least 3 active joints) | If receiving methotrexate, on MTX for >=12 weeks before and including Day 1 with stable dose <=20 mg/m2 for >=8 weeks before and including Day 1, with folic acid or folinic acid supplementation per standard of care | If on oral glucocorticosteroids, stable dose for >=1 week before and including Day 1 (<=10 mg/day or 0.2 mg/kg/day, whichever is lower)",Diagnosis of enthesitis-related arthritis or juvenile psoriatic arthritis | Prior exposure to a JAK inhibitor,Stable methotrexate for >=12 weeks with stable dose <=20 mg/m2 for >=8 weeks; Folic acid or folinic acid supplementation with methotrexate; Stable oral glucocorticoids (<=10 mg/day or 0.2 mg/kg/day) for >=1 week,ALL,F,"Disease mismatch: the trial targets juvenile idiopathic arthritis, not rheumatoid arthritis. Additionally, the age window is 2–17 years, while the patient is 55, which is a hard exclusion.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,Correct: There is a hard disease mismatch (RA vs JIA) and a hard age exclusion (trial 2–17 years; patient 55). Either triggers F.,,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT03730454,0.5459970235824585,Fistulizing Crohn's Disease,A Multi-Center Randomized Trial of Transanastomotic Tube for Proximal Esophageal Atresia With Distal Tracheoesophageal Fistula Repair,NA,up to 6 months,Esophageal Atresia; Tracheoesophageal Fistula,Infants diagnosed with type C esophageal atresia (proximal esophageal atresia with distal tracheoesophageal fistula) | Primary repair of the esophageal atresia within the first 6 months of life,Other types of esophageal atresia without esophageal anastomosis creation | Major anomaly that influences likelihood of developing the primary outcome or affects surgical treatment considerations,(none),ALL,F,"Disease mismatch: the trial targets infants with esophageal atresia/tracheoesophageal fistula, not Crohn's disease. Additionally, the trial age range is up to 6 months, while the patient is 32 years old.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,F,"Correct: There is a hard disease mismatch (trial targets esophageal atresia/TEF, not Crohn’s) and an age hard exclusion (trial <=6 months; patient is 32 years). Either triggers F. Reasoning appropriately identifies these factors.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT03772977,0.7082419395446777,Dementia,The Brain Health Champion Study: Promoting Non-pharmacological Interventions in Cognitive Disorders and Those at Risk,NA,60 years to 79 years,Mild Cognitive Impairment; Mild Dementia; Subjective Cognitive Decline,"Age 60–79 years | Neurology participants: Diagnosis of Subjective Cognitive Disorder; Mild Cognitive Impairment due to Alzheimer disease, cerebrovascular disease, or mixed AD/CVD; or mild dementia due to AD, CVD, or mixed AD/CVD. | Primary care participants: CAIDE dementia risk score >= 6, or CAIDE = 5 plus a first-degree relative with ADRD, or type 2 diabetes or prediabetes (A1C >= 5.7).",Enrolled in another health behavior or non-pharmacologic intervention for a neurocognitive disorder. | Unable or unwilling to carry out regular physical exercise multiple times weekly. | Not recommended to participate by their Internist/Primary Care Provider due to health-related concerns.,(none),ALL,F,"The trial restricts neurology participants to mild dementia/MCI/SCD, and the patient has moderate-stage dementia (MMSE 19), which is a required stage mismatch. Although age and sex fit, the disease stage is outside the trial’s included cohorts.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,"Trial explicitly requires mild dementia/MCI/SCD (or risk cohort), while patient has moderate dementia, a required stage mismatch constituting a hard exclusion. Age/sex fit, but stage requirement is not met, so F is correct.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT03779334,0.620978057384491,Duchenne Muscular Dystrophy,An Open-Label Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,PHASE2,1 days to 6 weeks,Spinal Muscular Atrophy,Age from birth to 6 weeks at first dose | Gestational age 37-42 weeks for singletons or 34-42 weeks for twins | Body weight >= 3rd percentile for age | Genetic diagnosis of 5q-autosomal recessive SMA with SMN1 homozygous deletion or compound heterozygosity predictive of loss of function | No clinical signs or symptoms of SMA at screening or baseline | Adequate nutrition and hydration at screening | Adequately recovered from any acute illness at baseline,"Prior or concomitant participation in any investigational drug or device study | Prior or concomitant SMN2-targeting antisense oligonucleotide, SMN2-splicing modifier, or gene therapy | Significant concurrent syndromes or diseases | Inadequate venous or capillary blood access for study procedures | Requirement for invasive ventilation, tracheostomy, or awake non-invasive ventilation | Awake hypoxemia (SaO2 < 95%) | Multiple or fixed contractures and/or hip subluxation or dislocation at birth | Clinically significant systolic or diastolic blood pressure or heart rate abnormalities | Clinically relevant ECG abnormalities; QTc (Bazett) > 460 ms; personal or first-degree family history of congenital long QT syndrome | Use of CYP3A4 inhibitors within 2 weeks, CYP3A4 inducers within 4 weeks, OCT2 or MATE substrates within 2 weeks, or known FMO1/FMO3 inhibitors or substrates (including maternal exposure if breastfeeding) | Clinically significant abnormal laboratory test results | Hypersensitivity to risdiplam or its excipients | Treatment with oral salbutamol or other oral beta-2 adrenergic agonists for SMA (inhaled beta-2 agonists allowed) | Exposure during pregnancy/lactation to drugs with known retinal toxicity or anticipated need for retinal-toxic drugs during the study | Diagnosis of ophthalmic diseases",(none),ALL,F,"Disease mismatch: the trial targets presymptomatic 5q spinal muscular atrophy, while the patient has Duchenne muscular dystrophy. Also, the age window is birth to 6 weeks, and the patient is 11 years old.",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,"Disease mismatch (DMD vs SMA) and strict age window mismatch (birth–6 weeks vs 11 years) are hard exclusions, so F is correct. The grader correctly identified these factors.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT03779334,0.6553357839584351,Amyotrophic Lateral Sclerosis,An Open-Label Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,PHASE2,1 days to 6 weeks,Spinal Muscular Atrophy,Age from birth to 6 weeks at first dose | Gestational age 37-42 weeks for singletons or 34-42 weeks for twins | Body weight >= 3rd percentile for age | Genetic diagnosis of 5q-autosomal recessive SMA with SMN1 homozygous deletion or compound heterozygosity predictive of loss of function | No clinical signs or symptoms of SMA at screening or baseline | Adequate nutrition and hydration at screening | Adequately recovered from any acute illness at baseline,"Prior or concomitant participation in any investigational drug or device study | Prior or concomitant SMN2-targeting antisense oligonucleotide, SMN2-splicing modifier, or gene therapy | Significant concurrent syndromes or diseases | Inadequate venous or capillary blood access for study procedures | Requirement for invasive ventilation, tracheostomy, or awake non-invasive ventilation | Awake hypoxemia (SaO2 < 95%) | Multiple or fixed contractures and/or hip subluxation or dislocation at birth | Clinically significant systolic or diastolic blood pressure or heart rate abnormalities | Clinically relevant ECG abnormalities; QTc (Bazett) > 460 ms; personal or first-degree family history of congenital long QT syndrome | Use of CYP3A4 inhibitors within 2 weeks, CYP3A4 inducers within 4 weeks, OCT2 or MATE substrates within 2 weeks, or known FMO1/FMO3 inhibitors or substrates (including maternal exposure if breastfeeding) | Clinically significant abnormal laboratory test results | Hypersensitivity to risdiplam or its excipients | Treatment with oral salbutamol or other oral beta-2 adrenergic agonists for SMA (inhaled beta-2 agonists allowed) | Exposure during pregnancy/lactation to drugs with known retinal toxicity or anticipated need for retinal-toxic drugs during the study | Diagnosis of ophthalmic diseases",(none),ALL,F,"Disease mismatch (trial is for presymptomatic infant SMA, not ALS) and the patient is far outside the age range (62 years vs. ≤6 weeks).",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,F,Correct: There is a hard disease mismatch (ALS vs SMA) and a hard age window conflict (62 years vs ≤6 weeks). Either triggers an F per the rubric.,,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT03887455,0.5751073360443115,Dementia,"A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease",PHASE3,50 years to 90 years,Alzheimer's Disease (early),"MCI due to Alzheimer's disease meeting NIA-AA core clinical criteria (intermediate likelihood) | Global CDR = 0.5 and CDR Memory Box >= 0.5 at Screening and Baseline (for MCI cohort) | Probable Alzheimer's disease dementia (mild) meeting NIA-AA core clinical criteria | Global CDR 0.5–1.0 and CDR Memory Box >= 0.5 at Screening and Baseline (for mild AD dementia cohort) | Objective episodic memory impairment: WMS-IV Logical Memory II at least 1 SD below age-adjusted mean | Positive biomarker for brain amyloid pathology | Age >= 50 and <= 90 years | MMSE score >= 22 and <= 30 at Screening and Baseline | BMI > 17 and < 35 at Screening | If on acetylcholinesterase inhibitor or memantine, must be on a stable dose for >= 12 weeks prior to Baseline","Any neurological condition contributing to cognitive impairment beyond Alzheimer's disease | History of transient ischemic attack, stroke, or seizures within 12 months of Screening | Psychiatric diagnosis or symptoms that could interfere with study procedures (e.g., hallucinations, major depression, delusions) | Geriatric Depression Scale score >= 8 at Screening | Contraindications to MRI scanning (e.g., pacemaker/defibrillator, ferromagnetic implants not approved for MRI) | Clinically significant brain MRI lesions suggesting non-AD dementia | More than 4 microhemorrhages (<= 10 mm), a single macrohemorrhage > 10 mm, superficial siderosis, vasogenic edema on MRI | Evidence on MRI of cerebral contusion, encephalomalacia, aneurysm, vascular malformation, infective lesion, multiple lacunar infarcts, major territorial stroke, severe small vessel disease, severe white matter disease, space-occupying lesion, or brain tumor (except meningioma or arachnoid cyst < 1 cm) | Immunological disease not adequately controlled or requiring treatment with immunoglobulins, systemic monoclonal antibodies (or derivatives), systemic immunosuppressants, or plasmapheresis during the study | Bleeding disorder not adequately controlled, including platelet count < 50,000/µL or INR > 1.5 if not on anticoagulant treatment | Other significant uncontrolled medical conditions (cardiac, respiratory, gastrointestinal, renal) that could affect safety or assessments | Participation in a clinical study with any therapeutic monoclonal antibody, antibody-derived protein, immunoglobulin therapy, or vaccine within 6 months before Screening unless randomized to placebo | Participation in a clinical study with any anti-amyloid therapy (including monoclonal antibodies or BACE inhibitors) unless only placebo was received | Any known prior exposure to lecanemab | Participation in a clinical study with any new chemical entity for Alzheimer's disease within 6 months prior to Screening unless in a placebo arm | Hypersensitivity to lecanemab (BAN2401) or any monoclonal antibody treatment | Malignant neoplasms not stably and adequately controlled (except basal/squamous cell carcinoma in situ of skin or localized prostate cancer) | Severe visual or hearing impairment preventing accurate psychometric testing",Stable dose of acetylcholinesterase inhibitor and/or memantine for >= 12 weeks prior to Baseline (treatment-naive also allowed); For autoinjector substudy: at least 6 months prior exposure to lecanemab 10 mg/kg IV biweekly or lecanemab Dose 1 subcutaneous weekly; For subcutaneous Dose 3 autoinjector substudy: prior lecanemab (IV and/or SC) and completion of Extension Week 79 or later,ALL,F,"The trial requires a positive amyloid biomarker and early AD (MCI/mild) with MMSE 22–30, but the patient is amyloid PET/CSF negative and has moderate dementia with MMSE 19.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,"Hard exclusion applies: the trial requires a positive amyloid biomarker, while the patient is definitively amyloid-negative. Additionally, required early AD stage/MMSE 22–30 is not met (patient is moderate with MMSE 19). Grade F is correct per rubric.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT03902951,0.6171972155570984,Castration-Resistant Prostate Cancer,"A Single-Arm, Open-Label, Phase II Study of Systemic and Tumor Directed Therapy for Recurrent Oligometastatic M1 Prostate Cancer",PHASE2,18 years,Metastatic Prostate Adenocarcinoma; Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation; Recurrent Prostate Carcinoma; Prostate Cancer (Stage IVB),"Histologically confirmed prostate adenocarcinoma after radical prostatectomy (adenocarcinoma with neuroendocrine differentiation allowed; primary small cell not allowed) | 1–5 visible metastases by PSMA PET-CT | At least one metastasis M1a–M1b | No visceral metastases | Any number of pelvic nodal metastases allowed if largest < 2 cm | Metastases amenable to SBRT | Biopsy of one metastasis attempted unless unsafe | Fit to undergo SBRT to all visible sites and ADT | Total testosterone > 150 ng/dL prior to ADT | ECOG 0–1 | Hemoglobin >= 9.0 g/dL (independent of transfusion/growth factors within 3 months) | Platelet count >= 100,000/µL (independent of transfusion/growth factors within 3 months) | Serum albumin >= 3.0 g/dL | Glomerular filtration rate >= 45 mL/min | Serum potassium >= 3.5 mmol/L | Total bilirubin <= 1.5 x ULN (Gilbert syndrome exception allowed if direct bilirubin <= 1.5 x ULN) | AST or ALT <= 2.5 x ULN | Medications that lower seizure threshold discontinued or substituted >= 4 weeks prior to study entry","Evidence of spinal cord compression (radiologic or clinical) | Prior pelvic malignancy | Prior pelvic radiation aside from salvage prostate radiation | Concurrent malignancy aside from superficial skin cancers or superficial bladder tumors | Inability to undergo radiotherapy or ADT | Primary small cell carcinoma of the prostate | Inflammatory bowel disease or active collagen vascular disease | History of seizure or condition predisposing to seizure | Prior stroke within 1 year prior to randomization | Brain arteriovenous malformation, Schwannoma, meningioma, or other benign CNS/meningeal disease which may require surgery or radiotherapy | Severe or unstable angina within 6 months prior to randomization | Myocardial infarction within 6 months prior to randomization | Symptomatic congestive heart failure within 6 months prior to randomization | Arterial or venous thromboembolic events within 6 months prior to randomization | Clinically significant ventricular arrhythmias within 6 months prior to randomization | Uncontrolled hypertension | Gastrointestinal disorder affecting absorption | Active infection including HIV or viral hepatitis | Chronic corticosteroid requirement > 10 mg prednisone/prednisolone once daily | Concomitant strong CYP3A4 inducers | Treatment with CYP2D6 substrates with a narrow therapeutic index (unless an alternative or dose reduction is used) | Baseline moderate or severe hepatic impairment (Child-Pugh Class B or C) | Presence of visceral metastases (M1c)",Discontinue or substitute medications that lower the seizure threshold >= 4 weeks before study entry,MALE,F,"The trial explicitly excludes patients with visceral metastases (M1c), and the patient has liver metastases. Therefore, they fail a hard exclusion criterion.",Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),CORRECT,F,"The trial explicitly excludes patients with visceral metastases (M1c). The patient has liver metastases, a visceral site, triggering a hard exclusion. The grader correctly assigned F with appropriate reasoning.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT03915951,0.8452445864677429,Metastatic Non-Small Cell Lung Cancer,"A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer",PHASE2,18 years,Non-small Cell Lung Cancer (metastatic),"Histologically confirmed non-small cell lung cancer, Stage IV | BRAF V600 mutation in tumor (V600E; V600K/D allowed) | Treatment-naive or one prior line of systemic therapy for advanced/metastatic disease | Measurable disease per RECIST v1.1 | ECOG performance status 0–1 | Adequate bone marrow, hepatic, and renal function","EGFR mutation, ALK fusion, or ROS1 rearrangement | More than one prior line of systemic therapy in the advanced/metastatic setting | Prior treatment with any BRAF inhibitor | Prior treatment with any MEK inhibitor | Impaired cardiovascular function or clinically significant cardiovascular disease | Thromboembolic or cerebrovascular events within 12 weeks prior to first dose | History or current evidence of retinal vein occlusion or risk factors for RVO | History of retinal degenerative disease | Concurrent neuromuscular disorder associated with elevated CK | Symptomatic brain metastases, leptomeningeal disease, or other active CNS metastases",Treatment-naive allowed; One prior line with platinum-based chemotherapy allowed; One prior line with PD-1/PD-L1 inhibitor allowed,ALL,F,"The trial explicitly excludes patients with EGFR mutations, and this patient has an EGFR exon 19 deletion. It also requires a BRAF V600 mutation, which is not documented for this patient.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"Correct: Trial explicitly excludes EGFR-mutant NSCLC, and the patient has an EGFR exon 19 deletion. That is a hard exclusion, warranting grade F. The note about required BRAF V600 (unknown for patient) is ancillary and not needed for F.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT03924414,0.6197726130485535,Dementia,TOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's Disease,PHASE4,60 years,Parkinson Disease; Progressive Supranuclear Palsy; Multiple System Atrophy; Corticobasal Degeneration; Vascular Parkinsonism; Dementia With Lewy Bodies,"Age >= 60 years | Diagnosis of Parkinson's disease or neurodegenerative parkinsonism (e.g., progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, vascular parkinsonism, dementia with Lewy bodies) confirmed by neurologist assessment or telemedicine screening | Willing and able to continue follow-up for >= 2 years | Able to provide informed consent","History of hip fracture | Any bisphosphonate use within the last 12 months | Use of other osteoporosis treatments (e.g., SERMs, denosumab) within the last 6 months | Tooth extraction or invasive dental procedure within the past 30 days or planned in the next 12 months | Non-ambulatory (unable to walk without assistance of another person) | Undergoing kidney dialysis | Diagnosis of multiple myeloma or Paget's disease",(none),ALL,F,"Hard exclusion: The trial requires Parkinson’s disease or neurodegenerative parkinsonism (including dementia with Lewy bodies), while the patient has dementia without a specified parkinsonian diagnosis.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,"Correct F. The trial is limited to Parkinson’s disease or neurodegenerative parkinsonism (including DLB). The patient has unspecified dementia without a parkinsonian diagnosis, so the disease is not included in the trial cohorts—this is a hard exclusion per the rubric.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT03924414,0.5265384316444397,Amyotrophic Lateral Sclerosis,TOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's Disease,PHASE4,60 years,Parkinson Disease; Progressive Supranuclear Palsy; Multiple System Atrophy; Corticobasal Degeneration; Vascular Parkinsonism; Dementia With Lewy Bodies,"Age >= 60 years | Diagnosis of Parkinson's disease or neurodegenerative parkinsonism (e.g., progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, vascular parkinsonism, dementia with Lewy bodies) confirmed by neurologist assessment or telemedicine screening | Willing and able to continue follow-up for >= 2 years | Able to provide informed consent","History of hip fracture | Any bisphosphonate use within the last 12 months | Use of other osteoporosis treatments (e.g., SERMs, denosumab) within the last 6 months | Tooth extraction or invasive dental procedure within the past 30 days or planned in the next 12 months | Non-ambulatory (unable to walk without assistance of another person) | Undergoing kidney dialysis | Diagnosis of multiple myeloma or Paget's disease",(none),ALL,F,"Disease mismatch: This trial enrolls Parkinson’s disease or parkinsonism disorders, while the patient has amyotrophic lateral sclerosis (ALS), which is not included.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,F,"Disease mismatch: patient has ALS, while trial enrolls Parkinson’s/parkinsonism disorders only. This is a hard exclusion, so F is correct.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT03934840,0.7148563861846924,Castration-Resistant Prostate Cancer,"A Phase II Study of Carboplatin, Cabazitaxel and Abiraterone in High Volume Metastatic Castration Sensitive Prostate Cancer",PHASE2,18 years,"Prostate Cancer (metastatic, castration-sensitive)",Histologically confirmed prostate cancer | High-volume metastatic disease (visceral metastases or >=3 bone lesions) | Androgen deprivation therapy for <=3 months by day 1 of study chemotherapy; prior courses of ADT with radiation allowed | Testosterone <=50 ng/dL; continue primary ADT with an LHRH analogue if no orchiectomy | ECOG Performance Status 0–1 | Age >= 18 years,"Prior chemotherapy, PARP inhibitor, or immunotherapy for prostate cancer | Prior abiraterone or enzalutamide unless therapy was <2 weeks | Radiation therapy within 14 days prior to first dose | Major surgery within 28 days prior to first dose | Other systemic therapies for prostate cancer within 28 days or 5 half-lives (whichever is shorter) prior to day 1 of chemotherapy, except anti-androgens like bicalutamide | PSA <2.0 ng/mL at diagnosis | Peripheral neuropathy > Grade 1 | Active second malignancy that could interfere with participation | Central nervous system involvement unless >=4 weeks from prior therapy, clinically stable, and only if symptomatic screening is indicated | Severe psychiatric illness or social situation limiting compliance | History of non-compliance to medical regimens or inability to grant consent","Androgen deprivation therapy <= 3 months before day 1; prior ADT courses with radiation allowed; Must continue androgen deprivation therapy with LHRH analogue or have undergone orchiectomy; Radiation therapy washout >=14 days before first dose; Major surgery washout >=28 days before first dose; Other systemic prostate cancer therapies require washout of >=28 days or 5 half-lives (whichever is shorter), except bicalutamide; Prior abiraterone or enzalutamide allowed only if <2 weeks exposure",MALE,F,The trial is for metastatic castration-sensitive prostate cancer and explicitly excludes prior abiraterone or enzalutamide exposure >2 weeks; the patient has castration-resistant disease with prior abiraterone and enzalutamide beyond 2 weeks. These are hard exclusion conflicts.,Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),CORRECT,F,"Correct: The trial explicitly excludes prior abiraterone or enzalutamide exposure >2 weeks, which the patient has. Additionally, the trial requires castration-sensitive disease while the patient is castration-resistant. Either constitutes a hard exclusion under the rubric, so F is appropriate.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT03976323,0.7815374135971069,Metastatic Non-Small Cell Lung Cancer,A Phase 3 Study of Pembrolizumab in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants With Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC),PHASE3,18 years,"Non-Small Cell Lung Cancer (nonsquamous, metastatic)",Histologically or cytologically confirmed nonsquamous non-small cell lung cancer | Stage IV nonsquamous non-small cell lung cancer | EGFR/ALK/ROS1-directed therapy not indicated | Measurable disease per RECIST 1.1 | Archival or newly obtained tumor tissue available; adequate sample confirmation by central lab | Life expectancy >= 3 months | ECOG performance status 0 or 1 | No prior systemic treatment for advanced/metastatic NSCLC | Adequate organ function,"Predominantly squamous cell histology NSCLC | Active additional malignancy requiring treatment or progressed within past 3 years | Known active CNS metastases and/or carcinomatous meningitis | Severe hypersensitivity (>= Grade 3) to pembrolizumab or its excipients | Known hypersensitivity to cisplatin, carboplatin, pemetrexed, or olaparib components/excipients | Active autoimmune disease requiring systemic treatment within past 2 years | Diagnosis of immunodeficiency or chronic systemic steroid therapy | Known history of HIV infection | Known history of hepatitis B infection | Known active hepatitis C virus infection | Interstitial lung disease or history of pneumonitis requiring systemic steroids | Prior therapy with olaparib or any PARP inhibitor | Prior therapy with PD-L1, anti PD-L2, CTLA-4, OX-40, CD137, or other stimulatory/co-inhibitory T-cell agents | Myelodysplastic syndrome or acute myeloid leukemia or features suggestive of MDS/AML | History of a second malignancy unless curatively treated with no evidence of disease for 2 years | Completed palliative radiotherapy within 7 days of first study dose or not recovered from radiation-related toxicities or requiring corticosteroids",No prior systemic therapy for advanced/metastatic NSCLC; No prior PARP inhibitor; No prior anti–PD-(L)1/PD-L2/CTLA-4 or other T-cell targeting agents; Palliative radiotherapy washout >= 7 days,ALL,F,"The trial requires no prior systemic therapy for metastatic NSCLC and that EGFR/ALK/ROS1-directed therapy is not indicated, but the patient has an EGFR exon 19 deletion and has received systemic EGFR therapy (osimertinib) for 2 years. These are hard exclusions for this first-line study.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,Clear hard exclusions: the trial requires no prior systemic therapy for metastatic NSCLC and that EGFR/ALK/ROS1-directed therapy not be indicated. The patient has metastatic EGFR exon 19+ NSCLC and has received osimertinib for 2 years. Thus F is appropriate.,,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT03976362,0.7991423606872559,Metastatic Non-Small Cell Lung Cancer,A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC),PHASE3,18 years,Squamous Non-Small Cell Lung Cancer (metastatic),Histologically or cytologically confirmed squamous non-small cell lung cancer | Stage IV disease | Measurable disease per RECIST 1.1 | No prior systemic therapy for advanced/metastatic NSCLC | Archival or newly obtained tumor tissue available for central adequacy confirmation | ECOG performance status 0–1 | Life expectancy >= 3 months | Adequate organ function,"Non-squamous histology NSCLC | Additional malignancy requiring active treatment within past 3 years | Known active central nervous system metastases or carcinomatous meningitis | Hypersensitivity to carboplatin, paclitaxel, nab-paclitaxel, or olaparib | Severe hypersensitivity (>= Grade 3) to pembrolizumab or its excipients | Active autoimmune disease requiring systemic treatment within past 2 years | Immunodeficiency or chronic systemic steroid therapy | Known HIV infection | Known hepatitis B infection | Known active hepatitis C virus infection | Interstitial lung disease or history of pneumonitis requiring systemic steroids | Prior therapy with olaparib or any PARP inhibitor | Prior therapy with PD-1/PD-L1/PD-L2 or CTLA-4/OX-40/CD137 agents | Myelodysplastic syndrome or acute myeloid leukemia, or features suggestive of MDS/AML",No prior systemic therapy for advanced/metastatic NSCLC,ALL,F,"Explicit exclusion: the trial requires no prior systemic therapy for advanced/metastatic NSCLC, but the patient has already received osimertinib for metastatic disease. Additionally, the trial is restricted to squamous NSCLC, which is not confirmed for this patient.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"Correct: The trial explicitly requires no prior systemic therapy for advanced/metastatic NSCLC, while the patient has received osimertinib for metastatic disease—this is a hard exclusion, yielding F. The squamous histology requirement is unknown for the patient and would not alone trigger F, but the prior-therapy conflict already does.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT04038619,0.5301774740219116,Fistulizing Crohn's Disease,Fecal Microbiota Transplantation (FMT) for Immune-Checkpoint Inhibitor Induced-Diarrhea/Colitis in Genitourinary Cancer Patients,PHASE1,18 years,Breast Cancer; Cervical Cancer; Colitis; Diarrhea; Lung Cancer; Malignant Genitourinary System Neoplasm; Melanoma; Ovarian Cancer; Uterine Cancer,"Diagnosis of malignancy in genitourinary, melanoma, non-melanoma skin, lung, head and neck, sarcoma/lymphoma, gastrointestinal (luminal GI, hepatobiliary, pancreas), gynecologic (ovarian, uterine, cervical), or breast cancer | Treatment with any immune checkpoint inhibitor (ICPI) agent(s) | New onset of >= grade 2 ICPI-induced diarrhea and/or colitis within 45 days prior to FMT, without involvement of non-GI toxicity | Prior steroid use allowed if last dose > 30 days before FMT or treatment duration < 7 days beyond one week prior to FMT | Prior immunosuppressant (e.g., infliximab, vedolizumab) use allowed if last dose >= 3 months prior when used for conditions other than ICI-induced GI toxicities | No active concomitant GI infection at initiation of protocol therapy as confirmed by stool tests or treating physician assessment | Cleared for enrollment by Infectious Diseases consultant or treating physician if positive infection workup or screening tests prior to therapy | Life expectancy > 6 months","Age < 18 years | Persistent GI infection with positive stool test(s) despite completing 5 days of antibiotics before protocol therapy | History of inflammatory bowel disease or radiation enteritis/colitis with active disease at treatment initiation | Pregnant or breastfeeding | Positive urine or serum pregnancy test or refusal to test unless clearly peri- or post-menopausal or objective evidence of no pregnancy within 30 days prior to treatment | Immunosuppressive treatment at onset of ICPI-induced diarrhea/colitis | Medical conditions high risk for colonoscopy (e.g., severe heart failure, brain hemorrhage, septic shock) | Concurrent non-GI toxicity at time of study treatment | Donors at risk for monkeypox infection or exposure","Prior treatment with any ICPI agent(s) required; Prior corticosteroids permitted with washout/restrictions as specified; Prior immunosuppressants (e.g., infliximab, vedolizumab) permitted if last dose >= 3 months and used for non-ICI GI indications",ALL,F,"Disease mismatch: the trial targets ICPI-induced diarrhea/colitis in cancer patients, not fistulizing Crohn's disease. Additionally, the trial excludes patients with active inflammatory bowel disease.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,F,"Hard exclusion applies: disease mismatch (trial is for ICPI-induced colitis in cancer patients; patient has Crohn’s disease and no cancer/ICPI exposure). Additionally, the trial explicitly excludes active inflammatory bowel disease. Thus F is correct.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT04042025,0.5601574182510376,Duchenne Muscular Dystrophy,A Long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101,PHASE3,Not specified,Spinal Muscular Atrophy Type I; Spinal Muscular Atrophy Type II; Spinal Muscular Atrophy Type III,Spinal muscular atrophy with prior treatment with onasemnogene abeparvovec in a Novartis Gene Therapies-sponsored clinical study,,Prior treatment with onasemnogene abeparvovec in a Novartis Gene Therapies-sponsored clinical study,ALL,F,"The trial targets spinal muscular atrophy patients previously treated with onasemnogene abeparvovec in a Novartis-sponsored study. The patient has Duchenne muscular dystrophy and lacks the required prior therapy, constituting a disease mismatch and failure of key inclusion criteria.",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,"Hard exclusion: disease mismatch (patient has Duchenne muscular dystrophy; trial is for spinal muscular atrophy). Additionally, the trial requires prior onasemnogene abeparvovec exposure, which the patient lacks. F is correct.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT04042025,0.5726581811904907,Amyotrophic Lateral Sclerosis,A Long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101,PHASE3,Not specified,Spinal Muscular Atrophy Type I; Spinal Muscular Atrophy Type II; Spinal Muscular Atrophy Type III,Spinal muscular atrophy with prior treatment with onasemnogene abeparvovec in a Novartis Gene Therapies-sponsored clinical study,,Prior treatment with onasemnogene abeparvovec in a Novartis Gene Therapies-sponsored clinical study,ALL,F,"Hard exclusion: the trial targets spinal muscular atrophy (Types I–III), whereas the patient has amyotrophic lateral sclerosis (ALS), which is not included. Additionally, the trial requires prior onasemnogene abeparvovec exposure in a Novartis study, which is not indicated for this patient.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,F,"Correct: Hard exclusion due to disease mismatch (ALS vs SMA). The trial’s requirement of prior onasemnogene abeparvovec also wouldn’t be met, but the disease mismatch alone warrants F.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT04043897,0.5107550621032715,Fistulizing Crohn's Disease,Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis,PHASE2,18 years,Microscopic Colitis,"Collagenous colitis or lymphocytic colitis diagnosed on colon biopsies reviewed by 2 pathologists | CC defined histologically by subepithelial collagen band thickness >10 micrometer, lamina propria lymphoplasmacytic inflammation, lack of crypt architectural distortion, and regenerative epithelial changes | LC defined histologically by >20 intraepithelial lymphocytes per 100 epithelial cells in the area of highest density, lamina propria lymphoplasmacytic inflammation, and regenerative epithelial changes | Active flare: >3 watery/loose stools per day on >4 of 7 days over >4 weeks in the past 3 months",,(none),ALL,F,"Hard exclusion: the trial targets microscopic colitis (collagenous or lymphocytic) requiring histologic confirmation, while the patient has fistulizing Crohn's disease. Age and sex fit, but the disease mismatch excludes eligibility.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,F,"Correctly identified a hard exclusion: the trial targets microscopic colitis (collagenous or lymphocytic), while the patient has fistulizing Crohn’s disease. Age/sex fit are irrelevant once disease mismatch is present. Grade F is appropriate.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT04095364,0.716774046421051,Recurrent Clear Cell Ovarian Carcinoma,"A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum",PHASE3,18 years,Ovarian Low Grade Serous Carcinoma; Fallopian Tube Low Grade Serous Carcinoma; Primary Peritoneal Low Grade Serous Carcinoma,"Newly diagnosed stage II–IV low-grade serous ovarian cancer (ovarian, fallopian tube, or primary peritoneal) | Prior history of serous borderline tumor allowed | p53 immunohistochemistry nonaberrant (consistent with TP53 wildtype) | Age >= 18 years | Attempt at maximal upfront cytoreductive surgery (optimal or suboptimal residual allowed) | Bilateral salpingo-oophorectomy performed | ECOG performance status 0–2 | Able to take oral medications | ANC >= 1500/µL | Platelets >= 100000/µL | Creatinine <= 1.5 x ULN | Bilirubin <= 1.5 x ULN | AST <= 3 x ULN | ALT <= 3 x ULN | Prior or concurrent malignancy allowed if not interfering with safety or efficacy assessment | HIV-infected patients on effective antiretroviral therapy with undetectable viral load within 6 months are eligible",Prior neoadjuvant or adjuvant chemotherapy for this disease | Prior radiotherapy for this disease | Previous hormonal therapy for this disease | Hypersensitivity to letrozole or intolerance/hypersensitivity to carboplatin/paclitaxel | Myocardial infarction or unstable angina within 6 months | New York Heart Association class II or greater congestive heart failure | Known central nervous system metastases | Active or uncontrolled systemic infection (except uncomplicated urinary tract infection) | Baseline neuropathy grade >= 2 | Aberrant p53 expression on IHC (consistent with TP53 mutation/high-grade serous ovarian cancer),(none),FEMALE,F,"Hard exclusion: The trial is for newly diagnosed low-grade serous ovarian/peritoneal carcinoma, but the patient has recurrent clear cell ovarian carcinoma. Additionally, the trial excludes patients with prior adjuvant chemotherapy, which this patient received.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; BRCA1 positive; Optimal debulking surgery performed; Received adjuvant carboplatin + paclitaxel + bevacizumab; Cytology-positive malignant pleural effusion at 5 months post-adjuvant,(none),Carboplatin; Paclitaxel; Bevacizumab; Optimal debulking surgery,Stage III,,36,years,female,(none),CORRECT,F,"Hard exclusion applies: the trial is for low-grade serous ovarian/peritoneal carcinoma, while the patient has recurrent clear cell ovarian carcinoma. This disease mismatch triggers an automatic F. The noted prior adjuvant chemotherapy is an additional exclusion but not necessary for the F decision.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT04095663,0.521765947341919,Fistulizing Crohn's Disease,Comparison of Surgery and Medicine on the Impact of Diverticulitis (COSMID) Trial,NA,18 years,Diverticulitis,Age >= 18 years | At least one episode of diverticulitis confirmed by CT scan (or pending confirmation) | Colonoscopy completed or scheduled to rule out other colon pathology per screening guidelines | History of recurrent uncomplicated diverticulitis without current symptoms (AUD in remission) OR persistent signs/symptoms related to diverticular disease >= 3 months after recovery from an episode of AUD (excluding IBS and other conditions),"Previous operation for diverticulitis | Current or prior endoscopic or surgical interventions for fistula or stricture, or current significant bleeding related to diverticular disease | Right-sided diverticulitis | Comorbid or prior surgical conditions that contraindicate elective surgery (e.g., liver failure, renal failure, malignancy, frozen abdomen) | Actively undergoing chemotherapy or radiation for malignancy | Immunodeficiency (e.g., ANC < 500/µL, chronic immunosuppressive drugs such as oral corticosteroids or anti-TNF agents, or known AIDS with recent CD4 < 200/µL) | Taking prescription medication to treat active inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis) | Taking prescription medication for irritable bowel syndrome | Pregnant or expectation of becoming pregnant in the 30 days following baseline/screening | Abdominal or pelvic surgery in the past month",(none),ALL,F,"Disease mismatch: the trial targets diverticulitis, while the patient has fistulizing Crohn's disease. The trial also excludes individuals treated for active inflammatory bowel disease.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,F,"Correctly applied hard exclusion: disease mismatch (trial is for diverticulitis, patient has fistulizing Crohn’s disease). That alone mandates F. Additional mention of IBD medication exclusion is unnecessary but does not affect the correct F grade.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT04103476,0.6005065441131592,Dementia,Atherosclerosis Intervention With Novel Tissue Selective Estrogen Complex Therapy,PHASE2,45 years to 59 years,Atherosclerosis; Cognitive Decline,Women 45-59 years old | <6 years postmenopausal | Serum estradiol <30 pg/mL | Cessation of regular menses >6 months,"Hysterectomy | Clinical signs, symptoms, or personal history of cardiovascular disease | Diabetes mellitus or fasting serum glucose >126 mg/dL | Life-threatening illness with prognosis <5 years | Cirrhosis or liver disease | History of deep vein thrombosis or pulmonary embolism | History of breast cancer | Current use of postmenopausal hormone replacement therapy within 1 month of randomization | Uncontrolled hypertension (>180/>110 mmHg) | Plasma triglycerides >500 mg/dL | Serum creatinine >2.0 mg/dL",Discontinue postmenopausal hormone replacement therapy >=1 month before randomization,FEMALE,F,"The trial restricts enrollment to females aged 45–59, whereas the patient is a 68-year-old male. Additionally, the trial's disease focus (atherosclerosis/cognitive decline) does not explicitly include dementia.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,"Multiple hard exclusions apply: trial restricts to females (patient is male), age 45–59 (patient is 68), and disease mismatch (trial lists atherosclerosis/cognitive decline, not dementia). Therefore F is correct and the grader’s reasoning aligns with the rubric.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT04154956,0.8322389125823975,Metastatic Non-Small Cell Lung Cancer,"Randomized, Open-label, Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated, Metastatic Nonsquamous, Non-small-cell Lung Cancer Patients With CEACAM5-positive Tumors",PHASE3,18 years,Non-squamous Non-small Cell Lung Cancer (metastatic),Histologically or cytologically confirmed non-squamous non-small cell lung cancer with metastatic disease | Progression after platinum-based chemotherapy | Progression after an immune checkpoint inhibitor | CEACAM5 expression >=2+ in >=50% of tumor cells by IHC (central lab) | At least one measurable lesion per RECIST v1.1 | ECOG performance status 0-1,"Untreated brain metastases or history of leptomeningeal disease; if previously treated brain metastases, no documented non-progressive disease on imaging >=4 weeks after CNS therapy and >=2 weeks before first dose | Significant concomitant illnesses that would impair participation or interpretation | Invasive malignancy within 3 years other than cured local tumors (e.g., resected/ablated basal or squamous cell skin cancer or cervical carcinoma in situ) | Unresolved prior treatment-related toxicity >= grade 2 (except alopecia, vitiligo, or controlled thyroiditis) | Known AIDS-related illnesses or HIV requiring antiretroviral therapy, or unresolved viral hepatitis | History of and/or unresolved corneal disorders; contact lens use not permitted | Concurrent anticancer therapy | Prior treatment with docetaxel, maytansinoid ADCs (DM1 or DM4), or any CEACAM5-targeting drug | Contraindication to corticosteroid premedication | Poor bone marrow, liver, or kidney function | Hypersensitivity to study interventions or components (including EDTA, paclitaxel, polysorbate 80)",Progression after platinum-based chemotherapy; Progression after immune checkpoint inhibitor,ALL,F,The trial requires progression after both platinum-based chemotherapy and an immune checkpoint inhibitor; the patient has only received osimertinib and has not had these prior therapies. Therefore the required treatment setting is not met.,Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),INCORRECT,D,"No hard exclusions apply. The patient’s disease and age/sex fit, but there is a clear soft mismatch on the line-of-therapy/prior-exposure anchor: the trial requires progression after platinum chemotherapy and an immune checkpoint inhibitor, which the patient lacks. That warrants a D, not an F. CEACAM5 status is unknown and should not trigger F per rubric.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT04190862,0.6677473187446594,Fistulizing Crohn's Disease,"An Open-Label, Single-Center, Investigator Initiated Phase 1B Trial of E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas",PHASE1,18 years,Anal Fistula,Age >= 18 years | Medically eligible and agrees to undergo fistulotomy | Simple perianal fistula with 2 or fewer fistula tracts | Maximum fistula tract length 3 inches | No history of Crohn's disease or Ulcerative Colitis | Females of childbearing potential: negative pregnancy test at screening | Females of childbearing potential: willing to use a highly effective method of contraception during the study | Males who can father a child: willing to use a recommended method of contraception and refrain from sperm donation from the start of conditioning therapy for at least 1 year after completion,"Concomitant rectovaginal fistulas | Abscess present | Active infection (e.g., redness, swelling, tenderness, or fever) | Rectal and/or anal stenosis | Seton in place unless removed prior to treatment | Ongoing steroid treatment or steroid use within the last 4 weeks | Renal impairment: creatinine clearance < 90 mL/min or serum creatinine >= 1.5 x ULN | Hepatic impairment: total bilirubin >= 1.5 x ULN | Hepatic impairment: AST >= 2.5 x ULN | Hepatic impairment: ALT >= 2.5 x ULN | History of abuse of alcohol or other addictive substances within 6 months | Active malignant tumor within 5 years | Abnormal, severe, progressive, uncontrolled hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral disease | Congenital or acquired immunodeficiency including HIV infection or AIDS | Major surgery or severe trauma within the previous 6 months | Candidate for solid organ transplantation or high likelihood of needing a solid organ transplant | Pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment | Hypersensitivity or allergy to DMSO | Inability or unwillingness to comply with study procedures | Receiving or received any investigational drug within 3 months prior to E-CEL UVEC cell therapy",(none),ALL,F,"The trial explicitly excludes any history of Crohn’s disease, while the patient has fistulizing Crohn’s. It also excludes patients with a seton in place unless removed, and the patient currently has a draining seton.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,F,"Hard exclusion applies: the trial requires no history of Crohn’s disease, but the patient has fistulizing Crohn’s. This alone yields F. The seton-in-place issue could be conditional, but is not needed to justify F.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT04205812,0.8323574066162109,Metastatic Non-Small Cell Lung Cancer,"A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304)",PHASE3,18 years,Squamous Non-Small Cell Lung Cancer (metastatic); Nonsquamous Non-Small Cell Lung Cancer (metastatic),Histologically or cytologically confirmed non-small cell lung cancer (squamous or nonsquamous) that is Stage IV (AJCC v8) | No prior systemic treatment for advanced/metastatic non-small cell lung cancer | Measurable disease per RECIST v1.1 | ECOG performance status 0–1 | Life expectancy >= 3 months | Adequate organ function per protocol-specified laboratory values,"Clinically significant cardiac disease within 6 months | Major surgery within 3 weeks before first dose | Thoracic radiation therapy > 30 Gy within 6 months | Peripheral neuropathy >= Grade 2 (for participants who may receive cisplatin, paclitaxel, or nab-paclitaxel) | Untreated central nervous system metastases or carcinomatous meningitis | History of interstitial lung disease or noninfectious pneumonitis that required systemic steroids | Active infection requiring systemic therapy or active tuberculosis | Superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervical cancer, or other in situ cancers | Contraindications to study chemotherapy agents | Active autoimmune disease requiring systemic treatment in the past 2 years | Receiving systemic antibiotics or steroid therapy <= 7 days prior to first dose | Receipt of a live vaccine within 30 days before the first dose (and until 90 days after last dose of study drug) | Known active hepatitis B virus or hepatitis C virus infection",No prior systemic therapy for advanced/metastatic non-small cell lung cancer,ALL,F,"The trial requires first-line metastatic NSCLC with no prior systemic therapy, but the patient has received osimertinib for metastatic disease, violating this requirement. Other criteria do not clearly disqualify based on available data.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),INCORRECT,D,"Patient disease, age, and sex match; stage (metastatic) matches. However, the trial requires first-line (no prior systemic therapy) and the patient has received osimertinib, creating a clear line-of-therapy/prior-exposure mismatch. Per rubric, this is a soft mismatch on a core anchor (D), not a hard exclusion (F) because it is not listed under trial_exclusion_criteria; inclusion requirements alone do not trigger F.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT04238143,0.5696934461593628,Rheumatoid Arthritis,Adipose-Derived Biocellular Regenerative Therapy in Treatment of Osteoarthritis (OA) and Associated Connective Tissue Degeneration and Pain,NA,18 years to 90 years,Osteoarthritis; Knee Osteoarthritis; Shoulder Osteoarthritis; Ankle/Foot Osteoarthritis; Hip Osteoarthritis; Osteoarthritis (multiple joints),"Documented osteoarthritic inflammatory and/or degenerative changes in the knee, hip, shoulder, Achilles tendon, sacroiliac joint, wrist/hand, foot/ankle, or plantar fasciitis | No systemic disorders that would preclude safely undergoing the procedures | Adequate perivascular and extracellular matrix donor tissues available",Systemic or psychological impairment that would preclude tolerance and understanding of procedures and follow-up | Active cancer or receiving chemotherapy or radiation therapy | Pregnancy | Active infections increasing risk for treatment | High-dose steroid use or receipt of corticosteroids within 6 months before treatment | Medication or opiate addiction or active treatment for drug rehabilitation | History of severe traumatic brain injuries | Investigator judges medical issues would prevent completing study requirements,(none),ALL,F,"The trial targets osteoarthritis, while the patient has rheumatoid arthritis, creating a disease mismatch hard exclusion. Although age and sex fit, the disease is not eligible.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Correct: The patient has rheumatoid arthritis while the trial targets osteoarthritis only, which is a hard disease mismatch per the rubric. F is appropriate regardless of other factors.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT04253964,0.8170062899589539,Metastatic Non-Small Cell Lung Cancer,Phase II Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-Small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy,PHASE2,18 years,Non-Small Cell Lung Cancer (metastatic or unresectable),Histologic or cytologic diagnosis of non-small cell lung cancer that is metastatic or unresectable with no curative options | No prior systemic treatment (chemotherapy or immunotherapy) for non-curative intent | Age >= 18 years | ECOG performance status 0-2 | Life expectancy > 3 months | Adequate organ and marrow function | Absolute neutrophil count >= 1000/µL | Platelets >= 100000/µL | Women of child-bearing potential and men agree to use adequate contraception during study treatment,"Presence of a targetable activating alteration for which first-line targeted therapy is indicated (e.g., EGFR activating mutation, ALK rearrangement, ROS1 rearrangement, BRAF mutation) | Active autoimmune disease requiring systemic treatment within the past 2 years | History of non-infectious pneumonitis that required systemic corticosteroids | Uncontrolled intercurrent illness (e.g., active infection, symptomatic congestive heart failure, unstable angina, clinically significant arrhythmia, or significant psychiatric illness) | Pregnancy or breastfeeding",No prior systemic therapy for advanced/metastatic disease; Prior curative-intent therapy allowed,ALL,F,"The trial explicitly excludes patients with targetable activating alterations (e.g., EGFR mutations) and requires no prior systemic therapy for metastatic disease; this patient has an EGFR exon 19 deletion and has received osimertinib for 2 years.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"The trial explicitly excludes patients with targetable activating alterations (e.g., EGFR mutations), which the patient has (EGFR exon 19). This is a hard exclusion, so F is correct. The noted prior systemic therapy for metastatic disease also conflicts with the trial’s inclusion criteria, further supporting ineligibility.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT04267887,0.7361431121826172,Castration-Resistant Prostate Cancer,Advanced ChemoHormonal Therapy for Treatment Naïve Metastatic Prostate Cancer: Apalutamide and Abiraterone Acetate With Prednisone and Androgen Deprivation Therapy After Treatment With Docetaxel and Androgen Deprivation Therapy,PHASE2,18 years,Prostate Cancer (metastatic castration-sensitive),"Histologically or cytologically confirmed prostate cancer or strong clinical suspicion with metastatic pattern and PSA > 50 ng/mL | High-risk disease: either (a) at least 2 of visceral metastases, >=3 bone lesions, Gleason 8–10; or (b) >=4 bone lesions with >=1 outside vertebral column or pelvis and/or visceral metastases | Prior neoadjuvant or adjuvant ADT allowed if >= 24 months elapsed before restarting ADT for metastatic castration-sensitive disease | ADT-sensitive disease with no PSA progression or new metastatic deposits since starting ADT | Completed up to 6 cycles of docetaxel for metastatic castration-sensitive disease with <= 16 weeks since day 21 of the final cycle | Life expectancy > 18 months | ECOG performance status <= 2 | Hemoglobin > 9.0 g/dL | Leukocytes > 3,000/µL | Absolute neutrophil count > 1,500/µL | Platelets >= 100,000/µL | Total bilirubin <= 1.5 x ULN | AST/ALT < 2.5 x ULN | Albumin > 3 g/dL | eGFR > 30 mL/min | Potassium >= 3.5 mmol/L | Medications known to lower the seizure threshold discontinued or substituted >= 4 weeks prior to day 1","Unwilling to stop saw palmetto, PC-SPECs, or other herbal agents known to affect PSA | Receipt of other investigational agents within 30 days prior to day 1 | Prior exposure to apalutamide, enzalutamide, abiraterone, darolutamide, or any other second-generation antiandrogen therapy | History of allergic reactions to compounds similar to apalutamide or study agents | Another active malignancy other than non-melanoma skin cancer (unless metastatic) or superficial bladder cancer | Seizure or condition predisposing to seizure (e.g., prior stroke within 1 year, brain AVM, schwannoma, meningioma, or other benign CNS/meningeal disease requiring treatment) | Severe or unstable angina, recent myocardial infarction, symptomatic congestive heart failure or LVEF < 50%, thromboembolic events, or clinically significant ventricular arrhythmias within 6 months prior to day 1 | Uncontrolled hypertension | Gastrointestinal disorder affecting absorption | Active infection (e.g., HIV or viral hepatitis) | Chronic medical condition requiring > 10 mg prednisone/prednisolone daily | Baseline moderate or severe hepatic impairment (Child-Pugh Class B or C) | Inability to stop prohibited medications: atypical antipsychotics, bupropion, lithium, meperidine/pethidine, phenothiazine antipsychotics, tricyclic antidepressants, tramadol",Up to 6 cycles of docetaxel for metastatic castration-sensitive disease completed; <= 16 weeks since day 21 of final cycle; Prior neoadjuvant or adjuvant ADT allowed if >= 24 months elapsed before restarting ADT for metastatic castration-sensitive disease; Ongoing ADT with castration-sensitive disease and no PSA progression or new metastases since starting ADT,MALE,F,The trial targets metastatic castration-sensitive prostate cancer and excludes prior exposure to enzalutamide or abiraterone; the patient has castration-resistant disease and has received both enzalutamide and abiraterone.,Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),CORRECT,F,"Hard exclusions apply: the trial explicitly excludes prior exposure to enzalutamide/abiraterone, which the patient has, and the trial targets metastatic castration-sensitive disease while the patient has castration-resistant disease. Therefore F is correct.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT04314544,0.626903235912323,Rheumatoid Arthritis,"A Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)",PHASE3,18 years,Psoriatic Arthritis (active),Age >= 18 years | Rheumatoid factor negative | Anti-CCP antibody negative | Prior exposure to anti-TNF agent(s) for psoriasis or psoriatic arthritis,"Planned surgical intervention for a pretreatment condition between baseline and Week 24 | Active infection requiring systemic anti-infectives within 28 days before first dose | Serious infection requiring hospitalization or IV anti-infectives within 8 weeks before first dose | Recurrent or chronic infections (e.g., chronic pyelonephritis, chronic osteomyelitis, bronchiectasis) | History of hepatitis B infection | History of hepatitis C infection | History of HIV infection | Myocardial infarction, unstable angina, or ischemic stroke within 6 months before first dose | Active malignancy, including cutaneous basal or squamous cell carcinoma or melanoma | History of malignancy within 5 years except treated and cured cutaneous basal or squamous cell carcinoma, in situ cervical carcinoma, or in situ ductal breast carcinoma | History of alcohol or drug abuse within the previous 2 years | Unwilling or unable to use adequate contraception as specified | Donation or loss of >= 400 mL of blood within 8 weeks before dosing",Prior anti-TNF therapy for psoriasis or psoriatic arthritis,ALL,F,"Disease mismatch: the trial targets psoriatic arthritis, while the patient has rheumatoid arthritis. Additionally, the trial excludes anyone with a history of hepatitis B infection, which the patient has (HBsAg-negative, anti-HBc-positive).",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Correct F. There is a hard disease mismatch (trial targets psoriatic arthritis; patient has rheumatoid arthritis). Additionally, the trial explicitly excludes any history of hepatitis B infection, which the patient has (HBsAg–, anti-HBc+). Either condition independently warrants an F.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT04315233,0.7752338647842407,Recurrent Clear Cell Ovarian Carcinoma,A Phase I/Ib Trial of the CDK4/6 Antagonist Ribociclib And The HDAC Inhibitor Belinostat In Patients With Metastatic Triple Negative Breast Cancer And Recurrent Ovarian Cancer With Response Prediction By Genomics (CHARGE),PHASE1,18 years,"Triple-Negative Breast Cancer (metastatic); Ovarian Carcinoma (serous, recurrent)","Dose escalation: Pathologically confirmed metastatic or unresectable triple-negative breast cancer with measurable disease by RECIST 1.1, ER and PR <= 1% by IHC, HER2 negative, not amenable to curative therapy. | Dose escalation: Pathologically confirmed recurrent, unresectable serous ovarian carcinoma. | Dose expansion: Pathologically confirmed metastatic or unresectable triple-negative breast cancer with measurable disease by RECIST 1.1, ER and PR <= 1% by IHC, HER2 negative, not amenable to curative therapy. | Age >= 18. | ECOG performance status <= 2. | Able to swallow pills. | Adequate organ function per protocol thresholds. | At least one safely accessible metastatic site for biopsy and willingness to undergo up to 3 biopsies. | Negative pregnancy test for women of childbearing potential. | Agrees to use effective contraception for at least 6 months after last dose. | Able to provide informed consent.","Prior treatment with CDK4/6 inhibitors or HDAC inhibitors for cancer. | Major surgery, radiotherapy, anticancer therapy, or investigational agents within 4 weeks or <= 5 half-lives (whichever is shorter). | Active or progressive brain metastases or leptomeningeal disease unless CNS-specific treatment not required during first cycle per treating physician. | Requirement for valproic acid within 5 days before first belinostat dose or during study. | Active infection requiring systemic therapy. | Allergy or hypersensitivity to belinostat, ribociclib, or their binders. | Uncontrolled arrhythmia, congestive heart failure, or angina; MI, symptomatic pericarditis, or cardiac surgery within 6 months. | Left ventricular ejection fraction < 50%. | Clinically significant cardiac arrhythmias, complete left bundle branch block, or high-grade AV block. | Congenital long QT syndrome. | Baseline QTcF > 450 msec with heart rate 50–90 BPM required on qualifying ECG. | Concurrent use of UGT1A1 inhibitors within 7 days prior to day 1. | Concurrent herbal supplements unless approved; must discontinue >= 7 days prior to day 1. | Concurrent medications with known risk of Torsades de Pointes that cannot be discontinued or switched >= 7 days prior to start. | Unresolved diarrhea >= Grade 2 (CTCAE v5.0). | Use within 7 days prior to start of strong/moderate CYP3A4/5 inducers or inhibitors, certain narrow-therapeutic-index CYP3A4/5 substrates, or grapefruit/pomelo/star-fruit/Seville orange. | Current treatment with warfarin or other coumarin anticoagulants (other anticoagulants allowed). | Impaired GI function that may alter drug absorption (e.g., uncontrolled IBD, uncontrolled vomiting, major stomach or small bowel resection). | Pregnant or breastfeeding. | Women or men of childbearing potential not using highly effective contraception during treatment and for 6 months after. | Known HIV infection with detectable viral load within 6 months (controlled on ART with undetectable load eligible). | Known chronic HBV or HCV infection with detectable viral load (suppressed/undetectable viral load eligible). | Another malignancy (other than breast or ovarian in dose escalation) anticipated to need systemic treatment within 1 year.","Washout >= 4 weeks (or >= 5 half-lives) from major surgery, radiotherapy, anticancer therapy, or investigational agents before day 1.",ALL,F,"The ovarian cancer cohort requires recurrent serous ovarian carcinoma, while the patient has recurrent clear cell ovarian carcinoma—a required histologic subtype mismatch, which is a hard exclusion.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; BRCA1 positive; Optimal debulking surgery performed; Received adjuvant carboplatin + paclitaxel + bevacizumab; Cytology-positive malignant pleural effusion at 5 months post-adjuvant,(none),Carboplatin; Paclitaxel; Bevacizumab; Optimal debulking surgery,Stage III,,36,years,female,(none),CORRECT,F,"The trial’s ovarian cohort requires serous histology; the patient has clear cell ovarian carcinoma. This is a required subtype mismatch, which is a hard exclusion per the rubric. Grade F is correct.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT04331769,0.528365969657898,Duchenne Muscular Dystrophy,Randomized Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study,NA,18 years,Dilated Cardiomyopathy; Heart Failure With Reduced Ejection Fraction,"Age >= 18 years | Left ventricular ejection fraction >= 20% and <= 40% by transthoracic echocardiography assessed by core lab | Left ventricular end-diastolic diameter >= 55 mm by transthoracic echocardiography | NYHA class III, or ambulatory class IV, or NYHA class II with a heart failure hospitalization within the prior 12 months | Six-minute walk distance between 100 m and 450 m | Diagnosis and treatment for heart failure established >= 90 days before consent | On stable, optimally titrated guideline-directed medical therapy for >= 30 days (with documented intolerance if applicable) | When applicable, cardiac resynchronization therapy device placed > 90 days before screening | When applicable, implantable cardioverter-defibrillator placed > 30 days before screening","Myocardial infarction within 90 days prior to consent | Percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 90 days prior to consent | Untreated clinically significant coronary artery disease requiring revascularization | Severe aortic arch calcification, mobile aortic atheroma, intracardiac mass, thrombus, or vegetation by fluoroscopy or echocardiography | Suboptimal ventricular anatomy or wall thickness for device implantation by echocardiography and/or CT | Heart failure etiology other than ischemic or non-ischemic dilated cardiomyopathy (e.g., hypertrophic, amyloid, restrictive cardiomyopathy, uncorrected congenital heart disease, constrictive pericarditis) | Hemodynamic instability within 30 days prior to implant requiring inotropic or mechanical support | Planned cardiac surgery or interventions within 180 days post-randomization | Active bacterial endocarditis | Severe right ventricular dysfunction by right heart catheterization and/or echocardiography | Fixed pulmonary hypertension with pulmonary artery systolic pressure > 70 mmHg not responsive to vasodilator therapy | History of stroke within 90 days of consent or Modified Rankin Scale >= 2 from any prior stroke | Mitral regurgitation grade 3+ or 4+ | Untreated degenerative (primary) mitral valve disease (mild prolapse without need for intervention allowable) | Prior mitral or aortic valve replacement | Tricuspid regurgitation grade 4+ | Moderate or severe aortic stenosis (aortic valve area < 1.5 cm2 or peak velocity > 300 cm/sec) | Aortic regurgitation grade 2+, 3+, or 4+ | Anatomic constraints preventing appropriate access/implant (e.g., femoral arteries not supporting a 20F introducer sheath) | eGFR < 25 mL/min/1.73 m2 | Contraindication to anticoagulation during the procedure | Contraindication to 90 days of antiplatelet therapy | Known allergy to nitinol, polyester, or polyethylene | Prior true anaphylactic reaction to contrast agents not amenable to adequate pre-medication | Life expectancy < 1 year due to non-cardiac conditions | Currently participating in another interventional investigational study | On high dose steroids or immunosuppressant therapy | Pregnant, lactating, or of child-bearing potential without documented birth control","On guideline-directed medical therapy, stable and optimally titrated for >= 30 days; If an SGLT2 inhibitor is newly added or dose change exceeds stability parameters, delay screening >= 30 days after the change; CRT device placed > 90 days before screening when applicable; ICD placed > 30 days before screening when applicable",ALL,F,"Disease mismatch: the trial targets HFrEF/dilated cardiomyopathy, not Duchenne muscular dystrophy. The patient is also 11 years old (min age 18), and has LVEF 52% (trial requires 20–40%).",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,"Hard exclusions apply: disease mismatch (trial targets HFrEF/dilated cardiomyopathy, not DMD) and age <18 vs trial minimum 18. Either alone triggers F. Grader’s reasoning and grade are correct.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT04363164,0.7230435609817505,Castration-Resistant Prostate Cancer,A Randomized Phase II Study Comparing Sequential High Dose Testosterone and Enzalutamide to Enzalutamide Alone in Asymptomatic Men With Castration Resistant Metastatic Prostate Cancer,PHASE2,18 years to 90 years,"Prostate Adenocarcinoma (metastatic, castration-resistant)","ECOG performance status <=2 | Age >=18 years | Histologically confirmed prostate adenocarcinoma | On continuous androgen deprivation therapy (surgical castration or LHRH agonist/antagonist) | Castrate serum testosterone <50 ng/dL | Metastatic disease documented by CT or bone scan | Disease progression on abiraterone acetate plus ADT (PSA and/or radiographic per RECIST 1.1 or PCWG3) | Screening PSA >= 1.0 ng/mL | Biopsy required if soft tissue lesion amenable (pre-treatment and on-treatment) | No prior enzalutamide, apalutamide, darolutamide, or investigational AR-targeted therapy | Prior testosterone allowed | Prior docetaxel for hormone-sensitive disease allowed (<=6 doses) | Prior sipuleucel-T and radium-223 allowed if >4 weeks from last dose | Abiraterone discontinued >=2 weeks before starting therapy | Attempt to wean off prednisone; continue lowest achievable dose if unable to fully wean | Bilirubin < 2.5 x ULN | AST < 2.5 x ULN | ALT < 2.5 x ULN | Serum creatinine < 2.5 x ULN | Absolute neutrophil count >= 1500 /µL | Platelet count >= 100000 /µL | Hemoglobin >= 8 g/dL | At least 4 weeks since prior radiation or chemotherapy","Pain due to metastatic prostate cancer requiring treatment intervention with pain medication | ECOG performance status >=3 | Prior enzalutamide therapy | Prior chemotherapy with docetaxel or cabazitaxel for castration-resistant prostate cancer | Requires urinary self-catheterization for voiding due to obstruction from prostate cancer or BPH (indwelling Foley or suprapubic catheter allowed) | Disease sites/extent that increase risk from testosterone therapy (e.g., femoral metastases with fracture risk, severe/extensive spinal metastases with cord compression risk, extensive liver metastases) | Serious or unstable medical, psychiatric, or other condition that could interfere with safety or consent | Active uncontrolled infection, including known HIV/AIDS, hepatitis B, or hepatitis C | Any condition or mental impairment compromising consent, safety, or compliance | Current anticoagulation with warfarin, rivaroxaban, or apixaban (unless transitioned to enoxaparin prior to treatment) | History of thromboembolic event within 12 months not on systemic anticoagulation | Hematocrit >51% | Untreated severe obstructive sleep apnea | Uncontrolled or poorly controlled heart failure | Allergy to sesame seed oil or cottonseed oil | Major surgery within 3 weeks before screening or not fully recovered from prior surgery","Continuous androgen deprivation therapy required; Progression on abiraterone acetate plus ADT required; No prior enzalutamide, apalutamide, darolutamide, or investigational AR-targeted therapy; Prior testosterone allowed; Prior docetaxel for hormone-sensitive disease allowed (<=6 doses); Prior sipuleucel-T allowed (>4 weeks washout); Prior radium-223 allowed (>4 weeks washout); Abiraterone washout >=2 weeks before starting study therapy; At least 4 weeks since prior radiation or chemotherapy; Attempt to taper prednisone to lowest feasible dose before starting therapy",MALE,F,"Explicit exclusion applies: the trial disallows any prior enzalutamide, and the patient has previously received/en had progression on enzalutamide. Other factors (male, age 66, metastatic castration-resistant disease) align but do not override this hard exclusion.",Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),CORRECT,F,"The trial explicitly excludes patients with any prior enzalutamide; the patient has prior/progression on enzalutamide. This is a hard exclusion per the rubric, so F is correct. Other factors (age, sex, disease, stage) do not override the explicit exclusion.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT04436640,0.6091967821121216,Rheumatoid Arthritis,"A Multicenter, Open-Label Extension Study to Asses the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Study Participants With Active Axial Spondyloarthritis, Ankylosing Spondylitis, and Nonradiographic Axial Spondyloarthritis",PHASE3,18 years,Axial Spondyloarthritis; Ankylosing Spondylitis; Nonradiographic Axial Spondyloarthritis,Completed feeder study AS0010 (NCT03928704) or AS0011 (NCT03928743),Plans for pregnancy during the study or within 20 weeks after final dose (self or partner). | Meets withdrawal criteria in AS0010 or AS0011. | Ongoing serious adverse event or history of serious infections in feeder study (medical monitor approval required). | Positive or indeterminate interferon gamma release assay unless appropriately evaluated and treated.,(none),ALL,F,"Disease mismatch: the trial targets axial spondyloarthritis (AS/nr-axSpA), not rheumatoid arthritis. It also requires completion of a specific feeder study, which is not documented for this patient.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Correct F: The patient has rheumatoid arthritis while the trial targets axial spondyloarthritis/AS/nr-axSpA—this is a hard disease mismatch per rubric. Mention of feeder study completion is unnecessary and, if considered alone, would be unknown (not a hard exclusion), but the disease mismatch alone justifies F.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT04510051,0.7211015820503235,Recurrent Glioblastoma,"Phase I Study of Cellular Immunotherapy Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Children With Recurrent/Refractory Malignant Brain Tumors",PHASE1,4 years to 25 years,Malignant Brain Neoplasm (recurrent/refractory),"Karnofsky Performance Status >= 60% (except loss of mobility due to disease involvement) | Life expectancy > 4 weeks | Histologically confirmed malignant brain neoplasm progressed after prior conventional therapy | Radiographic progression/recurrence > 12 weeks after completion of initial conventional therapy (including initial radiation therapy) | IL13Ralpha2-positive tumor expression by IHC (H-score >= 50) confirmed by institutional pathology | Programmable shunt present if applicable and able to tolerate being switched off for >= 2 consecutive days | Platelets >= 50,000/µL | Total bilirubin <= 2 x ULN (unless Gilbert's disease) | AST <= 2 x ULN | ALT <= 2 x ULN | Creatinine clearance >= 75 mL/min/1.73m^2 | Seronegative for HIV Ag/Ab combo, negative for active HBV (HBsAg negative), and HCV as per RNA testing if antibody positive | Women of childbearing potential: negative pregnancy test | Females and males of childbearing potential agree to effective contraception or abstinence during study and for 6 months after last dose | Dexamethasone dose <= 0.1 mg/kg/day on day of PBMC collection | Adequate venous access for PBMC collection | At least 2 weeks since last dose of prior targeted agents, chemotherapy, or radiation before PBMC collection | Serum creatinine < 1.6 mg/dL (for CNS catheter placement eligibility) | WBC >= 2,000/µL (for CNS catheter placement eligibility) | ANC >= 1,000/µL (for CNS catheter placement eligibility) | Platelets > 50,000/µL (for CNS catheter placement eligibility) | INR <= 1.3 (for CNS catheter placement eligibility) | Bilirubin < 1.5 mg/dL (for CNS catheter placement eligibility) | ALT and AST < 2 x ULN (for CNS catheter placement eligibility) | Second-line radiation therapy completed >= 4 weeks prior to surgical resection/biopsy/catheter placement | No supplemental oxygen required to keep saturation > 95% and no progressive chest radiographic abnormalities (for lymphodepletion/infusion eligibility) | No pressor support required and no symptomatic cardiac arrhythmias (for lymphodepletion/infusion eligibility) | Afebrile (<= 38.5 C) with no positive blood cultures and no indications of meningitis within 48 hours prior to infusion | Hepatic: total bilirubin or transaminases <= 2 x ULN (for lymphodepletion/infusion eligibility) | Renal: serum creatinine < 1.8 mg/dL (for lymphodepletion/infusion eligibility) | No uncontrolled seizure activity (for lymphodepletion/infusion eligibility) | For each CAR T infusion: platelet count >= 50,000/µL (transfusion permitted to achieve >= 50,000/µL) | For each CAR T infusion: dexamethasone <= 0.1 mg/kg/day","Requires supplemental oxygen to keep saturation > 95% and not expected to resolve within 2 weeks | Requires pressor support and/or has symptomatic cardiac arrhythmias | Requires dialysis | Uncontrolled seizure activity and/or clinically evident progressive encephalopathy | Poorly controlled non-malignant intercurrent illness or illness severity deemed unsafe by investigators | Any other active malignancy | Being treated for severe infection or recovering from major surgery until recovery is complete | Uncontrolled illness including ongoing or active infection; known active hepatitis B or C infection; signs or symptoms of active infection, positive blood cultures, or radiologic evidence of infections | Confirmed HIV positivity within 4 weeks of enrollment | Pregnant or breastfeeding","Progressed after prior conventional therapy; At least 2 weeks since last targeted agent, chemotherapy, or radiation before PBMC collection; At least 6 weeks since completion of nitrosourea-containing chemotherapy before study treatment; At least 23 days since completion of temozolomide before study treatment; At least 4 weeks since completion of other non-nitrosourea cytotoxic chemotherapy before study treatment; If most recent treatment was a targeted agent only and toxicities resolved, at least 2 weeks since last dose before study treatment; At least 4 weeks since last bevacizumab dose before starting study treatment; Second-line radiation therapy completed at least 4 weeks prior to surgery/biopsy/catheter placement",ALL,F,"The trial only enrolls patients aged 4–25, while the patient is 40 years old, which is a hard age-window exclusion. Although IL13Rα2 positivity is also required and unknown here, the age criterion alone makes the patient ineligible.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),CORRECT,F,"Age window is a hard exclusion: trial allows 4–25 years; patient is 40. That alone mandates grade F. Mention of IL13Rα2 being unknown is correct to ignore for hard exclusion, but age already disqualifies.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT04577456,0.6011291742324829,Fistulizing Crohn's Disease,Pivotal Study to Evaluate the Safety and Efficacy of the Insides™ System in the Treatment of Subjects With a Double Enterostomy and/or Enterocutaneous Fistula and Type 2 Intestinal Failure.,NA,21 years,Enterocutaneous Fistula; High Output Stoma; Intestinal Failure,Age >= 21 years | Dependent on parenteral nutrition | Double enterostomy/enterocutaneous fistula with exposed afferent and efferent limbs visible on the abdominal wall | Minimum 2 weeks after DES/ECF creation | Distal limb can be intubated by >= 24 Fr feeding tube (dilation allowable),"Insufficient distal access channel for device insertion | Bowel obstruction proximal to the DES/ECF | Small bowel obstruction distal to the DES/ECF | Anastomotic leak distal to the DES/ECF | Perforation distal to the DES/ECF | Current Clostridioides difficile colitis | Current small intestinal bacterial overgrowth | Signs or symptoms of systemic infection | Pre-existing gastrointestinal motility disorders (e.g., slow transit constipation, outlet obstruction, fecal incontinence, gastroparesis) | Metabolic, neurogenic, or endocrine disorders causing colonic dysmotility (e.g., multiple sclerosis, Parkinson's disease, hypothyroidism) | Peritoneal metastatic disease known prior to DES/ECF closure | Liver cirrhosis | Hereditary coagulopathy (e.g., von Willebrand disease) | Severe chronic renal insufficiency (eGFR < 30 mL/min) | Active implantable medical devices (e.g., neuromodulation, cardiac systems) | Metal stents within 20 cm of intended controller use | Pregnancy or breastfeeding",(none),ALL,F,"Disease mismatch: the trial targets double enterostomy or enterocutaneous fistula with intestinal failure, whereas the patient has perianal fistulizing Crohn’s disease without an enterocutaneous fistula or stoma. Additionally, required features like parenteral nutrition dependence are not indicated.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,F,"Disease mismatch is a hard exclusion: the trial targets enterocutaneous fistula/double enterostomy with intestinal failure, not perianal fistulizing Crohn’s disease. Thus F is appropriate. Mention of parenteral nutrition was extra but not needed for the F decision.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT04592237,0.7712825536727905,Metastatic Non-Small Cell Lung Cancer,Randomized Phase II Study of Platinum-Taxane-Cetrelimab Induction Followed by Niraparib Plus or Minus Cetrelimab Maintenance in Men With Aggressive Variant Prostate Cancers,PHASE2,18 years,Aggressive Variant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Metastatic Prostate Neuroendocrine Carcinoma; Metastatic Prostate Small Cell Carcinoma; Stage IV Prostate Cancer,"Histologically or cytologically confirmed prostate carcinoma | Metastatic disease documented on imaging (bone scan, CT and/or MRI) | Meets at least one aggressive variant prostate carcinoma (AVPC) criterion | Histologically proven small cell (neuroendocrine) prostate carcinoma (AVPC criterion) | Exclusive visceral metastases (AVPC criterion) | Predominantly lytic bone metastases by x-ray or CT (AVPC criterion) | Bulky (>= 5 cm) lymphadenopathy or high-grade tumor mass in prostate/pelvis (AVPC criterion) | Low PSA (<= 10 ng/mL) at initial presentation or at symptomatic progression in the castrate-setting plus high-volume (>= 20) bone metastases (AVPC criterion) | Elevated LDH (>= 2 x ULN) or elevated CEA (>= 2 x ULN) without other etiologies (AVPC criterion) | Short interval (<= 180 days) to castration-resistant progression after initiation of hormonal therapy (AVPC criterion) | Loss or mutation in at least 2 of TP53, RB1, and PTEN by CLIA-certified testing, IHC and/or DNA sequencing (AVPC criterion) | Castration-resistant progression per RECIST without PSA rising to >= 1.0 ng/mL per PCWG3 (AVPC criterion) | Documented progressive disease by PSA progression (3 measurements >= 7 days apart with last >= 1.0 ng/mL), or new/increasing measurable disease (RECIST), or >= 2 new bone lesions (PCWG3), or increasing symptoms attributed to progression | Surgically or medically castrated with baseline testosterone <= 50 ng/dL | ECOG performance status <= 2 | Hemoglobin >= 10.0 g/dL (>= 8 g/dL if due to marrow infiltration) | Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1.0 x 10^9/L if due to marrow infiltration) | White blood cells (WBC) > 3 x 10^9/L (> 2 x 10^9/L if due to marrow infiltration) | Platelet count >= 100 x 10^9/L (>= 50 x 10^9/L if due to marrow infiltration) | Total bilirubin <= 1.5 x ULN (except Gilbert syndrome) | AST and ALT <= 2.5 x ULN (<= 5 x ULN with liver metastases) | Calculated creatinine clearance (Cockcroft-Gault) >= 30 mL/min | No features suggestive of MDS/AML on peripheral blood smear | Able to swallow study drugs whole (tablet/capsule)","Any prior treatment for CRPC with carboplatin, cisplatin, cabazitaxel, a PARP inhibitor, or an anti-PD-1/PD-L1 inhibitor | More than one prior line of chemotherapy | Unresolved toxicity from prior therapy > CTCAE grade 2 (except allowed ongoing LHRH therapy, bisphosphonates, or RANK ligand inhibitors) | Any unresolved CTCAE grade >= 2 toxicity from previous anti-cancer therapy (irreversible toxicities not expected to be exacerbated may be allowed) | History or current diagnosis of myelodysplastic syndrome or acute myeloid leukemia | Active uncontrolled infection | Active or symptomatic viral hepatitis or chronic liver disease | History of pneumonitis or extensive bilateral non-malignant lung disease | Another malignancy with >= 30% probability of recurrence within 24 months (except adequately treated non-melanoma skin cancer, curatively treated in-situ cervical cancer, or Ta urothelial carcinoma) | Serious underlying medical or psychiatric condition that would make study drug hazardous or confound adverse event interpretation (e.g., uncontrolled ventricular arrhythmia, recent myocardial infarction, superior vena cava syndrome, uncontrolled seizures, history of allogeneic transplant, primary immunodeficiency) | Unable to swallow oral medication or gastrointestinal disorders likely to interfere with absorption | Symptomatic uncontrolled brain metastases or spinal cord compression | Known hypersensitivity to niraparib, carboplatin, cabazitaxel, or anti-PD-1/PD-L1 inhibitors | Current or prior use of systemic immunosuppressive medication within 28 days before first cetrelimab dose (with specified corticosteroid exceptions) | Active or prior documented autoimmune or inflammatory disorders requiring systemic therapy (with specified exceptions such as vitiligo, alopecia, controlled hypothyroidism, certain inactive diseases, or celiac disease controlled by diet) | Receipt of live attenuated vaccine within 30 days prior to cetrelimab | Compulsory detention for treatment of psychiatric or physical illness",(none),MALE,F,"Disease mismatch: the trial is for aggressive variant/metastatic prostate cancer, while the patient has metastatic non-small cell lung cancer with EGFR exon 19 deletion. Therefore, the patient's disease is not included in the trial.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,Disease mismatch is a hard exclusion per rubric. Trial targets prostate cancer; patient has metastatic NSCLC. Grader correctly assigned F with appropriate reasoning.,,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT04592237,0.7733438611030579,Metastatic Urothelial Carcinoma,Randomized Phase II Study of Platinum-Taxane-Cetrelimab Induction Followed by Niraparib Plus or Minus Cetrelimab Maintenance in Men With Aggressive Variant Prostate Cancers,PHASE2,18 years,Aggressive Variant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Metastatic Prostate Neuroendocrine Carcinoma; Metastatic Prostate Small Cell Carcinoma; Stage IV Prostate Cancer,"Histologically or cytologically confirmed prostate carcinoma | Metastatic disease documented on imaging (bone scan, CT and/or MRI) | Meets at least one aggressive variant prostate carcinoma (AVPC) criterion | Histologically proven small cell (neuroendocrine) prostate carcinoma (AVPC criterion) | Exclusive visceral metastases (AVPC criterion) | Predominantly lytic bone metastases by x-ray or CT (AVPC criterion) | Bulky (>= 5 cm) lymphadenopathy or high-grade tumor mass in prostate/pelvis (AVPC criterion) | Low PSA (<= 10 ng/mL) at initial presentation or at symptomatic progression in the castrate-setting plus high-volume (>= 20) bone metastases (AVPC criterion) | Elevated LDH (>= 2 x ULN) or elevated CEA (>= 2 x ULN) without other etiologies (AVPC criterion) | Short interval (<= 180 days) to castration-resistant progression after initiation of hormonal therapy (AVPC criterion) | Loss or mutation in at least 2 of TP53, RB1, and PTEN by CLIA-certified testing, IHC and/or DNA sequencing (AVPC criterion) | Castration-resistant progression per RECIST without PSA rising to >= 1.0 ng/mL per PCWG3 (AVPC criterion) | Documented progressive disease by PSA progression (3 measurements >= 7 days apart with last >= 1.0 ng/mL), or new/increasing measurable disease (RECIST), or >= 2 new bone lesions (PCWG3), or increasing symptoms attributed to progression | Surgically or medically castrated with baseline testosterone <= 50 ng/dL | ECOG performance status <= 2 | Hemoglobin >= 10.0 g/dL (>= 8 g/dL if due to marrow infiltration) | Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1.0 x 10^9/L if due to marrow infiltration) | White blood cells (WBC) > 3 x 10^9/L (> 2 x 10^9/L if due to marrow infiltration) | Platelet count >= 100 x 10^9/L (>= 50 x 10^9/L if due to marrow infiltration) | Total bilirubin <= 1.5 x ULN (except Gilbert syndrome) | AST and ALT <= 2.5 x ULN (<= 5 x ULN with liver metastases) | Calculated creatinine clearance (Cockcroft-Gault) >= 30 mL/min | No features suggestive of MDS/AML on peripheral blood smear | Able to swallow study drugs whole (tablet/capsule)","Any prior treatment for CRPC with carboplatin, cisplatin, cabazitaxel, a PARP inhibitor, or an anti-PD-1/PD-L1 inhibitor | More than one prior line of chemotherapy | Unresolved toxicity from prior therapy > CTCAE grade 2 (except allowed ongoing LHRH therapy, bisphosphonates, or RANK ligand inhibitors) | Any unresolved CTCAE grade >= 2 toxicity from previous anti-cancer therapy (irreversible toxicities not expected to be exacerbated may be allowed) | History or current diagnosis of myelodysplastic syndrome or acute myeloid leukemia | Active uncontrolled infection | Active or symptomatic viral hepatitis or chronic liver disease | History of pneumonitis or extensive bilateral non-malignant lung disease | Another malignancy with >= 30% probability of recurrence within 24 months (except adequately treated non-melanoma skin cancer, curatively treated in-situ cervical cancer, or Ta urothelial carcinoma) | Serious underlying medical or psychiatric condition that would make study drug hazardous or confound adverse event interpretation (e.g., uncontrolled ventricular arrhythmia, recent myocardial infarction, superior vena cava syndrome, uncontrolled seizures, history of allogeneic transplant, primary immunodeficiency) | Unable to swallow oral medication or gastrointestinal disorders likely to interfere with absorption | Symptomatic uncontrolled brain metastases or spinal cord compression | Known hypersensitivity to niraparib, carboplatin, cabazitaxel, or anti-PD-1/PD-L1 inhibitors | Current or prior use of systemic immunosuppressive medication within 28 days before first cetrelimab dose (with specified corticosteroid exceptions) | Active or prior documented autoimmune or inflammatory disorders requiring systemic therapy (with specified exceptions such as vitiligo, alopecia, controlled hypothyroidism, certain inactive diseases, or celiac disease controlled by diet) | Receipt of live attenuated vaccine within 30 days prior to cetrelimab | Compulsory detention for treatment of psychiatric or physical illness",(none),MALE,F,"Disease mismatch: the trial is for prostate cancers, while the patient has metastatic urothelial carcinoma. Additionally, the trial excludes prior anti–PD-1/PD-L1 therapy and the patient previously received pembrolizumab.",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),CORRECT,F,"Correct: There is a hard exclusion due to disease mismatch (trial is for prostate cancers; patient has metastatic urothelial carcinoma), which alone mandates F. The added note about prior PD-1 therapy is not necessary and may be contextually specific to CRPC, but the disease mismatch already justifies F.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT04619797,0.8011409044265747,Metastatic Non-Small Cell Lung Cancer,"A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Patients With Previously Untreated Advanced Non-Squamous Non-Small-Cell Lung Cancer",PHASE2/PHASE3,18 years,Non-Squamous Non-Small Cell Lung Cancer (metastatic or unresectable),ECOG performance status 0–1 | Histologically or cytologically documented locally advanced unresectable or metastatic non-squamous NSCLC not eligible for curative surgery and/or definitive chemoradiotherapy | No prior systemic treatment for metastatic non-squamous NSCLC | Known tumor PD-L1 status | Measurable disease per RECIST v1.1 | Life expectancy >= 12 weeks | Adequate hematologic and end-organ function | Negative HIV test at screening | Serology negative for active hepatitis B virus or active hepatitis C virus at screening,"EGFR sensitizing mutations or ALK fusion oncogene | Pulmonary lymphoepithelioma-like carcinoma subtype of NSCLC | Symptomatic, untreated, or actively progressing CNS metastases | Active or history of autoimmune disease or immune deficiency | History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis | History of malignancy other than NSCLC within 5 years prior to randomization, except malignancies with negligible risk of metastasis or death | Severe infection within 4 weeks prior to initiation of study treatment or any active infection that could impact patient safety | Treatment with investigational therapy within 28 days prior to initiation of study treatment | Prior treatment with CD137 agonists or immune checkpoint blockade therapies including anti-CTLA-4, anti-TIGIT, anti-PD-1, or anti-PD-L1 antibodies | Treatment with systemic immunostimulatory agents within 4 weeks or 5 half-lives (whichever is longer) prior to initiation of study treatment | Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment or anticipated need for systemic immunosuppressive medication during study treatment | Known allergy or hypersensitivity or other contraindication to any component of the chemotherapy regimen | Pregnant or breastfeeding | Known targetable ROS1 or BRAF V600E genomic aberration",No prior systemic treatment for metastatic non-squamous NSCLC; Investigational therapy washout >= 28 days,ALL,F,The trial explicitly excludes patients with EGFR sensitizing mutations and requires no prior systemic therapy for metastatic NSCLC; this patient has an EGFR exon 19 deletion and has been on osimertinib for 2 years.,Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"Hard exclusion applies: the trial explicitly excludes EGFR-sensitizing mutations, and the patient has an EGFR exon 19 deletion. This alone yields F. Additionally, the trial requires no prior systemic therapy for metastatic disease, while the patient has received osimertinib, reinforcing ineligibility. The grader’s reasoning and grade align with the rubric.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT04623775,0.811528205871582,Metastatic Non-Small Cell Lung Cancer,A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC),PHASE2,18 years,Non-Small Cell Lung Cancer (metastatic or recurrent),Histologically confirmed non-small cell lung cancer (squamous or non-squamous) that is stage IVA/IVB or recurrent after multimodal therapy for locally advanced disease. | ECOG performance status <=1 at screening and prior to randomization. | Measurable disease by CT or MRI per RECIST 1.1. | No prior systemic anti-cancer treatment given as primary therapy for advanced or metastatic disease (including EGFR or ALK inhibitors).,"EGFR, ALK, ROS1, or BRAF V600E mutations that are sensitive to available targeted therapy. | Untreated central nervous system metastases. | Leptomeningeal metastases. | Concurrent malignancy requiring treatment or prior malignancy active within 2 years before randomization. | Prior treatment with PD-1, PD-L1, PD-L2, CTLA-4, or other T-cell co-stimulation/checkpoint pathway-targeting agents.",No prior systemic therapy for advanced or metastatic disease.,ALL,F,"The trial explicitly excludes patients with sensitizing EGFR mutations; the patient has an EGFR exon 19 deletion. Additionally, the study requires no prior systemic therapy for metastatic disease, whereas the patient has received osimertinib.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,The trial has explicit exclusion criteria that the patient violates: (1) exclusion of sensitizing EGFR mutations (patient has EGFR exon 19 deletion) and (2) no prior systemic therapy for metastatic disease (patient received osimertinib). Either is a hard exclusion → F. The grader’s reasoning and grade are correct.,,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT04636190,0.6017745733261108,Rheumatoid Arthritis,"A Retrospectively Enrolled and Prospectively Followed, Post-market, Multi-center Evaluation of the Clinical Outcomes of the Triathlon All-Polyethylene Tibia",NA,18 years,Knee Arthritis,Implanted with Triathlon All-Polyethylene Tibia with compatible Stryker femoral and patellar components; no pending revision or removal | Age >= 18 years at time of device implantation | Non-pregnant,"Active or suspected latent infection in or around the affected knee at time of implantation | Distant foci of infection that could cause hematogenous spread to the implant site at time of implantation | Skeletally immature at time of device implantation | Mental or neuromuscular disorder creating unacceptable risk of prosthesis instability, fixation failure, or postoperative complications | Bone stock compromised by disease, infection, or prior implantation that cannot provide adequate support and/or fixation | Severe knee instability secondary to absent collateral ligament integrity and function | Immunologically suppressed or receiving steroids in excess of normal physiological requirements at the time of surgery (e.g., > 30 days)",(none),ALL,F,"The trial targets knee arthritis patients with a specific knee implant, whereas the patient has rheumatoid arthritis—this is a disease mismatch constituting a hard exclusion.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Disease mismatch: trial targets knee arthritis with specific implant recipients, while patient has rheumatoid arthritis. Per rubric, disease mismatch is a hard exclusion → F. The grader’s reasoning aligns with this.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT04685590,0.5880361795425415,Dementia,Phase II Clinical Trial to Evaluate the Safety and Feasibility of Senolytic Therapy in Alzheimer's Disease,PHASE2,60 years,Alzheimer Disease (early stage); Mild Cognitive Impairment (amnestic),Age >= 60 years | Amnestic mild cognitive impairment or early Alzheimer's disease | Elevated cerebrospinal fluid (CSF) tau protein | Tau PET positive | Total cholesterol < 240 mg/dL | HbA1c <= 7% | PT/PTT/INR within normal limits,"Body mass index > 40 kg/m2 | Average QTcF at screening >= 450 msec in males or >= 460 msec in females | MRI contraindications (e.g., claustrophobia, ferromagnetic implants, cardiac pacemaker) | Pregnancy or possible pregnancy | Significant neurologic disease other than prodromal or early Alzheimer's disease (e.g., Parkinson's disease, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or significant head trauma with persistent deficits or structural brain abnormalities) | Current or history of alcohol or substance abuse or dependence within the past 2 years | Current suicidality or suicidal ideation | Uncontrolled diabetes (HbA1c > 7% or current use of insulin or sulfonylureas) | Poorly controlled blood pressure: systolic > 160 mmHg or diastolic > 90 mmHg | eGFR < 10 mL/min/1.73 m2 | Myocardial infarction, angina, stroke, or transient ischemic attack within the past 6 months | Chronic heart failure | Significant liver disease with total bilirubin > 2 x ULN | Inability to tolerate oral medication | Use of medications that are sensitive substrates or have a narrow therapeutic range for CYP3A4, CYP2C8, CYP2C9, or CYP2D6, or strong inhibitors or inducers of CYP3A4 | Current use of drugs that induce cellular senescence (alkylating agents, anthracyclines, platinums, other chemotherapy) | Therapeutic-dose anticoagulation (e.g., warfarin, heparin, low molecular weight heparin, factor Xa inhibitors) unless can be held for 2 days prior to lumbar puncture with prescriber approval | Use of H2 antagonists or proton pump inhibitors unable or unwilling to hold for at least 2 days prior to and during each 2-day dosing course | Co-enrollment in another ADRD study with a potentially disease-modifying intervention or study drug affecting senescent cells (eligible after washout >= 6 months from last dose to screening) | Use of anti-amyloid therapies (e.g., aducanumab, lecanemab) | Any condition that, in the Investigator's judgment, would put the subject at risk or preclude successful completion of the trial","Stable dose (>= 3 months) of FDA-approved Alzheimer's disease medications (e.g., donepezil, rivastigmine, galantamine) permitted; Prior disease-modifying ADRD investigational therapy allowed with washout >= 6 months before screening",ALL,F,"The trial enrolls only amnestic MCI or early Alzheimer’s disease, while the patient has moderate-stage dementia (MMSE 19), failing the required disease/stage criteria.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,"The trial requires amnestic MCI or early Alzheimer’s disease. The patient has moderate-stage dementia (MMSE 19), definitively lacking the required stage/setting, which is a hard exclusion per the rubric. Therefore F is correct.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT04704505,0.7489602565765381,Castration-Resistant Prostate Cancer,Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) (BAT-RAD Study),PHASE2,18 years,Prostate Adenocarcinoma (metastatic castration-resistant),"Histologically confirmed prostate adenocarcinoma; if mixed histology, >50% adenocarcinoma. | Bone metastases on Technetium-99m bone scan within 2 months of screening. | Castrate-resistant prostate cancer with testosterone <= 50 ng/dL and evidence of progression by PSA or new lesions. | PSA progression defined by two rising values >= 2 ng/mL at least 7 days apart or new lesions on imaging. | Serum PSA >= 2.0 ng/mL. | On bone health agents (zoledronic acid or denosumab) for >= 4 weeks before enrollment and continued during study. | ECOG performance status <= 1. | Asymptomatic or minimally symptomatic disease (no opioids). | Prior treatment with <= 1 novel AR-targeted drug permitted (abiraterone, enzalutamide, darolutamide, apalutamide). | Prior first-generation antiandrogens (bicalutamide, nilutamide) permitted. | Prior chemotherapy for hormone-sensitive prostate cancer allowed if given >= 12 months prior to entry. | Adequate bone marrow, renal, and liver function (ANC > 1,000/µL; Platelets > 100,000/µL; Hemoglobin >= 9 g/dL; AST/ALT <= 1 x ULN; Total bilirubin <= 1 x ULN). | No other malignancy within 5 years except adequately treated basal or squamous cell skin cancer. | Availability of tumor tissue for genomic analysis (archival or new biopsy).","Known visceral metastasis (lung, liver, brain). | Spinal cord compression, imminent long bone fracture, or conditions likely to require radiation or steroids for pain during active phase. | Previous treatment with chemotherapy for mCRPC, or any chemotherapy within 12 months prior to registration (adjuvant or hormone-sensitive chemo allowed if completed > 6 months before registration). | Radiation therapy (external beam or brachytherapy) within 28 days prior to registration. | Systemic bone-seeking radiopharmaceuticals (strontium-89, samarium-153, rhenium-186, rhenium-188) within the previous 24 weeks. | Use of strong opioid analgesics for cancer-related pain (e.g., oxycodone, morphine, methadone); weak opioids like codeine or tramadol permitted. | Investigational drug use within 4 weeks of treatment. | Intact prostate with urinary obstructive symptoms (including symptomatic BPH). | Current warfarin anticoagulation (other anticoagulants such as rivaroxaban, dabigatran, apixaban permitted). | Symptomatic nodal disease (scrotal, penile, or leg edema). | Serious uncontrolled medical disorder or active infection posing poor medical risk (e.g., uncontrolled diabetes, heart failure, COPD, IBD, Paget's disease, ventricular arrhythmia, recent MI within 12 months, thromboembolic events, or psychiatric disorder interfering with consent). | Disease extent or sites posing risk from testosterone therapy (e.g., femoral metastases with fracture risk, severe extensive spinal metastases with cord compression risk); low-volume visceral metastasis permitted at investigator discretion if bone disease predominant.","Bone health agents (zoledronic acid or denosumab) required for >= 4 weeks prior to enrollment and continued during study.; <= 1 prior novel AR-targeted therapy allowed (abiraterone, enzalutamide, darolutamide, apalutamide).; Prior first-generation antiandrogens permitted (bicalutamide, nilutamide).; Prior chemotherapy for hormone-sensitive prostate cancer allowed if completed >= 12 months before entry.",MALE,F,"The trial explicitly excludes patients with known visceral metastases (e.g., liver), which this patient has. Additionally, it allows ≤1 prior novel AR-targeted therapy, while the patient has received both abiraterone and enzalutamide.",Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),CORRECT,F,"Hard exclusion applies: trial excludes known visceral metastases and patient has liver metastases. The note about >1 prior AR-targeted therapy is also a mismatch (though framed as inclusion), but the visceral metastasis alone warrants F.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT04738487,0.8404600620269775,Metastatic Non-Small Cell Lung Cancer,"A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 With Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer",PHASE3,18 years,Non-Small Cell Lung Carcinoma (metastatic),"Histologically or cytologically confirmed Stage IV (M1a, M1b, or M1c) non-small cell lung cancer | Measurable disease per RECIST 1.1 | EGFR/ALK/ROS1-directed therapy not indicated; absence of ALK and ROS1 gene rearrangements | PD-L1 expression >=1% by IHC at central laboratory | ECOG performance status 0–1 | Life expectancy >=3 months | Adequate organ function","Prior systemic chemotherapy or targeted/biologic therapy for metastatic NSCLC | Prior therapy with PD-1, PD-L1, or PD-L2 agents or agents targeting CTLA-4, OX-40, or CD137 | Previous treatment with an agent targeting the TIGIT pathway | Radiotherapy within 2 weeks of start of study intervention (1-week washout permitted for <=2 weeks of palliative non-CNS radiation) | Live or live-attenuated vaccine within 30 days prior to first dose (investigational vaccines not allowed) | Participation in another investigational agent study or investigational device use within 4 weeks prior to first dose | Active or untreated CNS metastases or carcinomatous meningitis (treated, stable >=4 weeks without steroids >=14 days allowed) | Severe hypersensitivity (>=Grade 3) to pembrolizumab/vibostolimab, pembrolizumab, or excipients | Active autoimmune disease requiring systemic treatment within the past 2 years (replacement therapy allowed) | Diagnosis of immunodeficiency or chronic systemic steroids >10 mg prednisone equivalent daily or other immunosuppressive therapy within 7 days before first dose | History of non-infectious pneumonitis requiring steroids or current pneumonitis | Known interstitial lung disease | Active infection requiring systemic therapy | Known HIV infection | Known hepatitis B infection or active hepatitis C infection | Any condition, therapy, or laboratory abnormality preventing receipt of first-line platinum-doublet chemotherapy or that may confound results per investigator | Psychiatric or substance abuse disorder that would interfere with study requirements",No prior systemic therapy for metastatic NSCLC; Adjuvant/neoadjuvant or chemoradiation for nonmetastatic NSCLC allowed if completed >=6 months before metastatic diagnosis; Radiotherapy washout >=2 weeks (>=1 week for palliative non-CNS radiation <=2 weeks); Investigational agent/device washout >=4 weeks; Live vaccine washout >=30 days,ALL,F,"The trial requires first-line therapy with no prior systemic targeted/biologic therapy for metastatic NSCLC and that EGFR-directed therapy not be indicated; the patient has an EGFR exon 19 mutation and has received osimertinib for 2 years, violating both criteria.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"Hard exclusion applies: the trial excludes any prior systemic targeted/biologic therapy for metastatic NSCLC, and the patient has received osimertinib for 2 years. Additionally, the trial requires EGFR-directed therapy not be indicated, which is not met given the patient’s EGFR exon 19 mutation. Therefore F is correct.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT04742673,0.5814594030380249,Dementia,Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study,PHASE2,18 years,Delirium,"Age >= 18 years | Admitted to an ICU | Receiving treatment for respiratory failure and/or shock (e.g., mechanical ventilation, NIPPV, ECMO, optiflow, vasopressors, IABP)","Allergy to guanfacine, clonidine, or dexmedetomidine | Home antipsychotic use requiring continuation in the hospital | Second- or third-degree heart block, or persistent bradycardia < 50 beats/min requiring intervention (unless treated with a pacemaker) | Expected death within 24 hours of enrollment | Acute or subacute neurologic deficit causing inability to live independently after discharge (e.g., stroke, intracranial hemorrhage, cranial trauma, intracranial malignancy, anoxic brain injury, cerebral edema) | Dementia or other chronic neurologic disease/disorder causing inability to live independently at baseline | Active substance abuse | Psychotic disorder | Blindness or deafness preventing outcome assessments | Pregnancy or breastfeeding | Cardiac surgery within the current hospitalization",(none),ALL,F,"Disease mismatch: the trial targets delirium in ICU patients, while the patient has dementia. Additionally, the trial explicitly excludes patients with dementia causing inability to live independently.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,"Correct F due to hard exclusion: disease mismatch (trial is for delirium; patient has dementia). The added note about explicit exclusion may depend on independence status (unknown), but the disease mismatch alone justifies F.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT04743661,0.7876166105270386,Recurrent Glioblastoma,Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients With Recurrent Medulloblastoma and Ependymoma,PHASE2,up to 21 years,Recurrent Medulloblastoma; Recurrent Ependymoma,"Recurrent, progressive, or refractory medulloblastoma with histologic verification (Stratum 1) | Recurrent, progressive, or refractory ependymoma with histologic verification (Stratum 2) | Evidence of disease by MRI (measurable or non-measurable) or diffuse leptomeningeal disease, or tumor cells in CSF (Stratum 1) | Tumor cells in CSF allowed with or without radiographic disease (Stratum 2) | Age < 22 years at enrollment/screening | Appropriate intraventricular access device (programmable VP shunt or Ommaya) required prior to radioimmunotherapy; willingness to place/modify device as needed | Prior craniospinal irradiation for medulloblastoma unless contraindicated or not in patient’s best interest; <= 2 prior recurrences or refractory disease (Stratum 1) | Prior focal or craniospinal irradiation for ependymoma unless contraindicated or declined (Stratum 2) | Recovery from prior myelosuppressive chemotherapy; last dose >= 21 days (>= 42 days if nitrosourea) | Recovery from prior biologic/investigational agent; last dose >= 7 days (longer if delayed AEs expected) | Recovery from prior monoclonal antibody or long half-life agents; last dose >= 21 days | Radiation washout: CSI/whole brain/TBI/>=50% pelvis or spine completed >= 24 weeks before enrollment; measurable target not irradiated within 12 weeks; focal RT to symptomatic metastases >= 14 days | Autologous stem cell transplant completed >= 3 months prior to enrollment (Stratum 1) | Neurologic deficits stable >= 1 week; seizure disorders controlled on non–enzyme-inducing anticonvulsants; no enzyme-inducing antiepileptics within 1 week | Karnofsky/Lansky >= 50% | Adequate organ function (ANC, platelets, hemoglobin, renal, hepatic, coagulation per protocol thresholds) | Hypertension well controlled (<= 95th percentile) on stable medication if applicable | HIV-infected patients on effective ART with undetectable viral load within 6 months eligible | Chronic HBV with undetectable viral load on suppressive therapy eligible | HCV infection cured or on treatment with undetectable viral load eligible | Stable or decreasing dexamethasone dose for >= 7 days prior to enrollment allowed | Off colony-stimulating factors >= 1 week (>= 2 weeks for pegfilgrastim) | Use of effective contraception during study and specified period after therapy | Ependymoma: B7-H3 (CD276) positive by CLIA-certified IHC (Stratum 2)","Pregnancy | Breastfeeding (unless agrees not to breastfeed) | Prior combination therapy with bevacizumab, irinotecan, and temozolomide (Stratum 1) | Serious or non-healing wound, ulcer, or bone fracture | History of abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within 6 months | Known bleeding diathesis or coagulopathy | Significant vascular disease within 6 months (e.g., aortic aneurysm requiring repair, deep venous or arterial thrombosis) | Known thrombophilia (e.g., protein C/S deficiency, antithrombin III deficiency, Factor V Leiden, Factor II G20210A mutation, homocysteinemia, antiphospholipid antibody syndrome) | New CNS hemorrhage on baseline MRI within 14 days prior to enrollment | History within 6 months of stroke, myocardial infarction, transient ischemic attack, severe or unstable angina, peripheral vascular disease, or grade II or greater congestive heart failure | Serious and inadequately controlled cardiac arrhythmia | Hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies | Current use of NSAIDs, clopidogrel, dipyridamole, or aspirin > 81 mg/day that cannot be discontinued | Clinically significant unrelated systemic illness that would compromise tolerance of therapy or study procedures | Prior or concurrent malignancy that may interfere with safety/efficacy assessment of the investigational regimen | Concurrent anti-cancer or investigational drug therapy | Use of strong or moderate CYP3A4/5 inducers or inhibitors, or CYP3A4/5 substrates with a narrow therapeutic index, that cannot be discontinued >= 7 days prior to enrollment | Use of prohibited herbal preparations (e.g., St. John's wort, kava, ephedra, ginkgo, DHEA, yohimbe, saw palmetto, black cohosh, ginseng) that cannot be stopped >= 7 days prior to enrollment | Inability or unwillingness to comply with study visits, procedures, or drug administration plan","Progression after initial surgery, radiation therapy, or other therapies for ependymoma (Stratum 2); Prior craniospinal irradiation for medulloblastoma unless contraindicated or not in patient’s best interest (Stratum 1); Last myelosuppressive chemotherapy >= 21 days prior to enrollment (>= 42 days if prior nitrosourea); Last biologic or investigational anti-neoplastic agent >= 7 days prior to enrollment (longer if delayed AEs expected); Last monoclonal antibody or long half-life agent >= 21 days prior to enrollment; Radiation washout: CSI/whole brain/TBI/>=50% pelvis or spine completed >= 24 weeks before enrollment; Focal radiation to symptomatic metastatic disease completed >= 14 days before enrollment; Autologous stem cell transplant completed >= 3 months prior to enrollment (Stratum 1); Off colony-stimulating growth factors >= 1 week (>= 2 weeks for pegfilgrastim)",ALL,F,"Disease mismatch and age conflict: the study is for pediatric recurrent medulloblastoma or ependymoma with age <22, while the patient has recurrent glioblastoma and is 40 years old.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),CORRECT,F,Hard exclusions apply: disease mismatch (glioblastoma vs trial for medulloblastoma/ependymoma) and age conflict (40 years vs <22). Either triggers F. Grader’s reasoning and grade are correct.,,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT04748042,0.7512167096138,Castration-Resistant Prostate Cancer,"Focal Radiation With Pulsed Systemic Therapy of Abiraterone, ADT, Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON): A Phase II, Single Arm, Single Institution Study",PHASE2,18 years,Prostate Cancer (castration-sensitive),"Histologic or cytologic diagnosis of prostate adenocarcinoma | Prior radical prostatectomy or external beam radiation with curative intent to the prostate; if positive margins after prostatectomy, salvage or adjuvant radiation required | Newly diagnosed oligometastatic prostate cancer on molecular imaging (e.g., PSMA PET/CT or Axumin), with 1 to <=5 radiation treatment sites; each site up to 5 cm and may contain multiple lesions | No prior image-guided radiation to sites outside the prostate bed or pelvic lymph nodes (typically treated in salvage/adjuvant settings) | Post-prostatectomy: PSA >0.2 ng/mL confirmed >=4 weeks later with subsequent rise | After prior curative radiotherapy: meets Phoenix criteria for progression (nadir PSA + 2 ng/mL) | Medically fit for radiotherapy | All molecular positive disease sites can be safely treated with radiation per radiation oncologist | Candidate for androgen deprivation therapy and abiraterone per treating oncologist | Adequate organ and bone marrow function within 28 days before treatment per protocol | Prior ADT with or without second-generation androgen receptor inhibitors or abiraterone in the curative setting allowed if testosterone >150 ng/dL | ADT for metastatic disease allowed up to 4 weeks prior to registration; if prior curative ADT, testosterone recovery >150 ng/dL or >1 year since last curative ADT before recent ADT was resumed | ECOG <=1","Pure small cell or pure neuroendocrine prostate cancer histology | Prior orchiectomy | Prior exposure to PARP inhibitors, docetaxel, or cabazitaxel | Another malignancy within the past 3 years requiring treatment (except superficial squamous skin cancer or carcinoma in situ of bladder or head and neck) | Life expectancy <=3 years | Known parenchymal brain metastasis | Symptoms of cord compression requiring immediate radiation | Myelodysplastic syndrome or acute myeloid leukemia, or features suggestive of MDS/AML | Severe hepatic impairment (Child-Pugh Class C) | Active hepatitis B or hepatitis C infection | Concurrent use of strong or moderate CYP3A inducers (specified agents); required washout 5 weeks for phenobarbital or enzalutamide, 3 weeks for others before starting olaparib | Concurrent use of strong or moderate CYP3A inhibitors (specified agents); required washout 2 weeks before starting olaparib | Major surgery within 2 weeks prior to starting study treatment or not recovered from effects of surgery | Myocardial infarction or arterial thrombotic events (e.g., stroke) within the past 6 months | Resting EKG indicating uncontrolled, potentially reversible cardiac condition (e.g., unstable ischemia, uncontrolled symptomatic arrhythmia) or QTcF >500 ms, or congenital long QT syndrome | Severe or unstable angina, uncontrolled atrial fibrillation, or other cardiac arrhythmia requiring therapy | Active New York Heart Association Class II–IV heart failure | History of congestive heart failure requires LVEF >=50% within 6 months | Planned or scheduled cardiac surgery or percutaneous coronary intervention | Prior revascularization procedure within the past 12 months | Uncontrolled pituitary or adrenal dysfunction | Active infection or medical condition that contraindicates prednisone use | Chronic medical condition requiring systemic corticosteroid >10 mg prednisone daily | Prior allogeneic bone marrow transplant or double umbilical cord blood transplant | Participation in another clinical study with an investigational product or device within 1 month of registration | Uncontrolled hypertension (systolic >=160 mmHg or diastolic >=95 mmHg), unless white coat hypertension documented with acceptable home readings | Known hypersensitivity to olaparib, abiraterone, planned ADT agents (e.g., leuprolide, goserelin, degarelix), their excipients, or related classes | Immunocompromised state | Serious uncontrolled medical disorder or non-malignant systemic disease making the patient a poor medical risk (e.g., uncontrolled seizure disorder, superior vena cava syndrome, severe psychiatric disorder) | Persistent toxicities from prior therapy >= Grade 2 (except alopecia or sensory peripheral neuropathy) | Unable to swallow oral medications or gastrointestinal disorders likely to interfere with absorption",Prior radical prostatectomy or curative-intent external beam radiotherapy to the prostate required; Prior ADT with or without second-generation AR inhibitors or abiraterone in the curative setting allowed if testosterone >150 ng/dL; ADT for metastatic disease allowed up to 4 weeks prior to registration,MALE,F,"Hard exclusion: the trial is for newly diagnosed castration-sensitive, oligometastatic prostate cancer, while the patient has metastatic castration-resistant disease with progression on AR-targeted therapy.",Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),CORRECT,F,"Correct F: the trial requires castration-sensitive, newly diagnosed oligometastatic prostate cancer, while the patient has metastatic castration-resistant disease after AR-targeted therapy. This is a required stage/subtype mismatch, which is a hard exclusion per the rubric.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT04800874,0.5993735194206238,Duchenne Muscular Dystrophy,An Open Label Phase 2 Study of BBP-418 in Patients With Limb Girdle Muscular Dystrophy Type 2I (MLB-01-003),PHASE2,12 years to 55 years,Limb-Girdle Muscular Dystrophy Type 2I,Body weight >30 kg | Genetically confirmed diagnosis of LGMD2I and clinically affected with limb-girdle or distal weakness | Able to complete the 10-meter walk test in <=12 seconds unaided or are severe/non-ambulatory (unable or >12 seconds) | Previous enrollment in the natural history study MLB-01-001,"Gastrointestinal disease or surgeries that may affect absorption after oral administration | Significant cardiac, pulmonary, renal, hepatic, or endocrine disease other than that associated with LGMD2I | Any condition other than LGMD2I requiring therapy with prescription medicine (unless permitted by the investigator) | Any laboratory, vital sign, ECG abnormality, or clinical history/finding that increases risk or may confound results per investigator judgment | Pregnant or breastfeeding or planning to conceive during the study and for 12 weeks after last dose | History of drug abuse or alcoholism within 2 years prior to consent | Use of ribose or other sugar alcohol-containing supplement within 60 days before Day 1 | Use of a corticosteroid within 60 days before Day 1 | Platelet or bleeding disorder or other contraindication to muscle biopsy | Actively on an experimental therapy or device or received an experimental therapy or device within 60 days before Day 1",No ribose or other sugar alcohol supplements within 60 days before Day 1; No corticosteroids within 60 days before Day 1; No experimental therapy or device within 60 days before Day 1,ALL,F,"Disease mismatch: the trial targets LGMD2I, while the patient has Duchenne muscular dystrophy. The patient is also 11 years old (trial requires ≥12) and on corticosteroids within 60 days, which are exclusionary.",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,Correctly applied hard exclusions: disease mismatch (Duchenne vs LGMD2I) and age below minimum (11 vs ≥12). Ongoing corticosteroid use is also an explicit exclusion. F is appropriate.,,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT04849741,0.5590232610702515,Amyotrophic Lateral Sclerosis,"A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients With Alexander Disease",PHASE3,2 years to 65 years,Alexander Disease,Clinical phenotype and brain imaging consistent with Alexander disease | Documented GFAP gene mutation | Age 2 to 65 years at consent,"Clinically significant abnormalities on medical history or physical exam | Clinically significant laboratory abnormalities | Contraindication to or unwillingness to undergo MRI | Treatment with another investigational drug, biological agent, or device within 1 month or 5 half-lives | Previous treatment with an oligonucleotide within 4 months (single dose) or 12 months (multiple doses) | History of gene therapy, cell transplantation, or other experimental brain surgery | Obstructive hydrocephalus | Presence of a ventriculoperitoneal shunt or implanted CNS catheter | Brain or spinal disease that would interfere with lumbar puncture, CSF circulation, or safety assessment | Hospitalization for major surgery with general anesthesia within 12 weeks prior to screening or planned during the study | Any other condition that would make the patient unsuitable per investigator",(none),ALL,F,"Disease mismatch: the trial is for Alexander disease with required GFAP mutation, while the patient has ALS. Therefore, the patient does not meet the fundamental disease criteria.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,F,"Hard exclusion: disease mismatch. Trial targets Alexander disease (GFAP mutation), patient has ALS. Grader correctly assigned F with appropriate reasoning.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT04856982,0.7297921180725098,Amyotrophic Lateral Sclerosis,"A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation",PHASE3,18 years,Amyotrophic Lateral Sclerosis (SOD1 mutation-associated),Rapidly progressive SOD1 mutation confirmed by central reader or SOD1 mutation approved by external adjudication committee | Plasma neurofilament light chain (NfL) level below the protocol-defined threshold | Clinically presymptomatic for ALS (no clinically manifest ALS),"History or positive test for HIV at screening (testing may be omitted if not permitted by local regulations) | Current hepatitis C infection (positive HCV antibody with detectable HCV RNA); eligible if positive antibody with undetectable RNA | Current hepatitis B infection (positive HBsAg and/or anti-HBc); immune due to past infection or vaccination is eligible | History of systemic hypersensitivity to tofersen or formulation excipients, or to diagnostic agents used in the study | Confounding neuromuscular or neurological disorder expected to be progressive and/or associated with elevated neurofilament, per Investigator | Risk for increased or uncontrolled bleeding or bleeding risk that could increase risk for intra/postoperative bleeding | Significant cognitive impairment, clinical dementia, or unstable psychiatric illness (including psychosis, suicidal ideation, suicide attempt, or untreated major depression) within 90 days of screening that would interfere with study procedures | Current treatment with riluzole, edaravone, and/or sodium phenylbutyrate/taurursodiol without required washout | Use of off-label treatments for ALS | Treatment with another investigational drug, biological agent, or device within 1 month or 5 half-lives of the study agent (whichever is longer) | No prior treatment with small interfering RNA, stem cell therapy, or gene therapy | Anticipated need for antiplatelet or anticoagulant therapy that cannot be safely continued or held for lumbar puncture per local guidelines/Investigator | Current enrollment or planned enrollment in another interventional clinical study (noninterventional ALS natural history studies may be allowed)","Discontinue riluzole, edaravone, and/or sodium phenylbutyrate/taurursodiol for >= 5 half-lives before screening; No investigational treatment within 1 month or 5 half-lives (whichever is longer)",ALL,F,"The trial requires clinically presymptomatic adults with a confirmed SOD1 mutation, while the patient has manifest, diagnosed ALS (symptomatic), which fails the required setting. SOD1 status is also unknown and the patient is on riluzole, but the presymptomatic requirement alone is a hard mismatch.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,F,"The trial requires clinically presymptomatic SOD1 mutation carriers (no manifest ALS). The patient has diagnosed, symptomatic ALS, which is a definitive required setting mismatch and thus a hard exclusion per the rubric. SOD1 status is unknown and riluzole use/washout is not determinative, but the presymptomatic requirement alone justifies F.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT04865939,0.7750227451324463,Metastatic Urothelial Carcinoma,A Randomized Trial Comparing Intravesical Gemcitabine to Continuous Bladder Irrigation With Sterile Water to Prevent Bladder Cancer Implantation in Patients Undergoing Excision of Upper Tract Urothelial Carcinoma,PHASE3,18 years to 90 years,Urothelial Carcinoma (renal pelvis); Urothelial Carcinoma (ureter),Biopsy-proven upper tract urothelial carcinoma. | Planned excisional surgery (distal ureterectomy or nephroureterectomy) with curative intent. | Age 18–90 years. | Life expectancy > 1 year. | Agreement to use adequate contraception during study and for 90 days after.,Concurrent or prior bladder cancer with a disease-free interval < 3 years. | Synchronous bilateral upper tract urothelial carcinoma. | Planned radical cystectomy. | Bladder capacity < 100 mL. | History of allergic reactions to gemcitabine or similar agents.,(none),ALL,F,"Disease mismatch: the trial targets upper tract urothelial carcinoma patients undergoing planned curative excisional surgery, whereas the patient has metastatic urothelial carcinoma with no indication of upper tract disease or planned surgery.",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),CORRECT,F,"Correct: The trial is for upper tract urothelial carcinoma with planned curative excision, whereas the patient has metastatic urothelial carcinoma post-cystectomy without upper tract disease or planned surgery. This is a disease mismatch, a hard exclusion → F.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT04881617,0.7164024710655212,Dementia,Establishing Evidence-based Treatment for Speech and Language in Primary Progressive Aphasia,NA,Not specified,Primary Progressive Aphasia; Logopenic Progressive Aphasia; Nonfluent Progressive Aphasia; Semantic Dementia,"Primary Progressive Aphasia diagnosis per Gorno-Tempini et al., 2011 criteria | Mini-Mental State Examination score >= 15","Other neurological or psychiatric diagnosis contributing to cognitive-linguistic deficits | Significant uncorrected visual or hearing impairment that would interfere with participation | Mini-Mental State Examination score < 15 | Prominent initial non-speech-language impairment (cognitive, behavioral, or motoric)",(none),ALL,F,"Hard exclusion: Disease mismatch. The trial targets primary progressive aphasia variants (including semantic dementia), while the patient is listed with unspecified dementia without a PPA subtype diagnosis.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,Correct F. The trial targets Primary Progressive Aphasia variants (including semantic dementia) and requires a PPA diagnosis; the patient only has unspecified dementia without a PPA diagnosis. This is a hard disease mismatch per the rubric.,,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT04919382,0.7751345634460449,Metastatic Non-Small Cell Lung Cancer,"A Randomized, Multi-Cohort Phase II Trial of Temozolomide and Atezolizumab as Second or Third Line Treatment for Small Cell Lung Cancer",PHASE2,18 years,Small Cell Lung Cancer (metastatic),Age >= 18 years | ECOG performance status of 0 or 2 within 28 days prior to registration | Histologically or cytologically confirmed extensive-stage small cell lung cancer that is metastatic and/or recurrent | Progression or recurrence after platinum-based chemotherapy with immunotherapy | Maximum of 3 prior lines of systemic therapy in the metastatic setting | Measurable disease per RECIST v1.1 | ANC >= 1500/µL | Platelets >= 100000/µL | Serum bilirubin <= 1.5 x ULN or direct bilirubin <= ULN (<= 3 x ULN allowed with Gilbert syndrome) | AST <= 3 x ULN (<= 5 x ULN with liver metastases) | ALT <= 3 x ULN (<= 5 x ULN with liver metastases) | Serum creatinine <= 2.0 x ULN or creatinine clearance >= 50 mL/min | Albumin > 2.5 g/dL | INR <= 1.5 x ULN if not on therapeutic anticoagulation (stable regimen if on anticoagulation) | aPTT <= 1.5 x ULN if not on therapeutic anticoagulation (stable regimen if on anticoagulation) | Negative pregnancy test for females of childbearing potential | Ability to swallow and retain oral medication | Life expectancy > 3 months,"Prior temozolomide therapy | Participation in another investigational study with study therapy or device within 4 weeks of first dose | Prior chemotherapy, immunotherapy, targeted therapy, or radiation within 2 weeks prior to day 1 or unresolved toxicities > grade 1 (except <= grade 2 neuropathy or alopecia) | Symptomatic CNS metastases or untreated/actively progressing CNS metastases not meeting protocol criteria | History of intracranial or spinal cord hemorrhage | Recent CNS-directed therapy not meeting washout: stereotactic radiotherapy within 7 days, whole-brain radiotherapy within 14 days, or neurosurgical resection within 28 days | Ongoing requirement for corticosteroids for CNS disease at time of treatment | Active infection requiring systemic therapy, including tuberculosis, hepatitis B (HBsAg positive), active hepatitis C, or uncontrolled HIV infection | Active or history of autoimmune disease or immune deficiency requiring systemic treatment, with protocol-defined exceptions | History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or active pneumonitis | Significant cardiovascular disease within 3 months (NYHA class II or greater, myocardial infarction, cerebrovascular accident), unstable arrhythmia, or unstable angina | Live attenuated vaccine within 4 weeks prior to initiation of study treatment | Pregnant or breastfeeding | Severe allergic or anaphylactic reactions to chimeric or humanized antibodies or fusion proteins | Known hypersensitivity to Chinese hamster ovary cell products or components of atezolizumab | Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage (> once monthly) | Uncontrolled or symptomatic hypercalcemia (ionized calcium > 1.5 mmol/L, calcium > 12 mg/dL or corrected serum calcium > ULN) | History of leptomeningeal disease | Prior or concurrent malignancy that could interfere with safety or efficacy assessment | Psychiatric or substance abuse disorders that would interfere with protocol compliance","Progression after platinum-based chemotherapy with immunotherapy required; <=3 prior lines of systemic therapy for metastatic disease allowed; Washout >=2 weeks from prior chemotherapy, immunotherapy, targeted therapy, or radiation",ALL,F,"The trial targets metastatic small cell lung cancer after platinum-based chemo with immunotherapy. The patient has metastatic non-small cell lung cancer treated with osimertinib, so this is a disease mismatch (hard exclusion).",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"The trial is for small cell lung cancer, while the patient has non-small cell lung cancer. This is a disease mismatch, which is a hard exclusion per the rubric, warranting grade F. The grader’s reasoning correctly identified this.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT04928846,0.7737923264503479,Metastatic Non-Small Cell Lung Cancer,"A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer",PHASE3,18 years,"Non-Small Cell Lung Cancer (non-squamous, locally advanced/metastatic)","Life expectancy >= 12 weeks | c-MET overexpressing non-small cell lung cancer per IHC (VENTANA MET SP44 RxDx assay) with centrally assessed tumor tissue | Histologically or cytologically confirmed non-squamous NSCLC that is locally advanced or metastatic | Known EGFR activating mutation status | Known status of actionable gene alterations other than EGFR | Measurable disease per RECIST v1.1 | ECOG performance status 0–1 | No more than 1 prior line of systemic cytotoxic chemotherapy for locally advanced/metastatic disease | Neoadjuvant/adjuvant cytotoxic chemotherapy counts as a prior line if progression occurred within 6 months of completion | Progressed on at least 1 prior line of therapy for locally advanced/metastatic NSCLC | Without actionable gene alteration: progressed on or ineligible for platinum-based chemotherapy and an immune checkpoint inhibitor (monotherapy or in combination with chemotherapy) | With actionable gene alteration where ICI is not standard: progressed on or ineligible for targeted therapy to the driver alteration and platinum-based chemotherapy | If immune checkpoint inhibitor is standard for the actionable alteration: also progressed on or ineligible for an immune checkpoint inhibitor | Considered appropriate for docetaxel therapy by the treating physician | CNS metastases allowed if adequately treated, asymptomatic, and on stable or decreasing steroids (<= 10 mg/day prednisone equivalent) and/or anticonvulsants for >= 2 weeks before randomization","New, untreated CNS metastases | Leptomeningeal disease | Adenosquamous histology | Neuroendocrine histology | Sarcomatoid features | Actionable EGFR activating mutations (EGFR wildtype required) | Prior c-MET–targeted antibodies | Prior telisotuzumab vedotin | Prior antibody–drug conjugates targeting c-MET or containing monomethylauristatin E | Prior docetaxel therapy | History of other malignancy unless treated with curative intent and disease-free for >= 2 years, or adequately treated non-melanoma skin cancer/lentigo maligna, or carcinoma in situ without current disease | History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or active pneumonitis on screening CT (radiation pneumonitis fibrosis permitted) | Unresolved adverse event >= Grade 2 from prior anticancer therapy (except alopecia or anemia); stable replacement hormone therapy allowed | Major surgery within 21 days prior to randomization | Clinically significant medical conditions per protocol",Prior platinum-based chemotherapy required unless ineligible; Prior immune checkpoint inhibitor required unless ineligible or not standard for genotype; Prior targeted therapy to driver gene alteration required if actionable alteration present; No more than 1 prior line of systemic cytotoxic chemotherapy for advanced/metastatic disease; Neoadjuvant/adjuvant cytotoxic chemotherapy counts as a prior line if relapse within 6 months,ALL,F,"The trial explicitly excludes patients with actionable EGFR activating mutations and requires EGFR wildtype; the patient has an EGFR exon 19 deletion. The trial also requires c-MET overexpression, which is not provided.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,The trial explicitly excludes patients with actionable EGFR activating mutations and requires EGFR wildtype; the patient has an EGFR exon 19 deletion. This is a hard exclusion → F. The mention of missing c-MET overexpression is not required to reach F but does not affect the correct outcome.,,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT04940299,0.7926335334777832,Metastatic Urothelial Carcinoma,"A Phase II Study to Assess the Safety and Efficacy of Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma",PHASE2,18 years,Melanoma (unresectable/metastatic); Urothelial Carcinoma (locally advanced/metastatic); Non-Small Cell Lung Cancer (locally advanced/metastatic),"Histologically confirmed unresectable stage III or stage IV cutaneous melanoma (Cohort 1) | Consent to BRAF testing or documented BRAF V600 mutation status (Cohort 1) | Treatment-naive for unresectable/metastatic melanoma; prior adjuvant therapy allowed (Cohort 1) | Histologically or cytologically confirmed locally advanced or metastatic urothelial carcinoma of renal pelvis, ureter, bladder, or urethra; dominant transitional cell pattern if mixed histology (Cohort 2) | Cisplatin-ineligible or patient refuses standard chemotherapy; no prior systemic therapy for inoperable locally advanced/metastatic urothelial carcinoma (Cohort 2) | Cisplatin ineligibility may be due to GFR <60 and >=15 mL/min, NYHA class >= III heart failure, grade >=2 neuropathy, ECOG PS 2, or grade >=2 hearing loss (Cohort 2) | Prior intravesical chemotherapy allowed if completed >=4 weeks before treatment (Cohort 2) | If prior adjuvant/neoadjuvant chemo or chemoradiation for urothelial carcinoma, recurrence >12 months to be considered treatment-naive; no prior immuno-oncology in adjuvant/neoadjuvant (Cohort 2) | Histologically or cytologically confirmed locally advanced/metastatic NSCLC with EGFR mutation sensitive to EGFR TKI (G719X, exon 19 deletion, L858R, L861Q) (Cohort 3) | Received exactly one prior EGFR TKI in the advanced setting (Cohort 3) | Progressed on first/second-generation EGFR TKI and T790M negative by approved assay at progression, or progressed on osimertinib; EGFR TKI must be the last therapy (Cohort 3) | ECOG performance status <=1 | Measurable disease per RECIST 1.1 | Stable brain metastases <=3 cm without need for local intervention or systemic corticosteroids within 10 days prior to first treatment | Tumor tissue available for submission (FFPE block or unstained slides) from biopsy within 3 months prior to enrollment or approved archival tissue | Age >=18 years | WOCBP negative pregnancy test within 24 hours prior to start of treatment and agree to contraception; males with WOCBP partners agree to contraception","Symptomatic interstitial lung disease or condition interfering with detection/management of pulmonary toxicity | Uveal melanoma | Active or uncontrolled medical, psychiatric, or logistical condition increasing risk or interfering with study participation | Active second malignancy within 3 years except certain curable cancers (e.g., basal/squamous skin cancer, superficial bladder cancer, carcinoma in situ of prostate, cervix, or breast) | Active autoimmune disease requiring systemic treatment (exceptions: type I diabetes, hypothyroidism on replacement, skin disorders not requiring systemic treatment, or conditions not expected to recur) | Systemic corticosteroids >10 mg prednisone equivalent daily or other immunosuppressive medication within 14 days prior to first dose (exceptions allowed as specified) | History of organ or tissue transplant requiring systemic immunosuppression | Active infection requiring systemic therapy within 14 days prior to first dose | Unstable or significant cardiac disease within 12 months (e.g., unstable angina, myocardial infarction, TIA/CVA, NYHA class III/IV heart failure, uncontrolled significant arrhythmias) | Known HIV infection | Use of an investigational agent or device within 28 days prior to first dose | Live or attenuated vaccine within 30 days before first treatment | Prior treatment with anti–PD-1, anti–PD-L1, anti–PD-L2, anti–CTLA-4, or other T-cell costimulation/checkpoint agents except permitted adjuvant use | History of life-threatening toxicity from prior immune therapy unless unlikely to recur with standard countermeasures | Use of botanical preparations intended for general health support or to treat the study disease within 2 weeks prior to treatment initiation | Allergy or hypersensitivity to study drug components or severe hypersensitivity to any monoclonal antibody | Known hypersensitivity to tocilizumab, ipilimumab, or nivolumab | Prisoners or involuntarily incarcerated individuals | Compulsory detention for treatment of psychiatric or physical illness | WBC < 2000/µL | Absolute neutrophil count < 1500/µL | Platelets < 100000/µL | Hemoglobin < 9.0 g/dL (no transfusion within 14 days to meet criteria) | Serum creatinine > 1.5 x ULN unless creatinine clearance >= 40 mL/min | AST > 3.0 x ULN | ALT > 3.0 x ULN | Total bilirubin > 1.5 x ULN (except Gilbert syndrome < 3.0 x ULN) | Positive test indicating active hepatitis B or C infection","No prior systemic therapy for unresectable or metastatic melanoma; prior adjuvant therapy allowed (Cohort 1); No prior chemotherapy for inoperable locally advanced or metastatic urothelial carcinoma (Cohort 2); Prior intravesical chemotherapy allowed if completed >= 4 weeks before treatment (Cohort 2); If prior adjuvant/neoadjuvant chemotherapy or chemoradiation for urothelial carcinoma, recurrence must be > 12 months to be considered treatment-naive; no prior immuno-oncology in adjuvant/neoadjuvant (Cohort 2); Exactly one prior line of EGFR TKI therapy in advanced NSCLC and progressed; EGFR TKI must be last therapy (Cohort 3)",ALL,F,"The trial explicitly excludes prior treatment with PD-1/PD-L1/CTLA-4 agents, and the patient received pembrolizumab. Additionally, the urothelial carcinoma cohort requires no prior systemic therapy for metastatic disease, whereas the patient has progressed after second-line systemic therapy.",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),CORRECT,F,"Hard exclusion applies: trial excludes prior PD-1/PD-L1/CTLA-4 therapy and the patient received pembrolizumab. Additionally, the urothelial cohort requires no prior systemic therapy for advanced disease, while the patient is post–second line. Therefore F is correct.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT04953104,0.8376567363739014,Metastatic Urothelial Carcinoma,A Phase II Clinical Trial to Investigate ARID1A and/or KDM6A Mutation and CXCL13 Expression in the Pre-treatment Tumor Samples as a Combinatorial Predictive Biomarker for Immune Checkpoint Therapy in Metastatic Urothelial Cancer,PHASE2,18 years,Urothelial Carcinoma (metastatic or unresectable),"Tumor harboring ARID1A and/or KDM6A mutation. | Histologic or cytologic evidence of metastatic or surgically unresectable urothelial carcinoma of bladder, urethra, ureter, or renal pelvis; minor variants < 50% allowed. | Progression or recurrence after at least 1 platinum-containing chemotherapy regimen for metastatic or unresectable disease, or ineligible/refused frontline chemotherapy. | Measurable disease by CT or MRI per RECIST 1.1. | Evaluable tumor tissue (archival or new biopsy) available for biomarker analysis. | ECOG performance status 0–1. | Prior palliative radiotherapy completed >= 2 weeks before study drug; progression in previously radiated field allowed. | Adequate hematologic, hepatic, renal function per protocol laboratory thresholds. | Participation in protocol PA13-0291 with consent for biopsy and peripheral blood collection. | Females of childbearing potential: agree to contraception during treatment and for 5 months after last dose; negative pregnancy test within 24 hours prior to start. | Males sexually active with FCBP: agree to contraception during treatment; refrain from sperm donation.","Prior treatment with anti-PD-1, anti-PD-L1, anti-CTLA-4, or other agents targeting T-cell co-stimulation or immune checkpoints. | Active brain or leptomeningeal metastases unless treated and stable >= 4 weeks and off immunosuppressive corticosteroids (> 10 mg/day prednisone equivalents) for >= 2 weeks. | Serious or uncontrolled medical disorder that may increase risk or interfere with study treatment or interpretation. | Active malignancy within 3 years except for locally curable cancers (e.g., basal or squamous cell skin cancer, carcinoma in situ) or prostate cancer without PSA progression. | Active, known, or suspected autoimmune disease except allowed conditions (e.g., vitiligo, type I diabetes, residual hypothyroidism on replacement, psoriasis not requiring systemic therapy). | Systemic corticosteroids > 10 mg/day prednisone equivalents or other immunosuppressive medications within 14 days prior to study drug (except inhaled/topical or adrenal replacement). | Unresolved toxicities from prior therapy > Grade 1 (CTCAE v5) except alopecia, fatigue, and neuropathy (neuropathy must be <= Grade 2). | Chemotherapy, radiation therapy, biologics for cancer, or investigational therapy within 14 days or 5 half-lives (whichever is shorter) before first dose. | Positive test for HBV surface antigen or for HCV RNA/antibody indicating acute or chronic infection. | Known HIV infection or AIDS.","Progression or recurrence after at least 1 prior platinum-containing chemotherapy regimen for metastatic or unresectable urothelial carcinoma, or ineligible/refused frontline chemotherapy.; Prior palliative radiotherapy allowed if completed >= 2 weeks before study drug.; Washout required: no chemotherapy, radiation, biologics, or investigational therapy within 14 days or 5 half-lives before first dose (whichever is shorter).",ALL,F,"The trial explicitly excludes prior treatment with PD-1/PD-L1/CTLA-4 agents, and the patient previously received pembrolizumab (PD-1). This constitutes a hard exclusion despite disease/setting alignment.",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),CORRECT,F,"Correct: The trial explicitly excludes prior PD-1/PD-L1/CTLA-4 therapy, and the patient received pembrolizumab (PD-1). This is a hard exclusion per the rubric. Other factors (disease match, age, sex, biomarker unknown) do not override this.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT04995523,0.7747177481651306,Metastatic Non-Small Cell Lung Cancer,"Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC",PHASE1/PHASE2,18 years to 130 years,Non-Small-Cell Lung Carcinoma,"Age >= 18 years | Unresectable stage III or stage IV non-small cell lung cancer not amenable to curative surgery or radiation (per cohort-specific requirements) | Part A and Part B: Confirmed progression during treatment with a checkpoint inhibitor-containing regimen | Part C and Part D: No prior immune-oncology treatment for metastatic NSCLC | Part E: No prior systemic treatment for metastatic squamous NSCLC | Documented PD-L1 expression by PD-L1 IHC | ECOG performance status 0–1 | Life expectancy >= 12 weeks | At least 1 measurable lesion per RECIST v1.1 | Adequate bone marrow, liver, and kidney function","Sensitizing EGFR mutation | ALK fusion | Other actionable genomic alteration with an approved first-line targeted therapy (e.g., ROS1 fusion, NTRK fusion, BRAF V600E) | Previous treatment with anti-TIGIT therapy | Concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment | Part A and Part B: Primary or secondary resistance after treatment with >= 2 regimens including a checkpoint inhibitor | Part C and Part D: Any prior systemic immune-oncology agent (prior IO for curative intent for another malignancy permitted) | Part E: Any prior systemic treatment for metastatic NSCLC (including chemotherapy, anti-PD-1, anti-PD-L1, anti-CTLA-4) | Symptomatic central nervous system metastases | Thromboembolic event within 3 months prior to enrolment | Other invasive malignancy within 2 years prior to screening",Parts A/B: Progression on prior checkpoint inhibitor-containing regimen required; Parts C/D: No prior immune-oncology treatment for metastatic NSCLC required; Part E: No prior systemic treatment for metastatic NSCLC required; Treatment with one previous systemic chemotherapy allowed,ALL,F,"The trial explicitly excludes patients with sensitizing EGFR mutations; the patient has an EGFR exon 19 deletion. Therefore, despite having metastatic NSCLC and ECOG 0, he is ineligible.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"The trial explicitly excludes patients with sensitizing EGFR mutations, and the patient has an EGFR exon 19 deletion. This is a hard exclusion per the rubric, so grade F is correct. The grader’s reasoning correctly identified this key factor.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT05004129,0.5747302770614624,Duchenne Muscular Dystrophy,An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Tideglusib for the Treatment of Congenital or Childhood Onset DM1 (REACH CDM X),PHASE2/PHASE3,6 years to 45 years,Myotonic Dystrophy Type 1 (congenital/childhood onset),Diagnosis of congenital or childhood-onset myotonic dystrophy type 1 (DM1) | Genetic confirmation of DM1 | Age 6–45 years at screening | Clinical Global Impression-Severity (CGI-S) score >= 3 at screening,"Body mass index (BMI) < 13.5 kg/m^2 or > 40 kg/m^2 | New or change in medications/therapies within 4 weeks prior to baseline | Use of strong CYP3A4 inhibitors within 4 weeks prior to baseline | Concurrent use of drugs metabolized by CYP3A4 with a narrow therapeutic window (e.g., warfarin, digitoxin) | Enrollment in a clinical trial of an investigational drug within the last 6 months (except AMO-02-MD-2-003) | Significant neurological, cardiovascular, renal, hepatic, gastrointestinal, endocrine, or respiratory disease that may impact interpretability of results | Hypersensitivity to tideglusib or any components of its formulation, including strawberry",(none),ALL,F,"Disease mismatch: the trial enrolls patients with congenital/childhood-onset myotonic dystrophy type 1 (DM1), while the patient has Duchenne muscular dystrophy with a DMD exon 49-50 deletion. Although age and sex fit, the required disease is not met.",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,"The trial targets myotonic dystrophy type 1 (DM1), while the patient has Duchenne muscular dystrophy (DMD). This is a disease mismatch, which is a hard exclusion per the rubric, so grade F is correct.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT05009992,0.8077278733253479,Recurrent Glioblastoma,"A Combination Therapy Trial Using an Adaptive Platform Design for Children and Young Adults With Diffuse Midline Gliomas (DMGs) Including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression",PHASE2,2 years to 39 years,Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma (H3 K27M-mutant); WHO Grade III Glioma; Recurrent Diffuse Intrinsic Pontine Glioma; Recurrent Diffuse Midline Glioma (H3 K27M-mutant); Recurrent WHO Grade III Glioma,"Age 2 to 39 years | Diagnosis of diffuse midline glioma (including spinal cord tumors) by imaging and/or pathology | Post-radiation cohorts: within 4–14 weeks of completing radiation and no additional therapy beyond radiation | Progression cohorts: evidence of progression after completing standard-of-care radiation and no prior re-irradiation | Body weight >= 10 kg | Seizure disorder allowed if well controlled | Contraception required for participants of childbearing potential | Adequate tissue available for molecular analyses (minimum 10–20 unstained slides or 1 block with >= 40% tumor content) | No dyspnea at rest or exercise intolerance due to pulmonary insufficiency | Pulse oximetry > 92% on room air | QTc < 470 msec | Karnofsky >= 50 for >16 years or Lansky >= 50 for <=16 years | For targeted therapy cohorts: tumor harbors BRAFV600E, PDGFRA alteration (point mutation or amplification with >= 5 copies), FGFR1 alteration (point mutation, fusion, or amplification with >= 5 copies), or NF1 alteration","Histone H3 wildtype grade II diffuse astrocytoma | Thalamic or cerebellar H3K27M diffuse midline glioma (with limited specified exceptions) | Prior exposure to radiation therapy (pre-radiation cohorts) | Prior exposure to re-irradiation for tumor progression (progression cohorts) | Currently receiving another investigational drug or other anti-cancer agents | Immunodeficiency or active HIV, hepatitis B, or hepatitis C infection; autoimmune disorder requiring systemic cytotoxic or immunosuppressive therapy | Uncontrolled infection or other uncontrolled systemic illness | Pregnant or breastfeeding | Active illicit drug use or diagnosis of alcoholism | Allergy to compounds of similar composition to study agents | Evidence of disseminated disease, including diffuse leptomeningeal or CSF dissemination (except allowed in specified targeted cohorts) | Additional malignancy that is progressing or requires active treatment within 3 years | Concomitant use of potent CYP3A4/5 inhibitors within 72 hours prior to and during treatment | Concomitant use of potent CYP3A4/5 inducers (including enzyme-inducing antiepileptic drugs) within 2 weeks prior to and during treatment | History of congestive heart failure or family history of long QT syndrome",Any number of prior therapies allowed; must have recovered from acute toxicities; Washout: >= 7 days after last biologic agent or beyond known AE window; Washout: >= 5 half-lives from any investigational agent; Washout: >= 4 weeks from cytotoxic therapy (>= 23 days for temozolomide; >= 6 weeks for nitrosoureas); Washout: >= 6 weeks from therapeutic antibodies (>= 21 days for bevacizumab when tumor-directed); Washout: >= 4 weeks or >= 5 half-lives (whichever is shorter) from other anti-tumor therapies; Prior temozolomide during radiation allowed at standard pediatric dosing (90 mg/m2 daily for 42 days); Bevacizumab for radiation-induced edema allowed (up to 5 doses; no required washout); Dexamethasone allowed; dose must be stable or decreasing for >= 3 days before baseline MRI,ALL,F,"Disease mismatch: the trial enrolls diffuse midline gliomas/DIPG (and select grade III gliomas), not glioblastoma. Additionally, the patient is 40 years old, exceeding the trial’s 2–39 year age range.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),CORRECT,F,"Correct F. There is a hard exclusion due to disease mismatch (trial targets DMG/DIPG/H3K27M or Grade III glioma, not glioblastoma) and an independent hard exclusion for age (trial 2–39 years; patient 40). Either suffices for F.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT05016219,0.5787391066551208,Dementia,Phase 2 - The Use of Rhythmic Light Therapy to Entrain Gamma Oscillations and the Circadian System in Patients With Alzheimer's Disease,NA,55 years,Mild Cognitive Impairment; Alzheimer's Disease (mild),"Mild cognitive impairment | Mild Alzheimer's disease | Montreal Cognitive Assessment score 17–25 | Sleep disturbance with Pittsburgh Sleep Quality Index > 5 | Resides at home, independent living, or assisted living",Taking sleep medication | Residence in a skilled nursing facility or long-term care | Obstructing cataracts | Macular degeneration | Blindness | Severe sleep apnea | Restless legs syndrome | History of severe epilepsy,(none),ALL,F,"The trial enrolls only mild Alzheimer's disease or MCI, while the patient has moderate-stage dementia and is not specified to have Alzheimer's disease. This is a disease mismatch and also fails the trial’s required mild stage.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,"Correct: The patient has unspecified dementia at moderate stage, while the trial requires mild Alzheimer’s disease or MCI. That is a hard disease mismatch, and the required mild stage is also not met. Either constitutes a hard exclusion → F.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT05073471,0.5267122983932495,Amyotrophic Lateral Sclerosis,Patterned Sensory Enhancement (PSE) and Transcranial Direct Current Stimulation (tDCS) for Upper Extremity Performances in Patients With Corticobasal Syndrome,NA,18 years to 89 years,Corticobasal Syndrome,Corticobasal syndrome (CBS) diagnosis | Age 18-89 | Right-handed,"History of migraines | Scalp or skin condition (e.g., psoriasis or eczema) | Metallic implants including intracranial electrodes, surgical clips, shrapnel, or pacemaker | History of head injury with loss of consciousness requiring further investigation | Diagnosed psychological or neurological disorders | History of seizure | Prior adverse effects to tDCS or other brain stimulation (e.g., TMS) | Pregnancy | Inability or unwillingness to follow study procedures",(none),ALL,F,"The trial targets corticobasal syndrome, not ALS, so the patient’s disease does not match the trial’s disease cohort (hard exclusion). Age and sex fit, but disease mismatch makes the patient ineligible.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,F,"Correct: The trial targets corticobasal syndrome, not ALS, which is a hard disease mismatch → F. Grader’s reasoning appropriately identifies the hard exclusion; age/sex fit are irrelevant once disease mismatch applies.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT05081596,0.5858243703842163,Dementia,PATH-Pain: A Primary Care-Based Psychosocial Intervention To Improve Cognitive and Depression Outcomes in Older Adults With MCI and Early Stage AD,NA,60 years,Mild Cognitive Impairment; Alzheimer's Disease (early stage); Depression; Chronic Pain,"Age >= 60 years | Mild cognitive impairment (MCI) or early stage probable/possible Alzheimer's disease with MoCA 16–25 | MADRS total >= 5 | Off antidepressants, cholinesterase inhibitors, or memantine, or on a stable dosage for >= 12 weeks | Chronic pain on most days for >= 3 months and average pain intensity score >= 4 | Clinical Dementia Rating 0.5–1 | Capacity to consent | Participation of a study partner is required",Significant suicide risk | Medically or neurologically unstable to safely enroll | Psychiatrically unstable to safely enroll in randomized psychotherapy trial | Requiring psychiatric hospitalization at baseline | Lack of English fluency,"On stable dose or off antidepressants, cholinesterase inhibitors, or memantine for >= 12 weeks",ALL,F,"Hard exclusion: the trial requires MCI or early-stage Alzheimer's disease (CDR 0.5–1/MoCA 16–25), while the patient has moderate-stage dementia (MMSE 19), so the required stage is not met.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,"The trial explicitly requires MCI or early-stage Alzheimer’s (e.g., CDR 0.5–1), while the patient has moderate-stage dementia. This is a required stage/setting mismatch, which is a hard exclusion per the rubric. Grade F is correct.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT05083182,0.59808349609375,Rheumatoid Arthritis,"A Phase 3 Multicenter, Open-label Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of Subcutaneously Administered Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis (PSUMMIT-Jr)",PHASE3,5 years to 17 years,Juvenile Psoriatic Arthritis,"Diagnosis of juvenile psoriatic arthritis by Vancouver criteria with exclusion of enthesitis-related arthritis; diagnosis made >= 3 months prior to screening | Active disease in >= 3 joints at screening and at Week 0 (swelling or loss of motion with pain and/or tenderness) | Active disease despite previous non-biologic DMARD and/or NSAID therapy (non-biologic DMARD for >= 12 weeks or intolerance; NSAID for >= 4 weeks or intolerance) | Concurrent methotrexate, sulfasalazine, leflunomide, oral corticosteroids, or NSAIDs permitted on a stable dose | Up to date with all immunizations per local guidelines for immunosuppressed patients | Prior use of anti-TNFα agents, IL-17 inhibitors and other biologics (except non-responders to IL-23 inhibitors), and JAK inhibitors permitted with sufficient washout","Enthesitis-related arthritis | History of latent or active granulomatous infection (including tuberculosis, histoplasmosis, or coccidioidomycosis) | History of, or ongoing, chronic or recurrent infectious disease | Herpes zoster infection within 8 weeks prior to Week 0 | Known history of hepatitis C infection or positive test at screening",Non-biologic DMARD for >= 12 weeks or intolerance; NSAID for >= 4 weeks or intolerance; Prior anti-TNFα therapy permitted with washout; Prior IL-17 inhibitors and other biologics permitted (except non-responders to IL-23 inhibitors); Prior JAK inhibitors permitted with washout,ALL,F,"Hard exclusions apply: the trial targets juvenile psoriatic arthritis in pediatric participants (ages 5–17), whereas the patient has rheumatoid arthritis and is 55 years old.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,Disease mismatch (juvenile psoriatic arthritis vs rheumatoid arthritis) and age window conflict (trial 5–17 vs patient 55) are hard exclusions. The grader correctly assigned F and cited the key reasons.,,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT05123807,0.7401836514472961,Recurrent Clear Cell Ovarian Carcinoma,Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study),PHASE2,18 years,"Ovarian Cancer (mucinous, recurrent)",Histologically or cytologically confirmed recurrent primary mucinous ovarian cancer | Age >= 18 years | ECOG performance status <= 2 | ANC > 1500/µL | Platelets > 100000/µL | Total bilirubin <= 1.5 mg/dL | Creatinine <= 1.5 mg/dL | AST <= 3 x ULN | ALT <= 3 x ULN | > 2 weeks from prior chemotherapy or radiation therapy (except bevacizumab requires > 6 weeks),"Receiving concurrent investigational therapy or received investigational therapy within 30 days of HIPEC | Mucinous tumors with pathologic confirmation of a non-gynecologic site of origin | Known active CNS metastases | Hypersensitivity to any component of cisplatin | Uncontrolled intercurrent illness (e.g., ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illness/social situations limiting compliance) | Pregnant or nursing | Peripheral neuropathy >= grade 2 | History of allogenic transplant | History of prior HIPEC or intraperitoneal chemotherapy | Known bulky extra-abdominopelvic disease | Hearing impairment or tinnitus >= grade 2",> 2 weeks since prior chemotherapy or radiation therapy; > 6 weeks since prior bevacizumab,FEMALE,F,"The study requires recurrent primary mucinous ovarian cancer, but the patient has recurrent clear cell ovarian carcinoma, which is a disease/subtype mismatch and a hard exclusion.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; BRCA1 positive; Optimal debulking surgery performed; Received adjuvant carboplatin + paclitaxel + bevacizumab; Cytology-positive malignant pleural effusion at 5 months post-adjuvant,(none),Carboplatin; Paclitaxel; Bevacizumab; Optimal debulking surgery,Stage III,,36,years,female,(none),CORRECT,F,"The trial specifically requires recurrent primary mucinous ovarian cancer, while the patient has recurrent clear cell ovarian carcinoma. This is a disease/subtype mismatch, which is a hard exclusion per the rubric. Grade F is correct.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT05152823,0.5387037396430969,Duchenne Muscular Dystrophy,Phase I/IIa Intrathecal Gene Delivery Clinical Trial for IGHMBP2-Related Diseases,PHASE1/PHASE2,2 months to 14 years,Charcot-Marie-Tooth Disease Type 2S; Spinal Muscular Atrophy with Respiratory Distress 1,"Confirmation of two pathogenic variants in the IGHMBP2 gene from a CLIA-certified laboratory | Ambulatory status may be pre-ambulant, ambulant (able to walk 10 meters without assistance), or non-ambulant (unable to walk more than 10 meters unassisted) | Ability to cooperate with functional assessments as per PI's discretion","Prior participation in a gene or cell therapy program | Immunizations of any kind within 1 month prior to the study | Active infection based on clinical observations | Serological evidence of HIV infection, or Hepatitis B or C infection | Diagnosis of or ongoing treatment for an autoimmune disease | Persistent leukopenia or leukocytosis (WBC <= 3500/µL or >= 20000/µL) | Absolute neutrophil count < 1500/µL | Abnormal liver function: GGT > 2 x ULN (if no other laboratory abnormalities), elevated bilirubin, and/or abnormal PT/INR | Concomitant illness or requirement for chronic drug treatment that creates unnecessary risks for gene transfer per PI | AAV9 binding antibody titer > 1:50 | Abnormal laboratory values in the clinically significant range | Diagnosis of any other systemic illness that increases the risk of gene transfer or conditions that may compromise compliance, safety, or interpretability per PI | Any requirement for immunomodulatory therapy where a safe washout is not feasible | Contraindication for intrathecal injection | Positive JCV antibody test > 0.40",No prior gene or cell therapy; No immunizations within 1 month prior to study,ALL,F,"Disease mismatch and required biomarker not met: the trial targets IGHMBP2-related CMT2S/SMARD1 and requires two pathogenic IGHMBP2 variants, while the patient has Duchenne muscular dystrophy with a DMD exon 49-50 deletion.",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,"The trial targets IGHMBP2-related CMT2S/SMARD1 and requires IGHMBP2 variants, while the patient has Duchenne muscular dystrophy with a DMD exon 49-50 deletion. This is a clear disease mismatch, which is a hard exclusion → F. The grader’s reasoning and grade align with the rubric.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT05152823,0.5710121989250183,Amyotrophic Lateral Sclerosis,Phase I/IIa Intrathecal Gene Delivery Clinical Trial for IGHMBP2-Related Diseases,PHASE1/PHASE2,2 months to 14 years,Charcot-Marie-Tooth Disease Type 2S; Spinal Muscular Atrophy with Respiratory Distress 1,"Confirmation of two pathogenic variants in the IGHMBP2 gene from a CLIA-certified laboratory | Ambulatory status may be pre-ambulant, ambulant (able to walk 10 meters without assistance), or non-ambulant (unable to walk more than 10 meters unassisted) | Ability to cooperate with functional assessments as per PI's discretion","Prior participation in a gene or cell therapy program | Immunizations of any kind within 1 month prior to the study | Active infection based on clinical observations | Serological evidence of HIV infection, or Hepatitis B or C infection | Diagnosis of or ongoing treatment for an autoimmune disease | Persistent leukopenia or leukocytosis (WBC <= 3500/µL or >= 20000/µL) | Absolute neutrophil count < 1500/µL | Abnormal liver function: GGT > 2 x ULN (if no other laboratory abnormalities), elevated bilirubin, and/or abnormal PT/INR | Concomitant illness or requirement for chronic drug treatment that creates unnecessary risks for gene transfer per PI | AAV9 binding antibody titer > 1:50 | Abnormal laboratory values in the clinically significant range | Diagnosis of any other systemic illness that increases the risk of gene transfer or conditions that may compromise compliance, safety, or interpretability per PI | Any requirement for immunomodulatory therapy where a safe washout is not feasible | Contraindication for intrathecal injection | Positive JCV antibody test > 0.40",No prior gene or cell therapy; No immunizations within 1 month prior to study,ALL,F,"Disease mismatch: the trial targets IGHMBP2-related CMT2S/SMA-RD, not ALS. The patient is also 62 years old, outside the 2 months–14 years age range.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,F,"Correct: Hard exclusions apply. Disease mismatch (trial targets IGHMBP2-related CMT2S/SMARD1, not ALS) and age outside trial range (62 years vs 2 months–14 years). Either one triggers F per rubric.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT05162768,0.53605055809021,Duchenne Muscular Dystrophy,"A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Disease Resulting From Pathogenic Nuclear DNA Mutations (nPMD) NuPower",PHASE3,18 years to 70 years,Primary Mitochondrial Disease; Mitochondrial Myopathy,"Age 18 to 70 years at screening. | Primary mitochondrial disease with predominant myopathy including progressive external ophthalmoplegia (PEO) and exercise intolerance and/or skeletal muscle weakness. | Genetic confirmation of nuclear DNA mutation in mitochondrial replisome genes (e.g., POLG, POLG2, C10ORF2/TWINKLE, TYMP, DGUOK, TK2, RRM2B, RNASEH1, SSBP, MGME1, DNA2, SLC25A4/ANT1, SUCLG1, SUCLA2, MPV17) or other pathogenic nuclear DNA mutations.","Unable to perform 6MWT, 3TUG, or 5XSST (assistive device allowed if used consistently). | 6-minute walk distance <150 m or >450 m at screening. | Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 at screening. | In-patient hospitalization within 30 days prior to screening or planned hospitalization/surgery during the trial that could impact outcomes. | Clinically significant respiratory and/or cardiac disease that would interfere with assessments. | Prior interventional cardiac procedure within 3 months before screening (e.g., catheterization, PCI, balloon valvuloplasty). | History of or current severe neurologic impairment, severe epilepsy, severe ataxia, or severe neuropathy interfering with trial requirements. | Active malignancy or cancer remission <2 years (except appropriately treated localized squamous or non-invasive basal cell skin cancer). | History of solid organ transplant. | Known HIV, hepatitis B, or hepatitis C infection. | History of systemic eosinophilic illness and/or eosinophil count >1000 cells/µL at screening. | Participation in an interventional clinical trial within 30 days prior to current trial or concurrent non-interventional trial that may confound results. | Received elamipretide (MTP-131) within the past 1 year before screening. | History of active substance abuse during the prior year. | Pregnant, planning pregnancy, or breastfeeding/lactating.",(none),ALL,F,"Disease mismatch: the trial targets primary mitochondrial disease due to nuclear DNA mutations, while the patient has Duchenne muscular dystrophy. Age window conflict: the trial requires 18–70 years, and the patient is 11.",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,"Correct: There is a hard exclusion due to disease mismatch (trial targets primary mitochondrial disease, not DMD) and an age window conflict (trial 18–70 vs patient 11). Either alone triggers F.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT05166109,0.7044875621795654,Duchenne Muscular Dystrophy,A Phase II Pilot Trial of Vamorolone vs. Placebo for the Treatment of Becker Muscular Dystrophy,PHASE2,18 years to 64 years,Becker Muscular Dystrophy,"Written informed consent (HIPAA as applicable) prior to study procedures | Male with confirmed Becker muscular dystrophy | DMD gene in-frame mutation with clinical picture consistent with Becker dystrophy OR dystrophin gene alteration expected to allow internally deleted dystrophin with typical Becker clinical picture | Age >= 18 and < 65 years at consent | Able to perform 10-meter timed run/walk in <= 30 seconds (assistive devices allowed) | NSAA score <= 32 at screening | Clinical labs within normal range or not clinically significant; GGT, creatinine, and total bilirubin must be <= ULN; AST/ALT elevations may be allowed if deemed muscle-origin by PI | No oral glucocorticoids or other oral immunosuppressive agents for >= 3 months before first dose | Inhaled/topical glucocorticoids permitted if last use >= 4 weeks prior or on stable dose >= 4 weeks and expected to remain stable | Evidence of varicella immunity (positive IgG) or documentation of 2 varicella vaccine doses with second dose >= 14 days before first dose | Willing and able to comply with visits, medication administration, and procedures | Agrees to use barrier contraception during study and for 30 days after taper completion","Current or history of major renal or hepatic impairment, uncontrolled diabetes mellitus (diagnosis plus random glucose > 1.5 x ULN with symptoms of polyuria or polydipsia), or immunosuppression | Current or history of chronic systemic fungal or viral infections | Acute illness within 4 weeks prior to first dose | Use of mineralocorticoid receptor agents (e.g., spironolactone, eplerenone, canrenone, prorenone, mexrenone) within 4 weeks prior to first dose | Symptomatic cardiomyopathy or left ventricular ejection fraction < 40% | Allergy or hypersensitivity to vamorolone or its constituents | Severe behavioral or cognitive problems precluding participation | Any condition or laboratory abnormality that could affect safety, study completion, or assessment of results, per investigator | Use within 4 weeks prior to first dose of herbal remedies/supplements that can impact muscle strength/function (e.g., coenzyme Q10, creatine) | Live attenuated vaccine within 14 days prior to first dose | Current use of any investigational drug or use within 3 months prior to first dose | Prior enrollment in VBP15-BMD-001 or any other vamorolone study",No oral glucocorticoids or other oral immunosuppressive agents within 3 months prior to first dose; Inhaled/topical glucocorticoids allowed if stable for >= 4 weeks prior to first dose,MALE,F,"Hard exclusions: the trial targets Becker muscular dystrophy (patient has Duchenne), the patient is 11 years old (trial requires 18–64), and he is on oral glucocorticoids (deflazacort), which are prohibited within 3 months.",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,Correct F. There is a hard disease mismatch (trial is for Becker MD; patient has Duchenne MD) and an age conflict (trial 18–64 vs patient 11). Ongoing oral glucocorticoid use (deflazacort) also conflicts with explicit exclusion. Any one suffices for F.,,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT05222386,0.6775633692741394,Dementia,"Building Online Community to Improve Patient and Caregiver Outcomes in Parkinson Disease, Lewy Body Dementia and Related Disorders",NA,40 years,Corticobasal Degeneration; Dementia With Lewy Bodies; Lewy Body Parkinsonism; Multiple System Atrophy; Parkinson Disease; Parkinson Disease Dementia; Progressive Supranuclear Palsy; Vascular Parkinsonism,"Age > 40 years | Diagnosed with Parkinson disease or other causes of parkinsonism (e.g., progressive supranuclear palsy, multiple system atrophy, Lewy body dementia) by a community neurologist","Unable or unwilling to commit to study procedures | Additional medical illnesses requiring palliative services (e.g., metastatic cancer) | Already receiving palliative care or hospice services",(none),ALL,F,"Disease mismatch: the trial targets Parkinsonism-related disorders (including Lewy body dementia), while the patient has unspecified dementia without a parkinsonism/LBD diagnosis. Thus the patient does not meet the trial’s disease cohort.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,"Disease mismatch is a hard exclusion. The trial targets PD/parkinsonism-related disorders (including LBD/PD dementia), while the patient has unspecified dementia without a parkinsonism/LBD diagnosis. Per rubric, do not infer; thus patient disease is not included in the trial cohorts → F.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT05235204,0.5926704406738281,Fistulizing Crohn's Disease,Early Foley Catheter Removal After Diverticular Colovesical Fistula Repair,NA,18 years,Colovesical Fistula,Adults aged 18 and over | Undergoing surgical repair of diverticular colovesical fistula,"Active and untreated genitourinary cancers | Inflammatory bowel disease as the cause of colovesical fistula | Pre-existing bladder dysfunction with chronic indwelling urinary catheter, suprapubic catheter, or surgical urinary diversion | Require re-operation prior to Foley removal | Adults unable to consent | Pregnant women | Prisoners | Individuals less than 18 years old",(none),ALL,F,"Disease mismatch: the trial targets patients undergoing repair of diverticular colovesical fistula, whereas the patient has perianal fistulizing Crohn’s disease. Additionally, the trial excludes fistulas caused by inflammatory bowel disease.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,F,"Hard exclusion applies: disease mismatch (trial targets diverticular colovesical fistula repair; patient has perianal fistulizing Crohn’s disease). Additionally, the trial explicitly excludes IBD-caused fistulas. The grader’s F and reasoning are correct per the rubric.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT05250973,0.5396156311035156,Amyotrophic Lateral Sclerosis,"A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis",PHASE2,18 years,Amyloid Light Chain Amyloidosis,Newly diagnosed systemic amyloid light chain (AL) amyloidosis with Mayo Cardiac Stage II or IIIa cardiac involvement (Cohort 1) | At least one organ involved by systemic AL amyloidosis per consensus guidelines (Cohort 2) | ECOG performance status 0-2 | dFLC >= 40 mg/L at screening | Serum involved free light chain (iFLC) >= 40 mg/L with abnormal kappa:lambda ratio | Serum M-protein >= 0.5 g/dL,"Prior therapy for systemic AL amyloidosis or multiple myeloma, including CD38-targeting agents (except <=160 mg dexamethasone prior to enrollment) | Symptomatic multiple myeloma (e.g., lytic bone disease, plasmacytomas, >=60% marrow plasma cells, or myeloma-related hypercalcemia) | Treatment with an investigational drug or invasive investigational device within 14 days or <5 half-lives before randomization | Receipt of live, attenuated, or replicating investigational vaccines <4 weeks prior to randomization (except COVID-19 vaccines) | Planned stem cell transplant during the first 9 cycles of protocol therapy | Peripheral neuropathy: Grade 2 sensory or Grade 1 painful | Use of strong CYP3A4 inducers without >=5 half-life washout before first bortezomib dose","Washout from investigational drugs/devices: >=14 days or >=5 half-lives before randomization; No live, attenuated, or replicating investigational vaccines within 4 weeks prior to randomization (except COVID-19); Discontinue strong CYP3A4 inducers >=5 half-lives before first bortezomib dose",ALL,F,"Disease mismatch: the trial targets systemic AL amyloidosis, while the patient has amyotrophic lateral sclerosis (ALS), which is not included in the trial’s disease cohorts.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,F,"Disease mismatch is a hard exclusion: the trial is for AL amyloidosis, while the patient has ALS. The grader correctly assigned F based on this.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT05300581,0.5816720724105835,Rheumatoid Arthritis,Determining the Feasibility of Outpatient Parenteral Antibiotic Therapy for Persons Who Inject Opioids,NA,18 years to 100 years,Opioid Use Disorder; Endocarditis; Osteomyelitis; Discitis; Septic Arthritis; Epidural Abscess; Staphylococcus Aureus Bacteremia,Age 18-100 years | Endocarditis (injection-related) | Osteomyelitis (injection-related) | Discitis (injection-related) | Septic arthritis (injection-related) | Epidural abscess (injection-related) | Staphylococcus aureus bacteremia (injection-related) | History of injection opioid use within the last 1 year | Evaluated by addiction medicine consult service during current inpatient admission | Started or maintained on medications for opioid use disorder (methadone or buprenorphine) during admission,,On medications for opioid use disorder (methadone or buprenorphine) during admission,ALL,F,"Disease mismatch: the trial targets injection-related infections in persons with opioid use disorder, not rheumatoid arthritis. The patient's disease is not included in the trial's conditions.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Disease mismatch is a hard exclusion: the trial is for injection-related infections/OUD, not rheumatoid arthritis. The grader correctly applied the rubric and assigned F.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT05333471,0.5331460237503052,Fistulizing Crohn's Disease,A Pilot Study of Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated Colitis,PHASE1/PHASE2,10 years to 60 years,Chronic Granulomatous Disease-associated Colitis,"Age 10–60 years | Confirmed diagnosis of chronic granulomatous disease and CGD-associated colitis (or CGD-IBD with colitis on colonoscopy) | Fecal calprotectin >=200 microgram/g | Harvey-Bradshaw Index (HBI) score >=5 | No planned change in systemic antibiotic regimen for CGD for 1 month prior to FMT | No planned escalation in CGD-IBD treatment for 1 month prior to FMT | If receiving monoclonal antibodies for CGD-IBD, stable dose for >=12 weeks with no planned escalation | Women/participants who can become pregnant agree to use highly effective contraception during the study","Acute gastrointestinal infection, including active GI abscesses | Clostridioides difficile toxin gene positive by PCR at screening | History of intestinal obstruction related to CGD-IBD | History of fistulizing CGD-IBD or intra-abdominal abscesses due to CGD-IBD | History of CGD-IBD-related non-transversable intestinal strictures | History of adverse events attributable to prior FMT | Significant liver disease, including portal hypertension or cirrhosis (e.g., biopsy-proven nodular regenerative hyperplasia) | Pregnant or breastfeeding | History of severe food allergy | Contraindication to colonoscopy under anesthesia | Any condition that, in the investigator's opinion, contraindicates study participation",Stable systemic antibiotic regimen for CGD for >=1 month prior to FMT; No planned escalation of CGD-IBD therapy for 1 month prior to FMT; Stable dose of monoclonal antibody therapy for CGD-IBD for >=12 weeks prior to FMT,ALL,F,"Disease mismatch: the trial requires confirmed chronic granulomatous disease with CGD-associated colitis, while the patient has fistulizing Crohn's disease without CGD. Thus the mandatory disease/subtype criteria are not met.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,F,"The trial requires confirmed chronic granulomatous disease with CGD-associated colitis; the patient has fistulizing Crohn’s disease. This is a clear disease mismatch, a hard exclusion, so F is correct.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT05393258,0.7176371812820435,Recurrent Glioblastoma,A Pilot Study of Temporally-modulated Pulsed Radiation Therapy to Reirradiate Recurrent IDH-mutant Gliomas After Prior External Beam Radiation Therapy,NA,18 years,Astrocytoma (recurrent); Oligodendroglioma (recurrent),Histologically confirmed recurrent IDH-mutant glioma (astrocytoma or oligodendroglioma) with prior external beam radiation therapy (EBRT) to the same region | Recurrent tumor may be histologically confirmed or based on clinical assessment | Maximum tumor diameter <= 7 cm | Prior EBRT completed >= 2 years ago | Region for reirradiation received >= 45 Gy from prior EBRT | Region for reirradiation received <= 75 Gy from prior EBRT | Prior EBRT may be photon-based or proton-based | Prior stereotactic radiosurgery (SRS) to the same region permitted if cumulative EBRT+SRS dose <= 75 Gy | Prior SRS completed >= 6 months ago | Life expectancy >= 12 months | Age >= 18 years | Karnofsky performance status >= 70% | Females of childbearing potential agree to use effective contraception during the study,"Leptomeningeal or metastatic involvement | Prior grade >= 3 radiation necrosis at least possibly related to prior radiotherapy | Concurrent bevacizumab or other anti-VEGF therapy during TMPRT | Medical contraindication to MRI (e.g., unsafe metallic implants, incompatible pacemaker, inability to lie still for long periods, severe to end-stage kidney disease or on hemodialysis) | Pregnant",Prior external beam radiation therapy to the same region required; Prior EBRT dose to the region between 45 Gy and 75 Gy; Prior EBRT completed >= 2 years before enrollment; Prior stereotactic radiosurgery to the same region permitted; Cumulative EBRT plus SRS dose <= 75 Gy; Prior SRS completed >= 6 months before enrollment; Bevacizumab washout >= 4 weeks before start of TMPRT,ALL,F,"The trial requires recurrent IDH-mutant astrocytoma or oligodendroglioma, while the patient has recurrent IDH-wildtype glioblastoma. This is a required biomarker and disease mismatch.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),CORRECT,F,"Hard exclusions apply: the trial requires IDH-mutant astrocytoma/oligodendroglioma, while the patient has IDH-wildtype glioblastoma. This is both a required biomarker mismatch and a disease mismatch, triggering an F.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT05397639,0.588747501373291,Dementia,"A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Masupirdine (SUVN-502) for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type",PHASE3,50 years to 90 years,Alzheimer's Disease (agitation),Diagnosis of dementia of the Alzheimer's type per NIA-AA criteria. | Confirmed agitation per IPA Consensus Provisional Definition of Agitation in Cognitive Disorders. | MMSE score 8 to 24 (inclusive).,"Dementia predominantly of the non-Alzheimer's type (e.g., vascular dementia, Parkinson's disease, Lewy body disease, frontotemporal dementia). | Agitation not secondary to Alzheimer's disease (e.g., due to pain, other psychiatric disorder, delirium from metabolic disorder, systemic infection, or substance-induced).",(none),ALL,F,"Hard exclusion: The trial is specific to Alzheimer's disease with agitation, but the patient is listed only as having dementia (not AD) and is amyloid-negative, so the disease is not included in the trial’s target population. Age and MMSE fit, but the required AD subtype is not met.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),INCORRECT,D,"No hard exclusion is explicit. Trial requires Alzheimer’s-type dementia (and agitation), but the patient is only listed as ‘dementia’ and is amyloid-negative; this suggests a subtype mismatch but is not an explicit exclusion per the rubric (unknowns should not trigger F). This is a specific soft mismatch on the required subtype anchor → D.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT05399888,0.6196225881576538,Dementia,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease Dementia",PHASE2,50 years to 80 years,Mild Cognitive Impairment Due to Alzheimer's Disease; Alzheimer's Disease (mild dementia),Mild cognitive impairment due to Alzheimer's disease (NIA-AA Stage 3) or mild Alzheimer's disease dementia (NIA-AA Stage 4) | RBANS Delayed Memory Index score <= 85 | Clinical Dementia Rating (global) of 0.5 for MCI due to AD or 0.5–1 for mild AD dementia | Mini-Mental State Examination (MMSE) score 21–30 | CDR Memory Box score >= 0.5 | Evidence of amyloid pathology by PET or CSF,"Known allergy or hypersensitivity to BIIB080 or its excipients | Previous participation in a study with BIIB080 | Use of symptomatic (non-disease-modifying) AD medications at unstable doses within 8 weeks prior to screening or during screening | Use of commercially available disease-modifying AD medications (e.g., anti-amyloid monoclonal antibodies) | Prior participation in active or passive anti-amyloid immunotherapy without documentation of placebo | Prior participation in passive tau immunotherapy unless last administration >= 6 months or >= 5 half-lives before screening or documentation of placebo | Prior participation in investigational tau-targeting therapy that is not passive immunotherapy without documentation of placebo | Prior participation within 12 months in any other agent with purported disease-modifying effect in AD without documentation of placebo | Prior participation in any gene therapy with purported disease-modifying effect in AD without documentation of placebo | Current or previous use of disease-modifying AD medications outside investigational studies | Any vaccination within 10 days prior to Day -1 (except as specified for COVID-19 timing) | Contraindications to brain MRI | Current enrollment or planned enrollment in another interventional clinical study within 52 weeks prior to baseline | Any medical or psychiatric contraindication or clinically significant abnormality increasing risk (LTE period)",Symptomatic Alzheimer's disease medications at stable dose >= 8 weeks before screening,ALL,F,"The trial requires evidence of amyloid pathology (PET or CSF), but the patient is amyloid PET negative and CSF amyloid negative. Additionally, the trial targets MCI/mild AD, while the patient has moderate dementia (MMSE 19).",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,"Correct: The trial requires evidence of amyloid pathology and mild AD/MCI; the patient is amyloid negative and has moderate dementia (MMSE 19). This is a hard exclusion on required biomarker (and stage), so F is appropriate.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT05406700,0.8120824694633484,Recurrent Glioblastoma,A Phase 0 Clinical Trial to Evaluate Drug Concentrations and Pharmacodynamic Parameters of Niraparib in Tumor Tissue of Patients With Surgically Accessible Recurrent IDH 1/2 Gliomas,EARLY_PHASE1,18 years,Low-Grade Glioma (recurrent),Age >= 18 years | Histologically or cytologically confirmed glioma with documented IDH1 and/or IDH2 mutation at initial diagnosis | Radiographic evidence of progression/recurrence per RANO criteria for low-grade gliomas | Surgically accessible tumor and surgical candidate | >= 12 weeks from completion of CNS radiation | Stable or decreasing dose of glucocorticoids for 7 days prior to registration | Karnofsky Performance Score >= 70% | Expected survival >= 6 months | Adequate organ function,"Major surgery <= 4 weeks prior to initiating protocol therapy or not recovered from surgical effects | Systemic anticancer therapy < 28 days prior to first study drug dose | Lomustine < 6 weeks prior to first study drug dose | Investigational agent < 28 days prior to first study drug dose | Transfusion (platelets or red blood cells) <= 4 weeks prior to initiating protocol therapy | Use of colony-stimulating factors within 4 weeks prior to initiating protocol therapy | History of Grade 3 or 4 anemia, neutropenia, or thrombocytopenia due to prior chemotherapy that persisted > 4 weeks and was related to the most recent treatment | Serious, uncontrolled medical disorder or active, uncontrolled infection | Another malignancy diagnosed/treated within 2 years (except definitively treated basal/squamous cell skin cancer or cervical cancer) | Pregnant or breastfeeding | Known hypersensitivity to niraparib components | Known HIV infection or active hepatitis B or C | Conditions limiting oral drug ingestion or absorption (e.g., dysphagia, short-gut syndrome, gastroparesis) | Radiation therapy encompassing > 20% bone marrow within 2 weeks, or any radiation therapy within 1 week prior to Day 1 | Known or symptomatic leptomeningeal metastases",">= 12 weeks since completion of CNS radiation; No systemic anticancer therapy within 28 days before first dose; No lomustine within 6 weeks before first dose; No investigational agents within 28 days before first dose; Recovered from clinically relevant toxic effects of prior surgery, radiotherapy, or other anticancer therapy; No transfusions within 4 weeks before initiating protocol therapy; No colony-stimulating factors within 4 weeks before initiating protocol therapy; No radiation therapy encompassing > 20% bone marrow within 2 weeks before Day 1; No any radiation therapy within 1 week before Day 1",ALL,F,"The trial requires recurrent IDH1/2-mutant low-grade glioma, whereas the patient has recurrent IDH-wildtype glioblastoma. This is a hard exclusion due to required biomarker and disease subtype mismatch.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),CORRECT,F,"The trial requires IDH1/2-mutant recurrent low-grade glioma, while the patient has IDH-wildtype recurrent glioblastoma. This is both a disease mismatch and a required biomarker mismatch, which are hard exclusions per the rubric, so F is correct.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT05413304,0.8198649883270264,Recurrent Glioblastoma,Feasibility of Evaluating Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis,PHASE1,18 years to 39 years,High-Grade Glioma (recurrent); Diffuse Midline Glioma,Recurrent high-grade glioma or diffuse midline glioma based on clinical and/or radiologic findings | For cortical high-grade glioma: prior intra-operative pathology confirming disease | Age 18–39 years at enrollment | Ability to swallow tablets/pills | Karnofsky >= 50% within 14 days prior to enrollment | Adequate organ function per protocol-defined laboratory parameters,"Unable to safely undergo biopsy due to contraindications | Pregnant or breastfeeding | Serious preexisting medical conditions precluding participation (e.g., interstitial lung disease, severe dyspnea requiring oxygen, severe renal impairment, history of major gastric/small bowel resection impairing absorption, Crohn's disease, ulcerative colitis, or chronic condition causing baseline grade >=2 diarrhea) | Uncontrolled intercurrent illness (e.g., symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, active bleeding diathesis, renal transplant) | History of syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin, or sudden cardiac arrest | Active systemic bacterial, fungal, or viral infection (including active hepatitis B or C; certain controlled HIV may be eligible) | Requires strong or moderate CYP3A inhibitors or inducers | Inability to undergo MRI or contraindication to MRI | Refractory nausea/vomiting limiting oral drug administration | Known severe hypersensitivity to abemaciclib, temozolomide, or their excipients | Prior treatment with abemaciclib or another CDK4/6 inhibitor | Investigator deems participation not appropriate",>=4 weeks since any major surgery with recovery and no active infection; Recovered from chemotherapy to CTCAE <=1 (except alopecia or grade 2 neuropathy); Washout from last disease-directed therapy: >=14 days or >=4 half-lives (whichever is shorter) before treatment; Completed radiotherapy with recovery; >=14-day washout before treatment,ALL,F,"The trial requires age 18–39 at enrollment, and the patient is 40 years old, which is outside the permitted age range. While the disease and recurrent setting are appropriate, the age window conflict is a hard exclusion.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),CORRECT,F,"Patient is 40 years old while trial allows 18–39; this is a hard age-window exclusion per rubric. Disease/setting otherwise align, but hard exclusion mandates grade F.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT05422911,0.742012619972229,Castration-Resistant Prostate Cancer,"A Phase 2 Randomized Study of YONSA® (Abiraterone Acetate), Enzalutamide or Apalutamide as First Line Therapy in Veterans With Castrate-sensitive Prostate Cancer",PHASE2,Not specified,Prostate Cancer (castrate-sensitive),"Age >= 18 years | ECOG performance status 0–1 | Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine, signet-cell, or small-cell features | Receiving or will receive androgen-deprivation therapy with a GnRH agonist/antagonist or have undergone bilateral orchiectomy | High-risk disease with >= 3 rising PSA values at least 1 week apart | PSA >= 2 ng/mL | PSA doubling time <= 9 months during continuous androgen-deprivation therapy | Has not received abiraterone acetate, enzalutamide, or apalutamide at enrollment | Predicted life expectancy > 12 months | For patients on bisphosphonates or denosumab, dose stable for >= 4 weeks before randomization | AST <= 2.5 x ULN | ALT <= 2.5 x ULN | Creatinine clearance >= 30 mL/min or serum creatinine <= 1.8 mg/dL | Absolute neutrophil count >= 1000/µL | Platelet count >= 100000/µL | Hemoglobin > 9 g/dL","Prior cytotoxic chemotherapy for prostate cancer | Prior aminoglutethimide or ketoconazole for prostate cancer | Prior abiraterone acetate, apalutamide, or enzalutamide for prostate cancer | Prior participation in a clinical trial of an investigational androgen receptor or androgen synthesis inhibitor (unless placebo) | Hormonal therapy for prostate cancer within 4 weeks of randomization (other than GnRH agonist/antagonist) | Biologic therapy for prostate cancer within 4 weeks of randomization (other than approved bone-targeting agents) | Active second malignancy except disease-free >= 3 years, completely resected non-melanoma skin cancer, or successfully treated in situ carcinoma | History of seizure or condition predisposing to seizure (e.g., prior cortical stroke, significant brain trauma) | Deep vein thrombosis or pulmonary embolism within the past 3 months causing medical instability | Concurrent investigational agents",Androgen-deprivation therapy with a GnRH agonist/antagonist or prior bilateral orchiectomy required; Bisphosphonates or denosumab allowed if on a stable dose for >= 4 weeks before randomization,MALE,F,The trial is for first-line castrate-sensitive prostate cancer and explicitly excludes prior abiraterone/enzalutamide use; the patient has metastatic castration-resistant disease and has received both agents. This is both a disease-setting mismatch and an explicit exclusion.,Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),CORRECT,F,Hard exclusions apply: disease mismatch (trial is castrate-sensitive first-line; patient is castration-resistant) and explicit exclusion (no prior abiraterone/enzalutamide; patient has both). Therefore F is correct.,,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT05443906,0.5792176723480225,Dementia,Study of Adapted Exercise and Mindfulness Interventions to Improve Motor Function and Sleep Quality in Individuals with Neurodegenerative Disease,NA,5 years to 75 years,Adrenomyeloneuropathy; Cerebellar Ataxia; Leukoencephalopathy with Brainstem and Spinal Cord Involvement and Lactate Elevation; Leukodystrophy; Neurodegenerative Disease,"Males: X-linked adrenoleukodystrophy confirmed by biochemical determination or genetic testing | Females: X-linked adrenoleukodystrophy confirmed by biochemical determination, genetic testing, or pedigree analysis | Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL): confirmed DARS2 mutation by genetic analysis | Cerebellar ataxia due to stroke, tumor, or degeneration; genetically confirmed cerebellar disorders should provide genetic testing | Other similar neurodegenerative diseases as determined by chart review and clinical exam | Able to stand for 30 seconds without upper extremity support | Ambulatory (including use of a cane or a walker) | Able to walk for 2 minutes",Uncontrolled hypertension | Orthopedic conditions that interfere with safe participation | Diabetes that interferes with safe participation | Seizure disorder that interferes with safe participation | Peripheral vestibular loss that interferes with safe participation | Severe aphasia | Dementia | Pregnancy | Other medical or psychological conditions that would interfere with acquiring study information or performing exercises safely,(none),ALL,F,"The trial explicitly excludes participants with dementia, which the patient has. Therefore, the patient is ineligible despite meeting age and sex criteria.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,"The trial explicitly lists dementia as an exclusion criterion, and the patient has dementia. This is a hard exclusion per the rubric, so grade F is correct. The grader correctly identified this factor; no need to assess core anchors.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT05479981,0.6380753517150879,Duchenne Muscular Dystrophy,"A Phase 2 Extension Study to Evaluate the Long-Term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients",PHASE2,18 years to 66 years,Myotonic Dystrophy Type 1,Completion of AOC 1001-CS1 (MARINA) with satisfactory compliance and no significant tolerability issues,"Pregnancy, intent to become pregnant, or active breastfeeding | Unwilling or unable to continue to comply with contraceptive requirements | Any new conditions or worsening of existing conditions that would make the participant unsuitable for the study or interfere with participation",Completed AOC 1001-CS1 (MARINA) with satisfactory compliance and no significant tolerability issues,ALL,F,"Disease mismatch: the trial is for Myotonic Dystrophy Type 1, while the patient has Duchenne muscular dystrophy. Additionally, the trial requires adults 18–66 and prior completion of AOC 1001-CS1; the patient is 11 and has not completed that study.",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,"Hard exclusion due to disease mismatch (DM1 trial vs patient with DMD). Additionally, age <18 conflicts with trial’s 18–66 window. The grader’s F and reasoning are correct.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT05479981,0.540749192237854,Amyotrophic Lateral Sclerosis,"A Phase 2 Extension Study to Evaluate the Long-Term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients",PHASE2,18 years to 66 years,Myotonic Dystrophy Type 1,Completion of AOC 1001-CS1 (MARINA) with satisfactory compliance and no significant tolerability issues,"Pregnancy, intent to become pregnant, or active breastfeeding | Unwilling or unable to continue to comply with contraceptive requirements | Any new conditions or worsening of existing conditions that would make the participant unsuitable for the study or interfere with participation",Completed AOC 1001-CS1 (MARINA) with satisfactory compliance and no significant tolerability issues,ALL,F,"Disease mismatch: the trial targets Myotonic Dystrophy Type 1, while the patient has ALS.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,F,"Correct: The trial targets Myotonic Dystrophy Type 1, not ALS. This is a hard disease mismatch per rubric, so grade F is appropriate regardless of other factors.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT05511363,0.5763745307922363,Dementia,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease",PHASE3,55 years to 90 years,Alzheimer's Disease (psychosis),"Age 55 to 90 years | Possible or probable Alzheimer's disease diagnosis | Brain MRI or CT to rule out other CNS disease (within past 5 years or during screening) | History of psychotic symptoms meeting IPA criteria for >=2 months prior to screening | CGI-S score >=4 (moderate) at screening and baseline | Moderate to severe delusions or hallucinations per NPI-C criteria at screening and baseline | MMSE score 8 to 22, inclusive, at screening | Stable dose of cholinesterase inhibitor and/or memantine for >=6 weeks prior to screening (if taking) | BMI 18 to 40 kg/m2 | Female not pregnant or breastfeeding; effective contraception required for WOCBP and partners as specified","Psychotic symptoms primarily due to a condition other than Alzheimer's disease | Major depressive episode with psychotic features within 12 months prior to screening | History of bipolar disorder, schizophrenia, or schizoaffective disorder | Significant or severe medical conditions that could jeopardize safety or study validity | eGFR <60 mL/min/1.73 m2 (significant or severe renal impairment) | History of ischemic stroke within 12 months prior to screening or any hemorrhagic stroke | History of cerebral amyloid angiopathy, epilepsy, CNS neoplasm, unstable thyroid function, or unexplained syncope | NYHA Class 2 congestive heart failure | Grade 2 or greater angina pectoris | Sustained ventricular tachycardia, ventricular fibrillation, or torsade de pointes | Implantable cardioverter defibrillator | Myocardial infarction within 6 months prior to screening | Personal or family history suggestive of long QT syndrome | HIV infection, cirrhosis, biliary duct abnormalities, hepatobiliary carcinoma, or active hepatic viral infections | High risk of urinary retention, gastric retention, or narrow-angle glaucoma | Males: history of bladder stones | Males: history of recurrent urinary tract infections | Males: PSA >10 ng/mL at screening | Males: IPSS score of 5 (almost always) on items 1, 3, 5, or 6 | Males: sum of IPSS items 1, 3, 5, and 6 >=9 | History of irritable bowel syndrome or serious constipation requiring treatment within last 6 months | Risk of suicidal behavior per clinical assessment and/or C-SSRS | Clinically significant abnormal physical exam, ECG, or clinical laboratory findings at screening | Urine toxicology positive for substances other than permitted cannabis or short-/medium-acting benzodiazepines unless approved by Medical Monitor | Recent use of MAO inhibitors, anticonvulsants (e.g., lamotrigine, divalproex), lithium, or tricyclic antidepressants; SSRIs/SNRIs allowed only if stable >=8 weeks; mirtazapine or trazodone as hypnotic allowed only if started >=8 weeks | Investigator/Sponsor judgment of unsuitability for the study | Positive COVID-19 test within 2 weeks before or at screening | Unable to taper/discontinue prohibited concomitant medications | Prior exposure to KarXT | Known hypersensitivity to trospium or prior significant adverse events due to trospium | Received an investigational drug within 3 months prior to screening or >2 clinical studies in past year",Stable cholinesterase inhibitor and/or memantine for >=6 weeks prior to screening permitted; SSRIs or SNRIs permitted if on a stable dose for >=8 weeks prior to screening; Mirtazapine or trazodone may be used as hypnotic if started >=8 weeks prior to screening; No investigational drug within 3 months prior to screening,ALL,F,"Hard exclusion: the trial is for psychosis associated with Alzheimer's disease, but the patient is listed with nonspecific dementia (amyloid biomarkers negative, no AD diagnosis). Psychosis is also not documented.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),INCORRECT,D,"No hard exclusion applies. The patient has unspecified dementia (not a confirmed non-AD diagnosis) and psychosis is not documented, so disease mismatch is not definitive; unknowns should not trigger F. However, the trial requires possible/probable AD with psychosis, and the patient’s amyloid-negative biomarkers imply a likely mismatch with the AD requirement, constituting a soft mismatch. Thus grade D, not F.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT05548556,0.5916150808334351,Duchenne Muscular Dystrophy,"A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Pharmacodynamics, Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy",PHASE2,18 years to 65 years,Facioscapulohumeral Muscular Dystrophy,"Genetic confirmation of FSHD1 or FSHD2 | Clinical findings consistent with FSHD | Ability to walk unassisted | Ricci Clinical Severity Scale score >= 2.5 and <= 4 | Agreement to maintain the same frequency and intensity of physiotherapy, occupational therapy, and other exercise during the study","Pregnancy or breastfeeding, or intention to become pregnant during the study or within 17 months after the final dose | Current or previous treatment with anti-myostatin therapies | Treatment with any investigational therapy within 90 days prior to screening or 5 drug-elimination half-lives, whichever is longer | Contraindications to MRI | Clinically significant ECG abnormalities | Clinically significant cardiovascular disease | Clinically significant abnormal echocardiography at screening (except mitral valve prolapse) | Any major illness within 1 month before screening | Hypersensitivity to RO7204239 or its formulation components | History of malignancy (except in situ basal cell carcinoma of the skin and in situ cervical carcinoma excised with clean margins) | Clinically relevant history of anaphylactic reaction requiring inotropic support | Abnormal skin conditions, pigmentation, or lesions at intended abdominal SC injection site preventing visualization of injection-site reactions | Immobilization, surgical procedures, fracture, or trauma to upper or lower limbs within 90 days prior to screening (or longer if affecting motor assessments) | Planned surgery that may affect motor function assessments, including scapular fixation within 12 months prior to screening or planned during the study | Use within 90 days prior to enrollment of: oral beta-2 agonists (e.g., salbutamol); creatine; recombinant human growth hormone; recombinant human IGF-1; testosterone, oxandrolone, or other anabolic steroids; chronic systemic corticosteroids (except to manage injection reactions); agents anticipated to increase or decrease muscle volume or strength","No investigational therapy within 90 days prior to screening or 5 half-lives, whichever is longer; No use within 90 days prior to enrollment of oral beta-2 agonists, creatine, rhGH, rhIGF-1, anabolic steroids, or chronic systemic corticosteroids (except for injection reactions)",ALL,F,"The trial enrolls adults (18–65) with facioscapulohumeral muscular dystrophy who can walk unassisted and are not on chronic systemic steroids. The patient has Duchenne muscular dystrophy, is 11 years old, non-ambulatory, and on deflazacort—failing disease, age, functional, and medication criteria.",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,"Multiple hard exclusions apply: disease mismatch (Duchenne vs FSHD), age below minimum (11 vs 18–65), and explicit exclusion for chronic systemic corticosteroids (patient on deflazacort). Therefore F is correct regardless of ambulatory status.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT05626855,0.5825374126434326,Duchenne Muscular Dystrophy,"An Open-Label, Multicenter, Extension Trial to Evaluate the Long-Term Safety and Efficacy of Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Investigational Trials of Apitegromab",PHASE3,2 years,Spinal Muscular Atrophy Type 2; Spinal Muscular Atrophy Type 3,Estimated life expectancy >2 years | Female of childbearing potential: negative pregnancy test at baseline | Female of childbearing potential: agrees to use at least 1 highly effective contraceptive method during treatment and for 20 weeks after last dose,Unstable nutritional status over the past 6 months | Medical necessity for gastric or nasogastric feeding tube with majority of feeds by this route | Prior severe hypersensitivity reaction or intolerance to SMN-targeted therapies | Prior severe hypersensitivity reaction or intolerance to apitegromab | Chronic daytime noninvasive ventilatory support >16 hours/day | Active systemic infection or other acute/comorbid condition requiring acute treatment or inpatient observation | Pregnant or breastfeeding | Any condition or clinically significant laboratory or ECG abnormality that may compromise safety or compliance or interfere with trial interpretation,Completed prior apitegromab trial (TOPAZ or SAPPHIRE),ALL,F,"Disease mismatch: the trial targets Spinal Muscular Atrophy Type 2/3, while the patient has Duchenne Muscular Dystrophy. The trial also requires prior completion of an apitegromab trial, which is not present in the provided history.",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,"Correct: There is a hard exclusion due to disease mismatch (patient has Duchenne Muscular Dystrophy; trial targets SMA type 2/3). This alone mandates F per rubric. The noted requirement for prior apitegromab trial completion is also unmet, further supporting ineligibility.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT05626855,0.5849320888519287,Amyotrophic Lateral Sclerosis,"An Open-Label, Multicenter, Extension Trial to Evaluate the Long-Term Safety and Efficacy of Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Investigational Trials of Apitegromab",PHASE3,2 years,Spinal Muscular Atrophy Type 2; Spinal Muscular Atrophy Type 3,Estimated life expectancy >2 years | Female of childbearing potential: negative pregnancy test at baseline | Female of childbearing potential: agrees to use at least 1 highly effective contraceptive method during treatment and for 20 weeks after last dose,Unstable nutritional status over the past 6 months | Medical necessity for gastric or nasogastric feeding tube with majority of feeds by this route | Prior severe hypersensitivity reaction or intolerance to SMN-targeted therapies | Prior severe hypersensitivity reaction or intolerance to apitegromab | Chronic daytime noninvasive ventilatory support >16 hours/day | Active systemic infection or other acute/comorbid condition requiring acute treatment or inpatient observation | Pregnant or breastfeeding | Any condition or clinically significant laboratory or ECG abnormality that may compromise safety or compliance or interfere with trial interpretation,Completed prior apitegromab trial (TOPAZ or SAPPHIRE),ALL,F,"Hard exclusion: The trial targets spinal muscular atrophy (Type 2/3), while the patient has amyotrophic lateral sclerosis. Additionally, the study requires prior participation in an apitegromab trial, which is not documented.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,F,"Hard exclusion applies: disease mismatch (trial is for SMA type 2/3; patient has ALS), which mandates F. The note about prior apitegromab trial participation is unnecessary for the decision.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT05644522,0.8210699558258057,Duchenne Muscular Dystrophy,"Power Forward Study: A Cross-Sector, Multisite Clinical Trial of a Powered Knee-Ankle-Foot Orthosis",NA,18 years to 89 years,Cerebrovascular Accident; Multiple Sclerosis; Muscular Dystrophy; Paralysis; Post-Polio Syndrome; Spinal Cord Injury,"Regular use of a unilateral or bilateral KAFO or SCO or other passive KAFOs for impairment due to neurological or neuromuscular disease, orthopedic disease, or trauma",Knee and/or hip flexion contracture >15 degrees | Non-correctable knee varus/valgus >15 degrees | Severe spasticity | Inability to stabilize the trunk with or without assistive devices,(none),ALL,F,"The trial requires participants to be 18–89 years old, while the patient is 11. Although muscular dystrophy is targeted, the age window conflict is a hard exclusion.",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,"Age 11 is outside the trial’s 18–89 window, which is a hard exclusion. Disease (muscular dystrophy) matches, but age alone mandates F. The grader correctly identified and applied this hard exclusion.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT05644522,0.5888956785202026,Amyotrophic Lateral Sclerosis,"Power Forward Study: A Cross-Sector, Multisite Clinical Trial of a Powered Knee-Ankle-Foot Orthosis",NA,18 years to 89 years,Cerebrovascular Accident; Multiple Sclerosis; Muscular Dystrophy; Paralysis; Post-Polio Syndrome; Spinal Cord Injury,"Regular use of a unilateral or bilateral KAFO or SCO or other passive KAFOs for impairment due to neurological or neuromuscular disease, orthopedic disease, or trauma",Knee and/or hip flexion contracture >15 degrees | Non-correctable knee varus/valgus >15 degrees | Severe spasticity | Inability to stabilize the trunk with or without assistive devices,(none),ALL,F,"Disease mismatch: the trial targets stroke, MS, muscular dystrophy, post-polio syndrome, spinal cord injury, or paralysis, and ALS is not included. Additionally, required regular KAFO use is not documented, but the disease mismatch alone is a hard exclusion.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,F,"ALS is not among the trial’s listed diseases/cohorts, triggering the rubric’s hard exclusion for disease mismatch. Therefore an F is correct regardless of other criteria. The grader’s reasoning appropriately identified this.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT05701189,0.5655304193496704,Amyotrophic Lateral Sclerosis,"Phase 2, Randomized, Patient- and Rater-blinded Single-site Trial Evaluating Safety and Efficacy of Efgartigimod in Patients with Guillain-Barré Syndrome.",PHASE2,18 years,Guillain-Barre Syndrome,"Age >= 18 years | Diagnosis of Guillain-Barre Syndrome per NINDS criteria | Onset of GBS-related weakness <= 14 days prior to infusion | GBS Disability Scale (GBS-DS) score of 3, 4, or 5","Pregnant or lactating | GBS-DS of 2 or less | Severe bacterial, viral, or fungal infection or major infection requiring hospitalization or injectable antimicrobials within 8 weeks prior to screening | > 14 days since onset of symptoms | Known IgG deficiency | Recurrent Guillain-Barre Syndrome | Use of an investigational drug within 3 months or 5 half-lives prior to screening (whichever is longer) | History of malignancy (including malignant thymoma) or myelo/lymphoproliferative disorders unless cured >= 3 years; exceptions: completely excised non-melanoma skin cancer or cervical carcinoma in situ | Other significant serious disease or recent major surgery that could confound results or pose undue risk",(none),ALL,F,"Disease mismatch: the trial targets Guillain-Barré syndrome, while the patient has amyotrophic lateral sclerosis (ALS). This is a hard exclusion.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,F,"The trial targets Guillain-Barré syndrome, while the patient has ALS. This is a disease mismatch, a hard exclusion per the rubric, so grade F is correct.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT05703178,0.6053727269172668,Rheumatoid Arthritis,Web-based Pain Coping Skills Training to Improve Pain and Poor Adherence Caused by Aromatase Inhibitor-Associated Arthralgia In Breast Cancer Survivors (SKIP-Arthralgia): A Randomized Controlled Trial,PHASE3,18 years,Breast Cancer; Arthralgia; Chronic Pain,"Female sex | Age >= 18 years | Stage 0–III hormone receptor positive breast cancer | Completed primary cancer treatment (surgery, chemotherapy, and/or radiation therapy) | Postmenopausal | Currently taking aromatase inhibitor therapy (letrozole, exemestane, or anastrozole) | Musculoskeletal pain that developed or worsened since starting aromatase inhibitor therapy | >= 15 days of pain in the past 30 days | Worst pain rating >= 4/10 in the past week | ECOG performance status 0-2 | Stable analgesic regimen for >= 14 days prior to enrollment with no planned upward titration during the study","Metastatic disease | Other active cancer (except non-melanoma skin cancer) | Chemotherapy or radiation therapy completed < 4 weeks prior to enrollment | Major surgery completed < 8 weeks prior to enrollment (minor surgeries may be allowed) | Diagnosed or suspected condition interfering with consent or study activities (e.g., significant cognitive impairment or uncorrected hearing/vision)","Completed primary cancer treatment (surgery, chemotherapy, and/or radiation therapy); Currently receiving aromatase inhibitor therapy; Stable analgesic regimen >= 14 days before enrollment; No chemotherapy or radiation therapy within 4 weeks prior to enrollment; No major surgery within 8 weeks prior to enrollment",FEMALE,F,"Disease mismatch: the trial targets postmenopausal breast cancer survivors on aromatase inhibitors with AI-associated arthralgia, while the patient has rheumatoid arthritis with no evidence of breast cancer or AI therapy.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Hard exclusion: disease mismatch. The trial targets HR+ breast cancer survivors on aromatase inhibitors with AI-associated arthralgia, while the patient has rheumatoid arthritis and no evidence of breast cancer or AI therapy. Thus F is appropriate per rubric.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT05756569,0.7725474834442139,Metastatic Urothelial Carcinoma,Phase II Single-Arm Study of Enfortumab Vedotin (EV) Plus Pembrolizumab in the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology,PHASE2,18 years,Bladder Adenocarcinoma; Bladder Squamous Cell Carcinoma; Bladder Cancer (locally advanced); Bladder Cancer (metastatic); Renal Pelvis Carcinoma; Ureter Carcinoma; Urethral Carcinoma; Urachal Adenocarcinoma,"Age >= 18 years | ECOG 0–1 | Metastatic disease or unresectable locally advanced disease | Variant or non-urothelial bladder cancer of epithelial origin; predominant > 50% variant or non-urothelial in mixed tumors | Eligible primary sites include ureter, urethra, urachus, or renal pelvis | Measurable disease per RECIST 1.1 | Adequate organ and marrow function within 28 days of C1D1 | Tumor tissue available for submission or agree to undergo biopsy | Female of childbearing potential: negative pregnancy test prior to therapy | Use of effective contraception during treatment and for 6 months after last dose | Completion of all prior cancer therapy >= 4 weeks before start of study therapy | Life expectancy > 12 weeks","Neuroendocrine histology (small cell or large cell) or non-epithelial bladder tumors (e.g., bladder sarcoma, carcinosarcoma, paraganglioma, melanoma, primary lymphoma, lymphoepithelioma-like carcinoma) | Chemotherapy or radiotherapy within 4 weeks prior to study entry or unresolved >= grade 2 toxicities from prior treatment (except alopecia) | Receipt of other investigational agents or an investigational device within 21 days before first dose | Allergic reactions to compounds of similar chemical or biologic composition to study agents | Ongoing sensory or motor neuropathy grade >= 2 | Prior treatment with enfortumab vedotin or PD-1/PD-L1 inhibitors (including maintenance) | Uncontrolled diabetes mellitus with HbA1c >= 8% or HbA1c 7% to < 8% with symptomatic polyuria or polydipsia | Active central nervous system metastases | Another active malignancy within 24 months except for permitted in-situ or localized cancers | Currently receiving systemic antimicrobial therapy for active infection or high-dose steroids (> 10 mg prednisone equivalent) | Pregnancy or positive pregnancy test at baseline | Breastfeeding | Active autoimmune disease requiring systemic treatment within the past 2 years | Hepatitis B surface antigen positive | Active hepatitis C virus infection (HCV RNA detected) | Active tuberculosis | History of active keratitis or corneal ulcerations | History of allogeneic tissue or solid organ transplant | Congestive heart failure NYHA class III or IV, unstable angina, or serious cardiac arrhythmias within 6 months prior to first dose | Other uncontrolled illness (including cardiac arrhythmia or psychiatric illness) that would limit compliance","Any number of prior systemic therapies allowed (including untreated); Washout >= 4 weeks from prior surgery, radiotherapy, chemotherapy, immunotherapy, or investigational therapy; Washout >= 21 days from other investigational agents",ALL,F,"The trial excludes patients with prior enfortumab vedotin or PD-1/PD-L1 therapy, which this patient received, and it requires variant/non-urothelial histology while the patient has urothelial carcinoma.",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),CORRECT,F,"The trial explicitly excludes prior enfortumab vedotin or PD-1/PD-L1 exposure, which the patient has, and requires variant/non-urothelial histology while the patient has urothelial carcinoma. These are hard exclusions, so F is correct.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT05767034,0.6438535451889038,Rheumatoid Arthritis,"A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)",PHASE3,50 years to 100 years,Polymyalgia Rheumatica,"Age >= 50 years. | Male or non-pregnant, non-lactating female. | Diagnosis of polymyalgia rheumatica per ACR/EULAR criteria with bilateral shoulder pain and elevated CRP (>= 10 mg/L) and/or ESR (>= 30 mm/hr). | ACR/EULAR optional classification criteria totaling >= 4 points: morning stiffness > 45 min; hip pain or restricted range of motion; absence of rheumatoid factor and/or anti-citrullinated protein antibodies; absence of other joint involvement. | Treated with prednisone >= 10 mg/day (or equivalent) for at least 8 consecutive weeks at any time prior to screening. | At least one PMR relapse while tapering prednisone >= 5 mg/day within the past 12 weeks prior to baseline, with relapse defined by recurrence of bilateral shoulder/hip girdle pain and inflammatory stiffness not due to mimicking diseases, and elevated ESR (>= 30 mm/hr) and/or CRP (> ULN) attributable to PMR at relapse and/or screening. | Following the latest PMR relapse, treated per local recommendations and on prednisone 7.5–25 mg/day at screening and during screening.","Evidence or history of giant cell arteritis (cranial symptoms, extremity claudication, suggestive imaging and/or temporal artery biopsy). | Concurrent rheumatoid arthritis, other inflammatory arthritis, or other connective tissue diseases (e.g., systemic lupus erythematosus, systemic sclerosis, vasculitis, myositis, mixed connective tissue disease, ankylosing spondylitis). | Concurrent diagnosis or history of neuropathic muscular diseases or fibromyalgia. | Inadequately treated hypothyroidism (e.g., persistent symptoms or non-normalized TSH despite replacement). | Previous exposure to secukinumab or other biologics directly targeting IL-17 or the IL-17 receptor. | Treatment with tocilizumab or other IL-6/IL-6 receptor inhibitors within 12 weeks or within 5 half-lives (whichever is longer) prior to baseline; non-responders or those who relapsed during such treatment are excluded.",Prior prednisone >= 10 mg/day for >= 8 consecutive weeks.; On prednisone 7.5–25 mg/day at screening.; Washout from IL-6/IL-6 receptor inhibitors >= 12 weeks or >= 5 half-lives prior to baseline.,ALL,F,"Disease mismatch: the trial targets polymyalgia rheumatica, while the patient has rheumatoid arthritis. Additionally, the trial explicitly excludes patients with concurrent rheumatoid arthritis.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Hard exclusion applies: disease mismatch (trial is for PMR; patient has RA). Additionally, the trial explicitly excludes concurrent rheumatoid arthritis. The grader correctly identified these and assigned F.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT05786404,0.5336129665374756,Fistulizing Crohn's Disease,"A Randomized, Open-label, Pilot Study to Evaluate the Fecal Microbiota Transplantation (FMT) in the Treatment of Ulcerative Colitis",PHASE1,18 years,Ulcerative Colitis (active),Active ulcerative colitis: Partial Mayo score >= 3 with each subscore > 1 | Sexually active males and females of childbearing potential agree to use effective contraception during the study | Females of childbearing potential must have a negative urine pregnancy test at enrollment and on Week 1 Day 1 prior to dosing,"Severe ulcerative colitis (Mayo score > 7) | Unable to take retention enema or multiple oral capsules | Pregnant, breastfeeding, or planning pregnancy during the study | Receipt of systemic non-topical antibiotics within 14 days before Day 1 | Active HIV infection | Active hepatitis B infection | Active hepatitis C infection | History of recurrent Clostridioides difficile infection | Prior fecal microbiota transplantation within 6 months | Other active gastrointestinal conditions (e.g., irritable bowel syndrome, microscopic colitis, celiac disease, short gut syndrome, colostomy, colectomy, gastrointestinal fistulae or strictures, chronic parasitic infections, diverticulitis) | Known bile acid diarrhea | Compromised immune system (primary immune disorders or clinical immunosuppression) | Current systemic corticosteroids at prednisone > 20 mg/day or equivalent | History of active cancer and/or ongoing chemotherapy (superficial non-metastatic cancers and maintenance chemotherapy are permitted) | Use of an investigational drug within 90 days before screening | Significant uncontrolled systemic disease | Life expectancy < 1 year | Absolute neutrophil count < 500/µL",(none),ALL,F,"Disease mismatch: the trial enrolls active ulcerative colitis, while the patient has fistulizing Crohn's disease. Additionally, the trial explicitly excludes patients with gastrointestinal fistulae, which the patient has.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,F,"Clear hard exclusions: disease mismatch (UC trial vs Crohn’s patient) and explicit exclusion of gastrointestinal fistulae, which the patient has. The grader’s F and reasoning are correct.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT05832086,0.6668181419372559,Castration-Resistant Prostate Cancer,Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes,PHASE2,Not specified,"Prostate Adenocarcinoma (metastatic, castrate-sensitive)","Metastatic castrate-sensitive prostate adenocarcinoma confirmed by biopsy | Metastatic disease confirmed by biopsy or MRI | Receiving or planning to start first-line intensified androgen deprivation therapy within 30 days with abiraterone, apalutamide, enzalutamide, or darolutamide | Current or prior chemotherapy permitted","Allergy to any ingredients on the Xentigen Ingredient List | Diabetes not on stable doses of antihyperglycemic medication for >= 6 months or without physician consent to safely hold antihyperglycemics during the 5 days of FMD | Regularly practicing a fasting diet that would impact study participation | Significant cardiac, pulmonary, liver disease, or ongoing alcohol/drug abuse precluding enrollment | Body mass index < 20 kg/m2 | Actively trying to lose weight | Use of weight loss medications (e.g., naltrexone/bupropion, liraglutide, orlistat) | Planning to receive weight loss surgery in the next 6 months | Self-reported weight loss >= 10% in the last 6 months","Receiving or planning first-line intensified ADT with abiraterone, apalutamide, enzalutamide, or darolutamide within 30 days of registration; Prior or current chemotherapy allowed",MALE,F,"The trial requires metastatic castrate-sensitive prostate cancer on first-line intensified ADT, while the patient has metastatic castration-resistant disease with prior abiraterone and enzalutamide—an explicit required stage/setting mismatch.",Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),CORRECT,F,"The trial explicitly requires metastatic castrate-sensitive prostate cancer on first-line intensified ADT, while the patient has metastatic castration-resistant disease with prior abiraterone/enzalutamide. This is a required stage/setting mismatch the patient definitively lacks, which is a HARD EXCLUSION per the rubric. Grade F is correct.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT05849012,0.5669113397598267,Fistulizing Crohn's Disease,A Pilot Study Examining Low Sulfur Diet as Treatment for Persistent Symptoms in Quiescent Crohn's Disease,NA,18 years,Crohn's Disease (remission),"Prior diagnosis of Crohn's disease based on endoscopic, radiographic, and/or histologic findings | Quiescent Crohn's disease defined by fecal calprotectin < 150 mcg/g stool and/or absence of inflammation on colonoscopy within 30 and 90 days of enrollment, respectively | Persistent symptoms defined by abdominal pain and/or diarrhea T-scores >= 55 on the NIH PROMIS-GI scale",Prior total colectomy | Presence of an end ileostomy or colostomy | Changes in immunosuppressive medications within the past 4 weeks | Use of antibiotics or probiotics within the past 4 weeks | Active or suspected gastrointestinal stricture or stenosis | Habitual vegetarian or vegan diet | Unable or unwilling to follow a low sulfur diet | Underweight (BMI < 18.5 kg/m2) or significant unintentional weight loss (> 7.5% in the past 3 months) | Currently pregnant or breastfeeding,(none),ALL,F,"The trial requires quiescent (remission) Crohn's disease with objective inactivity, whereas the patient has active moderate-to-severe fistulizing perianal Crohn's disease, definitively failing the required setting.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,F,"The trial requires quiescent/remission Crohn’s as an inclusion criterion (a required setting), while the patient has active moderate-to-severe fistulizing disease. This is a hard exclusion per the rubric (required stage/setting mismatch), so F is correct.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT05857969,0.8032767176628113,Recurrent Glioblastoma,Adopting a Functional Precision Medicine Approach For Individualized Pediatric Cancer Treatments,PHASE1,1 days to 21 years,"Acute Lymphoblastic Leukemia (recurrent); Acute Myeloid Leukemia (recurrent); Brain Tumor (recurrent); Brainstem Glioma (recurrent); Ependymoma (recurrent); Gliosarcoma (recurrent); Large Cell Lymphoma (recurrent); Lymphoblastic Lymphoma (recurrent); Rhabdomyosarcoma (recurrent); Soft Tissue Sarcoma (recurrent); Acute Lymphoblastic Leukemia (refractory); Hodgkin Lymphoma (refractory); Malignant Germ Cell Tumor (refractory); Chronic Myelogenous Leukemia, BCR-ABL1 Positive (refractory)",Age <=21 years | Recurrent or refractory cancer (suspected or confirmed) | Scheduled for or recently had tumor biopsy/excision or bone marrow aspirate | Willing to provide blood or buccal swab for genetic testing,No malignant tissue available or accessible | Insufficient malignant tissue for ex vivo drug testing and/or genomic profiling | Newly diagnosed tumors | Tumors with high (>90%) cure rate with safe standard therapy,(none),ALL,F,"The trial only enrolls patients ≤21 years, and the patient is 40, creating a hard age window exclusion.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),CORRECT,F,"Patient age 40 exceeds trial maximum age 21, which is a hard age window exclusion per rubric. The grader correctly applied a HARD EXCLUSION and assigned F.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT05867329,0.5382735729217529,Fistulizing Crohn's Disease,A Sequential Multiple Assignment Randomized Trial (SMART) Feasibility Pilot Developing and Optimizing Patient-Tailored Adaptive Treatment Strategies (ATS) for Acute Severe Ulcerative Colitis (ASUC),PHASE4,18 years to 75 years,Ulcerative Colitis (acute severe),"Age 18–75 years | Diagnosis of ulcerative colitis confirmed by clinical history, endoscopy, and histology | Current hospitalization for ulcerative colitis treatment with expected initiation of IV corticosteroids | Acute severe ulcerative colitis: >= 4 bloody bowel movements/day plus at least one of the following—temperature > 37.5 C, pulse > 90 BPM, hemoglobin < 10.5 g/dL, ESR >= 30 mm/h, weight loss > 5 lb over 3 months, CRP >= 3.0 mg/dL, fecal calprotectin > 782 mg/kg (within 4 weeks), or oral corticosteroid use for >= 14 days at a dose equivalent to >= 30 mg/day | Prior exposure to at least one anti-TNF agent (adalimumab, certolizumab, infliximab, or golimumab; originator or biosimilar) | Able to take oral medication and adhere to the study regimen | Females of reproductive potential: negative pregnancy test at admission and agreement to use highly effective contraception during the 3-month follow-up","Indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or clinical features suggestive of Crohn's disease | Receiving continuous IV corticosteroids for >= 72 hours prior to enrollment | Pregnant or breastfeeding | Toxic megacolon during current admission | Hypersensitivity to methylprednisolone, cyclosporine, tofacitinib, or upadacitinib | Prior exposure to upadacitinib | Ongoing severe infection, including untreated or inadequately treated latent or active tuberculosis | Active CMV colitis defined as > 5 inclusion bodies per high powered field at baseline (unless allowed with concomitant antiviral therapy per teams) | Investigational agent or procedure within 30 days or five half-lives prior to baseline | Current malignancy except non-metastatic basal cell or squamous cell carcinoma of the skin | History of colectomy (total or subtotal), ileoanal pouch, Kock pouch, or ileostomy, or planned bowel surgery | Neutropenia (ANC < 1200/µL) or total white blood cell count < 2500/µL | Hemoglobin < 8 mg/dL | Platelet count < 80000/µL | eGFR < 30 mL/min/1.73 m2 | ALT >= 2 x ULN or AST >= 2 x ULN | Cirrhosis with Child-Pugh score >= 5 | Uncontrolled hypertension (systolic > 160 mmHg or diastolic > 100 mmHg despite therapy) | Recent (within 6 months) cerebrovascular accident, myocardial infarction, or coronary stenting | Recent (within 6 months) moderate-to-severe congestive heart failure (NYHA class III–IV) | Inherited or acquired thrombophilia (e.g., antiphospholipid syndrome, Factor V Leiden, prothrombin G20210A, deficiencies of antithrombin, protein C, protein S, heparin cofactor II, PAI-1/plasminogen disorders, dysfibrinogenemia, Factor XII deficiency) | Total cholesterol < 80 mg/dL at baseline | Chronic HBV infection with positive HBsAg and detectable DNA not on suppressive therapy; HCV RNA positive; or HIV with CD4 < 350/µL or AIDS-defining opportunistic infection | Solid organ or bone marrow transplant within 1 year or expected within 6 months | History of more than one episode of herpes zoster, disseminated zoster, or disseminated herpes simplex | Current use of medications increasing venous thromboembolism risk (e.g., hormone replacement therapy, testosterone, tamoxifen) | Live or attenuated live vaccines within 6 weeks prior to baseline or scheduled during study or within 140 days after last dose | History of lymphoproliferative disorder, lymphoma, leukemia, myeloproliferative disorder, multiple myeloma, or signs/symptoms of current hematologic disease | History of spontaneous gastrointestinal perforation (other than appendicitis or mechanical injury), diverticulitis, or significantly increased risk of GI perforation per investigator | Concomitant strong CYP3A4 inducers or inhibitors, including grapefruit or grapefruit juice | Conditions affecting oral drug absorption (e.g., gastrectomy, significant diabetic gastroenteropathy, gastric bypass; gastric banding permitted) | Any clinically significant medical condition or other reason that, in the investigator’s opinion, would interfere with participation or pose risk","Prior exposure to at least one anti-TNF agent (adalimumab, certolizumab, infliximab, or golimumab; originator or biosimilar)",FEMALE,F,"Hard exclusions apply: the study targets acute severe ulcerative colitis and excludes Crohn’s disease, while the patient has fistulizing Crohn’s disease; additionally, the trial enrolls only females and the patient is male.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,F,"Correct use of hard exclusions: the trial targets acute severe ulcerative colitis and excludes Crohn’s disease, while the patient has Crohn’s disease; additionally, the trial is female-only and the patient is male. Either condition triggers an F.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT05876780,0.5468103885650635,Duchenne Muscular Dystrophy,"A Multicenter, Open-label, Single-dose, Systemic Gene Transfer Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9003 on Subjects With Limb Girdle Muscular Dystrophy, Type 2E/R4 (β-Sarcoglycan Deficiency)",PHASE1,4 years to 50 years,Limb Girdle Muscular Dystrophy (beta-sarcoglycan deficiency),Cohort 1: Ambulatory per protocol-defined criteria. | Cohort 2: Non-ambulatory and age 4 to 50 years. | Pathogenic or likely pathogenic SGCB gene mutation (1 homozygous or 2 heterozygous). | Ability to cooperate with muscle testing.,"Clinically significant illness or medical condition (e.g., cardiac, pulmonary, hepatic, renal, hematologic, immunologic, neuromuscular other than LGMD2E/R4, behavioral disease, infection, malignancy) or need for chronic drug treatment that increases risk or compromises compliance/safety. | Exposure to gene therapy, investigational medication, or other protocol-specified treatment within protocol-defined time limits. | Any contraindication to corticosteroid use.",Washout from prior gene therapy or investigational medication per protocol-defined time limits.,ALL,F,"Disease mismatch: the trial targets LGMD2E/R4 (SGCB beta-sarcoglycan deficiency), while the patient has Duchenne muscular dystrophy (DMD exon 49–50 deletion). The required SGCB mutation biomarker is not present.",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,"Correct: The trial targets LGMD2E/R4 (SGCB deficiency) while the patient has Duchenne muscular dystrophy, a hard disease mismatch leading to F. The grader’s added note about SGCB mutation absence is unnecessary (and somewhat inferential), but the hard exclusion stands, so the assigned F is correct.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT05877300,0.5615940690040588,Fistulizing Crohn's Disease,Safety and Feasibility Study of the CELLSPAN Esophageal Implant (CEI) in Patients Requiring Short Segment Esophageal Replacement,PHASE1,18 years,Refractory Benign Esophageal Stricture; Esophageal Perforation; Esophageal Fistula,"Age >= 18 years | Medical condition requiring esophageal reconstruction: refractory benign esophageal strictures, esophageal perforation, chronic/persistent esophageal fistula, or combination of perforation/fistula with RBES | Failed at least 3 prior treatments for the esophageal condition | Candidate for short segment esophageal reconstruction (<= 6 cm full circumferential excision) | Target esophageal segment within thoracic cavity (above diaphragm and >= 4 cm below larynx) | High-risk candidate for minimally invasive esophageal reconstruction; requires thoracotomy and not amenable to laparoscopic or robotic gastric pull-up due to medical contraindication","Requires or undergoes esophageal segmental excision > 6 cm | Target esophageal segment extends below diaphragm or < 4 cm below larynx | Pre-existing implants/structures adjacent to target site that could abrade scaffold/regenerated tissue (e.g., pacemaker lead, vascular clips, vascular grafts) | Contraindication to use of covered metallic stent adjunct | Post-ablation stricture for Barrett's esophagus treated < 1 year prior to planned procedure | Comorbidity or contraindication precluding study procedures (including adipose biopsy and esophageal resection) | Diabetes mellitus (CCI = 1) | Connective tissue disorder (CCI = 1) | Immunocompromised state | Chemotherapy, radiotherapy, or chemoradiotherapy within 60 days | Inability to tolerate major thoracotomy | Active infection at biopsy or thoracotomy incision site | Peripheral vascular disease (CCI = 1) | Charlson Comorbidity Index > 2 | Life expectancy < 1 year | Pregnant or nursing; pregnancy planned within 1 year after index procedure | Untreated neurological, psychological, or psychiatric disorder interfering with trial participation | Immunodeficiency | Chimeric antigen receptor T-cell (CAR-T) therapy within 30 days | Systemic steroid therapy > 10 mg prednisone equivalent daily within 30 days or intended during 12 months post-implant | Protease inhibitors, immunosuppressants, or anti-cytokine therapies within 30 days or intended during 12 months post-implant | Infection requiring antibiotic therapy | Allergy to nitinol | Current participation in another investigational drug or device study | Prisoner status | High risk of opioid addiction if pain management required per investigator assessment","Failed >= 3 prior treatments for esophageal condition; No chemotherapy, radiotherapy, or chemoradiotherapy within 60 days; No CAR-T therapy within 30 days; No systemic steroids > 10 mg prednisone equivalent within 30 days; No protease inhibitors, immunosuppressants, or anti-cytokine therapies within 30 days",ALL,F,"Disease mismatch: the trial targets esophageal conditions (e.g., esophageal stricture/perforation/fistula), not fistulizing Crohn's disease. The patient's condition is not included in the trial’s targeted diseases.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,F,"Clear hard exclusion: disease mismatch. The trial targets esophageal conditions (stricture/perforation/esophageal fistula) requiring esophageal reconstruction, while the patient has fistulizing Crohn’s disease with perianal fistula. Hard exclusion triggers F regardless of other factors.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT05942300,0.7158204913139343,Recurrent Clear Cell Ovarian Carcinoma,Phase I Trial of CPI-0209 in Combination With Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer,PHASE1,18 years,"Ovarian Cancer (recurrent, platinum-sensitive); Fallopian Tube Cancer (recurrent, platinum-sensitive); Primary Peritoneal Cancer (recurrent, platinum-sensitive)","Platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer (>6 months after last platinum) eligible for platinum-based chemotherapy | Documented disease recurrence/progression per GCIG-RECIST | At least 1 prior line of platinum-based therapy; prior bevacizumab or PARP inhibitor allowed | ECOG performance status 0-2 and life expectancy >=3 months | Adequate organ function | Able to swallow oral CPI-0209 | Treated CNS metastases allowed if therapy completed >=8 weeks prior, asymptomatic off systemic corticosteroids >=4 weeks, and stable/regressed on imaging >=4 weeks after therapy","Borderline or low malignant potential histology | Platinum-resistant disease (progressive disease within 6 months of completing platinum therapy) | Known hypersensitivity to CPI-0209 excipients | Gastrointestinal dysfunction or disease that may significantly alter absorption of study drugs | Concurrent malignancy or malignancy within 3 years except adequately treated basal or squamous cell carcinoma, non-melanomatous skin cancer, or curatively resected cervical cancer, or if deemed cured per investigator | History of HIV infection | Active infection requiring systemic treatment | Severe or uncontrolled medical conditions that pose unacceptable risk (e.g., chronic pancreatitis, chronic active hepatitis, significant cardiac or pulmonary disease) | Current treatment with warfarin or other coumadin-derived anticoagulants (heparin/LMWH/fondaparinux allowed) | Use of herbal supplements unless discontinued >=7 days prior to study drug | Consumption of strong CYP3A4/5 inducers or inhibitors not discontinued >=7 days prior; unwilling to avoid Seville oranges, grapefruit, and related products during study | Pregnant or breastfeeding | Participation in another investigational study within 30 days or within 5 half-lives of the investigational product, whichever is longer | Radiotherapy <=4 weeks prior to study drug (<=2 weeks if limited field for palliation) or not recovered to <=Grade 1; or >=25% of bone marrow irradiated | Major surgery within 14 days prior to study drug or not recovered from major surgery | Not recovered from prior anticancer therapy toxicities to <=Grade 1 (exceptions: any grade alopecia; controlled endocrine toxicities; neuropathy <=Grade 2) | Grade 3 baseline neuropathy | Child-Pugh class B or C hepatic impairment",At least 1 prior platinum-based chemotherapy required; Prior bevacizumab allowed; Prior PARP inhibitor allowed,FEMALE,F,"The trial requires platinum-sensitive recurrence (>6 months after last platinum) and explicitly excludes platinum-resistant disease; the patient recurred 5 months after adjuvant platinum, indicating platinum resistance.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; BRCA1 positive; Optimal debulking surgery performed; Received adjuvant carboplatin + paclitaxel + bevacizumab; Cytology-positive malignant pleural effusion at 5 months post-adjuvant,(none),Carboplatin; Paclitaxel; Bevacizumab; Optimal debulking surgery,Stage III,,36,years,female,(none),CORRECT,F,"The trial explicitly requires platinum-sensitive recurrence (>6 months after last platinum) and excludes platinum-resistant disease. The patient recurred at 5 months post-platinum, meeting the exclusion. This is a hard exclusion per rubric, so F is correct.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT05946824,0.607130765914917,Castration-Resistant Prostate Cancer,"Daily-Adaptive Stereotactic Body Radiation Therapy for Biochemically Recurrent, Radiologic Apparent Prostate Cancer After Radical Prostatectomy",PHASE2,18 years,Prostate Cancer (recurrent after surgery),"Adenocarcinoma of the prostate with previous surgical resection | Radiologically detected prostate bed or regional nodal recurrence (iliac, obturator, perirectal, or presacral nodes; generally below the aortic bifurcation) | Prostate bed recurrence within the prostate region or RTOG consensus surgical field | At least two serum detectable PSA levels > 0.02 ng/dL at least 30 days apart",Metastatic disease | Prior radiation therapy to the pelvis region | Inflammatory bowel disease | Hospitalization for a gastrointestinal diagnosis in the preceding 3 months | Hospitalization for a urinary tract issue/diagnosis in the preceding 3 months | PSA > 10 ng/dL at study entry,Prior radical prostatectomy,MALE,F,"The trial explicitly excludes metastatic disease, whereas the patient has metastatic castration-resistant prostate cancer with liver and bone metastases. Therefore, the patient fails a hard exclusion.",Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),CORRECT,F,"Correct: The trial explicitly excludes metastatic disease, and the patient has metastatic CRPC with liver and bone metastases. This is a hard exclusion, so F is appropriate. The disease/setting also mismatches (biochemical/local recurrence post-prostatectomy vs metastatic CRPC), reinforcing ineligibility.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT05973630,0.6070272922515869,Duchenne Muscular Dystrophy,"A Phase 1-2, Open-label, Dose Escalation Study to Evaluate the Safety of 2 Doses of Intravenous ATA-200, an Adeno-associated Viral Vector Carrying the Human SGCG Gene, in Patients with Gamma-sarcoglycanopathy (LGMDR5)",PHASE1/PHASE2,6 years to 13 years,Limb-Girdle Muscular Dystrophy R5,Confirmed diagnosis of LGMDR5 before age 10 based on clinical presentation and genotyping | Ambulant male or female aged 6 to <12 years at screening | Able to perform the 10-meter walk test in <15 seconds | Able to rise from a chair with or without arm support,"Detectable neutralizing antibodies against AAV8 | Cardiomyopathy with left ventricular ejection fraction <50% | Respiratory assistance | Concomitant medical condition that might interfere with LGMDR5 evolution | Acute illness within 4 weeks of anticipated investigational product administration | Previous participation in gene and cell therapy trials | Any condition that would contraindicate immunosuppressant treatment | Any vaccination within 1 month prior to planned investigational product administration | Serology consistent with HIV exposure or active hepatitis B or C infection | Grade 2 or higher abnormalities in liver function tests, creatinine, hemogram, or coagulation",(none),ALL,F,"The trial targets gamma-sarcoglycanopathy (LGMDR5), whereas the patient has Duchenne muscular dystrophy with a DMD exon 49-50 deletion. This disease mismatch constitutes a hard exclusion.",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,"Disease mismatch: trial targets LGMDR5 (gamma-sarcoglycanopathy), while the patient has Duchenne muscular dystrophy. This is a hard exclusion per rubric, so F is correct. Other criteria are irrelevant once a hard exclusion applies.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT05973630,0.5526973009109497,Amyotrophic Lateral Sclerosis,"A Phase 1-2, Open-label, Dose Escalation Study to Evaluate the Safety of 2 Doses of Intravenous ATA-200, an Adeno-associated Viral Vector Carrying the Human SGCG Gene, in Patients with Gamma-sarcoglycanopathy (LGMDR5)",PHASE1/PHASE2,6 years to 13 years,Limb-Girdle Muscular Dystrophy R5,Confirmed diagnosis of LGMDR5 before age 10 based on clinical presentation and genotyping | Ambulant male or female aged 6 to <12 years at screening | Able to perform the 10-meter walk test in <15 seconds | Able to rise from a chair with or without arm support,"Detectable neutralizing antibodies against AAV8 | Cardiomyopathy with left ventricular ejection fraction <50% | Respiratory assistance | Concomitant medical condition that might interfere with LGMDR5 evolution | Acute illness within 4 weeks of anticipated investigational product administration | Previous participation in gene and cell therapy trials | Any condition that would contraindicate immunosuppressant treatment | Any vaccination within 1 month prior to planned investigational product administration | Serology consistent with HIV exposure or active hepatitis B or C infection | Grade 2 or higher abnormalities in liver function tests, creatinine, hemogram, or coagulation",(none),ALL,F,"Disease mismatch: the trial is for LGMDR5 (gamma-sarcoglycanopathy), not ALS, and the age window is 6–13 while the patient is 62—both are hard exclusions.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,F,"Correct: The trial targets LGMDR5 and restricts age to 6–13, while the patient has ALS and is 62. Both are hard exclusions, so F is appropriate and the reasoning is sound.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT06008093,0.8135332465171814,Metastatic Non-Small Cell Lung Cancer,"A Phase IIIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for First-line Treatment in Metastatic Non-small Cell Lung Cancer Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)",PHASE3,18 years to 130 years,"Non-Small Cell Lung Cancer (non-squamous, metastatic)","Histologically or cytologically confirmed Stage IV non-squamous NSCLC not amenable to curative surgery or radiation | Tumor harbors STK11 or KEAP1 or KRAS mutation (co-mutations allowed) | Tumor lacks activating EGFR mutations and lacks ALK fusions | No prior chemotherapy or other systemic therapy for metastatic NSCLC | Prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation allowed if progression > 6 months from end of last therapy | No prior exposure to immune-mediated therapy (excluding therapeutic anti-cancer vaccines) within 6 months of randomization | ECOG performance status 0–1 | Life expectancy >= 12 weeks | At least one measurable lesion per RECIST 1.1 (>= 10 mm) not previously irradiated and suitable for repeated measurements | Adequate organ and bone marrow function | Negative pregnancy test for women of childbearing potential | Use of effective contraception (male and female) | Body weight > 30 kg","Acute or uncontrolled diseases or history of allogeneic organ transplant | Mixed small cell lung cancer and NSCLC histology | Major surgery within 28 days prior to first dose or need for major surgery during study | Active or prior autoimmune or inflammatory disorders (exceptions: vitiligo, alopecia, stable hypothyroidism on replacement, chronic skin conditions not requiring systemic therapy, inactive disease > 5 years after consultation, celiac disease controlled by diet) | Medical contraindication to platinum-based doublet chemotherapy | History of another malignancy except curatively treated with no active disease >= 2 years or adequately resected non-melanoma skin cancer or curatively treated in situ disease | Persistent CTCAE Grade >= 2 toxicities from prior therapy (except alopecia and vitiligo); Grade <= 2 neuropathy may be allowed per investigator | Spinal cord compression unless asymptomatic and stable | Significant cardiac disease (e.g., symptomatic CHF, unstable angina, uncontrolled significant arrhythmias, symptomatic/uncontrolled atrial fibrillation, sustained ventricular tachycardia) | Concurrent anticancer chemotherapy, investigational product, biologic, or hormonal therapy (non-cancer hormonal therapy allowed) | Radiation therapy not meeting allowed criteria (definitive >= 6 months prior; or specific palliative settings) | Untreated or unstable brain metastases (must be treated and stable; not RECIST target lesions) | History of leptomeningeal carcinomatosis | Active tuberculosis infection | Active hepatitis: HBsAg positive or anti-HBc with detectable HBV DNA; HCV antibody positive with detectable HCV RNA; HBV/HCV or HBV/HDV coinfection | HIV infection not well controlled | Immunosuppressive medication within 14 days before first dose (exceptions: local/topical/inhaled steroids; physiologic doses <= 10 mg/day prednisone equivalent; premedication/single palliative dose) | Receipt of live attenuated vaccine within 30 days before first dose | Concurrent enrollment in another interventional clinical study (except observational or follow-up) | Hypersensitivity to study drugs or excipients | Pregnant or breastfeeding or planning pregnancy; breastfeeding restrictions apply during and after therapy",No prior systemic therapy for metastatic NSCLC; Prior platinum-containing adjuvant/neoadjuvant or definitive chemoradiation allowed if progression > 6 months from last therapy; No prior immune-mediated therapy within 6 months before randomization,ALL,F,"The trial requires absence of activating EGFR mutations, but the patient has an EGFR exon 19 deletion, and it is a first-line study with no prior systemic therapy allowed while the patient has received osimertinib for 2 years.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"Hard exclusions apply: the trial requires absence of activating EGFR mutations and specific STK11/KEAP1/KRAS mutations, while the patient has an EGFR exon 19 deletion. Additionally, the study is first-line with no prior systemic therapy for metastatic disease allowed, but the patient received osimertinib for 2 years. Thus F is appropriate per the rubric.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06041789,0.5785478353500366,Dementia,Effect of Acetylcholinesterase Inhibitors on Bone Metabolism and Fracture Risk Factors Among Older Adults With Mild to Moderate Alzheimer's Disease,PHASE2,50 years,Osteoporosis; Alzheimer's Disease (mild to moderate),"Diagnosis of cognitive impairment (clinical, radiographic, or laboratory biomarker assessment) | Female: age >55 years or <55 years and >=12 months postmenopausal | Male: age >50 years | Geriatric Depression Scale score <6","Current use of acetylcholinesterase inhibitor or memantine | History of bradycardia, heart block, long QT, unexplained syncope, or other contraindication to donepezil | ECG: heart rate <50 bpm, PR interval >200 ms, QTc >440 ms (men) or >460 ms (women), or atrioventricular block | Current use of osteoporosis medications (e.g., bisphosphonates, SERM, denosumab, teriparatide, abaloparatide, calcitonin) | Bisphosphonate use within the last 5 years | Use within the last 6 months of estrogens, testosterone, androgen deprivation therapy, aromatase inhibitors, antiepileptics, heparin, or thiazolidinediones | Disorders associated with secondary osteoporosis (e.g., collagen vascular disease, malabsorption, inflammatory bowel disease, severe liver disease/cirrhosis, hyperthyroidism) | History of low-trauma fracture of the humerus, wrist, or vertebra | History of hip fracture, hip replacement, or non-ambulatory status | Long-term corticosteroid use (>6 months) | History of Parkinson's disease, HIV, or Huntington's disease | History of solid organ transplantation | History of bariatric surgery or planned weight loss by bariatric surgery or weight loss medication in the next 12 months | Severe renal impairment (eGFR <30 mL/min) | Active malignancy undergoing chemotherapy, surgery, or radiation therapy (except non-melanoma skin cancer) | Estimated 1-year mortality >25%",(none),ALL,F,"Hard exclusion: The trial targets mild to moderate Alzheimer's disease, but the patient is listed only with dementia (no AD diagnosis) and has amyloid-negative biomarkers, so the disease does not match the trial’s specified condition.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,"Disease mismatch is a hard exclusion. The trial targets Alzheimer’s disease (mild–moderate), while the patient is labeled only with dementia without an AD diagnosis; per rubric we cannot infer AD. Thus F is appropriate. The amyloid-negativity mention wasn’t necessary but doesn’t change the hard exclusion outcome.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT06051942,0.6498956680297852,Castration-Resistant Prostate Cancer,PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs,NA,up to 80 years,Benign Prostatic Hyperplasia; Localized Prostate Cancer,International Prostate Symptom Score (IPSS) >= 8 | Gleason Grade Group 1-3 | Prostate-specific antigen (PSA) <= 20 ng/mL | Cancer stage <= T2c,Previous surgical treatment of benign prostatic hyperplasia | MRI evidence of extracapsular extension of cancer | Severe illness that would prevent complete participation or confound results,(none),MALE,F,"Disease mismatch: the trial targets benign prostatic hyperplasia and localized (≤T2c) prostate cancer, while the patient has metastatic castration-resistant prostate cancer. This fails the trial’s disease and stage requirements.",Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),CORRECT,F,"Disease mismatch is a hard exclusion: the trial targets BPH/localized (≤T2c) prostate cancer, while the patient has metastatic castration-resistant prostate cancer. The grader correctly assigned F and explained the key mismatch.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT06147037,0.7606950998306274,Metastatic Urothelial Carcinoma,"A Phase 1, First-in-human, Multicentre, Open-label, Dose Escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours",PHASE1,18 years,Gastric Cancer; Head and Neck Squamous Cell Carcinoma; Metastatic Colorectal Carcinoma; Non-small Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma; Renal Cell Carcinoma,"Histologically or cytologically confirmed solid tumor that is metastatic, locally advanced, recurrent, or inoperable | Disease progressed despite prior treatment and no additional effective standard therapy available, contraindicated, not tolerable, or refused | Measurable disease per RECIST v1.1 | ECOG performance status 0–1 | Adequate organ function","Previous treatment with any systemic radiopharmaceutical | Prior anti-cancer therapy unless adequate washout and recovery from toxicities | Contraindications to or inability to perform required imaging procedures | Radiation therapy within 28 days prior to the first dose of [111In]-FPI-2107 | Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (>= once per month) | Known CNS metastatic disease unless treated and stable",Prior anti-cancer therapy permitted with adequate washout and recovery; Prior radiation therapy permitted if >28 days before first [111In]-FPI-2107 dose,ALL,F,"Disease mismatch: the trial targets specific cancers (gastric, HNSCC, colorectal, NSCLC, pancreatic, renal cell) and does not include urothelial carcinoma, so the patient’s disease is not eligible.",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),CORRECT,F,"Correct: The trial’s diseases_targeted list does not include urothelial carcinoma, triggering the rubric’s hard exclusion for disease mismatch. Despite broad solid tumor wording in inclusion criteria, the rubric uses the diseases_targeted field; thus F is appropriate.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06159673,0.5766936540603638,Dementia,"A Master Protocol for Three Independent, Seamlessly Enrolling, Double-blind, Placebo-controlled Efficacy and Safety Studies of ACP-204 in Adults With Alzheimer's Disease Psychosis",PHASE2/PHASE3,55 years to 95 years,Alzheimer's Disease Psychosis,"Age >=55 and <=95 years | Possible or probable Alzheimer's disease per 2011 NIA-AA criteria | Psychosis meeting International Psychogeriatrics Association criteria in major or mild neurocognitive disorder | Evidence of amyloid plaque deposition by blood-based biomarker, PET, or CSF consistent with Alzheimer's disease | Prior brain MRI or CT consistent with Alzheimer's disease | MMSE score >=6 and <=24 | Psychotic symptoms for >=2 months | Stable dose of a cholinesterase inhibitor or memantine, if applicable","Psychotic symptoms primarily attributable to delirium, substance abuse, or a medical or psychiatric condition other than dementia | History of cerebral amyloid angiopathy | History of epilepsy | History of central nervous system neoplasm | History of unexplained syncope | Atrial fibrillation | Symptomatic orthostatic hypotension | Protocol-defined exclusionary clinical laboratory findings | Treatment with anti-tau therapy or donanemab within 2 months prior to screening | In hospice receiving end-of-life palliative care or bedridden",Stable dose of cholinesterase inhibitor; Stable dose of memantine,ALL,F,"The trial requires evidence of amyloid plaque deposition (blood/PET/CSF) consistent with Alzheimer's disease, but the patient is amyloid PET and CSF amyloid negative, which is a required biomarker mismatch. Psychosis for ≥2 months is also required and not documented.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,"The trial requires positive evidence of amyloid plaque deposition; the patient has amyloid PET and CSF amyloid negative, a definitive required biomarker mismatch, which is a hard exclusion → F. The psychosis requirement is undocumented (unknown) and should not drive F, but the biomarker mismatch alone justifies F.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT06173505,0.7711784243583679,Metastatic Non-Small Cell Lung Cancer,"A Phase 1b/2, Open-label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer",PHASE1/PHASE2,18 years,Nonsquamous Non-small Cell Lung Cancer,"Histologically confirmed locally advanced (unresectable) or metastatic nonsquamous non-small cell lung cancer | Documented absence of tumor-activating EGFR mutation, ALK rearrangement, ROS1 rearrangement, and other actionable driver alterations with approved first-line targeted therapies | PD-L1 IHC TPS < 49% | No prior systemic treatment for advanced/metastatic NSCLC | Measurable disease per RECIST 1.1 | ECOG performance status 0–1 | Life expectancy >= 3 months | Adequate liver function | Adequate kidney function | Adequate thyroid function | Adequate bone marrow function","Active central nervous system metastases or carcinomatous meningitis (treated, radiologically stable brain metastases allowed) | Active known or suspected autoimmune disease | Systemic corticosteroids or other immunosuppressive medications within 14 days prior to first dose | Symptomatic interstitial lung disease | HIV infection with CD4+ T-cell count < 350 cells/µL, HIV viral load > 400 copies/mL, history of AIDS-defining opportunistic infection within 12 months, or not on stable ART >= 4 weeks | Positive test for hepatitis C RNA | Positive hepatitis B surface antigen or positive hepatitis B core antibody unless HBV DNA negative with ongoing monitoring | Clinically unstable or uncontrolled disorder or disease that could pose risk or interfere with study",No prior systemic therapy for advanced/metastatic NSCLC,ALL,F,"The trial requires absence of EGFR and other actionable drivers and no prior systemic therapy for advanced NSCLC; the patient has an EGFR exon 19 mutation and has received osimertinib for 2 years, violating explicit exclusions.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"Correct F: The trial explicitly requires absence of EGFR driver alterations and no prior systemic therapy for advanced/metastatic NSCLC. The patient has an EGFR exon 19 mutation and has been on osimertinib for 2 years, both constituting hard exclusions under the rubric.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT06185673,0.593180775642395,Duchenne Muscular Dystrophy,"A Phase 1b/2a, Open-label, Dose Escalation Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia",PHASE1/PHASE2,up to 65 years,Oculopharyngeal Muscular Dystrophy,"Age 50-65 years at NH study enrollment with genetically diagnosed heterozygous OPMD (GCN10/GCN12, GCN10/GCN13, GCN10/GCN14, GCN10/GCN15, GCN10/GCN16) or age <=65 years with genetically diagnosed homozygous OPMD (GCN12/GCN12, GCN13/GCN13, GCN14/GCN14, GCN15/GCN15, GCN16/GCN16). | Eligible and willing to undergo surgical dissection of the pharyngeal region with intubation under general anesthesia for study drug administration. | Moderate dysphagia defined as PhAMPC >2.7%(C2-4)^2 with natural sips of thin liquid barium or PhAMPC >2.1%(C2-4)^2 with teaspoon delivery of moderately thick liquid barium.","Prior treatment with an adeno-associated virus (AAV) vector. | Presence of anti-AAV9 antibody titer >1:50. | Pregnant or breastfeeding. | Pharyngeal muscle not amenable to intramuscular injection due to clinically significant atrophy by HRAN assessment. | Contraindication to videofluoroscopy procedures or radiopaque contrast agents. | Gene therapy within 6 months prior to Screening. | Contraindication to proposed study procedures or medications (e.g., corticosteroids). | Prior cricopharyngeal myotomy or cricopharyngeal botulinum toxin injection. | Cricopharyngeal dilation within 12 months prior to Screening. | Hospitalization within 12 months for pneumonia of nonpathogenic origin (e.g., aspiration pneumonitis) or bacterial pneumonia in the setting of pre-existing dysphagia. | Intubation within 30 days prior to Screening. | Very restricted diet textures (IDDSI Functional Diet Scale score <=3). | Neuromuscular diseases distinct from OPMD or other diseases that may significantly interfere with characterization of dysphagia. | Other disorders associated with dysphagia (e.g., severe GERD, esophageal stricture, esophageal infection, drug-induced dysphagia, esophageal rings/webs, spastic motility disorders). | Concomitant illness likely to significantly decrease life expectancy or any malignancy other than curatively treated skin cancer or in situ cervical carcinoma, unless adequately treated or in complete remission for >=5 years. | Any diagnosis of head and neck cancer at any time. | Any history of neck irradiation. | Major surgical procedure to the mouth or neck (except routine dental procedures, tonsillectomy, or adenoidectomy). | Abnormal liver function: ALT or AST >2.5 x ULN. | Immunocompromised state or receiving immunosuppressant therapy. | Clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, psychiatric, neurologic, or allergic diseases (excluding untreated, not clinically significant, seasonal allergies). | NCI CTCAE grade 3 hypertension (systolic >=160 mmHg or diastolic >=100 mmHg). | Malnutrition or cachexia (e.g., unintended weight loss >5-10% in 1-6 months with BMI <18.5-20 kg/m^2, or weight loss >5% over 6 months or BMI <20 kg/m^2 with ongoing weight loss >2%). | Treatment with an investigational drug/device or approved therapy for investigational use within 3 months or 5 half-lives prior to Screening.",(none),ALL,F,"Disease mismatch: the trial targets oculopharyngeal muscular dystrophy (OPMD), while the patient has Duchenne muscular dystrophy (DMD). Additionally, the trial enrolls adults with OPMD, and the patient is 11 years old.",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,"Correct: The trial targets OPMD, while the patient has DMD—this is a hard disease mismatch. Additionally, the trial’s inclusion criteria specify adult ages (50–65 or ≤65 with homozygous OPMD), and the patient is 11, creating an age window conflict. Either constitutes a hard exclusion → F.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06189963,0.6000585556030273,Dementia,"A Phase I/IIa, Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Moderate Alzheimer's Disease",PHASE1/PHASE2,40 years to 85 years,Alzheimer Disease (moderate),Diagnosis of Alzheimer's dementia per 2011 NIA-AA guidelines | Age 40 to 85 years | At least 6 years of formal education and fluency in test language | Females of childbearing potential: negative urine pregnancy test at screening and before first dose | Participants of reproductive potential agree to abstinence or effective contraception during treatment and for 30 days after last dose | Positive amyloid PET of the brain within the past 6 months | CDR-SB score >= 9.5 and < 16.0,"Substantial concomitant cerebrovascular disease (Fazekas Grade 3) | History of stroke or intracranial hemorrhage temporally related to worsening cognition | Substance use disorder not in remission for at least 12 months | History of cancer (except basal cell carcinoma) or cancer treatment within the last 5 years | Uncontrolled cardiovascular illness (e.g., chronic congestive heart failure, tachycardia, arrhythmias, uncontrolled hypertension) | Cerebrovascular accident, transient ischemic attack, or unexplained loss of consciousness within the last year | Significant pulmonary disease predisposing to hypoxia | Significant ischemic heart disease, myocardial infarction within the last 2 years and/or residual angina, orthopnea, conduction defects, or NYHA class III or IV heart disease | Significant liver disease (e.g., cirrhosis, active hepatitis B or C, primary or metastatic liver neoplasm) | ALT, AST, or alkaline phosphatase > 3 x ULN | Significant gastrointestinal disorders (e.g., GI bleeding within 2 years, malabsorption syndromes, post-gastrectomy, active peptic ulcer disease) | Clinically significant immunological disorders (e.g., significant allergies, lupus erythematosus, scleroderma) | Uncontrolled or unstable hematological disease (e.g., refractory anemia, refractory myelosuppression) | Neurological diseases affecting cognition (e.g., primary Lewy body dementia, Huntington's disease, Parkinson's disease, encephalitis, epilepsy, vascular or multi-infarct dementia, stroke, congenital mental deficiency, multiple sclerosis) | Psychiatric disorders impacting cognition (e.g., schizophrenia, intellectual disability) | Unstable or uncontrolled major depression or anxiety within the last 12 months | History of seizures in the past 3 years | Uncontrolled endocrine disease (e.g., uncontrolled diabetes mellitus, manifest hyperthyroidism) | Severe renal impairment (GFR < 30 mL/min/1.73 m2) | Infection with HIV, hepatitis B, hepatitis C, or any other active infection or active systemic disease | Current treatment with anticoagulants (except aspirin at or below a prophylactic dose) | Use of memantine or acetylcholinesterase inhibitors above recommended dose range or not on a stable dose for 30 days prior to enrollment | Any contraindication to brain MRI and/or amyloid PET | Any condition that, in the investigator's opinion, puts the participant's safety at risk | Medically unstable or uncontrolled conditions | Any suicidal behavior in the past 2 years | Suicidal ideation type 4 or 5 on C-SSRS in the past 3 months",Stable dose of memantine or acetylcholinesterase inhibitors for >=30 days prior to enrollment,ALL,F,"The trial requires a positive amyloid PET within the past 6 months, while the patient’s amyloid PET is negative. This required biomarker mismatch is a hard exclusion.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,"Trial requires positive amyloid PET; patient has documented negative amyloid PET. This is a required biomarker mismatch, which is a hard exclusion per rubric, thus F. Other factors (age/sex/stage) do not override the hard exclusion.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT06224660,0.7811301946640015,Duchenne Muscular Dystrophy,"A Phase 1b, Open-Label, Controlled Trial Evaluating the Safety and Efficacy of SRD-001 (AAV1/SERCA2a) in Subjects With Cardiomyopathy Secondary to Duchenne Muscular Dystrophy",PHASE1,18 years,Dilated Cardiomyopathy (Duchenne Muscular Dystrophy-associated),"Diagnosis of Duchenne muscular dystrophy with confirmatory genetic testing | Cardiomyopathy with left ventricular scar in at least 3 of 16 segments | Left ventricular ejection fraction < 40% | Individualized, optimized cardiac medical therapy and glucocorticoid treatment for at least 12 months prior to enrollment | Willing and able to provide informed consent",Abnormal blood pressure | Non-DMD-related liver function test elevations | Cystatin C >= 1.2 mg/L | Thrombocytopenia | Anemia | Inadequate pulmonary function,On optimized cardiac medical therapy for >=12 months; On glucocorticoid treatment for >=12 months,MALE,F,"Hard exclusion: the trial requires participants ≥18 years, but the patient is 11. Additionally, the trial requires LVEF < 40%, while the patient’s LVEF is 52%.",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,"Age is a hard exclusion: trial min age is 18, patient is 11. This alone warrants F. The patient also lacks the required LVEF <40%, reinforcing ineligibility. The grader correctly applied the rubric.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT06244082,0.7573704123497009,Duchenne Muscular Dystrophy,A Phase 2 Open-label Study to Evaluate the Pharmacodynamics and Long-Term Safety and Tolerability of AOC 1044 Administered Intravenously to DMD Participants With Mutations Amenable to Exon 44 Skipping,PHASE2,7 years to 27 years,Duchenne Muscular Dystrophy (exon 44 amenable),"Age 7–27 years at consent (de novo). | Clinical diagnosis of Duchenne Muscular Dystrophy or symptom onset at or before age 6 years (de novo). | DMD gene mutation amenable to exon 44 skipping (de novo). | Weight >= 23 kg (de novo). | Ambulatory or non-ambulatory (de novo). | Ambulatory: LVEF >= 50% (de novo). | Ambulatory: FVC >= 50% (de novo). | Non-ambulatory: LVEF >= 45% (de novo). | Non-ambulatory: FVC >= 40% (de novo). | PUL 2.0 entry item A >= 3 (de novo). | If on corticosteroids, stable dose for >= 30 days before screening and throughout the study (de novo). | No significant tolerability issues with AOC 1044 (rollover).",New or worsening condition that could affect safety or ability to comply (rollover). | Serum hemoglobin < lower limit of normal (de novo). | Uncontrolled hypertension (de novo). | Uncontrolled diabetes (de novo). | Prior treatment with any cell or gene therapy (de novo). | Prior treatment with another exon 44 skipping agent within 6 months prior to informed consent (de novo). | Recent treatment with an investigational drug (de novo). | History of multiple drug allergies (de novo).,Corticosteroids allowed if on a stable dose for >= 30 days before screening and throughout the study,MALE,F,"The trial requires a DMD mutation amenable to exon 44 skipping, but the patient has a deletion of exons 49–50, which is typically exon 51–amenable, not exon 44–amenable. This required biomarker mismatch is a hard exclusion.",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,"The trial requires a DMD mutation amenable to exon 44 skipping. The patient has a deletion of exons 49–50, which is not exon 44–amenable (typically exon 51–amenable). This is a definitive required biomarker mismatch, a hard exclusion. Age and sex fit but are irrelevant once the hard exclusion applies.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT06246513,0.5865613222122192,Duchenne Muscular Dystrophy,"A Phase 3 Multinational, Open-label, Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9003 in Subjects With Limb Girdle Muscular Dystrophy 2E/R4",PHASE3,4 years,Limb-Girdle Muscular Dystrophy (type 2E/R4),Ambulatory cohort: able to walk without assistive aid | Ambulatory cohort: 10-meter walk test <30 seconds | Ambulatory cohort: NSAD >=25 | Non-ambulatory cohort: 10-meter walk test >=30 seconds or unable to perform | Non-ambulatory cohort: PUL 2.0 entry scale score >=3 | One homozygous or two heterozygous pathogenic/likely pathogenic SGCB (beta-sarcoglycan) DNA mutations | Able to cooperate with muscle testing | AAVrh74 antibody titer <1:400 by ELISA,Left ventricular ejection fraction <40% or clinical signs/symptoms of cardiomyopathy | Forced vital capacity <=40% of predicted or requirement for nocturnal ventilation | Diagnosis of an autoimmune disease with active immunosuppressant treatment | Any other clinically significant illness or medical condition other than LGMD2E/R4,(none),ALL,F,"Disease mismatch: the trial targets LGMD2E/R4, while the patient has Duchenne muscular dystrophy. Additionally, the trial requires pathogenic SGCB mutations, which the patient does not have (DMD exon 49-50 deletion).",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,"Correct: The patient has Duchenne muscular dystrophy, while the trial targets LGMD2E/R4—this is a disease mismatch (hard exclusion). The trial also requires pathogenic SGCB mutations, which the patient does not have (has DMD exon 49-50 deletion), another hard exclusion. Therefore F is appropriate.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT06257706,0.5883981585502625,Fistulizing Crohn's Disease,An Interventional Study to Evaluate Treating to a Target of Transmural Healing in Patients With Moderately to Severely Active Crohn's Disease,PHASE4,18 years to 80 years,Crohn Disease (moderately to severely active),Age 18 to 80 years | Moderately-to-severely active Crohn disease: CDAI 220 to 450 and SES-CD >= 6 (or >= 4 if isolated ileal disease) | C-reactive protein >= 5 mg/L and/or fecal calprotectin >= 250 µg/g at screening | Bowel wall thickness on intestinal ultrasound > 4.0 mm in the ileum or any colonic segment (excluding rectum) | Biologic-naive or prior exposure to no more than 1 advanced therapeutic (approved biologic or small molecule) for Crohn disease | Stable dose of 5-ASA initiated >= 4 weeks prior to screening may be continued | Persons of childbearing potential: negative serum pregnancy test prior to randomization and use of highly effective contraception during study,"Prior treatment with vedolizumab, etrolizumab, or natalizumab | Previously exposed to 2 or more advanced therapeutics (approved biologic or small molecule) for Crohn disease | Change in oral corticosteroid dose within 2 weeks prior to randomization or prednisone > 40 mg (or equivalent) at randomization | Inflammation only proximal to terminal ileum not reachable by ileocolonoscopy | Crohn disease complication requiring procedural intervention (e.g., symptomatic small bowel stricture with > 3 cm prestenotic dilatation) | Previous extensive colonic resection or missing > 2 of 5 segments; ileorectal anastomosis; proctocolectomy | Ostomy or ileoanal pouch | Short bowel syndrome | Fibrotic-only stricture in ileum or colon without active inflammation, including any impassable stenosis | Abscess > 2 cm detected by intestinal ultrasound (participants with draining fistulas are not excluded) | Serious underlying disease other than Crohn disease that may interfere with participation or compromise safety | Positive stool test for Clostridioides difficile toxin | Known HIV infection | Known hepatitis B or hepatitis C infection | Known active or latent tuberculosis | Other systemic or opportunistic infection (including cytomegalovirus), any other clinically significant extraintestinal infection, or recurring infection within 6 months of randomization | Active cerebral or meningeal disease, signs, symptoms, or any history of progressive multifocal leukoencephalopathy | Hypersensitivity, allergy, or intolerance to vedolizumab excipients or any contraindication to vedolizumab | Active severe infection such as sepsis, cytomegalovirus, listeriosis, or opportunistic infection | Unwilling to withhold protocol-prohibited medications during the trial | Participation in another clinical trial with investigational therapy within 30 days or 5 half-lives (whichever is longer) prior to randomization | History of alcohol or drug abuse that may interfere with compliance | Prior enrollment in the current study and received study treatment | Pregnant, lactating, or intending pregnancy; or intending to donate ova or sperm during and up to 18 weeks after last dose | Live or live-attenuated vaccine within 4 weeks prior to randomization or planned during the study",Biologic-naive or <= 1 prior advanced therapeutic for Crohn disease allowed; Stable 5-ASA for >= 4 weeks prior to screening allowed; No change to oral corticosteroid dosing within 2 weeks prior to randomization,ALL,F,"The trial explicitly excludes patients previously exposed to 2 or more advanced therapeutics for Crohn’s disease; this patient has failed both infliximab and ustekinumab (two advanced therapies). While age and disease activity fit, the prior therapy history is a hard exclusion.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,F,"The trial excludes participants previously exposed to 2 or more advanced therapeutics; the patient has failed infliximab and ustekinumab (two advanced therapies). This is a hard exclusion, so F is correct.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06264362,0.715561032295227,Dementia,Developing a Nonpharmacological Pain Intervention for Community-dwelling Older Adults With Dementia,NA,60 years,Dementia (mild); Knee Osteoarthritis,Age >= 60 years | Mild or very mild dementia | Knee pain lasting >= 3 months | Average knee pain intensity >= 2/10,Life expectancy < 1 year | Recent changes to pain or psychotropic medications within 60 days | Knee surgery within the past 1 year | Medical condition that contraindicates exercise | Currently receiving rehabilitation services,(none),ALL,F,"The trial requires mild or very mild dementia, whereas the patient has moderate-stage dementia (MMSE 19), failing a mandatory inclusion criterion. Other factors (e.g., knee pain) are unknown but do not override this explicit mismatch.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,"Trial requires mild/very mild dementia; patient has moderate dementia (MMSE 19), a definitive failure of a required stage/severity criterion, which is a hard exclusion per rubric. Other criteria like knee pain are unknown and do not affect the hard exclusion. The grader’s F is correct.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT06377384,0.5966877937316895,Rheumatoid Arthritis,"A Pilot and Feasibility Study Focusing on Lifestyle, Environmental Modifications, and Transdisciplinary Clinical Care for Children With Chronic Illness: Protocol for the FLIGHT Study",PHASE1,2 years to 15 years,Juvenile Idiopathic Arthritis; Asthma; Eczema; Allergies; Crohn's Disease; Ulcerative Colitis; Lupus; Obesity; Type 2 Diabetes; Autism Spectrum Disorder; Attention-Deficit/Hyperactivity Disorder; Depression; Obsessive-Compulsive Disorder; Anxiety Disorder,"Diagnosis in immune/autoimmune conditions (e.g., juvenile idiopathic arthritis, juvenile rheumatoid arthritis, asthma, eczema, atopic illness, allergies, Crohn's disease, ulcerative colitis, lupus) | Diagnosis in conditions of metabolic dysregulation (e.g., obesity, type 2 diabetes) | Diagnosis in mood/behavioral/developmental conditions (e.g., autism spectrum disorder, ADHD/ADD, depression, obsessive-compulsive disorder, anxiety)","Condition severe enough to preclude participation in an intensive, multi-modal lifestyle intervention | Pregnancy",(none),ALL,F,"The trial targets pediatric conditions (e.g., juvenile idiopathic/juvenile rheumatoid arthritis) with an age range of 2–15, while the patient is a 55-year-old adult with rheumatoid arthritis. This creates both a disease cohort mismatch and an age window conflict.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Age window conflict (2–15 vs patient 55) and disease mismatch (trial targets juvenile arthritis, not adult RA) are hard exclusions. The grader correctly identified these and assigned F.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT06436742,0.5411390066146851,Duchenne Muscular Dystrophy,"A Phase 1b, Double-Blinded, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of ARGX-119 in Adult Participants with DOK7-Congenital Myasthenic Syndromes",PHASE1,18 years,Congenital Myasthenic Syndrome (DOK7),"Age >= 18 years | Genetically confirmed congenital myasthenic syndrome due to DOK7 mutation | If taking oral beta agonists (e.g., albuterol, salbutamol, ephedrine), on a stable regimen for > 3 months and agree to remain on the same stable dose through the study","Congenital myasthenic syndrome due to mutation in a gene other than DOK7 | Medical condition that would interfere with accurate assessment of CMS, confound results, or pose undue risk, per investigator | History of malignancy unless cured with no recurrence for > 5 years (basal or squamous cell skin cancer, carcinoma in situ of cervix or breast, incidental prostate cancer may be included at any time) | Received a different study drug in another clinical study within 12 weeks or 5 half-lives before screening | Current participation in another interventional clinical study | Prior participation in any gene therapy or cell therapy study | Pregnant or lactating, or intending to become pregnant during the study",Stable oral beta agonist therapy >= 3 months if used,ALL,F,"This study enrolls adults with genetically confirmed DOK7-congenital myasthenic syndrome, whereas the patient has Duchenne muscular dystrophy with a DMD exon 49-50 deletion and is 11 years old. This fails the disease, required biomarker, and age criteria.",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,"Clear hard exclusions: disease mismatch (trial is for DOK7 congenital myasthenic syndrome, patient has Duchenne muscular dystrophy) and age mismatch (trial >=18, patient is 11). Grader’s F and reasoning are consistent with the rubric.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT06452277,0.7686145305633545,Metastatic Non-Small Cell Lung Cancer,"A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations",PHASE3,18 years,"Non-Small Cell Lung Cancer (non-squamous, advanced/metastatic)",Age >= 18 years | Histologically or cytologically confirmed locally advanced non-squamous non-small cell lung cancer not suitable for definitive therapy or metastatic non-squamous non-small cell lung cancer (Stage III–IV) | Activating HER2 mutation in the tyrosine kinase domain confirmed by tissue molecular test in an accredited laboratory | No prior systemic therapy for locally advanced or metastatic disease | No prior HER2 exon 20 insertion–targeted therapy | Prior adjuvant or neoadjuvant therapy allowed if completed >= 12 months before screening | Eligible to receive platinum-pemetrexed doublet chemotherapy and pembrolizumab per product information,"Prior malignancy unless curatively treated with no recurrence for 5 years (specific in situ cancers, superficial bladder cancer, limited-stage prostate cancer, and basal or squamous skin cancers allowed if appropriately treated) | Tumors harboring other targetable alterations with approved available therapy (except HER2 mutation in the TKD) | Inability to discontinue chronic systemic corticosteroids | Pre-existing peripheral neuropathy Grade >= 2 (CTCAE v5.0) | History of severe hypersensitivity reaction to a monoclonal antibody | Radiotherapy outside of the brain within 21 days prior to start of study intervention or unresolved radiation-related toxicities or requirement for corticosteroids",No prior systemic therapy for locally advanced or metastatic disease; No prior HER2 exon 20 insertion–targeted therapy; Adjuvant or neoadjuvant therapy allowed if completed >= 12 months before screening,ALL,F,"This first-line trial requires a HER2-activating mutation and no prior systemic therapy; the patient has an EGFR exon 19 deletion and has received osimertinib. Additionally, the trial excludes tumors with other targetable alterations (e.g., EGFR).",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"Hard exclusion applies: the trial explicitly excludes tumors with other targetable alterations with approved therapy (e.g., EGFR), which the patient has. While lack of documented HER2 mutation alone wouldn’t trigger F under the rubric, and prior systemic therapy is an inclusion mismatch (not a hard exclusion by itself), the explicit exclusion criterion is sufficient for an F.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT06456073,0.5357873439788818,Fistulizing Crohn's Disease,"An Open-Label, Single-Center, Investigator Initiated Phase 1B Trial of E-CEL UVEC Cell Therapy for the Treatment of Chronic Anal Fissure",PHASE1,18 years,Chronic Anal Fissure,Age >= 18 years | Anterior or posterior chronic anal fissure for >= 6 weeks | Inadequate response to medical therapy: failed vasodilator treatment for 1 month and declined or failed botulinum injection | Pain on defecation NRS >= 4 | Systolic blood pressure >= 90 and < 140 mmHg | Diastolic blood pressure >= 60 and < 90 mmHg | Respiratory rate >= 12 and <= 20 breaths per minute | Pulse >= 60 and <= 100 beats per minute | Temperature >= 97.8 F and <= 99.1 F | O2 saturation > 92%,"Lateral anal fissure | Peri-anal or rectovaginal fistula, rectal or anal stenosis, peri-anal abscess, or non-healing peri-anal post-surgical wounds | Active, untreated or medically unresponsive infection of the anal fissure or fistula | Active systemic infection (controlled HIV infection allowed) | Inflammatory bowel disease (Crohn's disease or ulcerative colitis) | Currently receiving systemic chemotherapy or local pelvic radiation | Renal impairment: serum creatinine >= 1.5 x ULN | Hepatic impairment: total bilirubin >= 1.5 x ULN and AST/ALT >= 2.5 x ULN | Active alcohol or substance use that would interfere with study follow-up | Active malignant tumor (unless in remission for >= 6 months without maintenance chemotherapy and/or radiation) | Abnormal, severe, progressive, or uncontrolled hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral diseases (ongoing or within 6 months) | Congenital immunodeficiencies | Major surgery or severe trauma within the previous 3 months | Candidates for solid organ transplantation or high likelihood of needing a solid organ transplant | Pregnant or breastfeeding, or planning pregnancy or breastfeeding during the study | Known hypersensitivity or allergy to DMSO",Failed topical vasodilator therapy for >= 1 month; Declined or failed botulinum injection,ALL,F,"Disease mismatch: the trial targets chronic anal fissure and explicitly excludes inflammatory bowel disease (Crohn's) and peri-anal fistula. The patient has fistulizing Crohn's disease with an active perianal fistula, which is a hard exclusion.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,F,"Correct: There is a hard exclusion. The trial targets chronic anal fissure and explicitly excludes inflammatory bowel disease (Crohn’s) and peri-anal fistula, both of which apply to the patient with fistulizing Crohn’s and active perianal fistula. Disease mismatch also applies.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT06456593,0.5962986946105957,Fistulizing Crohn's Disease,"A Phase 2b, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease",PHASE2,18 years to 75 years,Crohn Disease (moderate to severe),"Age 18 to 75 years | Confirmed Crohn disease by endoscopy and histology | Moderately to severely active Crohn disease: CDAI 220–450 | SES-CD >= 6 for ileo-colonic or colonic disease, or SES-CD >= 4 for isolated ileal disease (per central reading) | Documented inadequate response, loss of response, or intolerance to at least one: corticosteroids, immunosuppressants, biologic or biosimilar therapies, or JAK inhibitors","Ulcerative colitis or indeterminate colitis | Crohn disease without ileal and/or colonic involvement | Untreated active external or perianal fistula or abscess (recent abscess must be drained and adequately treated per protocol timelines) | Symptomatic bowel stricture or stenosis not passable on endoscopy | Current stoma or ileoanal pouch | More than two missing complete segments among terminal ileum, right colon, transverse colon, left colon, and sigmoid/rectum | Combined prior small bowel resections > 100 cm | Surgical bowel resection within 3 months prior to baseline | Any manifestation likely to require surgery during the study | Use of prohibited concomitant therapies for Crohn disease | Prior natalizumab or any other alpha4beta1 integrin agonist | Failure of more than three advanced therapies for Crohn disease, or failure of two different mechanisms of action of advanced therapies | History of or active malignancy (except subjects with >= 5-year disease-free survival) | History of colonic cancer or dysplasia adenomatous polyps, or evidence of such polyps at screening endoscopy | Primary sclerosing cholangitis, autoimmune hepatitis, or primary biliary cirrhosis | Serious illness requiring hospitalization (not related to Crohn disease) within 4 weeks prior to screening | Chronic or recurrent grade 3–4 infection within 2 months prior to screening or history of opportunistic infection while not on immunosuppressive therapy | Herpes zoster reactivation within 2 months prior to screening | Active infection at screening or major infection requiring hospitalization or IV antibiotics within 1 month prior to or during screening | Positive stool assay or culture for pathogens requiring treatment or positive Clostridioides difficile toxin at screening | HIV infection | Acute or chronic hepatitis B infection | Acute or chronic hepatitis C infection (unless successfully treated with no detectable HCV RNA for >= 1 year) | Active tuberculosis or untreated latent tuberculosis | Uncontrolled ischemic heart disease or history of congestive heart failure | Congenital or acquired long QT syndrome or marked baseline prolonged QTc | History of torsade de pointes | Clinically relevant pulmonary, hepatic, or renal abnormality; encephalopathy; neuropathy; unstable CNS pathology including seizure disorder; or other significant medical problems | Live vaccine within 3 months prior to screening or planned during the study | Acute or chronic pancreatitis | Hemoglobin <= 8.0 g/dL | Absolute neutrophil count < 750/µL | Platelets < 100,000/µL | eGFR < 60 mL/min | Total bilirubin > 1.5 x ULN (except Gilbert syndrome) | AST > 2 x ULN or ALT > 2 x ULN | Did not meet protocol-specified washout periods prior to screening endoscopy | Use of any investigational or nonregistered product within 3 months or within 5 half-lives prior to baseline, whichever is longer | Prior obefazimod exposure or known hypersensitivity to obefazimod or excipients | Illicit drug or alcohol abuse or dependence | Any condition that could compromise safety or adherence in the investigator's opinion","Inadequate response, loss of response, or intolerance to at least one of: corticosteroids, immunosuppressants, biologic or biosimilar therapies, or JAK inhibitors for Crohn disease; No investigational or nonregistered product within 3 months or 5 half-lives prior to baseline; Meet protocol-specified washout periods before screening endoscopy",ALL,F,"Despite disease and age matching, the trial explicitly excludes patients who have failed two different mechanisms of advanced therapies; this patient failed infliximab (anti-TNF) and ustekinumab (anti–IL-12/23).",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,F,"The trial explicitly excludes patients who have failed two different mechanisms of advanced therapies. The patient failed infliximab (anti-TNF) and ustekinumab (IL-12/23), triggering a hard exclusion. Age/sex/disease otherwise match but hard exclusion → F.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT06477133,0.6251145601272583,Castration-Resistant Prostate Cancer,"A Randomized, Controlled Trial of Magnesium Sulfate as an Adjunctive Analgesic in Prostate Surgery",PHASE4,18 years,Prostatectomy,Age >= 18 years | Undergoing robotic prostatectomy under general anesthesia | Able and willing to provide informed consent,Age < 18 years | End-stage renal disease | Allergy to magnesium sulfate | Unable to comply with study procedures,(none),MALE,F,"Disease mismatch: the trial targets patients undergoing robotic prostatectomy (perioperative analgesia), not metastatic castration-resistant prostate cancer. Although age and sex fit, the disease/setting does not.",Castration-Resistant Prostate Cancer,PSMA-positive,Age 66 years; Male; Castration-resistant prostate cancer; Metastatic disease; PSMA PET avid disease; Liver metastases; Bone metastases; Progression on enzalutamide; Prior abiraterone (Zytiga); Prior leuprolide (Lupron),(none),Abiraterone (Zytiga); Enzalutamide; Leuprolide (Lupron),metastatic,,66,years,male,(none),CORRECT,F,"The trial targets patients undergoing robotic prostatectomy (perioperative analgesia) and lists “Prostatectomy” as the disease context, which does not include metastatic castration-resistant prostate cancer. This is a disease mismatch, a hard exclusion per the rubric, so F is correct. The grader’s reasoning correctly identified this.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT06482437,0.5521506071090698,Duchenne Muscular Dystrophy,"A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 Over 21 Days in Ambulatory Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease",PHASE2,18 years to 70 years,Charcot-Marie-Tooth Disease,Age 18 to 70 years | Diagnosis of Charcot-Marie-Tooth type 1 or type 2 confirmed by genetic testing | Body mass index 18 to 35 kg/m2 and weight >= 40 kg,"Other significant disease that may interfere with study assessments, including other neuromuscular diseases | Clinically significant laboratory abnormalities at screening | Received another investigational medicinal product within 30 days or 5 half-lives prior to Day 1 | Pregnant or breastfeeding",No investigational product within 30 days or 5 half-lives prior to Day 1,ALL,F,"Disease mismatch: the trial targets Charcot-Marie-Tooth disease (CMT1/2), not Duchenne muscular dystrophy. The patient is also 11 years old (trial requires 18–70) and non-ambulatory, while the study enrolls ambulatory adults.",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,"There is a clear hard exclusion: disease mismatch (trial targets Charcot-Marie-Tooth, patient has Duchenne muscular dystrophy). Additionally, the patient is 11 years old vs trial minimum age 18. Either hard exclusion mandates grade F. The grader’s reasoning correctly identified these factors.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT06482437,0.622705340385437,Amyotrophic Lateral Sclerosis,"A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 Over 21 Days in Ambulatory Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease",PHASE2,18 years to 70 years,Charcot-Marie-Tooth Disease,Age 18 to 70 years | Diagnosis of Charcot-Marie-Tooth type 1 or type 2 confirmed by genetic testing | Body mass index 18 to 35 kg/m2 and weight >= 40 kg,"Other significant disease that may interfere with study assessments, including other neuromuscular diseases | Clinically significant laboratory abnormalities at screening | Received another investigational medicinal product within 30 days or 5 half-lives prior to Day 1 | Pregnant or breastfeeding",No investigational product within 30 days or 5 half-lives prior to Day 1,ALL,F,"Disease mismatch: the trial targets Charcot–Marie–Tooth disease (type 1 or 2), while the patient has ALS. Additionally, the trial excludes other neuromuscular diseases, which would include ALS.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,F,Correct: There is a hard exclusion due to disease mismatch (trial is for Charcot–Marie–Tooth disease; patient has ALS). The grader’s added note about excluding other neuromuscular diseases further supports ineligibility but isn’t necessary. Grade F is appropriate.,,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT06557512,0.7988107204437256,Recurrent Glioblastoma,A Pilot Trial of Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma (SRS-AIM),NA,18 years,Meningioma; Recurrent Meningioma,Age >= 18 years | Histologic diagnosis of newly diagnosed WHO grade 2 meningioma or recurrent WHO grade 1 meningioma with radiographic evidence of recurrence and WHO grade 1 histology at most recent resection | Gross-total surgical resection (Simpson grade I–III) within 180 days of enrollment | ECOG 0–1 (Karnofsky >= 70%) | Post-operative MRI indicating anatomy suitable for hypofractionated stereotactic radiosurgery,Extensive multifocal meningiomas (>= 3) or metastatic disease | Tumor within 2 mm of the optic apparatus or brainstem | Another active primary malignancy unless complete remission achieved >= 2 years prior and no additional therapy required during the study period | Pregnancy | Underlying medical or psychiatric condition that would interfere with evaluation of study treatment or interpretation of safety/results | Uncontrolled seizures (>3 disabling seizures per day while on anti-epileptic drugs) | Prior intracranial radiotherapy overlapping the planned stereotactic radiosurgery target,Gross-total surgical resection (Simpson grade I–III) required within 180 days prior to enrollment,ALL,F,"Disease mismatch: the trial targets WHO grade 2 or recurrent grade 1 meningioma, while the patient has recurrent glioblastoma (IDH-wildtype). This triggers a hard exclusion.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),CORRECT,F,Disease mismatch is a hard exclusion: the trial is for meningioma while the patient has recurrent glioblastoma. The grader correctly assigned F based on this.,,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT06560411,0.6024980545043945,Duchenne Muscular Dystrophy,Evaluation of Automatic Expiratory Positive Airway Pressure (Auto-EPAP) for Management of Upper Airway Obstruction During Non-Invasive Ventilation With Vivo 45 LS,NA,18 years,Chronic Obstructive Pulmonary Disease; Neuromuscular Disease; Obesity Hypoventilation Syndrome; Obstructive Sleep Apnea,Age >= 18 years | Documented respiratory failure with sleep hypoventilation and historical transcutaneous CO2 (PtCO2) increase >= 10 mmHg and/or daytime hypercapnia > 45 mmHg | Currently using non-invasive positive pressure ventilation for 1 month | Apnea-hypopnea index >= 5/hr | EPAP settings reviewed within <= 12 months,"Non-compliance with NIV (use < 4 hours/night) | Pregnant | On oxygen therapy >= 5 L/min | Invasive interface (e.g., tracheostomy) | Acute exacerbation within the last 3 months resulting in hospitalization | Acutely ill, medically complicated, or medically unstable | NIV therapy medically contraindicated | Surgery of the upper airway, nose, sinus, or middle ear within the previous 90 days | Untreated non-obstructive sleep disorders (e.g., insomnia, periodic limb movement syndrome, restless legs syndrome) | Severe bullous lung disease | Recurrent pneumothorax or pneumomediastinum | Cerebrospinal fluid leak | Recent cranial surgery or trauma",Currently using non-invasive ventilation for 1 month,ALL,F,"The trial requires participants to be at least 18 years old, while the patient is 11, which is a hard age-window exclusion. Other criteria are irrelevant once this exclusion applies.",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,"Patient is 11 years old while the trial minimum age is 18, which is a hard age-window exclusion. Therefore F is correct; no need to assess other anchors.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT06588855,0.5188158750534058,Fistulizing Crohn's Disease,"A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Patients With Moderately to Severely Active Ulcerative Colitis",PHASE3,16 years to 80 years,Ulcerative Colitis (moderately to severely active),"Confirmed diagnosis of ulcerative colitis | Moderately to severely active ulcerative colitis assessed by modified Mayo Score | Body weight >= 40 kg | Up to date colorectal cancer screening per local standards | Inadequate response, loss of response, or intolerance to at least one conventional or advanced ulcerative colitis therapy","Complications of ulcerative colitis (e.g., fulminant colitis, toxic megacolon) | Crohn's disease, indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or radiation colitis | Presence of an ostomy or ileoanal pouch | Primary sclerosing cholangitis | Pregnancy or breastfeeding | Past or current colonic dysplasia, adenomas, or neoplasia not completely removed | Malignancy within 5 years except adequately treated non-metastatic basal cell or squamous cell skin cancer or in situ cervical cancer | Infection with Clostridioides difficile, cytomegalovirus, HIV, hepatitis B, or hepatitis C | Active tuberculosis or latent/inadequately treated tuberculosis | Prior exposure to anti-TL1A therapy or other protocol-prohibited medicines","Inadequate response, loss of response, or intolerance to at least one conventional or advanced ulcerative colitis therapy",ALL,F,"Disease mismatch: the trial is for ulcerative colitis and explicitly excludes Crohn's disease, which the patient has.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,F,"Disease mismatch is a hard exclusion. The trial is for ulcerative colitis and explicitly excludes Crohn’s disease, while the patient has Crohn’s disease. Grade F is correct.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT06600321,0.7556064128875732,Metastatic Urothelial Carcinoma,A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma,PHASE1,18 years,Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma,"Histologic, cytologic, or AASLD clinical diagnosis of hepatocellular carcinoma | At least one prior line of systemic therapy for unresectable advanced or metastatic disease | At least one WNT-pathway activating mutation | Child-Pugh class A or B7",Fibrolamellar hepatocellular carcinoma | Sarcomatoid hepatocellular carcinoma | Mixed cholangiohepatocellular carcinoma | Symptomatic extrahepatic disease | Received anti-cancer therapy or investigational drugs <= 3 weeks prior to first dose,At least one prior line of systemic therapy for unresectable advanced or metastatic disease; Washout >= 3 weeks from prior anti-cancer therapy or investigational drugs,ALL,F,"Hard exclusion: the trial is for advanced/metastatic hepatocellular carcinoma, while the patient has metastatic urothelial carcinoma. Therefore, the disease does not match the trial’s targeted population.",Metastatic Urothelial Carcinoma,(none),Biopsy confirmed metastatic urothelial carcinoma; Progressing after second line therapy; Prior neoadjuvant gemcitabine/cisplatin (4 cycles); Prior enfortumab vedotin plus pembrolizumab with progression after 6 cycles; Status post cystectomy with pathologic complete response; Age 55 years; Male; Chronic kidney disease with eGFR 35 mL/min; History of type 2 diabetes mellitus; History of COPD,(none),Neoadjuvant gemcitabine/cisplatin; Cystectomy; Enfortumab vedotin plus pembrolizumab,metastatic,after second line therapy,55,years,male,(none),CORRECT,F,"Disease mismatch is a hard exclusion: trial targets hepatocellular carcinoma, while the patient has metastatic urothelial carcinoma. The grader correctly assigned F based on this.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT06623240,0.5978066921234131,Rheumatoid Arthritis,"A Randomized, Double-Blind, Phase 2, Efficacy and Safety Cross-Over Study of Allogeneic HB-adMSCs vs Placebo for the Treatment of Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis",PHASE2,2 years to 16 years,Juvenile Idiopathic Arthritis (oligoarticular); Juvenile Idiopathic Arthritis (polyarticular),"Age >= 2 years and < 17 years | Diagnosed with oligoarticular or polyarticular juvenile idiopathic arthritis by a pediatric rheumatologist | Rheumatoid factor test result documented | >= 3 affected joints at screening | Body weight > 10 kg | Either not on current JIA treatment due to failure of at least 2 approved medications, or on a stable arthritis therapy regimen for >= 3 months prior to screening | Abnormal CRP > 1 mg/dL and/or abnormal ESR at screening","WBC < 3000/µL or > 15000/µL | Hemoglobin < 8 g/dL | Absolute neutrophil count < 1500/µL | Platelets < 150000/µL | Sodium < 120 mEq/L or > 150 mEq/L | Glucose > 150 mg/dL | Potassium < 3.5 mEq/L or > 6 mEq/L | BUN > 25 mg/dL | Creatinine > 2 mg/dL | BUN/Creatinine ratio > 50 | AST > 100 U/L | ALT > 100 U/L | Vital sign abnormalities at screening as determined by investigator | Significant uncontrolled concurrent medical conditions (e.g., diabetes mellitus, Crohn's disease, lupus, multiple sclerosis) | Active malignancy including cutaneous basal cell carcinoma, squamous cell carcinoma, or melanoma | Alcohol addiction/dependency or current substance use/abuse | Received any stem cell treatment within 1 year before first dose other than Hope Biosciences stem cells | Receiving any investigational therapy or any approved therapy for investigational use within 1 year prior to first dose (except COVID-19 vaccines) | Other laboratory abnormality or medical condition posing safety risk or preventing study completion in investigator's opinion | Known hepatitis B, hepatitis C, or HIV infection | Systemic infection requiring treatment with antibiotics, antivirals, or antifungals within 30 days prior to first dose",Failed at least 2 approved therapies for JIA; Stable arthritis therapy for >= 3 months prior to screening permitted,ALL,F,"Hard exclusions apply: the trial targets juvenile idiopathic arthritis (not rheumatoid arthritis) and requires age 2–16, while the patient is 55. Therefore, the patient does not meet the trial’s disease and age criteria.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Correct: There is a disease mismatch (JIA vs adult RA) and an age conflict (trial 2–16, patient 55), both hard exclusions per rubric, so F is warranted.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT06666712,0.7177836298942566,Recurrent Glioblastoma,Chronic Convection Enhanced Delivery of Topotecan for Recurrent Malignant Glioma,PHASE1,18 years,"Malignant Glioma (recurrent, WHO grade III–IV)","Recurrent malignant glioma, IDH-mutant, WHO grade 3–4; progression on imaging with suspicion of histologic recurrence | Patients with prior WHO grade 2 IDH-mutant glioma now demonstrating high-grade (WHO grade 3–4) features | Failed standard-of-care treatment | MRI within 30 days showing an enhancing mass without significant mass effect | Tumor volume <32 cc and stereotactically accessible | Karnofsky performance status >=70% | Age >=18 years | Adequate organ and marrow function per protocol thresholds | Women of childbearing potential: negative pregnancy test within 7 days of entry and use of birth control; men and women must use contraception per protocol timelines","Diffuse subependymal or cerebrospinal fluid disease | Tumors involving the cerebellum or both cerebral hemispheres | Active infection requiring treatment or unexplained febrile illness | Known HIV, hepatitis B, or hepatitis C positivity | Systemic diseases conferring unacceptable anesthetic/operative risk | Prior systemic topotecan for the tumor | Inability to undergo MRI or PET imaging | Allergy to topotecan, other topoisomerase inhibitors, or gadolinium compounds | Concomitant use of drugs metabolized solely by CYP3A4/5 with a narrow therapeutic index or strong CYP2C8 inhibitors, or agents with QT prolongation risk that are CYP3A substrates (must discontinue >=2 weeks before treatment) | Uncontrolled intercurrent illness (e.g., congestive heart failure, unstable angina, cardiac arrhythmia, significant psychiatric illness) | Positive pregnancy test within 7 days of registration | Breastfeeding",Failed standard-of-care therapy for malignant glioma,ALL,F,"The trial requires IDH-mutant malignant glioma (WHO grade 3–4), but the patient’s glioblastoma is IDH-wildtype. This required biomarker mismatch is a hard exclusion.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),CORRECT,F,"Trial requires IDH-mutant malignant glioma; patient is IDH-wildtype. This is a required biomarker mismatch and a hard exclusion per rubric, so F is correct.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT06692738,0.7787777185440063,Metastatic Non-Small Cell Lung Cancer,"A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)",PHASE3,18 years,"Non-small Cell Lung Cancer (squamous, metastatic)",Histologically or cytologically confirmed squamous non-small cell lung cancer. | Stage IV metastatic NSCLC not amenable to curative treatment. | No actionable driver oncogenes with approved first-line targeted therapies per local testing. | Tumor PD-L1 expression on tumor cells (TC) >= 1%. | At least one measurable lesion by RECIST 1.1 not previously irradiated (>= 10 mm longest diameter; lymph nodes short axis >= 15 mm) suitable for repeated measurements by CT or MRI. | Adequate organ and bone marrow function.,"Presence of small cell or neuroendocrine histology components. | Active or uncontrolled brain metastases; allowed only if asymptomatic, stable, off steroids and anticonvulsants >= 7 days; >= 2 weeks since local therapy with recovery from acute effects. | Any prior systemic therapy for advanced or metastatic NSCLC. | Any prior treatment with an anti-PD-1 or anti-PD-L1 agent. | Any prior exposure to anti-TIGIT therapy or other anticancer therapy targeting immune-regulatory receptors or mechanisms. | History of another primary malignancy unless treated with curative intent with no active disease for >= 2 years and low risk of recurrence. | Active or prior autoimmune or inflammatory disorders requiring chronic steroids or other immunosuppressive treatment. | Active primary immunodeficiency or active infectious disease(s). | Active tuberculosis infection.",No prior systemic therapy for advanced/metastatic NSCLC,ALL,F,"Explicit exclusions apply: the trial requires no prior systemic therapy for metastatic NSCLC and no actionable driver oncogenes, while the patient has an EGFR exon 19 deletion and has been on osimertinib for 2 years for metastatic disease.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,Age 40 years; Male; Metastatic non-small cell lung cancer; De novo metastatic disease; Bone metastases; Liver metastases; Brain metastases on MRI; EGFR exon 19 deletion; On osimertinib for 2 years; ECOG 0; No significant comorbidities,(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"Hard exclusions apply: the trial excludes any prior systemic therapy for advanced/metastatic NSCLC, and requires no actionable driver oncogenes. The patient has received osimertinib for metastatic disease and harbors an EGFR exon 19 deletion. Thus F is correct.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT06716931,0.6237598061561584,Duchenne Muscular Dystrophy,Investigating Benefits of a Physical Therapist (PT)-Guided Exercise Program in Myotonic Dystrophy Type 2 (DM2),NA,18 years to 70 years,Myotonic Dystrophy Type 2,Genetically confirmed myotonic dystrophy type 2 | Age >= 18 and <= 70 years | Ambulatory without assistance or device | Normal ECG within 3 months prior to screening | Body mass index >= 20 and <= 30,Younger than 18 years or older than 70 years | Pacemaker | Blood pressure < 90/50 mmHg or > 160/90 mmHg at screening | Resting heart rate < 60 or > 100 beats/minute at screening | Any fall within the last 6 months | History of syncope or family history of sudden death | Pregnant or planning to become pregnant | Positive urine pregnancy test,(none),ALL,F,"Disease mismatch: the trial is for myotonic dystrophy type 2, while the patient has Duchenne muscular dystrophy. Additionally, the patient is 11 years old and non-ambulatory, conflicting with the trial’s age (18–70) and ambulatory requirements.",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,"Correct: There is a hard disease mismatch (DM2 trial vs DMD patient), which mandates F. Additionally, the patient is below the trial’s minimum age (11 vs ≥18), another hard exclusion. The grader’s reasoning and grade align with the rubric.",,
I have a 62-year-old male patient diagnosed with amyotrophic lateral sclerosis (ALS) 14 months ago. He has limb-onset disease and an ALSFRS-R score of 38. His forced vital capacity (FVC) is stable at 85% of predicted. He is currently taking riluzole. What trial options are available?,NCT06716931,0.538923442363739,Amyotrophic Lateral Sclerosis,Investigating Benefits of a Physical Therapist (PT)-Guided Exercise Program in Myotonic Dystrophy Type 2 (DM2),NA,18 years to 70 years,Myotonic Dystrophy Type 2,Genetically confirmed myotonic dystrophy type 2 | Age >= 18 and <= 70 years | Ambulatory without assistance or device | Normal ECG within 3 months prior to screening | Body mass index >= 20 and <= 30,Younger than 18 years or older than 70 years | Pacemaker | Blood pressure < 90/50 mmHg or > 160/90 mmHg at screening | Resting heart rate < 60 or > 100 beats/minute at screening | Any fall within the last 6 months | History of syncope or family history of sudden death | Pregnant or planning to become pregnant | Positive urine pregnancy test,(none),ALL,F,"Disease mismatch: the trial targets genetically confirmed myotonic dystrophy type 2, while the patient has amyotrophic lateral sclerosis. This constitutes a hard exclusion.",Amyotrophic Lateral Sclerosis,(none),Diagnosed with amyotrophic lateral sclerosis (ALS); Limb-onset disease; ALSFRS-R score 38; Forced vital capacity (FVC) 85% of predicted; Currently taking riluzole; Time since diagnosis 14 months; Age 62 years; Male sex,(none),Riluzole,,,62,years,male,(none),CORRECT,F,"Correct: The patient has ALS, while the trial targets genetically confirmed myotonic dystrophy type 2. This is a disease mismatch, a hard exclusion per the rubric, so grade F is appropriate.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06750432,0.574731707572937,Dementia,"A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PMN310 in Patients With Early Alzheimer's Disease",PHASE1,50 years,Alzheimer Disease (early),Age >= 50 years | Ambulatory with adequate vision and hearing for assessments | MCI due to Alzheimer’s disease or mild AD dementia per NIA-AA (Stage 3–4) | Global CDR 0.5–1.0 and memory box score >= 0.5 at Screening and Baseline | Objective episodic memory impairment (>= 1 SD below age-adjusted mean on WMS-IV Logical Memory II) | MMSE 20–28 inclusive at Screening | Positive amyloid PET scan within 6 months of Screening or during Screening | Body mass index 18.5–35 kg/m2 inclusive | Patients of reproductive potential agree to use effective contraception during treatment and for 120 days after last dose | Females of childbearing potential: negative pregnancy tests; not breastfeeding | Postmenopausal or surgically sterile patients are eligible | Reliable caregiver available for study visits and assessments | Adequate venous access for IV infusions and blood collection | Stable dose (>= 3 months) of acetylcholinesterase inhibitors or memantine allowed,"Residing in a continuous care or long-term care nursing facility | Other neurodegenerative or neurological disorders contributing to cognitive impairment (e.g., Parkinson’s disease, Huntington’s disease, frontotemporal dementia, dementia with Lewy bodies) | QTcF > 450 msec (males) or > 470 msec (females) | ALT >= 2 x ULN, AST >= 2 x ULN, or total bilirubin >= 1.5 x ULN | Creatinine clearance < 30 mL/min | Clinically significant physical or psychiatric illness posing risk or affecting study completion (including suicidal risk/behavior) | Unstable or clinically significant cardiovascular disease within 1 year (e.g., unstable angina, myocardial infarction, chronic heart failure, significant conduction abnormalities) | Clinically significant hepatic or renal impairment; positive hepatitis B surface antigen or hepatitis C antibody | Poorly managed hypertension (systolic > 160 mmHg and/or diastolic > 95 mmHg) or hypotension (systolic < 90 mmHg and/or diastolic < 60 mmHg) | Uncontrolled diabetes (HbA1c > 7.5%) or insulin-dependent diabetes | Significant systemic illness within 30 days before first dose | Seizure within 3 years prior to Screening | Prior malignancy (except adequately treated non-melanoma skin cancer or cervical carcinoma in situ) | Brain MRI findings: > 4 microhemorrhages; > 1 lobar microhemorrhage; superficial siderosis; subarachnoid hemorrhage; any other hemorrhage > 10 mm; > 2 lacunar infarcts or cortical infarct; severe perivascular spaces or multisport-pattern white matter hyperintensities (PI review required) | History of stroke or TIA within 12 months | Contraindication to PET or brain MRI | Negative amyloid PET scan within 6 months of Screening or during Screening | Pregnant or breastfeeding | Alcohol or substance abuse within 12 months prior to dosing | Positive alcohol breath test or positive illicit drug screen at Screening | HIV antibody positive | COVID-19 infection within 2 weeks of Screening or ongoing symptoms at Screening | Currently receiving anti-amyloid treatment or received within 9 months prior to Screening (marketed or investigational); investigational placebo recipients are not excluded | Contraindication to lumbar puncture (e.g., INR > 1.4, platelet count < 120,000/µL, local infection, anticoagulant use except low-dose aspirin, significant spinal abnormalities) | Blood or blood product donation within 56 days prior to first dose | Received an investigational active agent within 30 days or 5 half-lives (whichever is longer) | History of severe hypersensitivity to PMN310 components",Stable dose of acetylcholinesterase inhibitors or memantine for >= 3 months allowed; Washout from anti-amyloid therapy >= 9 months prior to Screening; Washout from investigational active agents >= 30 days or 5 half-lives (whichever is longer),ALL,F,"The trial requires early Alzheimer’s disease with a positive amyloid PET. This patient is amyloid PET negative/CSF amyloid negative (definitively missing the required biomarker) and has MMSE 19 consistent with moderate dementia, outside the trial’s early-stage criteria.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,"Correct: The trial requires early AD with positive amyloid PET (and explicitly excludes negative amyloid PET). The patient has negative amyloid PET and MMSE 19 (moderate), so there is a hard biomarker requirement mismatch → F.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT06816498,0.5425188541412354,Duchenne Muscular Dystrophy,"An Open-label, Single-center, Single-participant Study of an Experimental Antisense Oligonucleotide Treatment for a Patient With LMNB1 Mutation Associated Autosomal Dominant Leukodystrophy (ADLD)",PHASE1/PHASE2,51 years to 51 years,Autosomal Dominant Leukodystrophy,Autosomal dominant leukodystrophy caused by an LMNB1 duplication mutation,"Any condition that, in the opinion of the investigator, would prevent completion of study procedures",(none),MALE,F,"Disease mismatch (trial targets LMNB1-associated ADLD, patient has Duchenne muscular dystrophy), required biomarker absent (LMNB1 duplication), and the trial age window is exactly 51 while the patient is 11.",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,"There is a clear disease mismatch (ADLD vs Duchenne muscular dystrophy) and an age window conflict (trial requires exactly 51 years; patient is 11), both hard exclusions. The grader’s F is correct. Mention of LMNB1 biomarker absence is not necessary but does not affect the correct F.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT06820528,0.5697106719017029,Rheumatoid Arthritis,Trapeziectomy and Suture Suspensionplasty for Thumb Carpometacarpal Arthritis - Is In-Clinic Therapy Needed?,NA,18 years,CMC Arthritis; Hand Arthritis,Age > 18 years | Undergoing CMC arthroplasty | Ability to read and write in English | Ability to provide informed consent,Revision CMC arthroplasty | Acute traumatic dislocation of the CMC joint as indication for surgery | Concomitant treatment of MCP hyperextension,(none),ALL,F,"Disease mismatch hard exclusion: the trial targets CMC/hand arthritis in patients undergoing CMC arthroplasty, not systemic rheumatoid arthritis. The patient's condition (RA) is not listed among the trial diseases.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Disease mismatch triggers a hard exclusion: the trial focuses on CMC/hand arthritis in patients undergoing CMC arthroplasty, while the patient has rheumatoid arthritis with no indication of CMC OA. Therefore F is appropriate per rubric.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06821568,0.5948872566223145,Dementia,Long-term Home-based Transcranial Electrical Stimulation for Cognitive and Motor Function in Older Adults With an Increased Risk of Dementia: a Randomized Controlled Trial,NA,65 years to 90 years,Alzheimer Disease and Related Dementias; Cognition; Mobility Disability,Age 65-90 years | Subjective cognitive complaints per screening questions | Montreal Cognitive Assessment (MoCA) score >=21 | Slow gait speed defined as usual walking speed >=1 SD below age- and sex-adjusted means on 4-Meter walk | Able to walk unassisted for at least 2 minutes and Functional Activities Questionnaire (FAQ) score <9,"Formal education less than 8th grade | Previous physician diagnosis of dementia | Current diagnosis of a major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depressive disorder) | Moderate-to-severe depressive symptoms (Geriatric Depression Scale-15 score >=9) | History of head trauma with prolonged loss of consciousness | History of fainting spells of unknown etiology that might constitute seizures | History of seizures, epilepsy, or first-degree family history of epilepsy (except a single benign seizure per neurologist judgment) | Hospitalization within the past 3 months due to acute illness or musculoskeletal injury significantly affecting gait or balance | Unstable or uncontrolled medical conditions that may pose risk with potential provoked seizure (e.g., cardiac malformation, dysrhythmia, asthma) | Substance use disorder within the past 6 months | Hairstyle or headdress preventing electrode contact with the scalp or interfering with stimulation (e.g., thick braids, hair weave, afro, wig) | Chronic vertigo | Myocardial infarction within the past 6 months | Active cancer receiving chemotherapy or radiation therapy | Legal blindness | Visual hallucinations (history or self-report) | Pacemaker | Contraindications to MRI or tDCS (e.g., unprovoked seizure within past 2 years, risk of ferromagnetic objects, implanted medical devices such as deep brain stimulator, infusion pump, cochlear implant, pacemaker; active dermatological condition on the scalp) | History of REM sleep behavior disorder | Medical history and CNS-active medications deemed unsafe by study physician based on dose, recent changes, duration, or combinations",(none),ALL,F,"The trial explicitly excludes participants with a previous physician diagnosis of dementia, while the patient has documented moderate-stage dementia. Other key inclusions (e.g., MoCA ≥21, slow gait criteria) are not met or unknown.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,"Explicit exclusion applies: trial excludes anyone with a previous physician diagnosis of dementia, and the patient has moderate-stage dementia. Under the rubric, that is a hard exclusion → F. Other inclusion details are irrelevant once a hard exclusion is triggered.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT06864403,0.6365879774093628,Fistulizing Crohn's Disease,Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch,PHASE4,18 years to 80 years,Chronic Pouchitis; Crohn's-like Disease of the Pouch,"Age >=18 and <=80 years | Diagnosis of chronic pouchitis or Crohn's-like disease of the pouch | Chronic antibiotic-dependent pouchitis: symptoms responsive to antibiotics but relapse after stopping, requiring continuous antibiotics | Chronic antibiotic-refractory pouchitis: lack of response or minimal improvement with standard antibiotics | Crohn's-like disease of the pouch: fistula >=12 months post-IPAA, stricture of pouch body or pre-pouch ileum, or pre-pouch ileitis (pouchitis may coexist) | History of ulcerative colitis and prior IPAA (1, 2, modified -2, or 3 stage) with ileostomy takedown | Provider is considering initiating mirikizumab for treatment","Prior exposure to mirikizumab | Known hypersensitivity to mirikizumab or its metabolites | Current Clostridioides difficile infection | Known HIV infection or active hepatitis B or C | Clinically significant liver disease (PSC allowed if liver function tests <1.5 x ULN) | Severe hepatic impairment (Child-Pugh class C) | Decreased kidney function with eGFR <45 mL/min/1.73 m^2 | History of malignancy except basal cell carcinoma, non-metastatic squamous cell carcinoma of the skin, or prior malignancy cured >=5 years before screening without recurrence | Clinically significant laboratory abnormalities at screening or baseline per investigator | Pregnant or breastfeeding, or of childbearing potential without highly effective contraception | Participation in another interventional clinical trial within 30 days before screening | Any disorder that may jeopardize safety or protocol compliance per investigator",(none),ALL,F,"Disease mismatch: the trial targets chronic pouchitis or Crohn’s-like disease of the pouch (post-IPAA), whereas the patient has fistulizing Crohn’s disease with no evidence of a pouch history.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,F,"Correct F due to disease mismatch. The trial targets chronic pouchitis or Crohn’s-like disease of the pouch (post-IPAA), not general fistulizing Crohn’s disease. Patient’s disease is not among the trial’s listed diseases/cohorts, triggering a hard exclusion. Age/sex are fine, but disease mismatch alone warrants F.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT06876350,0.5765183568000793,Rheumatoid Arthritis,Patient Satisfaction for Post-Operative Carpometacarpal Arthroplasty: Wood Casting Versus Thermoplastic Splint,NA,18 years,Carpometacarpal Joint Arthritis,Age >= 18 years | Intact medical decision-making capacity | Eligible for surgical intervention,Pregnancy,(none),ALL,F,"Disease mismatch: the trial targets post-operative carpometacarpal joint arthritis (thumb CMC arthroplasty), not rheumatoid arthritis. The patient's disease is outside the trial’s scope, triggering a hard exclusion.",Rheumatoid Arthritis,HBsAg negative; anti-HBc positive,"Seropositive rheumatoid arthritis; Active disease with DAS28 score of 5.5; History of treated Hepatitis B (HBsAg negative, anti-HBc positive); Moderate chronic kidney disease (eGFR 45 mL/min/1.73 m^2)",(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Correct F due to hard exclusion: disease mismatch. Trial targets carpometacarpal joint arthritis in post-op splinting context, while patient has rheumatoid arthritis with no indication of CMC arthritis or surgical status. Other criteria (age, sex) do not override this hard mismatch.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT06914479,0.7584134936332703,Recurrent Glioblastoma,"A Phase 1 Study of a Combined Cytotoxic and Immune-Stimulatory Therapy in Pediatric and Young Adult Patients With Recurrent, Primary Malignant Brain Tumors",PHASE1,3 years to 39 years,Malignant Brain Tumor (recurrent); Diffuse Hemispheric Glioma (H3 G34-mutant),"Age 3-25 years with malignant primary brain tumor at recurrence/relapse/progression after completion of up-front standard therapy | Age 26-39 years with diffuse hemispheric glioma, H3 G34-mutant, at recurrence/relapse/progression after completion of up-front standard therapy | Weight >= 10 kg and BSA > 0.5 m^2 | On stable or decreasing corticosteroid dose for >= 3 days prior to baseline MRI | Surgical resection of recurrence/relapse/progression is clinically indicated | Willing to provide archival FFPE and/or frozen tissue specimens, if available | Recovered from acute side effects of prior therapy | Therapy washouts from start of study treatment: >= 7 days after last biologic agent or beyond known AE window; 5 half-lives from any investigational agent; 4 weeks from cytotoxic therapy (23 days for temozolomide; 6 weeks for nitrosoureas); 6 weeks from antibody therapy (21 days for bevacizumab); 6 weeks from cellular therapy; 4 weeks or 5 half-lives (whichever shorter) from other antitumor therapies | Prior radiotherapy: >= 28 days from focal RT; >= 150 days from craniospinal irradiation | Bevacizumab for RT-induced edema allowed (up to 5 doses; no washout required) | Prior temozolomide during radiation at standard pediatric dosing allowed; prior dexamethasone allowed | ANC >= 1000/µL | Platelets >= 100000/µL (transfusion independent) | Creatinine clearance or GFR >= 70 mL/min/1.73 m^2 or serum creatinine within normal limits for age | Bilirubin <= 2 x ULN | ALT <= 3 x ULN | Serum albumin <= 2 g/dL | Performance score >= 60 (Karnofsky if >16 years; Lansky if <=16 years) | Females of child-bearing potential and males agree to use adequate contraception during treatment and for 30 days after last dose","Not clinically appropriate for tumor resection per neurosurgeon | Disseminated disease including diffuse leptomeningeal disease or CSF dissemination | Primary brainstem or primary spinal tumors | History of prior gene therapy | Ongoing valacyclovir therapy that cannot be stopped due to a medical condition | Known allergy to valacyclovir | Concurrent use of other investigational agents (non-diagnostic) | Currently receiving anti-cancer agents | Known disorders affecting immune system (e.g., HIV, hepatitis B or C) or autoimmune disorder requiring systemic cytotoxic or immunosuppressive therapy | Uncontrolled infection or other uncontrolled systemic illness | Current diagnosis of bipolar disorder or major depressive disorder | Congenital immune deficiency syndrome or acquired autoimmune disease | Pregnant or breastfeeding; FOCBP must have negative pregnancy test prior to therapy | Active illicit drug use or diagnosis of alcoholism | History of kidney transplant | History of allogeneic stem cell transplantation | Another malignancy that is progressing or requires active treatment within 3 years","Completed up-front standard-of-care therapy required; Washout: >= 7 days since last biologic agent or beyond known AE window; Washout: 5 half-lives from any investigational agent; Washout: 4 weeks from cytotoxic therapy (23 days for temozolomide; 6 weeks for nitrosoureas); Washout: 6 weeks from antibody therapy (21 days for bevacizumab); Washout: 6 weeks from cellular therapy (e.g., modified T cells, NK cells, dendritic cells); Washout: 4 weeks or 5 half-lives (whichever is shorter) from other antitumor therapies; Prior radiotherapy: >= 28 days from focal RT; >= 150 days from craniospinal irradiation; Bevacizumab for RT-induced edema allowed (<= 5 doses; no washout required); Prior temozolomide during radiation at standard pediatric dosing allowed; Prior dexamethasone allowed",ALL,F,"The patient is 40 years old, which is outside the trial's age range (3-39), constituting a hard exclusion. Additionally, the older cohort (26-39) requires H3 G34-mutant disease, which does not match the patient's IDH-wildtype glioblastoma.",Recurrent Glioblastoma,IDH wildtype,Histologically confirmed glioblastoma; IDH wildtype; Recurrent disease after standard therapy; ECOG 1; Age 40 years; Male; Prior gross total resection; Completed adjuvant radiation with concurrent temozolomide; Completed adjuvant temozolomide,(none),Gross total resection; Radiation therapy with concurrent temozolomide; Adjuvant temozolomide,,,40,years,male,(none),CORRECT,F,Hard exclusion applies: patient age 40 exceeds trial maximum age 39. This alone mandates F per rubric. The grader’s additional note about the 26–39 H3 G34-mutant cohort is accurate but unnecessary; age exclusion is sufficient.,,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT06986382,0.5308340787887573,Fistulizing Crohn's Disease,"Phase 1b/2a Trial of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset (EO), Medically Refractory (MR) Crohn Disease (CD)",PHASE1/PHASE2,2 years to 30 years,"Crohn Disease (medically refractory, early-onset or monogenic)","Monogenic cause of inflammatory bowel disease with a causative mutation for which HSCT is known to be curative (e.g., IL10/IL10RA/IL10RB, XIAP, IPEX, WAS, CD40L, CGD, LRBA, CTLA4, DOCK8, SCID syndromes) | Known monogenic cause of Crohn disease expressed in lymphohematopoietic cells where HSCT has not been previously performed, with moderate disease activity and failure/toxicity to at least two treatment pathways | Suspected monogenic cause of Crohn disease with a rare deleterious variant in a lymphohematopoietic-expressed gene and moderate disease activity or corticosteroid-dependence despite trials of at least two biologic/small molecule therapies of different mechanisms or significant toxicity | Medically refractory Crohn disease with suspected strong genetic component, with moderate or severe activity and corticosteroid-dependence despite trials of at least two biologic/small molecule therapies or significant toxicity | Disease severity unlikely to be tolerable long-term (e.g., not amenable to surgery without risk of short bowel syndrome or permanent ileostomy; requirement for long-term parenteral nutrition; intolerable extraintestinal symptoms) | Features suggesting high genetic contribution (e.g., parental consanguinity, strong family history in first-degree relatives, diagnosis <6 years, extraintestinal manifestations, family history of IBD or autoimmune disease) | Age >2 years and <30 years | Donor and recipient identical at least one allele at HLA-A, HLA-B, HLA-C, HLA-DQB1, and HLA-DRB1 by high-resolution typing | Karnofsky/Lansky performance status >=50%","Ulcerative colitis | Crohn disease responsive to medical therapy without corticosteroid-dependence or significant toxicity | Deleterious mutation in a gene expressed in epithelial or stromal cells but not in lymphohematopoietic cells (e.g., TTC7A), or mutation expected to be more deleterious outside lymphohematopoietic cells | Active hemophagocytic lymphohistiocytosis | Hepatic dysfunction: ALT >5 x ULN, AST >5 x ULN, or direct bilirubin >3 x ULN | Cirrhosis with bridging fibrosis (grade F3 or greater) or sclerosing cholangitis | Severe cardiovascular disease (e.g., left ventricular ejection fraction <40% or severe diastolic dysfunction) | Severe renal dysfunction: serum creatinine >1.5 x ULN or 24-hour creatinine clearance <50 mL/min/m2 | HIV infection or chronic hepatitis B or hepatitis C infection | Past exposure to therapeutic radiation | Previous allogeneic HSCT | Active malignancy or history of malignancy within 2 years (except nonmelanoma skin cancer or carcinoma in situ) | Pregnant or lactating | Severe concurrent uncontrolled disease increasing risk from study participation","Failure or significant toxicity after at least two biologic or small-molecule therapies with different mechanisms (e.g., TNF inhibitors, anti-IL12/23 antibodies, JAK inhibitors, anti-integrin); Corticosteroid dependence despite prior biologic/small-molecule therapies",ALL,F,"Disease matches, but the patient is 32 years old, which is outside the trial’s age window (>2 and <30; max_age 30). This constitutes a hard age exclusion.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,F,"Patient age 32 exceeds the trial’s maximum age (30), which is a hard exclusion per rubric. Disease category (Crohn’s) matches, but the age window conflict mandates grade F. Grader’s reasoning aligns with the rubric.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06995638,0.622193455696106,Dementia,Web-based Technology and Cognitive Training: Improving Executive Control in Cognitively Healthy Older Adults: the MUltitasking STrategy (MUST) Study,NA,60 years to 75 years,Healthy Aging; Alzheimer&#39;s Disease (AD),Age 60-75 | Adequate English proficiency | Willingness to attend 2 in-person assessments | Willingness to attend a blood test | Willingness to attend online intervention sessions | Willingness to attend an online follow-up assessment,"Montreal Cognitive Assessment score < 26 | History of cognitive impairment, dementia, stroke, seizure disorder, or other neuropsychiatric condition judged to impact cognitive performance | Taking medications known to influence cognitive performance | Sensory impairment (e.g., visual, auditory) incompatible with use of a standard computer workstation | Physical impairment (e.g., severe arthritic, orthopedic, neurologic) incompatible with use of a standard computer workstation | Enrollment in a concurrent study that could affect the outcome of this study",(none),ALL,F,"The trial explicitly excludes participants with a history of cognitive impairment or dementia, and the patient has moderate-stage dementia. Although age fits, this explicit exclusion makes the patient ineligible.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Progressive cognitive decline for 2 years; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate,,68,years,male,(none),CORRECT,F,"The trial explicitly excludes participants with a history of cognitive impairment or dementia, and the patient has moderate-stage dementia. This is a hard exclusion per the rubric, so F is correct. Age and sex eligibility do not override this.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT07098715,0.6299593448638916,Fistulizing Crohn's Disease,Closure Of Cryptoglandular Fistula-in-ano And Associated Non-healing Draining Wounds With Kerecis SurgiClose,NA,18 years,Fistula-in-ano; Draining Wound,Age >= 18 years | Cryptoglandular fistula-in-ano,Age < 18 years | Pregnant | Allergy or sensitivity to fish material | Inflammatory bowel disease | Fistula-in-ano associated with anal cancer | Fistula-in-ano associated with rectal cancer | Fistula-in-ano associated with extramammary Paget's disease | Fistula-in-ano associated with hidradenitis suppurativa | Fistula-in-ano associated with anal condyloma | Active infection or abscess,(none),ALL,F,"The trial explicitly excludes patients with inflammatory bowel disease, and the patient has Crohn's disease; moreover, the trial targets cryptoglandular (non-IBD) fistula-in-ano.",Fistulizing Crohn's Disease,(none),Moderate-to-severe fistulizing Crohn's disease; CDAI score 350; Refractory to infliximab; Refractory to ustekinumab; Active perianal fistula with draining seton in place; Recently completed IV antibiotics for perianal abscess,(none),Failed infliximab; Failed ustekinumab,,,32,years,male,(none),CORRECT,F,"Explicit hard exclusion: trial excludes inflammatory bowel disease, and the patient has Crohn’s disease (IBD). Therefore F is correct. The grader’s reasoning correctly identified this.",,
I'm looking for trial options for an 11-year-old boy with Duchenne muscular dystrophy confirmed by a deletion of exons 49-50. He lost ambulation 8 months ago and is now dependent on a power wheelchair. He is on a stable regimen of deflazacort and lisinopril for early cardiomyopathy (LVEF 52%). His Performance of Upper Limb (PUL) score is 18. His parents are interested in trials for non-ambulatory patients.,NCT07132775,0.5607781410217285,Duchenne Muscular Dystrophy,"Evaluation of the Safety and Efficacy of a Full-Body Electrostimulation Garment for Individuals With Neurological and Neuromuscular Conditions That Cause Spasticity, Hyperreflexia, and Pain",NA,18 years to 75 years,Multiple Sclerosis; Fibromyalgia; Neurological Disorder; Neuromuscular Disorder,"Age 18 to 75 years | Medical clearance from physician | Spasticity, pain, or hyperreflexia due to neurological or neuromuscular conditions, or a diagnosis of Multiple Sclerosis or Fibromyalgia | Multiple Sclerosis: definite diagnosis for at least 1 month | Multiple Sclerosis: ability to walk independently or with support (EDSS < 7) | Multiple Sclerosis: absence of relapses in the last 3 months | Multiple Sclerosis: spasticity with Modified Ashworth Scale (MAS) >= 1+ | Multiple Sclerosis: Berg Balance Scale (BBS) score < 46 | Fibromyalgia: definite diagnosis for at least 3 months | Able to follow instructions and report pain and/or discomfort | Able to ambulate 10 meters without body weight support with or without assistive devices and/or caregiver assistance","Implanted medical devices or equipment that can be disrupted by magnets (e.g., shunts) | Swollen, infected, or inflamed areas or skin eruptions (e.g., phlebitis, thrombophlebitis, varicose veins) in areas where the suit will be used | No established somatic or neuropsychiatric diagnosis prior to enrollment | Pregnant or nursing",(none),ALL,F,"Patient is 11 years old, but the trial requires age 18–75, which is a hard exclusion. The trial also requires ability to ambulate 10 meters, whereas the patient is non-ambulatory.",Duchenne Muscular Dystrophy,DMD exon 49-50 deletion,Age 11 years; Male sex; Duchenne muscular dystrophy confirmed by deletion of exons 49-50; Non-ambulatory (lost ambulation 8 months ago); Power wheelchair dependent; Stable deflazacort regimen; Early cardiomyopathy with LVEF 52%; Performance of Upper Limb (PUL) score 18,(none),Deflazacort; Lisinopril,,,11,years,male,(none),CORRECT,F,"Age 11 is below trial minimum 18, which is a hard exclusion per rubric, so F is correct. The noted ambulation requirement is an additional mismatch but not needed to justify F.",,
